[
  {
    "drugs": [
      {
        "name": "Simvastatin",
        "drug_class": "HMG-CoA reductase inhibitor",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "Simvastatin inhibits STAT1 activation and reduces T cell proliferation and effector function, potentially interfering with IFN-\u03b3 signaling involved in autoimmune depigmentation.",
    "relevance_score": 1,
    "paper_idx": 0,
    "pmid": "19804627",
    "title": "Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent.",
    "year": "2009",
    "doi": "10.1186/1471-2180-9-211",
    "journal": "BMC microbiology",
    "authors": [
      "Tubby S",
      "Wilson M",
      "Nair S"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "malignant melanoma",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "SC1982",
        "pathogen": "malignant melanoma",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "SC1982 showed an S100B-dependent death response in melanoma cell assays, indicating potential as a repurposed agent targeting S100B in melanoma."
      }
    ],
    "mechanism": "covalent binding to Cys84 on S100B to inhibit its interaction with p53, thereby restoring p53 tumor suppressor activity",
    "relevance_score": 3,
    "paper_idx": 1,
    "pmid": "22493700",
    "title": "Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.",
    "year": "2012",
    "doi": "10.1371/journal.pone.0034538",
    "journal": "PloS one",
    "authors": [
      "Machado D",
      "Couto I",
      "Perdig\u00e3o J"
    ]
  },
  {
    "drugs": [
      {
        "name": "methylene blue",
        "drug_class": "photosensitiser",
        "approved_for": "vital organ staining, septic shock treatment"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "methylene blue",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Methylene blue combined with laser light effectively inactivates key staphylococcal virulence factors and kills MRSA in vitro."
      }
    ],
    "mechanism": "generation of reactive oxygen species upon light activation leading to oxidation and inactivation of bacterial virulence factors and bacteria.",
    "relevance_score": 4,
    "paper_idx": 2,
    "pmid": "22927795",
    "title": "Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent.",
    "year": "2012",
    "doi": "10.1371/journal.pbio.1001379",
    "journal": "PLoS biology",
    "authors": [
      "Cha H",
      "Byrom M",
      "Mead P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thiabendazole",
        "drug_class": "antifungal/anti-helminthic",
        "approved_for": "systemic infections, antifungal, anti-helminthic"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Thiabendazole",
        "pathogen": "none",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thiabendazole inhibits angiogenesis and disassembles established blood vessels, acting as a vascular disrupting agent in animal models and human cells."
      }
    ],
    "mechanism": "disrupts existing blood vessels by impairing vessel integrity and endothelial cell migration without inducing significant apoptosis",
    "relevance_score": 5,
    "paper_idx": 3,
    "pmid": "23062620",
    "title": "Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to \u03b2-lactams.",
    "year": "2013",
    "doi": "10.1021/cb300413m",
    "journal": "ACS chemical biology",
    "authors": [
      "Farha M",
      "Leung A",
      "Sewell E"
    ]
  },
  {
    "drugs": [
      {
        "name": "isoniazid",
        "drug_class": "first-line anti-tuberculosis agent",
        "approved_for": "tuberculosis"
      },
      {
        "name": "thioridazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia, nausea, vomiting"
      },
      {
        "name": "verapamil",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension, angina"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR (multidrug resistant), isoniazid and rifampicin resistance"
      }
    ],
    "findings": [
      {
        "drug": "isoniazid",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Efflux pump inhibitors such as thioridazine, chlorpromazine, and verapamil can reduce the MIC of isoniazid and inhibit efflux activity, potentially preventing resistance development."
      }
    ],
    "mechanism": "Inhibition of bacterial efflux pumps to increase intracellular antibiotic concentration and prevent resistance emergence.",
    "relevance_score": 4,
    "paper_idx": 4,
    "pmid": "23936064",
    "title": "Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.",
    "year": "2013",
    "doi": "10.1371/journal.pone.0069646",
    "journal": "PloS one",
    "authors": [
      "Carlson-Banning K",
      "Chou A",
      "Liu Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "Simvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "Atorvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "Pravastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MSSA/MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Simvastatin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 15.65,
        "fici": null,
        "key_result": "Simvastatin exhibited antimicrobial activity against S. aureus, inhibiting biofilm formation and reducing viability of mature biofilms."
      }
    ],
    "mechanism": "Proposed mechanism involves disruption of biofilm formation and bacterial viability, possibly through interference with bacterial cell processes.",
    "relevance_score": 4,
    "paper_idx": 5,
    "pmid": "25033456",
    "title": "Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.",
    "year": "2014",
    "doi": "10.1371/journal.pntd.0002977",
    "journal": "PLoS neglected tropical diseases",
    "authors": [
      "Planer J",
      "Hulverson M",
      "Arif J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ticlopidine",
        "drug_class": "antiplatelet",
        "approved_for": "prevention of thrombotic stroke"
      },
      {
        "name": "Clopidogrel",
        "drug_class": "antiplatelet",
        "approved_for": "prevention of thrombotic events"
      },
      {
        "name": "Prasugrel",
        "drug_class": "antiplatelet",
        "approved_for": "prevention of thrombotic cardiovascular events"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      }
    ],
    "findings": [
      {
        "drug": "Ticlopidine",
        "pathogen": "MRSA",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.063,
        "key_result": "Ticlopidine strongly potentiated the activity of \u03b2-lactam antibiotics against MRSA, restoring sensitivity in resistant strains."
      },
      {
        "drug": "Clopidogrel",
        "pathogen": "MRSA",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.125,
        "key_result": "Clopidogrel synergized with cefuroxime to enhance activity against MRSA."
      },
      {
        "drug": "Prasugrel",
        "pathogen": "MRSA",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Prasugrel showed synergy with cefuroxime against MRSA."
      }
    ],
    "mechanism": "Ticlopidine inhibits TarO, an enzyme involved in WTA biosynthesis, leading to mislocalization of PBP4, impairing peptidoglycan cross-linking, and sensitizing MRSA to \u03b2-lactam antibiotics.",
    "relevance_score": 5,
    "paper_idx": 6,
    "pmid": "25268459",
    "title": "Covalent small molecule inhibitors of Ca(2+)-bound S100B.",
    "year": "2014",
    "doi": "10.1021/bi5005552",
    "journal": "Biochemistry",
    "authors": [
      "Cavalier M",
      "Pierce A",
      "Wilder P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "anti-oxidative, anti-inflammatory, anti-atherosclerotic properties (not yet approved for antimicrobial use)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus (including MRSA)",
        "resistance_profile": "MDR"
      },
      {
        "name": "Streptococcus",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterococcus",
        "resistance_profile": "VRE"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Ebselen exhibited potent antimicrobial activity against MRSA with MIC90 of 0.25 mg/L, exceeding that of vancomycin and linezolid."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Enterococcus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Ebselen inhibited Enterococcus with MIC90 of 0.5 mg/L, showing strong activity against VRE."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen showed synergistic activity with conventional antibiotics against MRSA."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen demonstrated synergy with antibiotics in reducing bacterial load."
      }
    ],
    "mechanism": "Inhibition of bacterial translation process without affecting mitochondrial biogenesis",
    "relevance_score": 4,
    "paper_idx": 7,
    "pmid": "25515946",
    "title": "Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?",
    "year": "2015",
    "doi": "10.1007/s10096-014-2296-3",
    "journal": "European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology",
    "authors": [
      "Dalhoff A"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "salicylanilide anthelmintic",
        "approved_for": "treating tapeworm infections in humans"
      },
      {
        "name": "oxyclozanide",
        "drug_class": "salicylanilide anthelmintic",
        "approved_for": "veterinary treatment of parasitic flatworms (flukes)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Niclosamide exhibited strong in vitro and in vivo activity against MRSA with MIC of 0.125 \u03bcg/ml and was bacteriostatic."
      },
      {
        "drug": "oxyclozanide",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Oxyclozanide showed activity against MRSA with MIC of 0.5 \u03bcg/ml and was bactericidal, permeabilizing bacterial membranes."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Niclosamide was effective against Enterococcus faecium with MIC of 0.25 \u03bcg/ml."
      },
      {
        "drug": "oxyclozanide",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Oxyclozanide was effective against Enterococcus faecium with MIC of 2 \u03bcg/ml."
      }
    ],
    "mechanism": "Oxyclozanide may exert its antibacterial effect through bacterial membrane permeabilization, leading to cell death.",
    "relevance_score": 4,
    "paper_idx": 8,
    "pmid": "25521459",
    "title": "Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.",
    "year": "2015",
    "doi": "10.1038/jid.2014.529",
    "journal": "The Journal of investigative dermatology",
    "authors": [
      "Agarwal P",
      "Rashighi M",
      "Essien K"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "clinical trials for cardiovascular disease, arthritis, stroke, atherosclerosis, cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "multidrug-resistant, MRSA, VRSA, linezolid-resistant, mupirocin-resistant"
      },
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Ebselen showed potent bactericidal activity against multidrug-resistant S. aureus, including MRSA and VRSA, with MICs ranging from 0.125 to 0.5 \u03bcg/ml."
      },
      {
        "drug": "ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen significantly suppressed toxin production (PVL and \u03b1-hemolysin) in MRSA USA300."
      },
      {
        "drug": "ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Ebselen significantly reduced established biofilms of S. aureus and S. epidermidis, decreasing biofilm mass by approximately 60% at 2 \u03bcg/ml."
      },
      {
        "drug": "ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Topical ebselen (1% and 2%) significantly reduced bacterial load in a mouse model of MRSA skin infection."
      },
      {
        "drug": "ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen acted synergistically with topical antimicrobials such as mupirocin, fusidic acid, retapamulin, and daptomycin against S. aureus."
      }
    ],
    "mechanism": "Inhibition of bacterial protein synthesis, with secondary effects on DNA, RNA, and lipid synthesis, and suppression of toxin production.",
    "relevance_score": 5,
    "paper_idx": 9,
    "pmid": "25897961",
    "title": "Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0124595",
    "journal": "PloS one",
    "authors": [
      "Rajamuthiah R",
      "Fuchs B",
      "Conery A"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "gold(I) complex",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "complex 4",
        "drug_class": "gold(I)-alkynyl chromone complex",
        "approved_for": "none"
      },
      {
        "name": "complex 5",
        "drug_class": "gold(I)-alkynyl chromone complex",
        "approved_for": "none"
      },
      {
        "name": "complex 6",
        "drug_class": "gold(I)-alkynyl chromone flavone complex",
        "approved_for": "none"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MSSA/MRSA"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "susceptible"
      }
    ],
    "findings": [
      {
        "drug": "complex 4",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Complex 4 exhibited bactericidal activity against MSSA and MRSA strains."
      },
      {
        "drug": "complex 5",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Complex 5 showed bactericidal activity against MSSA and MRSA strains."
      },
      {
        "drug": "complex 6",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Complex 6 demonstrated bactericidal activity against MSSA and MRSA strains."
      }
    ],
    "mechanism": "Inhibition of thioredoxin reductase (TrxR), DNA damage, caspase activation, and cell cycle disturbance in cancer cells; bactericidal activity likely through disruption of bacterial redox systems.",
    "relevance_score": 4,
    "paper_idx": 10,
    "pmid": "26020797",
    "title": "Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0128098",
    "journal": "PloS one",
    "authors": [
      "Graziano T",
      "Cuzzullin M",
      "Franco G"
    ]
  },
  {
    "drugs": [
      {
        "name": "monensin",
        "drug_class": "antibiotic (ionophore monovalent cation ionophore)",
        "approved_for": "antibacterial (original indication)"
      },
      {
        "name": "erlotinib",
        "drug_class": "EGFR tyrosine kinase inhibitor",
        "approved_for": "non-small cell lung cancer, pancreatic cancer, others"
      },
      {
        "name": "genestein",
        "drug_class": "tyrosine kinase inhibitor (plant-derived isoflavone)",
        "approved_for": "not approved; used as dietary supplement"
      },
      {
        "name": "AG-490",
        "drug_class": "JAK2/EGFR inhibitor",
        "approved_for": "not approved; experimental"
      },
      {
        "name": "oxaliplatin",
        "drug_class": "platinum-based chemotherapeutic agent",
        "approved_for": "colorectal cancer, gastric cancer, others"
      }
    ],
    "pathogens": [
      {
        "name": "human ovarian cancer cells",
        "resistance_profile": "chemotherapy-resistant ovarian cancer"
      }
    ],
    "findings": [
      {
        "drug": "monensin",
        "pathogen": "human ovarian cancer cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Monensin inhibits proliferation, migration, induces apoptosis, and suppresses multiple cancer-related pathways in ovarian cancer cells."
      },
      {
        "drug": "monensin",
        "pathogen": "human ovarian cancer cells",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.3,
        "key_result": "Monensin synergizes with EGFR inhibitors and oxaliplatin to enhance anti-proliferative effects and induce apoptosis."
      }
    ],
    "mechanism": "Monensin inhibits EGFR expression and downstream signaling pathways including Elk1/SRF, AP1, NF\u03baB, and STAT, leading to reduced proliferation and increased apoptosis in ovarian cancer cells.",
    "relevance_score": 2,
    "paper_idx": 11,
    "pmid": "26111644",
    "title": "Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.",
    "year": "2015",
    "doi": "10.1038/srep11596",
    "journal": "Scientific reports",
    "authors": [
      "Thangamani S",
      "Younis W",
      "Seleem M"
    ]
  },
  {
    "drugs": [
      {
        "name": "ciclopirox",
        "drug_class": "antifungal agent",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "ciclopirox",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox inhibits growth of multidrug-resistant Acinetobacter baumannii at 5-15 \u00b5g/ml."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox inhibits growth of multidrug-resistant Escherichia coli at 5-15 \u00b5g/ml."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox inhibits growth of multidrug-resistant Klebsiella pneumoniae at 5-15 \u00b5g/ml."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciclopirox reduces growth of Pseudomonas aeruginosa clinical isolates, requiring higher concentrations for complete inhibition."
      }
    ],
    "mechanism": "Ciclopirox affects galactose metabolism and lipopolysaccharide (LPS) biosynthesis pathways, likely through iron chelation and interference with UDP-galactose/UDP-glucose utilization.",
    "relevance_score": 5,
    "paper_idx": 12,
    "pmid": "26222252",
    "title": "Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.",
    "year": "2015",
    "doi": "10.1371/journal.pone.0133877",
    "journal": "PloS one",
    "authors": [
      "Thangamani S",
      "Younis W",
      "Seleem M"
    ]
  },
  {
    "drugs": [
      {
        "name": "polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "bacterial infections, last-resort for MDR Gram-negative bacteria"
      },
      {
        "name": "closantel",
        "drug_class": "anthelmintic",
        "approved_for": "parasitic worm infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, polymyxin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "polymyxin B",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Polymyxin B alone was effective against susceptible strains but ineffective against resistant strains."
      },
      {
        "drug": "closantel",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Closantel alone was inactive against most isolates but showed synergistic activity when combined with polymyxin B against resistant strains."
      },
      {
        "drug": "polymyxin B + closantel",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination successfully inhibited development of resistance and achieved synergistic killing against resistant isolates."
      }
    ],
    "mechanism": "The combination enhances bacterial killing and inhibits resistance development, possibly through synergistic interactions that improve efficacy of polymyxin B against resistant strains.",
    "relevance_score": 4,
    "paper_idx": 13,
    "pmid": "26284040",
    "title": "Repurposing celecoxib as a topical antimicrobial agent.",
    "year": "2015",
    "doi": "10.3389/fmicb.2015.00750",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Thangamani S",
      "Younis W",
      "Seleem M"
    ]
  },
  {
    "drugs": [
      {
        "name": "celecoxib",
        "drug_class": "non-steroidal anti-inflammatory drug (NSAID)",
        "approved_for": "pain, fever, inflammation"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Streptococcus spp.",
        "resistance_profile": null
      },
      {
        "name": "Listeria spp.",
        "resistance_profile": null
      },
      {
        "name": "Bacillus spp.",
        "resistance_profile": null
      },
      {
        "name": "Mycobacterium spp.",
        "resistance_profile": null
      },
      {
        "name": "Acinetobacter spp.",
        "resistance_profile": null
      },
      {
        "name": "Pseudomonas spp.",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "celecoxib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Celecoxib exhibits broad-spectrum antimicrobial activity against Gram-positive pathogens including MRSA."
      },
      {
        "drug": "celecoxib",
        "pathogen": "Acinetobacter spp.",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Celecoxib is active against Acinetobacter when outer membrane permeability is artificially increased."
      },
      {
        "drug": "celecoxib",
        "pathogen": "Pseudomonas spp.",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Celecoxib is active against Pseudomonas when outer membrane permeability is artificially increased."
      },
      {
        "drug": "celecoxib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Celecoxib inhibits multidrug efflux pumps in S. aureus, increasing bacterial sensitivity to antibiotics."
      },
      {
        "drug": "celecoxib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Celecoxib exhibits synergy with conventional antimicrobials against S. aureus."
      },
      {
        "drug": "celecoxib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Topical celecoxib reduces bacterial load in MRSA skin infection models."
      }
    ],
    "mechanism": "Inhibition of RNA, DNA, and protein synthesis, and inhibition of bacterial efflux pumps.",
    "relevance_score": 4,
    "paper_idx": 14,
    "pmid": "26528965",
    "title": "Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones.",
    "year": "2015",
    "doi": "10.3390/molecules201119647",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Hikisz P",
      "Szczupak \u0141",
      "Koceva-Chy\u0142a A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thioridazine",
        "drug_class": "Phenothiazine derivative",
        "approved_for": "Antipsychotic"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium avium complex (MAC)",
        "resistance_profile": "not specified"
      },
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Thioridazine",
        "pathogen": "Mycobacterium avium complex (MAC)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine effectively kills MAC in vitro with high intracellular concentrations and prevents resistance at high bacterial burdens."
      },
      {
        "drug": "Thioridazine",
        "pathogen": "Mycobacterium avium complex (MAC)",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine inhibits efflux pumps, potentially enhancing antimicrobial activity against MAC."
      },
      {
        "drug": "Thioridazine",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine shows antimicrobial activity against MRSA in vitro, with efficacy affected by protein binding."
      }
    ],
    "mechanism": "Inhibition of the electron transport chain and efflux pump inhibition, leading to bacterial killing.",
    "relevance_score": 4,
    "paper_idx": 15,
    "pmid": "26553420",
    "title": "Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.",
    "year": "2015",
    "doi": "10.1038/srep16407",
    "journal": "Scientific reports",
    "authors": [
      "Thangamani S",
      "Mohammad H",
      "Abushahba M"
    ]
  },
  {
    "drugs": [
      {
        "name": "clemastine",
        "drug_class": "antihistamine",
        "approved_for": "allergy"
      },
      {
        "name": "fluoxetine",
        "drug_class": "selective serotonin reuptake inhibitor",
        "approved_for": "depression"
      },
      {
        "name": "pyrimethamine",
        "drug_class": "antifolate",
        "approved_for": "malaria"
      },
      {
        "name": "posaconazole",
        "drug_class": "azole antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "amlodipine",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension"
      },
      {
        "name": "benznidazole",
        "drug_class": "nitroimidazole",
        "approved_for": "Chagas disease"
      }
    ],
    "pathogens": [
      {
        "name": "Trypanosoma cruzi",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "clemastine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clemastine showed potent activity with an EC50 of 0.4 \u00b5M against T. cruzi."
      },
      {
        "drug": "fluoxetine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluoxetine exhibited an EC50 of 4.4 \u00b5M against T. cruzi."
      },
      {
        "drug": "pyrimethamine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pyrimethamine had an EC50 of 3.8 \u00b5M against T. cruzi."
      },
      {
        "drug": "posaconazole",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Posaconazole demonstrated activity in combination with other drugs, with synergy observed in vitro."
      },
      {
        "drug": "amlodipine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amlodipine combined with posaconazole showed enhanced efficacy in lowering parasitemia in mice."
      },
      {
        "drug": "benznidazole",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Benznidazole is the current standard treatment for Chagas disease."
      }
    ],
    "mechanism": "The proposed mechanisms involve inhibition of parasite growth pathways, with some drugs potentially affecting ergosterol biosynthesis, serotonin pathways, or calcium channels, and synergistic effects likely due to combined targeting of different parasite survival mechanisms.",
    "relevance_score": 4,
    "paper_idx": 16,
    "pmid": "26639992",
    "title": "Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells.",
    "year": "2015",
    "doi": "10.1038/srep17523",
    "journal": "Scientific reports",
    "authors": [
      "Deng Y",
      "Zhang J",
      "Wang Z"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"ciprofloxacin\",\n      \"drug_class\": \"fluoroquinolone\",\n      \"approved_for\": \"bacterial infections\"\n    },\n    {\n      \"name\": \"ofloxacin\",\n      \"drug_class\": \"flu",
    "paper_idx": 17,
    "pmid": "26669752",
    "title": "Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.",
    "year": "2016",
    "doi": "10.1038/ja.2015.127",
    "journal": "The Journal of antibiotics",
    "authors": [
      "Tran T",
      "Cheah S",
      "Yu H"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"simvastatin\",\n      \"drug_class\": \"antihyperlipidemic\",\n      \"approved_for\": \"hyperlipidemia\"\n    }\n  ],\n  \"pathogens\": [\n    {\n      \"name\": \"Methicillin-resistan",
    "paper_idx": 18,
    "pmid": "26776881",
    "title": "Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.",
    "year": "2016",
    "doi": "10.1038/srep19525",
    "journal": "Scientific reports",
    "authors": [
      "D\u00edez-Mart\u00ednez R",
      "Garc\u00eda-Fern\u00e1ndez E",
      "Manzano M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"Auranofin\",\n      \"drug_class\": \"anti-rheumatic agent\",\n      \"approved_for\": \"rheumatoid arthritis\"\n    }\n  ],\n  \"pathogens\": [\n    {\n      \"name\": \"Methicillin-re",
    "paper_idx": 19,
    "pmid": "26936660",
    "title": "Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens.",
    "year": "2016",
    "doi": "10.1038/srep22571",
    "journal": "Scientific reports",
    "authors": [
      "Thangamani S",
      "Mohammad H",
      "Abushahba M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"chlorpromazine\",\n      \"drug_class\": \"phenothiazine/neuroleptic\",\n      \"approved_for\": \"antipsychotic\"\n    },\n    {\n      \"name\": \"promazine\",\n      \"drug_class\": ",
    "paper_idx": 20,
    "pmid": "27029292",
    "title": "Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria.",
    "year": "2013",
    "doi": "10.3390/antibiotics2010058",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Dastidar S",
      "Kristiansen J",
      "Molnar J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold(I) compound",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Streptococcus pneumoniae",
        "resistance_profile": "multiresistant"
      },
      {
        "name": "Streptococcus pyogenes",
        "resistance_profile": "not specified, but biofilm-forming strains tested"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Auranofin-loaded PLGA nanoparticles showed strong bactericidal activity, practically sterilizing multiresistant pneumococcal strains at 0.25 \u03bcM."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Auranofin-NPs decreased bacterial populations in biofilms by about 4 logs more than free auranofin."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pyogenes",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Auranofin-loaded NPs killed S. pyogenes strains more effectively than free auranofin, with a decrease of 1-2 logs."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pyogenes",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Auranofin-NPs at 0.25 \u03bcM killed about 4 logs of biofilm-grown S. pyogenes cells."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "In zebrafish embryos, treatment with auranofin-NPs at 0.5 \u03bcM resulted in 100% survival against pneumococcal infection, outperforming free auranofin."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Auranofin-NPs provided about 15% greater protection than free auranofin in zebrafish embryo infection model."
      }
    ],
    "mechanism": "likely involves sustained release of auranofin from PLGA nanoparticles, enhancing stability and delivery to bacterial cells, leading to bactericidal activity.",
    "relevance_score": 4,
    "paper_idx": 21,
    "pmid": "27216055",
    "title": "Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.",
    "year": "2016",
    "doi": "10.1128/AAC.02985-15",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Deshpande D",
      "Srivastava S",
      "Musuka S"
    ]
  },
  {
    "drugs": [
      {
        "name": "fluoxetine",
        "drug_class": "selective serotonin re-uptake inhibitor",
        "approved_for": "depression"
      },
      {
        "name": "thioridazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      }
    ],
    "pathogens": [
      {
        "name": "Proteus mirabilis",
        "resistance_profile": "efflux-mediated biofilm formation"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "biofilm formation"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "biofilm formation"
      }
    ],
    "findings": [
      {
        "drug": "fluoxetine",
        "pathogen": "Proteus mirabilis",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro|computational",
        "mic_ug_ml": 256,
        "fici": null,
        "key_result": "Fluoxetine inhibits efflux and significantly reduces crystalline biofilm formation in P. mirabilis."
      },
      {
        "drug": "thioridazine",
        "pathogen": "Proteus mirabilis",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro|computational",
        "mic_ug_ml": 800,
        "fici": null,
        "key_result": "Thioridazine inhibits efflux, reduces crystalline biofilm formation, and extends catheter blockage time in P. mirabilis."
      },
      {
        "drug": "thioridazine",
        "pathogen": "Escherichia coli",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine inhibits biofilm formation in E. coli."
      },
      {
        "drug": "thioridazine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine inhibits biofilm formation in P. aeruginosa."
      }
    ],
    "mechanism": "Inhibition of the Bcr/CflA efflux pump, disrupting biofilm-associated crystal formation and bacterial motility.",
    "relevance_score": 5,
    "paper_idx": 22,
    "pmid": "28085074",
    "title": "The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.",
    "year": "2017",
    "doi": "10.3390/molecules22010114",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Laudy A",
      "Kuli\u0144ska E",
      "Tyski S"
    ]
  },
  {
    "drugs": [
      {
        "name": "amitriptyline",
        "drug_class": "tricyclic antidepressant",
        "approved_for": "depression"
      },
      {
        "name": "alendronate",
        "drug_class": "bisphosphonate",
        "approved_for": "osteoporosis"
      },
      {
        "name": "carboplatin",
        "drug_class": "platinum-based chemotherapeutic agent",
        "approved_for": "cancer"
      },
      {
        "name": "nicergoline",
        "drug_class": "ergoline derivative",
        "approved_for": "cerebral insufficiency"
      },
      {
        "name": "ticlopidine",
        "drug_class": "antiplatelet agent",
        "approved_for": "prevent stroke"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "efflux pump-mediated resistance"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "efflux pump-mediated resistance"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug resistance including efflux pumps"
      },
      {
        "name": "Stenotrophomonas maltophilia",
        "resistance_profile": "efflux pump-mediated resistance"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug resistance including efflux pumps"
      }
    ],
    "findings": [
      {
        "drug": "amitriptyline",
        "pathogen": "all studied species",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 100,
        "fici": null,
        "key_result": "Amitriptyline showed the highest direct antibacterial activity with MICs ranging 100-800 mg/L against all studied species."
      },
      {
        "drug": "alendronate",
        "pathogen": "some clinical strains of P. aeruginosa and S. maltophilia",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 200,
        "fici": null,
        "key_result": "Alendronate was active against clinical strains of P. aeruginosa and S. maltophilia, with MICs \u2264200 mg/L in most strains."
      },
      {
        "drug": "carboplatin",
        "pathogen": "P. aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carboplatin was active only against clinical strains of P. aeruginosa."
      },
      {
        "drug": "ticlopidine",
        "pathogen": "all studied species",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 25,
        "fici": null,
        "key_result": "Ticlopidine's MIC decreased significantly in the presence of efflux pump inhibitor, indicating efflux pump substrate activity."
      },
      {
        "drug": "nicergoline",
        "pathogen": "E. coli, K. pneumoniae, A. baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 50,
        "fici": null,
        "key_result": "Nicergoline MICs decreased from >800 mg/L to 50-200 mg/L with efflux pump inhibitor, indicating efflux pump substrate activity."
      }
    ],
    "mechanism": "efflux pump substrate activity leading to decreased intracellular drug concentration, which can be reversed by efflux pump inhibitors.",
    "relevance_score": 4,
    "paper_idx": 23,
    "pmid": "28606995",
    "title": "Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.",
    "year": "2017",
    "doi": "10.15252/emmm.201707661",
    "journal": "EMBO molecular medicine",
    "authors": [
      "Zou L",
      "Lu J",
      "Wang J"
    ]
  },
  {
    "drugs": [
      {
        "name": "meropenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "cefoperazone",
        "drug_class": "cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "captopril",
        "drug_class": "ACE inhibitor",
        "approved_for": "hypertension"
      },
      {
        "name": "thiosalicylic acid",
        "drug_class": "salicylate",
        "approved_for": "analgesic, anti-inflammatory"
      },
      {
        "name": "S-mandelic acid",
        "drug_class": "aromatic acid",
        "approved_for": "not approved for clinical use"
      },
      {
        "name": "l-phenylalanine",
        "drug_class": "amino acid",
        "approved_for": "dietary supplement"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "metallo-\u03b2-lactamase (IMP, NDM, VIM) producing strains"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "metallo-\u03b2-lactamase (VIM, IMP) producing strains"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "NDM-1 producing strains"
      }
    ],
    "findings": [
      {
        "drug": "thiomandelic acid 3",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.07,
        "key_result": "Thiomandelic acid 3 significantly lowered the MIC of meropenem against IMP-producing Klebsiella pneumoniae with strong synergy (FIC \u22640.07)."
      },
      {
        "drug": "2-mercapto-3-phenylpropionic acid 4",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.13,
        "key_result": "Compound 4 significantly potentiated meropenem activity against IMP-producing Klebsiella pneumoniae with strong synergy (FIC \u22640.13)."
      },
      {
        "drug": "captopril 1",
        "pathogen": "various MBL-producing strains",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Captopril showed moderate to weak synergy at 64 \u03bcg/mL with some MBL-producing strains."
      },
      {
        "drug": "thiosalicylic acid 2",
        "pathogen": "various MBL-producing strains",
        "activity_type": "none",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thiosalicylic acid 2 displayed no appreciable synergy with meropenem."
      }
    ],
    "mechanism": "zinc chelation and inhibition of metallo-\u03b2-lactamases by thiol groups",
    "relevance_score": 4,
    "paper_idx": 24,
    "pmid": "28820574",
    "title": "Thiol-Containing Metallo-\u03b2-Lactamase Inhibitors Resensitize Resistant Gram-Negative Bacteria to Meropenem.",
    "year": "2017",
    "doi": "10.1021/acsinfecdis.7b00094",
    "journal": "ACS infectious diseases",
    "authors": [
      "Tehrani K",
      "Martin N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Glatiramer Acetate",
        "drug_class": "immunomodulatory agent",
        "approved_for": "multiple sclerosis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "various resistance profiles including MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "clinical MDR isolates"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "various, including MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Glatiramer Acetate",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 31,
        "fici": null,
        "key_result": "Glatiramer acetate effectively kills P. aeruginosa within minutes, showing higher activity than LL-37."
      },
      {
        "drug": "Glatiramer Acetate",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 500,
        "fici": null,
        "key_result": "Glatiramer acetate inhibits E. coli growth with a MIC of 500 \u00b5g/ml, demonstrating bactericidal activity."
      },
      {
        "drug": "Glatiramer Acetate",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Glatiramer acetate demonstrated bactericidal effects on clinical MDR isolates of A. baumannii."
      },
      {
        "drug": "Glatiramer Acetate",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 500,
        "fici": null,
        "key_result": "Glatiramer acetate is less effective against S. aureus, with limited bactericidal activity observed."
      }
    ],
    "mechanism": "Glatiramer acetate disrupts bacterial membranes through its cationic and amphiphilic properties, leading to rapid bacterial cell death.",
    "relevance_score": 4,
    "paper_idx": 25,
    "pmid": "28873428",
    "title": "Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.",
    "year": "2017",
    "doi": "10.1371/journal.pone.0183457",
    "journal": "PloS one",
    "authors": [
      "Ogunniyi A",
      "Khazandi M",
      "Stevens A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Meloxicam",
        "drug_class": "NSAID",
        "approved_for": "anti-inflammatory"
      },
      {
        "name": "Tetracycline",
        "drug_class": "Tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Gentamicin",
        "drug_class": "Aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Tobramycin",
        "drug_class": "Aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ciprofloxacin",
        "drug_class": "Fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ceftriaxone",
        "drug_class": "Cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ofloxacin",
        "drug_class": "Fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Norfloxacin",
        "drug_class": "Fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ceftazidime",
        "drug_class": "Cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "DNase",
        "drug_class": "Enzyme",
        "approved_for": "mucolytic therapy"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "biofilm-associated antimicrobial resistance"
      }
    ],
    "findings": [
      {
        "drug": "Meloxicam",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Meloxicam significantly inhibits P. aeruginosa biofilm formation and enhances the efficacy of various antibiotics at sub-MIC levels."
      }
    ],
    "mechanism": "Inhibition of biofilm formation, motility, extracellular matrix production, and quorum sensing gene expression, possibly through interference with QS signaling pathways.",
    "relevance_score": 4,
    "paper_idx": 26,
    "pmid": "28939900",
    "title": "Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus mirabilis.",
    "year": "2017",
    "doi": "10.1038/s41598-017-12445-w",
    "journal": "Scientific reports",
    "authors": [
      "Nzakizwanayo J",
      "Scavone P",
      "Jamshidi S"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "selenium-containing compound / thioredoxin reductase inhibitor",
        "approved_for": "antioxidant / neuroprotective"
      },
      {
        "name": "silver (Ag+)",
        "drug_class": "metal ion / antimicrobial agent",
        "approved_for": "wound dressings / topical antimicrobial"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterobacter cloacae",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "silver (Ag+)",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 42,
        "fici": null,
        "key_result": "Silver inhibits E. coli growth with MIC of 42 \u03bcM, which is significantly reduced to 4.2 \u03bcM in the presence of ebselen."
      },
      {
        "drug": "ebselen",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen enhances the antibacterial activity of silver, reducing its MIC and exhibiting synergistic effects."
      },
      {
        "drug": "silver (Ag+)",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver combined with ebselen shows bactericidal activity against MDR K. pneumoniae strains."
      },
      {
        "drug": "silver (Ag+)",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver with ebselen is effective against drug-resistant A. baumannii strains."
      },
      {
        "drug": "silver (Ag+)",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver combined with ebselen exhibits bactericidal effects on MDR P. aeruginosa."
      },
      {
        "drug": "silver (Ag+)",
        "pathogen": "Enterobacter cloacae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver with ebselen shows synergistic bactericidal activity against MDR E. cloacae."
      },
      {
        "drug": "ebselen",
        "pathogen": "multiple GSH-positive bacteria",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen inhibits bacterial thioredoxin reductase, disrupting redox systems and enhancing silver's efficacy."
      }
    ],
    "mechanism": "Silver ions inhibit bacterial thioredoxin and thioredoxin reductase activities, leading to depletion of GSH, increased ROS, and disruption of essential redox systems. Ebselen acts as a competitive inhibitor of bacterial TrxR, further impairing redox balance. The combination causes rapid bacterial cell death through redox system disruption and oxidative stress.",
    "relevance_score": 5,
    "paper_idx": 27,
    "pmid": "28948099",
    "title": "Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens.",
    "year": "2017",
    "doi": "10.7717/peerj.3765",
    "journal": "PeerJ",
    "authors": [
      "Naz S",
      "Ngo T",
      "Farooq U"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "rheumatoid arthritis agent (gold-containing compound)",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "vancomycin-resistant enterococci (VRE)",
        "resistance_profile": "vancomycin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "VRE",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Auranofin exhibits potent antimicrobial activity against VRE with an MIC of 1 \u03bcg/mL and significantly reduces VRE burden in mouse gut models."
      }
    ],
    "mechanism": "not explicitly proposed in the paper",
    "relevance_score": 4,
    "paper_idx": 28,
    "pmid": "29085751",
    "title": "Statins: antimicrobial resistance breakers or makers?",
    "year": "2017",
    "doi": "10.7717/peerj.3952",
    "journal": "PeerJ",
    "authors": [
      "Ko H",
      "Lareu R",
      "Dix B"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterobacter spp.",
        "resistance_profile": "MDR"
      },
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR/XDR"
      }
    ],
    "findings": [
      {
        "drug": null,
        "pathogen": "Enterococcus faecium",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "High conservation of drug binding pockets (up to 100%) among ESKAPE pathogens suggests potential for cross-species inhibitor activity."
      },
      {
        "drug": null,
        "pathogen": "Staphylococcus aureus",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Binding pockets of key enzymes are highly conserved, indicating possible broad-spectrum activity of inhibitors targeting these sites."
      },
      {
        "drug": null,
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Conservation of enzyme binding pockets supports potential for drug repurposing across species."
      },
      {
        "drug": null,
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "High sequence identity in binding pockets suggests inhibitors may be effective across multiple pathogens."
      },
      {
        "drug": null,
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Conserved binding sites among species indicate potential for broad-spectrum inhibitors."
      },
      {
        "drug": null,
        "pathogen": "Enterobacter spp.",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Binding pocket conservation supports drug repurposing strategies."
      },
      {
        "drug": null,
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "none",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Highly conserved enzyme pockets suggest inhibitors could target multiple bacterial species."
      }
    ],
    "mechanism": "Conservation of enzyme binding pockets across species indicates that inhibitors designed for one species may effectively bind and inhibit orthologous enzymes in others.",
    "relevance_score": 4,
    "paper_idx": 29,
    "pmid": "29142299",
    "title": "The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria.",
    "year": "2017",
    "doi": "10.1038/s41598-017-15969-3",
    "journal": "Scientific reports",
    "authors": [
      "Christiansen S",
      "Murphy R",
      "Juul-Madsen K"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"NCL195\",\n      \"drug_class\": \"antibacterial agent (analogs of robenidine)\",\n      \"approved_for\": \"none (experimental compound)\"\n    },\n    {\n      \"name\": \"Robenid",
    "paper_idx": 30,
    "pmid": "29178590",
    "title": "Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa.",
    "year": "2018",
    "doi": "10.1002/mbo3.545",
    "journal": "MicrobiologyOpen",
    "authors": [
      "She P",
      "Wang Y",
      "Luo Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "erythromycin",
        "drug_class": "macrolide antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "carglumic acid",
        "drug_class": "amino acid analog",
        "approved_for": "hyperammonemia"
      },
      {
        "name": "capecitabine",
        "drug_class": "antimetabolite chemotherapeutic agent",
        "approved_for": "colorectal cancer, breast cancer"
      },
      {
        "name": "ivermectin",
        "drug_class": "antiparasitic agent",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "erythromycin",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Erythromycin extended rotifer lifespan by 8-42% without significant effect on reproduction."
      },
      {
        "drug": "carglumic acid",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Carglumic acid extended rotifer lifespan by 8-42% without significant effect on reproduction."
      },
      {
        "drug": "capecitabine",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 3,
        "fici": null,
        "key_result": "Capecitabine extended rotifer lifespan by 8-42% without significant effect on reproduction."
      },
      {
        "drug": "ivermectin",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Ivermectin extended rotifer lifespan by 8-42% without significant effect on reproduction."
      }
    ],
    "mechanism": "not explicitly proposed in the paper; drugs may influence aging-related pathways through off-target effects or modulation of metabolic processes.",
    "relevance_score": 1,
    "paper_idx": 31,
    "pmid": "29298353",
    "title": "Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity.",
    "year": "2018",
    "doi": "10.1371/journal.pone.0189950",
    "journal": "PloS one",
    "authors": [
      "Nehme H",
      "Saulnier P",
      "Ramadan A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Verapamil",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension"
      },
      {
        "name": "Bedaquiline",
        "drug_class": "ATP synthase inhibitor",
        "approved_for": "multidrug-resistant tuberculosis"
      },
      {
        "name": "Clofazimine",
        "drug_class": "riminophenazine",
        "approved_for": "leprosy"
      },
      {
        "name": "Rifampin",
        "drug_class": "RNA polymerase inhibitor",
        "approved_for": "tuberculosis"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Verapamil",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 512,
        "fici": null,
        "key_result": "Verapamil synergizes with anti-TB drugs such as bedaquiline and clofazimine, but this effect is not due to increased intrabacterial drug accumulation."
      },
      {
        "drug": "Verapamil",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 512,
        "fici": 0.25,
        "key_result": "Verapamil increases intracellular ethidium bromide accumulation, indicating efflux pump inhibition or membrane energetics disruption."
      },
      {
        "drug": "Verapamil",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "anti_biofilm|direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 512,
        "fici": null,
        "key_result": "Verapamil exhibits bactericidal activity against nonreplicating and starved M. tuberculosis, indicating intrinsic antimycobacterial activity."
      }
    ],
    "mechanism": "Verapamil disrupts membrane energetics of M. tuberculosis, causing membrane depolarization and impairing membrane potential, which affects bacterial viability and potentiates anti-TB drugs.",
    "relevance_score": 5,
    "paper_idx": 32,
    "pmid": "29340835",
    "title": "Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers.",
    "year": "2018",
    "doi": "10.1007/s10522-018-9745-9",
    "journal": "Biogerontology",
    "authors": [
      "Snell T",
      "Johnston R",
      "Matthews A"
    ]
  },
  {
    "drugs": [
      {
        "name": "lacidipine",
        "drug_class": "dihydropyridine voltage-gated Ca2+ channel antagonist",
        "approved_for": "hypertension"
      },
      {
        "name": "phenothrin",
        "drug_class": "synthetic pyrethroid insecticide",
        "approved_for": "insecticide use"
      }
    ],
    "pathogens": [
      {
        "name": "Lassa virus",
        "resistance_profile": "none (no approved therapy)"
      },
      {
        "name": "Mopeia virus",
        "resistance_profile": "none (no approved therapy)"
      },
      {
        "name": "Guanarito virus",
        "resistance_profile": "none (no approved therapy)"
      }
    ],
    "findings": [
      {
        "drug": "lacidipine",
        "pathogen": "Lassa virus",
        "activity_type": "entry_inhibitor|efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Lacidipine inhibits LASV entry by blocking low-pH-induced membrane fusion and exhibits virucidal effects."
      },
      {
        "drug": "phenothrin",
        "pathogen": "Lassa virus",
        "activity_type": "entry_inhibitor|efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Phenothrin inhibits LASV entry by blocking membrane fusion, but does not exhibit virucidal activity."
      }
    ],
    "mechanism": "Lacidipine and phenothrin inhibit LASV entry by blocking low-pH-induced membrane fusion; lacidipine also exhibits virucidal effects likely through membrane partitioning and binding to GPC.",
    "relevance_score": 5,
    "paper_idx": 33,
    "pmid": "29463541",
    "title": "Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.",
    "year": "2018",
    "doi": "10.1128/AAC.02107-17",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Chen C",
      "Gardete S",
      "Jansen R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thioridazine",
        "drug_class": "phenothiazine antipsychotic",
        "approved_for": "schizophrenia and psychosis"
      },
      {
        "name": "Dicloxacillin",
        "drug_class": "\u03b2-lactam antibiotic",
        "approved_for": "staphylococcal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Thioridazine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine potentiates the effect of \u03b2-lactam antibiotics against MRSA and resistance involves mutations in the cls gene affecting membrane lipid cardiolipin."
      }
    ],
    "mechanism": "Thioridazine intercalates into bacterial membranes, depolarizes the plasma membrane, and resistance involves mutations in the cardiolipin synthase gene, suggesting membrane lipid composition influences its activity.",
    "relevance_score": 4,
    "paper_idx": 34,
    "pmid": "29706941",
    "title": "Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.",
    "year": "2018",
    "doi": "10.3389/fmicb.2018.00721",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Tran T",
      "Wang J",
      "Doi Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "bacterial infections caused by multidrug-resistant Gram-negative bacteria"
      },
      {
        "name": "mitotane",
        "drug_class": "antineoplastic agent",
        "approved_for": "adrenocortical carcinoma"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "polymyxin-resistant MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "polymyxin-resistant MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "NDM-producing, polymyxin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "polymyxin B",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxin B combined with mitotane enhances bacterial killing against resistant strains and prevents resistance emergence."
      },
      {
        "drug": "polymyxin B",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination therapy improves bacterial killing and inhibits regrowth in resistant P. aeruginosa strains."
      },
      {
        "drug": "polymyxin B",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Synergistic effect observed with mitotane against NDM-producing resistant K. pneumoniae."
      },
      {
        "drug": "mitotane",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mitotane enhances polymyxin B activity, likely by permeabilizing bacterial outer membrane allowing entry."
      },
      {
        "drug": "mitotane",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Synergistic killing with polymyxin B suggests mitotane acts as an adjuvant to improve efficacy."
      },
      {
        "drug": "mitotane",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination prevents regrowth and resistance in resistant K. pneumoniae strains."
      }
    ],
    "mechanism": "Polymyxin B permeabilizes the outer membrane of Gram-negative bacteria, facilitating mitotane entry into bacterial cells where it exerts antimicrobial effects, potentially affecting cell division.",
    "relevance_score": 4,
    "paper_idx": 35,
    "pmid": "29740519",
    "title": "Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis.",
    "year": "2018",
    "doi": "10.7717/peerj.4761",
    "journal": "PeerJ",
    "authors": [
      "Truong M",
      "Monahan L",
      "Carter D"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\"name\": \"chlorpromazine\", \"drug_class\": \"phenothiazine\", \"approved_for\": \"antipsychotic\"},\n    {\"name\": \"thioridazine\", \"drug_class\": \"phenothiazine\", \"approved_for\": \"antipsychoti",
    "paper_idx": 36,
    "pmid": "29742128",
    "title": "Tetracyclines function as dual-action light-activated antibiotics.",
    "year": "2018",
    "doi": "10.1371/journal.pone.0196485",
    "journal": "PloS one",
    "authors": [
      "He Y",
      "Huang Y",
      "Xi L"
    ]
  },
  {
    "drugs": [
      {
        "name": "flubendazole",
        "drug_class": "anthelminthic",
        "approved_for": "helminth infections"
      },
      {
        "name": "nifedipine",
        "drug_class": "L-type calcium channel blocker",
        "approved_for": "hypertension, angina"
      },
      {
        "name": "nisoldipine",
        "drug_class": "L-type calcium channel blocker",
        "approved_for": "hypertension"
      },
      {
        "name": "felodipine",
        "drug_class": "L-type calcium channel blocker",
        "approved_for": "hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "Cryptococcus deuterogattii",
        "resistance_profile": "none specified"
      },
      {
        "name": "Cryptococcus neoformans",
        "resistance_profile": "fluconazole-resistant isolates"
      },
      {
        "name": "Candida",
        "resistance_profile": "not specified"
      },
      {
        "name": "Saccharomyces",
        "resistance_profile": "not specified"
      },
      {
        "name": "Aspergillus",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "flubendazole",
        "pathogen": "Cryptococcus deuterogattii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.039,
        "fici": null,
        "key_result": "Flubendazole was very active against all pathogenic Cryptococcus species, including fluconazole-resistant isolates."
      },
      {
        "drug": "nifedipine",
        "pathogen": "Cryptococcus deuterogattii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nifedipine inhibited Cryptococcus and was also effective against Candida, Saccharomyces, and Aspergillus."
      },
      {
        "drug": "nisoldipine",
        "pathogen": "Cryptococcus deuterogattii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nisoldipine inhibited Cryptococcus and was effective against Candida, Saccharomyces, and Aspergillus."
      },
      {
        "drug": "felodipine",
        "pathogen": "Cryptococcus deuterogattii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Felodipine inhibited Cryptococcus species."
      }
    ],
    "mechanism": "calcium channel blockade and potential disruption of fungal cellular processes",
    "relevance_score": 4,
    "paper_idx": 37,
    "pmid": "29844350",
    "title": "Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.",
    "year": "2018",
    "doi": "10.1038/s41598-018-26674-0",
    "journal": "Scientific reports",
    "authors": [
      "AbdelKhalek A",
      "Abutaleb N",
      "Elmagarmid K"
    ]
  },
  {
    "drugs": [
      {
        "name": "cinnarizine",
        "drug_class": "antihistamine/vasodilator",
        "approved_for": "motion sickness and balance disorder"
      },
      {
        "name": "clofazimine",
        "drug_class": "antibiotic (riminophenazine)",
        "approved_for": "leprosy"
      },
      {
        "name": "meclizine",
        "drug_class": "antihistamine",
        "approved_for": "motion sickness and vertigo"
      },
      {
        "name": "butoconazole",
        "drug_class": "antifungal",
        "approved_for": "vaginal candidiasis"
      }
    ],
    "pathogens": [
      {
        "name": "Trypanosoma cruzi",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "cinnarizine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cinnarizine confirmed to have trypanocidal effects and inhibits putrescine uptake in T. cruzi."
      },
      {
        "drug": "clofazimine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clofazimine displayed inhibitory effects on putrescine uptake and showed trypanocidal activity."
      },
      {
        "drug": "meclizine",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Meclizine exhibited trypanocidal effects against epimastigotes and amastigotes, without inhibiting putrescine uptake."
      },
      {
        "drug": "butoconazole",
        "pathogen": "Trypanosoma cruzi",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Butoconazole showed trypanocidal effects but did not inhibit putrescine uptake."
      }
    ],
    "mechanism": "Inhibition of putrescine uptake in Trypanosoma cruzi, disrupting polyamine transport essential for parasite survival.",
    "relevance_score": 4,
    "paper_idx": 38,
    "pmid": "29888213",
    "title": "Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00173",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Alberca L",
      "Sbaraglini M",
      "Morales J"
    ]
  },
  {
    "drugs": [
      {
        "name": "UVI5008",
        "drug_class": "epigenetic modulator",
        "approved_for": "cancer treatment"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "UVI5008",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "UVI5008 inhibits growth of MSSA with an MIC of 8 \u03bcM and MRSA with an MIC of 25 \u03bcM."
      },
      {
        "drug": "UVI5008",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 25,
        "fici": null,
        "key_result": "UVI5008 degrades preformed biofilms of S. aureus by over 20% at 25 \u03bcM."
      }
    ],
    "mechanism": "interferes with bacterial DNA gyrase, disrupting DNA replication and structural integrity.",
    "relevance_score": 4,
    "paper_idx": 39,
    "pmid": "29899092",
    "title": "Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.",
    "year": "2018",
    "doi": "10.1128/JVI.00954-18",
    "journal": "Journal of virology",
    "authors": [
      "Wang P",
      "Liu Y",
      "Zhang G"
    ]
  },
  {
    "drugs": [
      {
        "name": "Demeclocycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Doxycycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Tetracycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Minocycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR (including tetracycline-resistant strains)"
      }
    ],
    "findings": [
      {
        "drug": "Demeclocycline",
        "pathogen": "E. coli",
        "activity_type": "direct_antibacterial|light_activated",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Demeclocycline combined with blue light effectively eradicates E. coli, including tetracycline-resistant strains, with >6 log reduction."
      },
      {
        "drug": "Demeclocycline",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial|light_activated",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Demeclocycline plus blue light kills MRSA bacteria with >6 log reduction at 10 \u03bcM concentration."
      },
      {
        "drug": "Doxycycline",
        "pathogen": "E. coli",
        "activity_type": "direct_antibacterial|light_activated",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Doxycycline combined with UVA light enhances bacterial killing, including tetracycline-resistant strains."
      },
      {
        "drug": "Tetracycline",
        "pathogen": "E. coli",
        "activity_type": "direct_antibacterial|light_activated",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tetracycline plus UVA light shows limited bacterial killing (~3-4 logs)."
      }
    ],
    "mechanism": "Photoactivation of tetracyclines with UVA or blue light produces reactive oxygen species (ROS) that kill bacteria, and tetracyclines can accumulate in bacterial ribosomes where they can be photoactivated to produce antimicrobial effects.",
    "relevance_score": 4,
    "paper_idx": 40,
    "pmid": "30013953",
    "title": "Evaluating New Compounds to Treat Burkholderia pseudomallei Infections.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00210",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Ross B",
      "Myers J",
      "Muruato L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"Simvastatin\",\n      \"drug_class\": \"HMG-CoA reductase inhibitor\",\n      \"approved_for\": \"hypercholesterolemia\"\n    },\n    {\n      \"name\": \"Atorvastatin\",\n      \"drug",
    "paper_idx": 41,
    "pmid": "30015451",
    "title": "Non-antibiotics, Efflux Pumps and Drug Resistance of Gram-negative Rods.",
    "year": "2018",
    "doi": "10.21307/pjm-2018-017",
    "journal": "Polish journal of microbiology",
    "authors": [
      "Laudy A"
    ]
  },
  {
    "drugs": [
      {
        "name": "phenothiazine",
        "drug_class": "phenothiazines",
        "approved_for": "antipsychotic use"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "phenothiazines",
        "approved_for": "antipsychotic use"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium smegmatis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "phenothiazine",
        "pathogen": "Mycobacterium smegmatis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 6.25,
        "fici": null,
        "key_result": "The functionalized phenothiazine demonstrated an MIC value comparable to the parent phenothiazine against M. smegmatis."
      }
    ],
    "mechanism": "not explicitly proposed in the paper",
    "relevance_score": 4,
    "paper_idx": 42,
    "pmid": "30085063",
    "title": "Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing.",
    "year": "2018",
    "doi": "10.1093/femsre/fuy031",
    "journal": "FEMS microbiology reviews",
    "authors": [
      "Buckner M",
      "Ciusa M",
      "Piddock L"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tape worm infection"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, colistin-resistant"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR, colistin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide in combination with colistin showed synergistic activity against colistin-resistant A. baumannii strains, reducing bacterial counts significantly."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide combined with colistin demonstrated synergistic activity against colistin-resistant K. pneumoniae strains, especially when colistin was added for a second time at 4 hours."
      }
    ],
    "mechanism": "Potential disruption of bacterial membrane charge and enhancement of colistin activity through synergistic interaction.",
    "relevance_score": 4,
    "paper_idx": 43,
    "pmid": "30089175",
    "title": "Molecular mechanisms of thioridazine resistance in Staphylococcus aureus.",
    "year": "2018",
    "doi": "10.1371/journal.pone.0201767",
    "journal": "PloS one",
    "authors": [
      "Wassmann C",
      "Lund L",
      "Thorsing M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"auranofin\",\n      \"drug_class\": \"anti-rheumatic agent\",\n      \"approved_for\": \"rheumatoid arthritis\"\n    },\n    {\n      \"name\": \"rifampicin\",\n      \"drug_class\": \"a",
    "paper_idx": 44,
    "pmid": "30177735",
    "title": "Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase.",
    "year": "2018",
    "doi": "10.1038/s41598-018-31135-9",
    "journal": "Scientific reports",
    "authors": [
      "Franci G",
      "Folliero V",
      "Cammarota M"
    ]
  },
  {
    "drugs": [
      {
        "name": "ascorbic acid",
        "drug_class": "vitamin",
        "approved_for": "nutritional supplement"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "psychotropic",
        "approved_for": "antipsychotic"
      },
      {
        "name": "aminocoumarins",
        "drug_class": "antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "quinolones",
        "drug_class": "antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "rifampicin",
        "drug_class": "antibiotic",
        "approved_for": "tuberculosis"
      }
    ],
    "pathogens": [
      {
        "name": "Enterobacteriaceae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "carbapenem-resistant"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "ESBL-producing"
      }
    ],
    "findings": [
      {
        "drug": "ascorbic acid",
        "pathogen": "Enterobacteriaceae",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ascorbic acid has been shown to impact plasmid stability and may contribute to plasmid curing in bacteria."
      },
      {
        "drug": "chlorpromazine",
        "pathogen": "Enterobacteriaceae",
        "activity_type": "anti_plasmid",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine, a psychotropic drug, has demonstrated potential to interfere with plasmid maintenance and reduce ARG prevalence."
      },
      {
        "drug": "aminocoumarins",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Aminocoumarins, including novobiocin, can inhibit plasmid replication, aiding in plasmid curing efforts."
      },
      {
        "drug": "quinolones",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Quinolones have been used to target plasmid stability and conjugation, contributing to plasmid curing strategies."
      },
      {
        "drug": "rifampicin",
        "pathogen": "various bacteria",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rifampicin has been explored as part of combination therapies to facilitate plasmid loss and combat AMR."
      }
    ],
    "mechanism": "The proposed mechanisms include interference with plasmid replication, stability, conjugation, and maintenance, often through chemical or drug interactions that destabilize plasmid DNA or inhibit transfer systems.",
    "relevance_score": 4,
    "paper_idx": 45,
    "pmid": "30250466",
    "title": "Treating Influenza Infection, From Now and Into the Future.",
    "year": "2018",
    "doi": "10.3389/fimmu.2018.01946",
    "journal": "Frontiers in immunology",
    "authors": [
      "Davidson S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\"name\": \"salicylate\", \"drug_class\": \"NSAID\", \"approved_for\": \"analgesic, antipyretic, anti-inflammatory\"},\n    {\"name\": \"diclofenac\", \"drug_class\": \"NSAID\", \"approved_for\": \"pain, ",
    "paper_idx": 46,
    "pmid": "30338245",
    "title": "Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00348",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Ayerbe-Algaba R",
      "Gil-Marqu\u00e9s M",
      "Jim\u00e9nez-Mej\u00edas M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"Oseltamivir\",\n      \"drug_class\": \"Neuraminidase inhibitor\",\n      \"approved_for\": \"Influenza\"\n    },\n    {\n      \"name\": \"Zanamivir\",\n      \"drug_class\": \"Neuramin",
    "paper_idx": 47,
    "pmid": "30406042",
    "title": "Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00365",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Bhandari V",
      "Chakraborty S",
      "Brahma U"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\"name\": \"MMV687251\", \"drug_class\": \"unknown\", \"approved_for\": \"none\"},\n    {\"name\": \"MMV676477\", \"drug_class\": \"unknown\", \"approved_for\": \"none\"},\n    {\"name\": \"MMV688179\", \"drug_c",
    "paper_idx": 48,
    "pmid": "30410476",
    "title": "Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against Pseudomonas aeruginosa.",
    "year": "2018",
    "doi": "10.3389/fmicb.2018.02541",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Torres N",
      "Montelongo-Jauregui D",
      "Abercrombie J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "raw": "{\n  \"drugs\": [\n    {\n      \"name\": \"Clomiphene Citrate\",\n      \"drug_class\": \"selective estrogen receptor modulator\",\n      \"approved_for\": \"ovarian stimulation, infertility\"\n    },\n    {\n      \"name\"",
    "paper_idx": 49,
    "pmid": "30410626",
    "title": "The design and synthesis of an antibacterial phenothiazine-siderophore conjugate.",
    "year": "2018",
    "doi": "10.3762/bjoc.14.242",
    "journal": "Beilstein journal of organic chemistry",
    "authors": [
      "Tarapdar A",
      "Norris J",
      "Sampson O"
    ]
  },
  {
    "drugs": [
      {
        "name": "diltiazem",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "influenza A(H1N1)pdm09",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "diltiazem",
        "pathogen": "influenza A(H1N1)pdm09",
        "activity_type": "host_targeted_inhibitor|synergy",
        "evidence_type": "in_vitro|in_vivo|ex_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem, a calcium channel blocker, demonstrated significant antiviral activity against influenza A(H1N1)pdm09 in vitro, in vivo, and ex vivo, and enhanced the efficacy of oseltamivir when used in combination."
      }
    ],
    "mechanism": "modulation of host antiviral response and cholesterol metabolism",
    "relevance_score": 5,
    "paper_idx": 50,
    "pmid": "30459446",
    "title": "GBF1 and Arf1 interact with Miro and regulate mitochondrial positioning within cells.",
    "year": "2018",
    "doi": "10.1038/s41598-018-35190-0",
    "journal": "Scientific reports",
    "authors": [
      "Walch L",
      "Pellier E",
      "Leng W"
    ]
  },
  {
    "drugs": [
      {
        "name": "verapamil",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension, angina"
      },
      {
        "name": "itraconazole",
        "drug_class": "antifungal agent",
        "approved_for": "fungal infections"
      },
      {
        "name": "5-fluorouracil",
        "drug_class": "antimetabolite",
        "approved_for": "various cancers including colorectal, breast, and gastrointestinal cancers"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "itraconazole",
        "pathogen": "breast cancer cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Itraconazole combined with 5-fluorouracil decreased cell viability and proliferation in breast cancer cell lines, showing potential as a repurposed adjuvant therapy."
      },
      {
        "drug": "verapamil",
        "pathogen": "breast cancer cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Verapamil combined with 5-fluorouracil reduced cell viability and proliferation, indicating potential to enhance breast cancer treatment."
      }
    ],
    "mechanism": "The proposed mechanism involves the drugs interfering with cellular processes such as drug efflux inhibition (verapamil) and disruption of fungal-like pathways or cellular metabolism (itraconazole), thereby enhancing the efficacy of 5-fluorouracil against breast cancer cells.",
    "relevance_score": 2,
    "paper_idx": 51,
    "pmid": "30479094",
    "title": "Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.",
    "year": "2019",
    "doi": "10.3802/jgo.2019.30.e10",
    "journal": "Journal of gynecologic oncology",
    "authors": [
      "Kobayashi Y",
      "Banno K",
      "Kunitomi H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Golgicide A (GCA)",
        "drug_class": "specific GBF1 inhibitor",
        "approved_for": "not approved; experimental compound"
      },
      {
        "name": "Brefeldin A (BFA)",
        "drug_class": "Arf1 activation inhibitor",
        "approved_for": "not approved; experimental compound"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Golgicide A (GCA)",
        "pathogen": "not applicable",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "GCA induces condensation of mitochondrial networks near the centrosome by inhibiting GBF1 activity."
      },
      {
        "drug": "Brefeldin A (BFA)",
        "pathogen": "not applicable",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "BFA treatment causes mitochondrial clustering near the microtubule-organizing center without affecting microtubule or ER morphology."
      }
    ],
    "mechanism": "Inhibition of GBF1 or Arf1 activation enhances dynein- and Miro-dependent retrograde mitochondrial transport along microtubules, leading to mitochondrial clustering near the centrosome.",
    "relevance_score": 1,
    "paper_idx": 52,
    "pmid": "30546859",
    "title": "Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa.",
    "year": "2018",
    "doi": "10.1016/j.csbj.2018.11.001",
    "journal": "Computational and structural biotechnology journal",
    "authors": [
      "Hussein M",
      "Han M",
      "Zhu Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "trans-cinnamaldehyde",
        "drug_class": "plant-derived compound",
        "approved_for": "not specified"
      },
      {
        "name": "salicylic acid",
        "drug_class": "salicylate",
        "approved_for": "analgesic, anti-inflammatory"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "virulence regulation via quorum sensing, biofilm formation"
      }
    ],
    "findings": [
      {
        "drug": "trans-cinnamaldehyde",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "trans-cinnamaldehyde significantly inhibits quorum sensing and reduces virulence factor production in P. aeruginosa without bactericidal effects."
      },
      {
        "drug": "salicylic acid",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "salicylic acid significantly inhibits quorum sensing and reduces virulence factor production in P. aeruginosa without bactericidal effects."
      }
    ],
    "mechanism": "interference with quorum sensing regulatory systems, downregulation of virulence gene expression",
    "relevance_score": 4,
    "paper_idx": 53,
    "pmid": "30558247",
    "title": "Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations.",
    "year": "2018",
    "doi": "10.3390/biom8040175",
    "journal": "Biomolecules",
    "authors": [
      "Correia A",
      "Silva D",
      "Correia A"
    ]
  },
  {
    "drugs": [
      {
        "name": "YM155",
        "drug_class": "fused imidazolium analogs",
        "approved_for": "anticancer"
      },
      {
        "name": "c5",
        "drug_class": "YM155 congener with short alkyl chain",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "YM155",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 50,
        "fici": null,
        "key_result": "YM155 exhibits weak antibacterial activity against MRSA with an MIC of 50 \u03bcg/ml."
      },
      {
        "drug": "c5",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 3.13,
        "fici": null,
        "key_result": "Chemical modification of YM155 to produce c5 significantly enhances antibacterial activity against MRSA with an MIC of 3.13 \u03bcg/ml."
      },
      {
        "drug": "c5",
        "pathogen": "MRSA",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The activity of c5 involves generation of reactive oxygen species (ROS), linked to respiratory electron transfer."
      },
      {
        "drug": "c5",
        "pathogen": "MRSA",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The antibacterial activity of c5 is compromised by antioxidants and anaerobic conditions, indicating ROS involvement."
      }
    ],
    "mechanism": "The antibacterial mechanism of c5 involves the generation of reactive oxygen species (ROS), likely during respiratory electron transfer, leading to bacterial cell damage.",
    "relevance_score": 4,
    "paper_idx": 54,
    "pmid": "30633761",
    "title": "Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0210547",
    "journal": "PloS one",
    "authors": [
      "Conley Z",
      "Carlson-Banning K",
      "Carter A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "antirheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin released from polyurethane coatings effectively inhibited MRSA growth for 8 to 26 days and completely prevented MRSA biofilm formation in vitro."
      }
    ],
    "mechanism": "Inhibition of bacterial thioredoxin reductase disrupting redox balance, leading to bacterial cell death.",
    "relevance_score": 5,
    "paper_idx": 55,
    "pmid": "30658640",
    "title": "Combined antibacterial effect of essential oils from three most commonly used Ethiopian traditional medicinal plants on multidrug resistant bacteria.",
    "year": "2019",
    "doi": "10.1186/s12906-019-2429-4",
    "journal": "BMC complementary and alternative medicine",
    "authors": [
      "Gadisa E",
      "Weldearegay G",
      "Desta K"
    ]
  },
  {
    "drugs": [
      {
        "name": "Polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "multi-drug resistant Gram-negative bacterial infections"
      },
      {
        "name": "Tamoxifen",
        "drug_class": "selective estrogen receptor modulator (SERM)",
        "approved_for": "breast cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR, polymyxin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Polymyxin B",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Polymyxin B alone has limited effect on polymyxin-resistant P. aeruginosa but disrupts outer membrane integrity."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen alone has minimal impact on bacterial metabolism but affects lipid metabolites."
      },
      {
        "drug": "Polymyxin B + Tamoxifen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination exhibits a synergistic bactericidal effect by disrupting cell envelope biogenesis and inhibiting lipid A modifications conferring resistance."
      }
    ],
    "mechanism": "Disruption of bacterial cell envelope biogenesis and inhibition of lipid A modifications that confer polymyxin resistance, leading to increased membrane permeability and bacterial death.",
    "relevance_score": 4,
    "paper_idx": 56,
    "pmid": "30662875",
    "title": "Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii.",
    "year": "2018",
    "doi": "10.3389/fcimb.2018.00438",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Cheng Y",
      "Sun W",
      "Xu M"
    ]
  },
  {
    "drugs": [
      {
        "name": "5-fluorouracil",
        "drug_class": "antineoplastic",
        "approved_for": "cancer"
      },
      {
        "name": "fluspirilene",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      },
      {
        "name": "Bay 11-7082",
        "drug_class": "anti-inflammatory",
        "approved_for": "research use"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "5-fluorouracil",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "5-fluorouracil resensitized A. baumannii to azithromycin and colistin in combination therapy."
      },
      {
        "drug": "fluspirilene",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluspirilene enhanced colistin activity against MDR A. baumannii, reducing its IC50 by 30-fold."
      },
      {
        "drug": "Bay 11-7082",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bay 11-7082 increased colistin efficacy, decreasing its IC50 by 4-fold."
      }
    ],
    "mechanism": "The non-antimicrobial drugs act as adjuvants, resensitizing multidrug resistant A. baumannii to existing antibiotics, likely by modulating bacterial resistance mechanisms or enhancing antibiotic uptake.",
    "relevance_score": 4,
    "paper_idx": 57,
    "pmid": "30665342",
    "title": "Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in Accra, Ghana.",
    "year": "2019",
    "doi": "10.1186/s12879-019-3714-z",
    "journal": "BMC infectious diseases",
    "authors": [
      "Abana D",
      "Gyamfi E",
      "Dogbe M"
    ]
  },
  {
    "drugs": [
      {
        "name": "ciclopirox",
        "drug_class": "antifungal",
        "approved_for": "topical antifungal"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug-resistant (MDR)"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "not affected by existing resistance mechanisms"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "not affected by existing resistance mechanisms"
      }
    ],
    "findings": [
      {
        "drug": "ciclopirox",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox inhibits growth of E. coli clinical isolates regardless of antibiotic resistance status."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox equally blocks growth of A. baumannii clinical isolates, unaffected by resistance mechanisms."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Ciclopirox inhibits K. pneumoniae growth regardless of resistance profile."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disruption of genes involved in enterobactin transport and synthesis lowers MIC, indicating interference with iron acquisition pathways."
      },
      {
        "drug": "ciclopirox",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciclopirox induces enterobactin production and affects bacterial swarming behavior."
      }
    ],
    "mechanism": "Ciclopirox alters lipopolysaccharide structure, stimulates enterobactin production, and interferes with iron transport pathways, affecting bacterial growth and motility.",
    "relevance_score": 4,
    "paper_idx": 58,
    "pmid": "30675370",
    "title": "Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention.",
    "year": "2019",
    "doi": "10.1038/s41522-018-0075-0",
    "journal": "NPJ biofilms and microbiomes",
    "authors": [
      "Kumar A",
      "Alam A",
      "Grover S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Cyclosporine-A",
        "drug_class": "Immunosuppressant",
        "approved_for": "Organ transplantation"
      },
      {
        "name": "Acarbose",
        "drug_class": "Alpha-glucosidase inhibitor",
        "approved_for": "Type 2 diabetes"
      },
      {
        "name": "Gallium nanoparticle (GaNP)",
        "drug_class": "Nanoparticle-based agent",
        "approved_for": "Cancer diagnostics and hypercalcemia"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "Biofilm-associated drug tolerance"
      },
      {
        "name": "Mycobacterium smegmatis",
        "resistance_profile": "Model organism for biofilm studies"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "Biofilm formation"
      },
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "Biofilm formation"
      },
      {
        "name": "Streptococcus mutans",
        "resistance_profile": "Biofilm formation"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "Biofilm formation"
      }
    ],
    "findings": [
      {
        "drug": "Cyclosporine-A",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cyclosporine-A inhibits biofilm formation and interacts with PpiB, reducing drug tolerance in M.tb."
      },
      {
        "drug": "Acarbose",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Acarbose interacts with PpiB and inhibits biofilm formation in M.tb, potentially enhancing drug efficacy."
      },
      {
        "drug": "Gallium nanoparticle (GaNP)",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "bactericidal|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gallium nanoparticles exhibit bactericidal activity and disrupt M.tb biofilm formation."
      }
    ],
    "mechanism": "Inhibition of PpiB, a peptidyl-prolyl isomerase involved in biofilm formation and drug tolerance, by binding of repurposed drugs such as cyclosporine-A and acarbose, and disruption of biofilm matrix by gallium nanoparticles.",
    "relevance_score": 4,
    "paper_idx": 59,
    "pmid": "30745898",
    "title": "Drug Repurposing for the Treatment of Bacterial and Fungal Infections.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00041",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Mir\u00f3-Canturri A",
      "Ayerbe-Algaba R",
      "Smani Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Florfenicol",
        "drug_class": "Amphenicols",
        "approved_for": "bovine respiratory disease, other veterinary uses"
      },
      {
        "name": "Vanoxerine",
        "drug_class": "Dopamine reuptake inhibitor",
        "approved_for": "clinical use as an anti-arrhythmic agent"
      },
      {
        "name": "Pentamidine",
        "drug_class": "Antiprotozoal agent",
        "approved_for": "Leishmaniasis, Pneumocystis pneumonia"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium smegmatis",
        "resistance_profile": "not specified"
      },
      {
        "name": "Mycobacterium bovis BCG",
        "resistance_profile": "not specified"
      },
      {
        "name": "Mycobacterium tuberculosis H37Rv",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Florfenicol",
        "pathogen": "Mycobacterium bovis BCG",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resistant mutants to florfenicol suggest new pathways that could be exploited in drug repurposing for TB."
      },
      {
        "drug": "Vanoxerine",
        "pathogen": "Mycobacterium bovis BCG",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resistant mutants to vanoxerine highlight potential new targets for anti-mycobacterial drug development."
      },
      {
        "drug": "Pentamidine",
        "pathogen": "Mycobacterium bovis BCG",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mutant analysis of pentamidine resistance indicates possible new pathways for TB drug targeting."
      }
    ],
    "mechanism": "Targeting of novel bacterial pathways as indicated by resistant mutant analysis, suggesting these drugs may inhibit mycobacterial growth through mechanisms distinct from their original indications.",
    "relevance_score": 4,
    "paper_idx": 60,
    "pmid": "30761132",
    "title": "Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.",
    "year": "2019",
    "doi": "10.3389/fimmu.2019.00060",
    "journal": "Frontiers in immunology",
    "authors": [
      "Pizzorno A",
      "Terrier O",
      "Nicolas de Lamballerie C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Albendazole",
        "drug_class": "benzimidazole derivative",
        "approved_for": "anthelmintic"
      }
    ],
    "pathogens": [
      {
        "name": "Cutaneous squamous cell carcinoma (SCC) cells",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Albendazole",
        "pathogen": "Cutaneous squamous cell carcinoma (SCC) cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.2,
        "fici": null,
        "key_result": "Albendazole induces apoptosis and decreases viability of SCC cells via ER stress and inhibition of Wnt/\u03b2-catenin signaling."
      }
    ],
    "mechanism": "Induces ER stress leading to apoptosis and inhibits Wnt/\u03b2-catenin signaling reducing cancer stemness.",
    "relevance_score": 1,
    "paper_idx": 61,
    "pmid": "30819135",
    "title": "High prevalence and characterization of extended-spectrum \u00df-lactamase producing Enterobacteriaceae in Chadian hospitals.",
    "year": "2019",
    "doi": "10.1186/s12879-019-3838-1",
    "journal": "BMC infectious diseases",
    "authors": [
      "Ouchar Mahamat O",
      "Lounnas M",
      "Hide M"
    ]
  },
  {
    "drugs": [
      {
        "name": "tetracycline",
        "drug_class": "tetracyclines",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolones",
        "approved_for": "bacterial infections"
      },
      {
        "name": "gentamycin",
        "drug_class": "aminoglycosides",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ceftazidime",
        "drug_class": "cephalosporins",
        "approved_for": "bacterial infections"
      },
      {
        "name": "chloramphenicol",
        "drug_class": "amphenicols",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ceftriaxone",
        "drug_class": "cephalosporins",
        "approved_for": "bacterial infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycosides",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin resistant S. aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "essential oils from B. cuspidata and T. schimperi",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.39,
        "fici": null,
        "key_result": "The combined essential oils of B. cuspidata and T. schimperi showed a 39 mm inhibition zone and MIC of 0.39 \u03bcl/ml against MRSA."
      },
      {
        "drug": "essential oils from B. cuspidata and T. schimperi",
        "pathogen": "MDR E. coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.39,
        "fici": null,
        "key_result": "The combined oils exhibited inhibition zones of 28-35 mm, MIC of 0.39-6.25 \u03bcl/ml, and MBC of 0.78-12.5 \u03bcl/ml against MDR E. coli."
      },
      {
        "drug": "essential oils from B. cuspidata and B. ogadensis",
        "pathogen": "MDR K. pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.78,
        "fici": null,
        "key_result": "The combination had MIC values ranging from 0.78-6.25 \u03bcl/ml against K. pneumoniae."
      },
      {
        "drug": "essential oils from B. cuspidata and B. ogadensis",
        "pathogen": "MDR E. coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.78,
        "fici": null,
        "key_result": "The combination showed MIC values from 0.78-6.25 \u03bcl/ml against E. coli."
      },
      {
        "drug": "essential oils from B. cuspidata and B. ogadensis",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1.56,
        "fici": null,
        "key_result": "The combination had MIC of 1.56 \u03bcl/ml against MRSA."
      }
    ],
    "mechanism": "The essential oils likely exert antimicrobial effects through disruption of bacterial cell membranes, leakage of cell contents, and inhibition of protein synthesis and DNA replication.",
    "relevance_score": 4,
    "paper_idx": 62,
    "pmid": "30852658",
    "title": "Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.",
    "year": "2019",
    "doi": "10.1007/s00253-019-09618-0",
    "journal": "Applied microbiology and biotechnology",
    "authors": [
      "Ahmed S",
      "Rudden M",
      "Smyth T"
    ]
  },
  {
    "drugs": [
      {
        "name": "5-fluorouracil (5-FU)",
        "drug_class": "antimetabolite, anticancer",
        "approved_for": "cancer (e.g., colorectal cancer)"
      },
      {
        "name": "5-fluorocytosine (5-FC)",
        "drug_class": "antimycotic, antifungal",
        "approved_for": "cryptococcal meningitis, fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "variable; includes MDR and pyoverdine-deficient strains"
      }
    ],
    "findings": [
      {
        "drug": "5-fluorouracil (5-FU)",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 20,
        "fici": null,
        "key_result": "5-FU exhibits growth inhibitory activity against P. aeruginosa and can select for resistant mutants with mutations in the upp gene."
      },
      {
        "drug": "5-fluorocytosine (5-FC)",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "5-FC does not significantly inhibit bacterial growth but reduces pyoverdine production; however, it can select for resistant mutants that are insensitive to both 5-FC and 5-FU."
      }
    ],
    "mechanism": "5-FU inhibits bacterial growth by targeting pyrimidine metabolism, with resistance arising from mutations in the upp gene; 5-FC requires conversion to 5-FU via cytosine deaminase for activity, but poor conversion limits its efficacy.",
    "relevance_score": 4,
    "paper_idx": 63,
    "pmid": "30858845",
    "title": "Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00350",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Jang H",
      "Chung I",
      "Lim C"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anti-helminthic",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis Beijing strain",
        "resistance_profile": "drug-sensitive (implied, virulent strain)"
      },
      {
        "name": "HIV-1",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "Mycobacterium tuberculosis Beijing strain",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Niclosamide inhibits growth of M. tuberculosis Beijing strain in liquid culture at concentrations as low as 5 \u03bcM."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Mycobacterium bovis BCG",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "Niclosamide limits growth of M. bovis BCG in liquid culture dose-dependently."
      },
      {
        "drug": "niclosamide",
        "pathogen": "HIV-1",
        "activity_type": "direct_antiviral",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1.25,
        "fici": null,
        "key_result": "Niclosamide inhibits HIV replication in human macrophages and T cells by affecting post-integration pro-virus transcription."
      },
      {
        "drug": "niclosamide",
        "pathogen": "HIV-1",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1.25,
        "fici": null,
        "key_result": "Niclosamide reduces HIV p24 expression in infected cells without toxicity, indicating suppression of viral transcription."
      }
    ],
    "mechanism": "Inhibition of host cell signaling pathways such as NF-\u03baB, leading to suppression of HIV pro-virus transcription and direct inhibition of mycobacterial growth.",
    "relevance_score": 4,
    "paper_idx": 64,
    "pmid": "30861059",
    "title": "Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.",
    "year": "2019",
    "doi": "10.1371/journal.pone.0213713",
    "journal": "PloS one",
    "authors": [
      "Kanvatirth P",
      "Jeeves R",
      "Bacon J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 65,
    "pmid": "30873389",
    "title": "Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00037",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Liu H",
      "Shukla S",
      "Vera-Gonz\u00e1lez N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Lifirafenib",
        "drug_class": "kinase inhibitor",
        "approved_for": "cancer (phase 1 clinical trial)"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multi-drug resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "Lifirafenib",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Lifirafenib predicted to inhibit multiple enzymes in the phenazine biosynthesis pathway, potentially reducing virulence of P. aeruginosa."
      }
    ],
    "mechanism": "Inhibition of enzymes involved in phenazine biosynthesis, disrupting pyocyanin production and bacterial virulence.",
    "relevance_score": 4,
    "paper_idx": 66,
    "pmid": "30915278",
    "title": "Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00049",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Imperi F",
      "Fiscarelli E",
      "Visaggio D"
    ]
  },
  {
    "drugs": [
      {
        "name": "Statins",
        "drug_class": "HMG-CoA reductase inhibitors",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "Bisphosphonates",
        "drug_class": "pyrophosphate analogs",
        "approved_for": "osteoporosis"
      },
      {
        "name": "Metformin",
        "drug_class": "biguanides",
        "approved_for": "type 2 diabetes"
      },
      {
        "name": "Non-steroidal anti-inflammatory drugs",
        "drug_class": "NSAIDs",
        "approved_for": "pain, inflammation"
      },
      {
        "name": "Ivermectin",
        "drug_class": "antiparasitic agents",
        "approved_for": "parasitic infections"
      },
      {
        "name": "Itraconazole",
        "drug_class": "antifungal agents",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "ovarian cancer",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "Statins",
        "pathogen": "ovarian cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Statins have shown to inhibit ovarian cancer cell proliferation and improve overall survival in patients."
      },
      {
        "drug": "Bisphosphonates",
        "pathogen": "ovarian cancer",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bisphosphonates inhibit proliferation of ovarian cancer cell lines and delay tumor formation in mouse models."
      },
      {
        "drug": "Metformin",
        "pathogen": "ovarian cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Metformin use is associated with improved progression-free survival and overall survival in ovarian cancer patients."
      },
      {
        "drug": "Non-steroidal anti-inflammatory drugs",
        "pathogen": "ovarian cancer",
        "activity_type": "potential_therapy",
        "evidence_type": "not_specified",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NSAIDs are mentioned as drugs with potential for repositioning but specific evidence for ovarian cancer is not detailed."
      },
      {
        "drug": "Ivermectin",
        "pathogen": "ovarian cancer",
        "activity_type": "potential_therapy",
        "evidence_type": "not_specified",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ivermectin is listed as a candidate for drug repositioning in ovarian cancer, but specific activity evidence is not provided."
      },
      {
        "drug": "Itraconazole",
        "pathogen": "ovarian cancer",
        "activity_type": "potential_therapy",
        "evidence_type": "not_specified",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Itraconazole is mentioned as a candidate for drug repositioning, with no detailed activity evidence provided."
      }
    ],
    "mechanism": "Repositioned drugs may exert antitumor effects through various mechanisms such as inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of tumor microenvironment, often via pathways like the mevalonate pathway or immune modulation.",
    "relevance_score": 4,
    "paper_idx": 67,
    "pmid": "31028540",
    "title": "The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.",
    "year": "2019",
    "doi": "10.1007/s00432-019-02920-4",
    "journal": "Journal of cancer research and clinical oncology",
    "authors": [
      "Skaga E",
      "Skaga I",
      "Grieg Z"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 68,
    "pmid": "31044071",
    "title": "In vitro polymyxin activity against clinical multidrug-resistant fungi.",
    "year": "2019",
    "doi": "10.1186/s13756-019-0521-7",
    "journal": "Antimicrobial resistance and infection control",
    "authors": [
      "Yousfi H",
      "Ranque S",
      "Rolain J"
    ]
  },
  {
    "drugs": [
      {
        "name": "ciclopirox",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "gallium",
        "drug_class": "metal-based agent",
        "approved_for": "iron overload conditions"
      },
      {
        "name": "zidovudine",
        "drug_class": "antiretroviral",
        "approved_for": "HIV infection"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "carbapenem-resistant, colistin-resistant"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "ciclopirox",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciclopirox demonstrated antibacterial activity against carbapenem and colistin-resistant K. pneumoniae in vitro."
      },
      {
        "drug": "gallium",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gallium showed potential as an adjuvant to disrupt iron metabolism in resistant K. pneumoniae in vitro."
      },
      {
        "drug": "zidovudine",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Zidovudine exhibited antibacterial activity against MDR A. baumannii in vitro."
      }
    ],
    "mechanism": "The proposed mechanisms involve disruption of bacterial metabolic pathways, iron metabolism interference, and targeting of bacterial DNA or membrane integrity, independent of traditional antibiotic targets.",
    "relevance_score": 4,
    "paper_idx": 69,
    "pmid": "31080089",
    "title": "Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing).",
    "year": "2019",
    "doi": "10.1016/j.tube.2019.04.008",
    "journal": "Tuberculosis (Edinburgh, Scotland)",
    "authors": [
      "Fan X",
      "Xu J",
      "Files M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 70,
    "pmid": "31105656",
    "title": "In vitro Antimicrobial Activity of Robenidine, Ethylenediaminetetraacetic Acid and Polymyxin B Nonapeptide Against Important Human and Veterinary Pathogens.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.00837",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Khazandi M",
      "Pi H",
      "Chan W"
    ]
  },
  {
    "drugs": [
      {
        "name": "oxacillin",
        "drug_class": "\u03b2-lactam antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "polymyxin B",
        "drug_class": "peptide antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "gentamicin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "rifampicin",
        "drug_class": "RNA polymerase inhibitor",
        "approved_for": "tuberculosis, bacterial infections"
      },
      {
        "name": "ofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial infections"
      },
      {
        "name": "erythromycin",
        "drug_class": "macrolide",
        "approved_for": "bacterial infections"
      },
      {
        "name": "meropenem",
        "drug_class": "carbapenem \u03b2-lactam",
        "approved_for": "bacterial infections"
      },
      {
        "name": "silver nanoparticles",
        "drug_class": "metal nanoparticle",
        "approved_for": "not specifically approved, used as antimicrobial agent"
      }
    ],
    "pathogens": [
      {
        "name": "drug-sensitive bacteria",
        "resistance_profile": "none specified"
      },
      {
        "name": "drug-resistant bacteria",
        "resistance_profile": "multidrug-resistant strains"
      }
    ],
    "findings": [
      {
        "drug": "gentamicin",
        "pathogen": "drug-resistant bacteria",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Synergistic antibacterial effects observed between highly membrane-active AMPs like protegrin 1 and gentamicin, suggesting increased bioavailability."
      },
      {
        "drug": "rifampicin",
        "pathogen": "drug-resistant bacteria",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Synergy mainly occurs between membrane-active AMPs and antibiotics with intracellular targets, indicating enhanced bacterial membrane interaction."
      },
      {
        "drug": "silver nanoparticles",
        "pathogen": "drug-resistant bacteria",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combined use with other antimicrobials can reduce effective concentrations and improve efficacy against resistant strains."
      }
    ],
    "mechanism": "The proposed mechanism of antimicrobial synergy involves increased bioavailability of antibiotics due to membrane disruption by AMPs, modulation of bacterial membrane interaction dynamics, and combined membrane destabilization effects.",
    "relevance_score": 4,
    "paper_idx": 71,
    "pmid": "31114762",
    "title": "Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00128",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Zharkova M",
      "Orlov D",
      "Golubeva O"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 72,
    "pmid": "31245302",
    "title": "Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00193",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Peyclit L",
      "Baron S",
      "Rolain J"
    ]
  },
  {
    "drugs": [
      {
        "name": "salinomycin",
        "drug_class": "ionophore antibiotic",
        "approved_for": "none (experimental/repurposed for cancer stem cell targeting)"
      },
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "helminth infections"
      }
    ],
    "pathogens": [
      {
        "name": "small cell lung cancer (SCLC)",
        "resistance_profile": "chemoresistant, CSC-associated resistance"
      }
    ],
    "findings": [
      {
        "drug": "salinomycin",
        "pathogen": "small cell lung cancer (SCLC)",
        "activity_type": "adjuvant|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Salinomycin exerted dose-dependent cytotoxicity against SCLC lines, with variable activity on tumorospheres."
      },
      {
        "drug": "niclosamide",
        "pathogen": "small cell lung cancer (SCLC)",
        "activity_type": "adjuvant|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Niclosamide showed high activity against some SCLC tumorospheres, indicating potential to target CSC-like properties."
      }
    ],
    "mechanism": "Inhibition of Wnt/\u03b2-catenin signaling and mitochondrial uncoupling, targeting cancer stemness and resistance pathways.",
    "relevance_score": 4,
    "paper_idx": 73,
    "pmid": "31281836",
    "title": "Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells.",
    "year": "2019",
    "doi": "10.1155/2019/3689517",
    "journal": "BioMed research international",
    "authors": [
      "Zhang Q",
      "Lian D",
      "Zhu M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 74,
    "pmid": "31319464",
    "title": "Pathway-Centric Structure-Based Multi-Target Compound Screening for Anti-Virulence Drug Repurposing.",
    "year": "2019",
    "doi": "10.3390/ijms20143504",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Xie L",
      "Xie L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Azithromycin",
        "drug_class": "macrolide antibiotic",
        "approved_for": "bacterial respiratory infections, other bacterial infections"
      },
      {
        "name": "Rifampicin",
        "drug_class": "rifamycin antibiotic",
        "approved_for": "tuberculosis, leprosy"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Azithromycin",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with azithromycin, inducing susceptibility in MDR E. coli at sub-micromolar concentrations."
      },
      {
        "drug": "Rifampicin",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with rifampicin, inducing susceptibility in MDR E. coli at sub-micromolar concentrations."
      },
      {
        "drug": "Azithromycin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Synergy observed with peptidomimetic H-(Lys-\u03b2NPhe)8-NH2, potentiating azithromycin against MDR K. pneumoniae."
      },
      {
        "drug": "Rifampicin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Synergy observed with peptidomimetic H-(Lys-\u03b2NPhe)8-NH2, potentiating rifampicin against MDR K. pneumoniae."
      },
      {
        "drug": "Azithromycin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with azithromycin, enhancing activity against P. aeruginosa."
      },
      {
        "drug": "Rifampicin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Peptidomimetic H-(Lys-\u03b2NPhe)8-NH2 synergized with rifampicin, enhancing activity against P. aeruginosa."
      }
    ],
    "mechanism": "Peptidomimetics increase outer membrane permeability and potentiate the activity of antibiotics like azithromycin and rifampicin against Gram-negative pathogens.",
    "relevance_score": 4,
    "paper_idx": 75,
    "pmid": "31334131",
    "title": "Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.",
    "year": "2019",
    "doi": "10.3389/fcimb.2019.00236",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Baker K",
      "Jana B",
      "Hansen A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 76,
    "pmid": "31354660",
    "title": "Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.01556",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Domalaon R",
      "Ammeter D",
      "Brizuela M"
    ]
  },
  {
    "drugs": [
      {
        "name": "desmethylclomipramine",
        "drug_class": "antidepressant",
        "approved_for": "depression"
      },
      {
        "name": "ionomycin",
        "drug_class": "calcium ionophore",
        "approved_for": "research use"
      },
      {
        "name": "sirolimus",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression"
      },
      {
        "name": "trimipramine",
        "drug_class": "tricyclic antidepressant",
        "approved_for": "depression"
      },
      {
        "name": "clomipramine",
        "drug_class": "tricyclic antidepressant",
        "approved_for": "obsessive-compulsive disorder"
      }
    ],
    "pathogens": [
      {
        "name": "Traumatic Brain Injury (TBI)",
        "resistance_profile": "N/A"
      }
    ],
    "findings": [
      {
        "drug": "desmethylclomipramine",
        "pathogen": "Traumatic Brain Injury",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Desmethylclomipramine showed anti-inflammatory and neuroprotective effects in vitro but failed to improve outcomes in vivo."
      },
      {
        "drug": "ionomycin",
        "pathogen": "Traumatic Brain Injury",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ionomycin reduced neuroinflammation and nitrite levels in vitro but lacked in vivo efficacy."
      },
      {
        "drug": "sirolimus",
        "pathogen": "Traumatic Brain Injury",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sirolimus improved neuronal viability and reduced neurotoxicity markers in vitro but was not tested in vivo for efficacy."
      },
      {
        "drug": "trimipramine",
        "pathogen": "Traumatic Brain Injury",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Trimipramine reduced neuroinflammation and nitrite production in vitro but did not demonstrate in vivo benefits."
      }
    ],
    "mechanism": "Modulation of post-TBI transcriptomics, upregulation of Nrf2 target genes, anti-inflammatory and antioxidant effects.",
    "relevance_score": 2,
    "paper_idx": 77,
    "pmid": "31439817",
    "title": "An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy.",
    "year": "2019",
    "doi": "10.1073/pnas.1906388116",
    "journal": "Proceedings of the National Academy of Sciences of the United States of America",
    "authors": [
      "Bulterys P",
      "Toesca I",
      "Norris M"
    ]
  },
  {
    "drugs": [
      {
        "name": "cloxacillin",
        "drug_class": "\u03b2-lactam antibiotic",
        "approved_for": "bacterial infections (e.g., skin, soft tissue)"
      },
      {
        "name": "thioridazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      },
      {
        "name": "miconazole",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "cloxacillin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.1,
        "key_result": "Combination of cloxacillin with thioridazine and miconazole significantly reduced MIC values and showed synergistic activity against S. aureus, including MRSA strains."
      },
      {
        "drug": "thioridazine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.14,
        "key_result": "Thioridazine acts as an efflux pump inhibitor, enhancing the antibacterial activity of cloxacillin against MRSA."
      },
      {
        "drug": "miconazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "autolysis_inducer|adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.14,
        "key_result": "Miconazole induces autolysis, synergizing with cloxacillin to inhibit MRSA growth."
      }
    ],
    "mechanism": "The combination therapy enhances antibacterial activity by inhibiting efflux pumps (thioridazine), inducing autolysis (miconazole), and disrupting cell wall synthesis (cloxacillin).",
    "relevance_score": 5,
    "paper_idx": 78,
    "pmid": "31446534",
    "title": "Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.",
    "year": "2020",
    "doi": "10.1007/s10637-019-00847-8",
    "journal": "Investigational new drugs",
    "authors": [
      "Hochmair M",
      "Rath B",
      "Klameth L"
    ]
  },
  {
    "drugs": [
      {
        "name": "burkfloxacin",
        "drug_class": "fluoroquinolone analog",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "flucytosine",
        "drug_class": "antifungal",
        "approved_for": "cryptococcal meningitis, fungal infections"
      },
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ceftazidime",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Burkholderia pseudomallei",
        "resistance_profile": "MDR"
      },
      {
        "name": "Burkholderia mallei",
        "resistance_profile": "MDR"
      },
      {
        "name": "Burkholderia thailandensis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "burkfloxacin",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Burkfloxacin potently inhibits growth of intracellular Burkholderia pseudomallei."
      },
      {
        "drug": "flucytosine",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Flucytosine inhibits intracellular cell\u2013cell spread of Burkholderia pseudomallei by targeting T6SS-5-mediated membrane fusion."
      },
      {
        "drug": "ciprofloxacin",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciprofloxacin shows similar in vitro activity to burkfloxacin against gram-negative bacteria."
      },
      {
        "drug": "ceftazidime",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceftazidime was less effective than BFX or 5-FC in murine models for treating melioidosis."
      }
    ],
    "mechanism": "5-FC is converted inside bacteria to 5-fluorouracil and subsequently to FUMP, which inhibits T6SS-5 assembly or secretion, impairing cell\u2013cell spread; burkfloxacin inhibits bacterial DNA gyrase, blocking bacterial replication.",
    "relevance_score": 5,
    "paper_idx": 79,
    "pmid": "31671916",
    "title": "In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.",
    "year": "2019",
    "doi": "10.3390/ijms20215395",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Lipponen A",
      "Natunen T",
      "Hujo M"
    ]
  },
  {
    "drugs": [],
    "pathogens": [],
    "findings": [
      {
        "drug": null,
        "pathogen": null,
        "activity_type": "none",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The paper focuses on anticancer drug sensitivity prediction using deep learning models and does not address antimicrobial resistance or drug repurposing for infectious diseases."
      }
    ],
    "mechanism": "none",
    "relevance_score": 1,
    "paper_idx": 80,
    "pmid": "31708908",
    "title": "Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis.",
    "year": "2019",
    "doi": "10.3389/fmicb.2019.02453",
    "journal": "Frontiers in microbiology",
    "authors": [
      "She P",
      "Zhou L",
      "Li S"
    ]
  },
  {
    "drugs": [
      {
        "name": "pitavastatin",
        "drug_class": "antihyperlipidemic statin",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "azole-resistant"
      },
      {
        "name": "Candida glabrata",
        "resistance_profile": "azole-resistant"
      },
      {
        "name": "Candida auris",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "pitavastatin",
        "pathogen": "Candida albicans",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.05,
        "key_result": "Pitavastatin significantly enhances the activity of azole antifungals against azole-resistant Candida strains, with broad-spectrum synergistic effects observed in approximately 89% of tested strains."
      },
      {
        "drug": "pitavastatin",
        "pathogen": "Candida glabrata",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Pitavastatin shows synergistic activity with fluconazole against C. glabrata, reducing MICs significantly."
      },
      {
        "drug": "pitavastatin",
        "pathogen": "Candida auris",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.38,
        "key_result": "Pitavastatin synergizes with fluconazole against C. auris, reducing fungal burdens and biofilm formation."
      }
    ],
    "mechanism": "Potentially involves inhibition of membrane efflux transporters and disruption of ergosterol biosynthesis pathways, enhancing azole antifungal efficacy.",
    "relevance_score": 5,
    "paper_idx": 81,
    "pmid": "31801292",
    "title": "Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy.",
    "year": "2019",
    "doi": "10.3390/ijms20236053",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Vitiello L",
      "Tibaudo L",
      "Pegoraro E"
    ]
  },
  {
    "drugs": [
      {
        "name": "P2",
        "drug_class": "antimicrobial peptide",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "P5",
        "drug_class": "antimicrobial peptide",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "P9",
        "drug_class": "antimicrobial peptide",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "vancomycin",
        "drug_class": "glycopeptide antibiotic",
        "approved_for": "bacterial infections including MRSA"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR, MRSA, persistent"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "VRE"
      }
    ],
    "findings": [
      {
        "drug": "P2",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "P2 exhibited high activity with MIC <2 \u03bcg/mL, killed 99% of persistent S. aureus, and disrupted biofilm formation."
      },
      {
        "drug": "P5",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "P5 significantly inhibited S. aureus biofilm, disrupted cell membranes, and downregulated virulence genes."
      },
      {
        "drug": "P9",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "P9 showed potent activity against S. aureus, inhibiting biofilm and virulence gene expression."
      },
      {
        "drug": "vancomycin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": 1.0,
        "key_result": "Peptides demonstrated synergistic interactions with vancomycin against VRE."
      }
    ],
    "mechanism": "Antimicrobial peptides disrupt bacterial membranes, bind to DNA, inhibit biofilm formation, and downregulate virulence genes; some inhibit key two-component systems like vanRS.",
    "relevance_score": 4,
    "paper_idx": 82,
    "pmid": "31861228",
    "title": "The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.",
    "year": "2019",
    "doi": "10.3390/antibiotics8040270",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Gajd\u00e1cs M",
      "Spengler G"
    ]
  },
  {
    "drugs": [
      {
        "name": "abacavir",
        "drug_class": "nucleoside analogue",
        "approved_for": "HIV treatment"
      },
      {
        "name": "azidothymidine (AZT)",
        "drug_class": "nucleoside analogue",
        "approved_for": "HIV treatment"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "ESBL-producing, plasmid-mediated resistance"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "carbapenemase-producing, plasmid-mediated resistance"
      }
    ],
    "findings": [
      {
        "drug": "azidothymidine (AZT)",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "AZT reduced plasmid transmission in E. coli by 83.3% at 0.25 \u03bcg/ml."
      },
      {
        "drug": "abacavir",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Abacavir reduced plasmid transmission in E. coli in the screening assay."
      },
      {
        "drug": "azidothymidine (AZT)",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AZT reduced plasmid transmission in K. pneumoniae by approximately 80.8%."
      },
      {
        "drug": "abacavir",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Abacavir also reduced plasmid transmission in K. pneumoniae."
      }
    ],
    "mechanism": "Proposed mechanism involves inhibition of plasmid transfer, possibly through interference with conjugation processes, as suggested by the activity of HIV nucleoside analogues on plasmid transmission.",
    "relevance_score": 4,
    "paper_idx": 83,
    "pmid": "31880892",
    "title": "Inhibition of Drug Resistance of Staphylococcus aureus by Efflux Pump Inhibitor and Autolysis Inducer to Strengthen the Antibacterial Activity of \u03b2-lactam Drugs.",
    "year": "2019",
    "doi": "10.33073/pjm-2019-047",
    "journal": "Polish journal of microbiology",
    "authors": [
      "Luan W",
      "Liu X",
      "Wang X"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 84,
    "pmid": "32041137",
    "title": "Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases.",
    "year": "2020",
    "doi": "10.3390/antibiotics9020065",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Pacios O",
      "Blasco L",
      "Bleriot I"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold(I) compound / anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Clostridium difficile",
        "resistance_profile": "none specified; activity demonstrated against C. difficile"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Clostridium difficile",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4.07,
        "fici": null,
        "key_result": "Auranofin showed bactericidal activity at concentrations as low as 4.07 \u00b5g/mL, effectively reducing bacterial cell density and spore viability in vitro."
      }
    ],
    "mechanism": "Auranofin inhibits thioredoxin reductase and sequesters inorganic selenium, disrupting selenium-dependent enzymes essential for C. difficile growth and sporulation.",
    "relevance_score": 4,
    "paper_idx": 85,
    "pmid": "32098822",
    "title": "HIV Drugs Inhibit Transfer of Plasmids Carrying Extended-Spectrum \u03b2-Lactamase and Carbapenemase Genes.",
    "year": "2020",
    "doi": "10.1128/mBio.03355-19",
    "journal": "mBio",
    "authors": [
      "Buckner M",
      "Ciusa M",
      "Meek R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold-containing compound",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Fosfomycin",
        "drug_class": "antibiotic",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "Linezolid",
        "drug_class": "oxazolidinone antibiotic",
        "approved_for": "skin infections, pneumonia"
      },
      {
        "name": "Chloramphenicol",
        "drug_class": "broad-spectrum antibiotic",
        "approved_for": "bacterial infections (limited use due to toxicity)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus (including MSSA and MRSA)",
        "resistance_profile": "methicillin-resistant and susceptible strains"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "clinical strains with resistance profiles not specified but known for biofilm formation"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|synergy|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 0.125,
        "fici": 0.375,
        "key_result": "Auranofin exhibits potent antimicrobial activity against S. aureus and shows synergistic effects with linezolid and fosfomycin both in vitro and in vivo."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial|synergy|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 1,
        "fici": 0.375,
        "key_result": "Auranofin demonstrates antimicrobial activity against E. faecalis and synergizes with chloramphenicol in vitro and in vivo."
      },
      {
        "drug": "Fosfomycin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Fosfomycin shows synergistic activity with auranofin against S. aureus."
      },
      {
        "drug": "Linezolid",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Linezolid exhibits synergistic effects with auranofin against S. aureus."
      },
      {
        "drug": "Chloramphenicol",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Chloramphenicol shows synergistic antimicrobial activity with auranofin against E. faecalis."
      }
    ],
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting bacterial redox homeostasis and biofilm formation, thereby enhancing the efficacy of conventional antibiotics.",
    "relevance_score": 5,
    "paper_idx": 86,
    "pmid": "32131427",
    "title": "Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance.",
    "year": "2020",
    "doi": "10.3390/antibiotics9030107",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Lagadinou M",
      "Onisor M",
      "Rigas A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Prednisone",
        "drug_class": "glucocorticoid corticosteroid",
        "approved_for": "inflammatory and autoimmune conditions, including DMD"
      },
      {
        "name": "Deflazacort",
        "drug_class": "glucocorticoid corticosteroid",
        "approved_for": "DMD"
      },
      {
        "name": "Eteplirsen",
        "drug_class": "antisense oligonucleotide",
        "approved_for": "exon 51 skipping in DMD"
      },
      {
        "name": "Simvastatin",
        "drug_class": "HMG-CoA reductase inhibitor (statin)",
        "approved_for": "hypercholesterolemia and cardiovascular diseases"
      },
      {
        "name": "N-acetylcysteine",
        "drug_class": "antioxidant/mucolytic agent",
        "approved_for": "acetaminophen toxicity, respiratory conditions"
      },
      {
        "name": "Safinamide",
        "drug_class": "MAO-B inhibitor",
        "approved_for": "Parkinson's disease"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Prednisone",
        "pathogen": "DMD",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Glucocorticoids like prednisone improve and stabilize skeletal muscle strength and prolong ambulation in DMD patients."
      },
      {
        "drug": "Deflazacort",
        "pathogen": "DMD",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Deflazacort, a glucocorticoid, is used as standard therapy to delay disease progression in DMD."
      },
      {
        "drug": "Eteplirsen",
        "pathogen": "DMD",
        "activity_type": "antisense therapy",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Eteplirsen facilitates exon 51 skipping, applicable to a subset of DMD patients."
      },
      {
        "drug": "Simvastatin",
        "pathogen": "DMD",
        "activity_type": "efflux_inhibitor|anti_inflammatory|anti_fibrotic",
        "evidence_type": "preclinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simvastatin reduces muscle damage, inflammation, oxidative stress, and fibrosis in mdx mouse models of DMD."
      },
      {
        "drug": "N-acetylcysteine",
        "pathogen": "DMD",
        "activity_type": "antioxidant|adjuvant",
        "evidence_type": "preclinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "N-acetylcysteine alleviates skeletal muscle dysfunction and histopathology in mdx mice."
      },
      {
        "drug": "Safinamide",
        "pathogen": "DMD",
        "activity_type": "efflux_inhibitor|antioxidant",
        "evidence_type": "preclinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Safinamide, a MAO-B inhibitor, targets oxidative stress pathways implicated in DMD pathology."
      }
    ],
    "mechanism": "Repurposed drugs target inflammation, oxidative stress, fibrosis, and gene splicing pathways involved in DMD pathogenesis.",
    "relevance_score": 4,
    "paper_idx": 87,
    "pmid": "32221472",
    "title": "Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae.",
    "year": "2020",
    "doi": "10.1038/s41598-020-62696-3",
    "journal": "Scientific reports",
    "authors": [
      "Elkashif A",
      "Seleem M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 88,
    "pmid": "32372011",
    "title": "Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species.",
    "year": "2020",
    "doi": "10.1038/s41598-020-64571-7",
    "journal": "Scientific reports",
    "authors": [
      "Eldesouky H",
      "Salama E",
      "Li X"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "gold-containing anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "sodium aurothiomalate",
        "drug_class": "gold-containing anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "aurothioglucose",
        "drug_class": "gold-containing anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Neisseria gonorrhoeae",
        "resistance_profile": "multidrug-resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.007,
        "fici": null,
        "key_result": "Auranofin inhibited growth of N. gonorrhoeae clinical isolates at MICs as low as 0.007 \u00b5g/mL and exhibited rapid bactericidal activity."
      },
      {
        "drug": "sodium aurothiomalate",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Sodium aurothiomalate inhibited N. gonorrhoeae at MICs around 0.25 \u00b5g/mL, showing antibacterial activity."
      },
      {
        "drug": "aurothioglucose",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Aurothioglucose inhibited N. gonorrhoeae at MICs around 0.5 \u00b5g/mL."
      },
      {
        "drug": "auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 1.2,
        "key_result": "Auranofin showed an additive effect when combined with azithromycin, ceftriaxone, cefixime, or tetracycline."
      },
      {
        "drug": "auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin reduced intracellular N. gonorrhoeae burden by over 99%, outperforming ceftriaxone."
      },
      {
        "drug": "auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin demonstrated prolonged post-antibiotic effect (>10 hours) and did not generate resistant mutants."
      }
    ],
    "mechanism": "Proposed mechanisms include direct antibacterial activity, intracellular bacterial clearance, and anti-inflammatory effects, possibly through inhibition of bacterial enzymes and modulation of host immune responses.",
    "relevance_score": 5,
    "paper_idx": 89,
    "pmid": "32377889",
    "title": "In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.",
    "year": "2020",
    "doi": "10.1007/s40268-020-00306-3",
    "journal": "Drugs in R&D",
    "authors": [
      "Roder C",
      "Athan E"
    ]
  },
  {
    "drugs": [
      {
        "name": "11 clinically approved generic drugs",
        "drug_class": "various",
        "approved_for": "various indications"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "11 clinically approved generic drugs",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Identified as potential candidates for repurposing as blockers of SARS-CoV-2 endocytosis pathways."
      }
    ],
    "mechanism": "targeting multiple host cell endocytic pathways to prevent viral entry",
    "relevance_score": 4,
    "paper_idx": 90,
    "pmid": "32402082",
    "title": "PaccMann: a web service for interpretable anticancer compound sensitivity prediction.",
    "year": "2020",
    "doi": "10.1093/nar/gkaa327",
    "journal": "Nucleic acids research",
    "authors": [
      "Cadow J",
      "Born J",
      "Manica M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Metformin",
        "drug_class": "biguanide",
        "approved_for": "type 2 diabetes mellitus"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR (multi-drug resistant)"
      }
    ],
    "findings": [
      {
        "drug": "Metformin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "host_modulation|adjuvant",
        "evidence_type": "in_vitro|retrospective",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Metformin enhances immune response and phagosome-lysosome fusion, potentially improving TB treatment outcomes."
      },
      {
        "drug": "Metformin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational|in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In silico studies suggest bacterial NDH-I as a potential target, but direct antibacterial activity of metformin is not conclusively demonstrated."
      },
      {
        "drug": "Metformin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "efflux_inhibitor|adjuvant",
        "evidence_type": "in_vivo|retrospective",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Retrospective studies indicate reduced mortality and improved treatment outcomes when used as adjunct therapy."
      }
    ],
    "mechanism": "Metformin modulates host immune responses, promotes phagosome-lysosome fusion, and may inhibit bacterial respiration via targeting bacterial NDH-I complex, thereby enhancing host defense against Mtb.",
    "relevance_score": 4,
    "paper_idx": 91,
    "pmid": "32411100",
    "title": "Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.00435",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Naicker N",
      "Sigal A",
      "Naidoo K"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 92,
    "pmid": "32423280",
    "title": "Insights into idarubicin antimicrobial activity against methicillin-resistant Staphylococcus aureus.",
    "year": "2020",
    "doi": "10.1080/21505594.2020.1770493",
    "journal": "Virulence",
    "authors": [
      "She P",
      "Li S",
      "Zhou L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Chlorpromazine",
        "drug_class": "antipsychotic",
        "approved_for": "psychosis"
      },
      {
        "name": "Amitriptyline",
        "drug_class": "tricyclic antidepressant",
        "approved_for": "depression"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug resistant"
      },
      {
        "name": "Salmonella enterica serovar Typhimurium",
        "resistance_profile": "multidrug resistant"
      }
    ],
    "findings": [
      {
        "drug": "Chlorpromazine",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine binds to AcrB and inhibits its efflux activity by interfering with substrate binding."
      },
      {
        "drug": "Amitriptyline",
        "pathogen": "Salmonella enterica serovar Typhimurium",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amitriptyline binds to AcrB and inhibits its efflux activity, reverting mutants to wild-type acrB sequence."
      }
    ],
    "mechanism": "Binding at the hydrophobic trap within AcrB's distal pocket, interfering with substrate binding and efflux function.",
    "relevance_score": 5,
    "paper_idx": 93,
    "pmid": "32428379",
    "title": "Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.",
    "year": "2020",
    "doi": "10.1111/febs.15369",
    "journal": "The FEBS journal",
    "authors": [
      "Glebov O"
    ]
  },
  {
    "drugs": [
      {
        "name": "idarubicin",
        "drug_class": "anthracycline antibiotic",
        "approved_for": "acute myeloid leukemia"
      },
      {
        "name": "fosfomycin",
        "drug_class": "antibiotic",
        "approved_for": "urinary tract infections and other bacterial infections"
      },
      {
        "name": "amifostine",
        "drug_class": "cytoprotective agent",
        "approved_for": "cytoprotection during chemotherapy and radiotherapy"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "idarubicin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Idarubicin kills MRSA by disrupting lipid bilayers and inhibiting DNA topoisomerase II, showing potential as an antimicrobial agent."
      },
      {
        "drug": "idarubicin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Idarubicin exhibits synergistic effects with fosfomycin against MRSA."
      },
      {
        "drug": "fosfomycin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fosfomycin enhances the antimicrobial efficacy of idarubicin against MRSA."
      },
      {
        "drug": "idarubicin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Idarubicin shows low probability of resistance development and good postantibiotic effects."
      },
      {
        "drug": "idarubicin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Idarubicin effectively inhibits and eradicates MRSA biofilms."
      }
    ],
    "mechanism": "Idarubicin disrupts bacterial lipid bilayers and inhibits DNA topoisomerase II, leading to bacterial cell death.",
    "relevance_score": 5,
    "paper_idx": 94,
    "pmid": "32443498",
    "title": "A Selective Serotonin Reuptake Inhibitor, a Proton Pump Inhibitor, and Two Calcium Channel Blockers Inhibit Candida albicans Biofilms.",
    "year": "2020",
    "doi": "10.3390/microorganisms8050756",
    "journal": "Microorganisms",
    "authors": [
      "Nobile C",
      "Ennis C",
      "Hartooni N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ellipticine Hydrochloride",
        "drug_class": "alkaloid",
        "approved_for": "cancer (anti-cancer activity)"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
        "resistance_profile": "colistin-resistant MDR"
      }
    ],
    "findings": [
      {
        "drug": "Ellipticine Hydrochloride",
        "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ellipticine hydrochloride binds to E. coli topoisomerase IV and exhibits antibacterial activity against colistin-resistant ExPEC strains."
      },
      {
        "drug": "Ellipticine Hydrochloride",
        "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "EH shows synergistic effects with colistin in most tested strains, enhancing antibacterial efficacy."
      },
      {
        "drug": "Ellipticine Hydrochloride",
        "pathogen": "Escherichia coli (ExPEC, colistin-resistant, mcr-1 positive)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In infected mice, EH treatment reduced bacterial load and inflammation, indicating therapeutic potential."
      }
    ],
    "mechanism": "Ellipticine hydrochloride inhibits bacterial topoisomerase IV, disrupting DNA replication and cell division.",
    "relevance_score": 5,
    "paper_idx": 95,
    "pmid": "32487753",
    "title": "Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.",
    "year": "2020",
    "doi": "10.1128/mBio.00465-20",
    "journal": "mBio",
    "authors": [
      "Grimsey E",
      "Fais C",
      "Marshall R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Sertraline",
        "drug_class": "Selective Serotonin Reuptake Inhibitor",
        "approved_for": "depression"
      },
      {
        "name": "Omeprazole",
        "drug_class": "Proton Pump Inhibitor",
        "approved_for": "gastric acid-related disorders"
      },
      {
        "name": "Amlodipine",
        "drug_class": "Calcium Channel Blocker",
        "approved_for": "hypertension"
      },
      {
        "name": "Nifedipine",
        "drug_class": "Calcium Channel Blocker",
        "approved_for": "angina, hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "biofilm-associated resistance"
      }
    ],
    "findings": [
      {
        "drug": "Sertraline",
        "pathogen": "Candida albicans",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sertraline inhibits C. albicans biofilm formation and disrupts mature biofilms."
      },
      {
        "drug": "Omeprazole",
        "pathogen": "Candida albicans",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Omeprazole inhibits C. albicans biofilm formation and shows potential as an antibiofilm agent."
      },
      {
        "drug": "Amlodipine",
        "pathogen": "Candida albicans",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amlodipine inhibits C. albicans biofilm formation and disrupts mature biofilms."
      },
      {
        "drug": "Nifedipine",
        "pathogen": "Candida albicans",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nifedipine inhibits C. albicans biofilm formation and shows antibiofilm activity."
      }
    ],
    "mechanism": "The proposed mechanisms involve interference with calcium signaling pathways and disruption of biofilm matrix formation, though specific molecular targets are not fully elucidated.",
    "relevance_score": 4,
    "paper_idx": 96,
    "pmid": "32528422",
    "title": "Repurposing Ellipticine Hydrochloride to Combat Colistin-Resistant Extraintestinal Pathogenic E. coli (ExPEC).",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.00806",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Lu H",
      "Liu M",
      "Lu W"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "none (experimental/repurposing candidate)"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (targeting viral protease)"
      },
      {
        "name": "HIV-1",
        "resistance_profile": "none (targeting capsid and integrase interactions)"
      },
      {
        "name": "Hepatitis C virus (HCV)",
        "resistance_profile": "none (targeting NS3 helicase)"
      },
      {
        "name": "Influenza A virus (H3N2)",
        "resistance_profile": "none (reducing viral titer and inflammation)"
      }
    ],
    "findings": [
      {
        "drug": "ebselen",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.67,
        "fici": null,
        "key_result": "Ebselen inhibits SARS-CoV-2 main protease (Mpro) with an IC50 of 0.67 \u03bcM, showing potential as an antiviral agent."
      },
      {
        "drug": "ebselen",
        "pathogen": "HIV-1",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen inhibits HIV-1 capsid assembly and interferes with integration by binding to LEDGF/p75, suggesting antiviral potential."
      },
      {
        "drug": "ebselen",
        "pathogen": "HCV",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen inhibits HCV NS3 helicase activity and viral replication."
      },
      {
        "drug": "ebselen",
        "pathogen": "Influenza A virus (H3N2)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen lowered viral titers and inflammatory cytokines in infected mice."
      }
    ],
    "mechanism": "Ebselen covalently binds to cysteine residues in viral proteases and other proteins, forming selenosulfide bonds that inhibit enzymatic activity, and also exerts anti-inflammatory effects.",
    "relevance_score": 4,
    "paper_idx": 97,
    "pmid": "32571820",
    "title": "Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.",
    "year": "2020",
    "doi": "10.1128/AAC.00559-20",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Biagi M",
      "Vialichka A",
      "Jurkovic M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Trifluoperazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia, psychosis"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Trifluoperazine",
        "pathogen": "bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The paper does not report any antibacterial activity of trifluoperazine."
      }
    ],
    "mechanism": "Inhibition of NUPR1 leading to autophagy suppression and apoptosis induction in multiple myeloma cells.",
    "relevance_score": 1,
    "paper_idx": 98,
    "pmid": "32598985",
    "title": "Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.",
    "year": "2020",
    "doi": "10.1016/j.freeradbiomed.2020.06.032",
    "journal": "Free radical biology & medicine",
    "authors": [
      "Sies H",
      "Parnham M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression, cancer"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (host-targeted therapy)"
      }
    ],
    "findings": [
      {
        "drug": "Rapamycin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rapamycin may help control COVID-19 by inhibiting host pathways involved in viral replication and cytokine storm."
      }
    ],
    "mechanism": "Inhibition of mTOR pathway, leading to reduced protein synthesis, autophagy induction, and modulation of immune response.",
    "relevance_score": 2,
    "paper_idx": 99,
    "pmid": "32605985",
    "title": "The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant Staphylococcus aureus.",
    "year": "2020",
    "doi": "10.1128/mBio.01140-20",
    "journal": "mBio",
    "authors": [
      "Kim W",
      "Zou G",
      "Pan W"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 100,
    "pmid": "32665275",
    "title": "New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.",
    "year": "2020",
    "doi": "10.1128/mBio.01340-20",
    "journal": "mBio",
    "authors": [
      "Marshall R",
      "Lloyd G",
      "Lawler A"
    ]
  },
  {
    "drugs": [
      {
        "name": "bedaquiline",
        "drug_class": "antitubercular",
        "approved_for": "tuberculosis"
      },
      {
        "name": "glibenclamide",
        "drug_class": "antidiabetic (sulfonylurea)",
        "approved_for": "type 2 diabetes mellitus"
      },
      {
        "name": "miconazole",
        "drug_class": "antifungal (imidazole)",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "bedaquiline",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bedaquiline showed promising predicted binding affinity as an inhibitor of the SARS-CoV-2 main protease based on virtual screening."
      },
      {
        "drug": "glibenclamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Glibenclamide demonstrated potential as a SARS-CoV-2 main protease inhibitor through shape and electrostatic similarity in virtual screening."
      },
      {
        "drug": "miconazole",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Miconazole was identified as a promising candidate for SARS-CoV-2 main protease inhibition based on in silico similarity and docking studies."
      }
    ],
    "mechanism": "binding to the viral main protease active site, potentially inhibiting viral replication",
    "relevance_score": 4,
    "paper_idx": 101,
    "pmid": "32787684",
    "title": "Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study.",
    "year": "2020",
    "doi": "10.4155/fmc-2020-0165",
    "journal": "Future medicinal chemistry",
    "authors": [
      "Ferraz W",
      "Gomes R",
      "S Novaes A"
    ]
  },
  {
    "drugs": [
      {
        "name": "rifampicin",
        "drug_class": "antituberculosis antibiotic",
        "approved_for": "tuberculosis"
      },
      {
        "name": "auranofin",
        "drug_class": "antirheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MCR-1 colistin-resistant"
      },
      {
        "name": "Enterobacter aerogenes",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "rifampicin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymer combination reduced rifampicin MIC by 2048-fold against A. baumannii, restoring activity."
      },
      {
        "drug": "auranofin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymer combination reduced auranofin MIC by 128-fold against A. baumannii, enhancing its activity."
      },
      {
        "drug": "colistimethate sodium",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymer significantly lowered colistin MIC from 15.6\u201331.3 \u00b5g/mL to 0.49 \u00b5g/mL in MCR-1 positive E. coli."
      }
    ],
    "mechanism": "The polymer binds nonspecifically to cytosolic enzymes or genes responsible for antibiotic resistance, disrupts bacterial defense mechanisms, and increases intracellular ROS, thereby reversing resistance phenotypes and potentiating antibiotic activity.",
    "relevance_score": 5,
    "paper_idx": 102,
    "pmid": "32810364",
    "title": "Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.",
    "year": "2020",
    "doi": "10.1002/2211-5463.12960",
    "journal": "FEBS open bio",
    "authors": [
      "Li A",
      "Chen X",
      "Jing Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "Statins",
        "drug_class": "HMGCR inhibitors",
        "approved_for": "hypercholesterolemia and cardiovascular diseases"
      },
      {
        "name": "Metformin",
        "drug_class": "biguanide",
        "approved_for": "type 2 diabetes mellitus"
      },
      {
        "name": "Bisphosphonates",
        "drug_class": "osteoporosis treatment",
        "approved_for": "osteoporosis and bone metastases"
      },
      {
        "name": "Ivermectin",
        "drug_class": "antiparasitic",
        "approved_for": "parasitic infections"
      },
      {
        "name": "Itraconazole",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "Ritonavir",
        "drug_class": "antiviral protease inhibitor",
        "approved_for": "HIV/AIDS"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "",
    "relevance_score": 1,
    "paper_idx": 103,
    "pmid": "32835306",
    "title": "Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.",
    "year": "2020",
    "doi": "10.1016/j.xcrm.2020.100059",
    "journal": "Cell reports. Medicine",
    "authors": [
      "Pizzorno A",
      "Padey B",
      "Julien T"
    ]
  },
  {
    "drugs": [
      {
        "name": "Pitavastatin",
        "drug_class": "hypolipidemic",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "Ridogrel",
        "drug_class": "anticoagulant",
        "approved_for": "anticoagulation"
      },
      {
        "name": "Rosoxacin",
        "drug_class": "antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (targeting viral enzyme)"
      }
    ],
    "findings": [
      {
        "drug": "Pitavastatin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pitavastatin displayed superior binding to the SARS-CoV-2 RdRp active site through interactions with ARG555 and divalent magnesium in molecular dynamics simulations."
      },
      {
        "drug": "Ridogrel",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ridogrel showed strong binding affinity to the RdRp active site, interacting with ARG555 and magnesium ions in molecular dynamics studies."
      },
      {
        "drug": "Rosoxacin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rosoxacin demonstrated effective binding to the SARS-CoV-2 RdRp active site, with interactions involving ARG555 and magnesium ions."
      }
    ],
    "mechanism": "Binding to the active site of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), potentially inhibiting viral RNA synthesis.",
    "relevance_score": 4,
    "paper_idx": 104,
    "pmid": "32845920",
    "title": "Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.",
    "year": "2020",
    "doi": "10.1371/journal.pone.0238195",
    "journal": "PloS one",
    "authors": [
      "Mohammed M",
      "Ahmed M",
      "Anwer B"
    ]
  },
  {
    "drugs": [
      {
        "name": "penicillic acid",
        "drug_class": "mycotoxin",
        "approved_for": "none (experimental compound)"
      },
      {
        "name": "papyracillic acid",
        "drug_class": "mycotoxin analog",
        "approved_for": "none (experimental compound)"
      },
      {
        "name": "auranofin",
        "drug_class": "gold(I) compound, anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "human pancreatic cancer cells",
        "resistance_profile": "nutrient deprivation vulnerability"
      }
    ],
    "findings": [
      {
        "drug": "penicillic acid",
        "pathogen": "human pancreatic cancer cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Penicillic acid preferentially induces apoptosis in nutrient-deprived pancreatic cancer cells by targeting redox systems and depleting GSH."
      },
      {
        "drug": "papyracillic acid",
        "pathogen": "human pancreatic cancer cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Papyracillic acid shows selective cytotoxicity under nutrient-deprived conditions by binding to GSH and increasing ROS levels in pancreatic cancer cells."
      },
      {
        "drug": "auranofin",
        "pathogen": "human pancreatic cancer cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin inhibits pancreatic cancer cell growth under nutrient-deprived conditions by disrupting redox balance, similar to PCA and PPA."
      }
    ],
    "mechanism": "PCA and PPA covalently bind to GSH, depleting cellular GSH levels, which leads to increased ROS and apoptosis in nutrient-deprived pancreatic cancer cells. Auranofin inhibits redox systems, contributing to oxidative stress.",
    "relevance_score": 4,
    "paper_idx": 105,
    "pmid": "32930523",
    "title": "Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19.",
    "year": "2020",
    "doi": "10.1002/prp2.653",
    "journal": "Pharmacology research & perspectives",
    "authors": [
      "Heister P",
      "Poston R"
    ]
  },
  {
    "drugs": [
      {
        "name": "daptomycin",
        "drug_class": "lipopeptide antibiotic",
        "approved_for": "treatment of Gram-positive infections including VRE and S. aureus"
      },
      {
        "name": "cholestyramine",
        "drug_class": "bile acid sequestrant",
        "approved_for": "lowering cholesterol levels"
      }
    ],
    "pathogens": [
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "VRE (vancomycin-resistant Enterococcus faecium), daptomycin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "daptomycin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Systemic daptomycin treatment can select for resistant E. faecium in the gut, but co-administration with cholestyramine reduces fecal shedding of resistant strains by up to 80-fold."
      },
      {
        "drug": "cholestyramine",
        "pathogen": "Enterococcus faecium",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cholestyramine binds daptomycin in the gut, inactivating it locally without affecting plasma concentrations, thereby preventing resistance emergence in gut colonizing E. faecium."
      }
    ],
    "mechanism": "Cholestyramine binds daptomycin in the gastrointestinal tract, preventing it from reaching and exerting selective pressure on gut bacteria, thus inhibiting the evolution of resistance.",
    "relevance_score": 4,
    "paper_idx": 106,
    "pmid": "32934086",
    "title": "Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.",
    "year": "2020",
    "doi": "10.1128/mBio.02068-20",
    "journal": "mBio",
    "authors": [
      "Copp J",
      "Pletzer D",
      "Brown A"
    ]
  },
  {
    "drugs": [
      {
        "name": "amodiaquine",
        "drug_class": "antimalarial",
        "approved_for": "malaria"
      },
      {
        "name": "probenecid",
        "drug_class": "uricosuric agent",
        "approved_for": "gout"
      },
      {
        "name": "ibuprofen",
        "drug_class": "NSAID",
        "approved_for": "pain/inflammation"
      },
      {
        "name": "2-amino-5-chlorobenzaxazole",
        "drug_class": "research tool",
        "approved_for": "none"
      },
      {
        "name": "ellagic acid",
        "drug_class": "antioxidant",
        "approved_for": "none"
      },
      {
        "name": "quercetin",
        "drug_class": "antioxidant/anti-inflammatory",
        "approved_for": "none"
      },
      {
        "name": "N-N diacryloylpiperazine",
        "drug_class": "chemical reagent",
        "approved_for": "none"
      },
      {
        "name": "epicatechin",
        "drug_class": "antioxidant/antiviral",
        "approved_for": "none"
      },
      {
        "name": "curcumin",
        "drug_class": "anti-inflammatory/anticancer",
        "approved_for": "none"
      },
      {
        "name": "quinine",
        "drug_class": "antimalarial",
        "approved_for": "malaria"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "curcumin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 50,
        "fici": null,
        "key_result": "Curcumin exhibited potent antibacterial activity with MIC of 50 \u03bcg/ml against P. aeruginosa and enhanced the effect of ciprofloxacin."
      },
      {
        "drug": "curcumin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 100,
        "fici": null,
        "key_result": "Curcumin showed antibacterial activity with MIC of 100 \u03bcg/ml against S. aureus and increased ciprofloxacin efficacy."
      },
      {
        "drug": "ellagic acid",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 100,
        "fici": null,
        "key_result": "Ellagic acid had MIC of 100 \u03bcg/ml against S. aureus."
      },
      {
        "drug": "curcumin + ciprofloxacin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination reduced MIC of ciprofloxacin from 0.5 \u03bcg/ml to 0.0625 \u03bcg/ml, indicating synergistic effect."
      },
      {
        "drug": "curcumin + ciprofloxacin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination reduced MIC of ciprofloxacin from 0.25 \u03bcg/ml to 0.0625 \u03bcg/ml, showing enhanced antibacterial activity."
      }
    ],
    "mechanism": "Curcumin causes protein and nucleic acid leakage from bacterial cell membranes, disrupting membrane integrity.",
    "relevance_score": 4,
    "paper_idx": 107,
    "pmid": "32952938",
    "title": "Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.",
    "year": "2020",
    "doi": "10.1016/j.csbj.2020.08.008",
    "journal": "Computational and structural biotechnology journal",
    "authors": [
      "Hussein M",
      "Hu X",
      "Paulin O"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tetrandrine",
        "drug_class": "bisbenzylisoquinoline calcium channel blocker",
        "approved_for": "silicosis"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (targeting host cell mechanisms)"
      },
      {
        "name": "MERS-CoV",
        "resistance_profile": "none (targeting host cell mechanisms)"
      },
      {
        "name": "HCoV-OC43",
        "resistance_profile": "none (targeting host cell mechanisms)"
      }
    ],
    "findings": [
      {
        "drug": "Tetrandrine",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 3,
        "fici": null,
        "key_result": "Tetrandrine demonstrated in vitro activity against SARS-CoV-2 pseudovirus with an estimated effective concentration of approximately 3 \u03bcg/mL."
      },
      {
        "drug": "Tetrandrine",
        "pathogen": "MERS-CoV",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.33,
        "fici": null,
        "key_result": "Tetrandrine showed efficacy against MERS-CoV in vitro with an IC50 of 0.055 \u03bcmol/L."
      },
      {
        "drug": "Tetrandrine",
        "pathogen": "HCoV-OC43",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.33,
        "fici": null,
        "key_result": "Tetrandrine inhibited HCoV-OC43 infection in vitro with an IC50 of 0.33 \u03bcmol/L."
      }
    ],
    "mechanism": "Antagonism of host cell TPC2 channels, inhibiting virus egress and replication, along with calcium channel blockade and anti-inflammatory effects.",
    "relevance_score": 4,
    "paper_idx": 108,
    "pmid": "32975381",
    "title": "Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.",
    "year": "2020",
    "doi": "10.1111/jcmm.15920",
    "journal": "Journal of cellular and molecular medicine",
    "authors": [
      "Wang P",
      "Wang J",
      "Xie Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "organo-selenium compound",
        "approved_for": "stroke, neurodegenerative diseases, bipolar disorder, COVID-19, ototoxicity, chemotherapy-induced hearing loss"
      },
      {
        "name": "silver ion",
        "drug_class": "metal ion",
        "approved_for": "antimicrobial uses (general)"
      }
    ],
    "pathogens": [
      {
        "name": "Uropathogenic Escherichia coli (UPEC) BC1",
        "resistance_profile": "multidrug-resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "ebselen",
        "pathogen": "UPEC BC1",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen exhibits potent bactericidal activity against MDR UPEC BC1 by disrupting redox homeostasis."
      },
      {
        "drug": "silver ion",
        "pathogen": "UPEC BC1",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver ion shows strong bactericidal activity against MDR UPEC BC1, especially in combination with ebselen."
      },
      {
        "drug": "ebselen and silver ion",
        "pathogen": "UPEC BC1",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination of ebselen and silver ion exerts synergistic bactericidal activity against MDR UPEC BC1."
      },
      {
        "drug": "ebselen and silver ion",
        "pathogen": "UPEC BC1",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Treatment with ebselen and silver ion significantly reduces bacterial loads in a mouse model of cystitis."
      }
    ],
    "mechanism": "Disruption of bacterial redox homeostasis through consumption of intracellular GSH and inhibition of thioredoxin reductase activity, leading to increased reactive oxygen species and bacterial cell death.",
    "relevance_score": 4,
    "paper_idx": 109,
    "pmid": "32978257",
    "title": "Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.",
    "year": "2020",
    "doi": "10.1074/jbc.RA120.013893",
    "journal": "The Journal of biological chemistry",
    "authors": [
      "Onodera T",
      "Momose I",
      "Adachi H"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "antirheumatic",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "co-producing MCR-1 and NDM-5"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial|synergy|adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin synergizes with antibiotics to kill carbapenem- and colistin-resistant bacteria and rescues infected mice."
      }
    ],
    "mechanism": "Auranofin irreversibly inhibits metallo-\u03b2-lactamases and MCR enzymes by displacing Zn(II) cofactors with Au(I), disrupting enzyme activity.",
    "relevance_score": 5,
    "paper_idx": 110,
    "pmid": "32995131",
    "title": "A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics.",
    "year": "2020",
    "doi": "10.1002/advs.202001374",
    "journal": "Advanced science (Weinheim, Baden-Wurttemberg, Germany)",
    "authors": [
      "Ding X",
      "Yang C",
      "Moreira W"
    ]
  },
  {
    "drugs": [
      {
        "name": "polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "bacterial infections, especially Gram-negative bacteria"
      },
      {
        "name": "prochlorperazine",
        "drug_class": "phenothiazine antipsychotic/antiemetic",
        "approved_for": "nausea, vomiting, vertigo"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "phenothiazine antipsychotic",
        "approved_for": "schizophrenia, psychosis"
      },
      {
        "name": "thiethylperazine",
        "drug_class": "phenothiazine antipsychotic/antiemetic",
        "approved_for": "nausea, vertigo"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, polymyxin-resistant"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR, polymyxin-resistant"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR, polymyxin-resistant and susceptible strains"
      }
    ],
    "findings": [
      {
        "drug": "polymyxin B + prochlorperazine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.15,
        "key_result": "The combination showed synergistic antibacterial activity against P. aeruginosa, including polymyxin-resistant strains, by disrupting bacterial cell membranes."
      },
      {
        "drug": "polymyxin B + prochlorperazine",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": "<0.5",
        "key_result": "The combination demonstrated synergistic activity against MDR A. baumannii, causing greater bacterial cell damage."
      },
      {
        "drug": "polymyxin B + chlorpromazine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": "<0.5",
        "key_result": "Synergistic effects observed with enhanced bacterial membrane disruption."
      },
      {
        "drug": "polymyxin B + thiethylperazine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": "<0.5",
        "key_result": "Synergistic antibacterial activity was demonstrated, including against resistant strains."
      }
    ],
    "mechanism": "Disruption of bacterial membrane integrity and biosynthesis of cell envelope components, leading to enhanced bacterial cell damage and death.",
    "relevance_score": 5,
    "paper_idx": 111,
    "pmid": "33031791",
    "title": "Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.",
    "year": "2020",
    "doi": "10.1016/j.cbi.2020.109282",
    "journal": "Chemico-biological interactions",
    "authors": [
      "Husain A",
      "Byrareddy S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 112,
    "pmid": "33061985",
    "title": "Repurposing of Drugs for Antibacterial Activities on Selected ESKAPE Bacteria Staphylococcus aureus and Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.1155/2020/8885338",
    "journal": "International journal of microbiology",
    "authors": [
      "Kamurai B",
      "Mombeshora M",
      "Mukanganyama S"
    ]
  },
  {
    "drugs": [
      {
        "name": "PQ401",
        "drug_class": "diarylurea",
        "approved_for": "originally IGF-1R inhibition in cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA, MDR, Tolerant, VRSA"
      }
    ],
    "findings": [
      {
        "drug": "PQ401",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "PQ401 kills antibiotic-resistant and tolerant S. aureus by disrupting bacterial membranes."
      },
      {
        "drug": "PQ401",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PQ401 shows synergism with gentamicin."
      }
    ],
    "mechanism": "Membrane disruption through lipid bilayer permeabilization, with the neutral form of PQ401 penetrating and embedding into bacterial membranes more effectively than the cationic form.",
    "relevance_score": 5,
    "paper_idx": 113,
    "pmid": "33067430",
    "title": "Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin.",
    "year": "2020",
    "doi": "10.1038/s41467-020-18939-y",
    "journal": "Nature communications",
    "authors": [
      "Sun H",
      "Zhang Q",
      "Wang R"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 114,
    "pmid": "33092251",
    "title": "Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.",
    "year": "2020",
    "doi": "10.3390/ijms21207768",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Nunes M",
      "Henriques Abreu M",
      "Bartosch C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thioridazine",
        "drug_class": "Phenothiazine antipsychotic",
        "approved_for": "Schizophrenia"
      },
      {
        "name": "Mesoridazine",
        "drug_class": "Phenothiazine derivative",
        "approved_for": "Antipsychotic"
      },
      {
        "name": "Sulforidazine",
        "drug_class": "Phenothiazine derivative",
        "approved_for": "Antipsychotic"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Thioridazine photoproducts",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Photoproducts of irradiated thioridazine show enhanced antimicrobial activity against S. aureus, including MRSA, with MIC values four to sixteen times lower than unirradiated TZ."
      },
      {
        "drug": "Thioridazine photoproducts",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Photoproducts do not significantly inhibit efflux pumps, as they do not reduce ciprofloxacin MICs in efflux-overexpressing strains."
      }
    ],
    "mechanism": "Photoproducts of TZ, such as mesoridazine and sulforidazine, may inhibit penicillin-binding proteins PBP3 and PBP2a, disrupting cell wall biosynthesis in S. aureus and MRSA strains.",
    "relevance_score": 4,
    "paper_idx": 115,
    "pmid": "33093568",
    "title": "Anti-staphylococcal activity and mode of action of thioridazine photoproducts.",
    "year": "2020",
    "doi": "10.1038/s41598-020-74752-z",
    "journal": "Scientific reports",
    "authors": [
      "Tozar T",
      "Santos Costa S",
      "Udrea A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Demeclocycline hydrochloride (DMCT)",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "originally for bacterial infections (e.g., Lyme disease, SIADH)"
      },
      {
        "name": "SAAP-148",
        "drug_class": "antimicrobial peptide",
        "approved_for": "not FDA approved; experimental antimicrobial peptide"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Demeclocycline hydrochloride (DMCT)",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "DMCT shows antibacterial activity and synergizes with SAAP-148 against P. aeruginosa."
      },
      {
        "drug": "SAAP-148",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "SAAP-148 synergizes with DMCT to enhance antibacterial effects against P. aeruginosa, including MDR strains."
      }
    ],
    "mechanism": "Synergistic antibacterial effect through combined action of tetracycline antibiotic and antimicrobial peptide, likely involving disruption of bacterial membranes and inhibition of protein synthesis.",
    "relevance_score": 5,
    "paper_idx": 116,
    "pmid": "33204411",
    "title": "Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19.",
    "year": "2020",
    "doi": "10.12688/f1000research.26359.1",
    "journal": "F1000Research",
    "authors": [
      "Baby K",
      "Maity S",
      "Mehta C"
    ]
  },
  {
    "drugs": [
      {
        "name": "remdesivir",
        "drug_class": "antiviral nucleotide analog",
        "approved_for": "COVID-19"
      },
      {
        "name": "favipiravir",
        "drug_class": "RNA polymerase inhibitor",
        "approved_for": "COVID-19"
      },
      {
        "name": "ritonavir/lopinavir",
        "drug_class": "protease inhibitors",
        "approved_for": "HIV/AIDS"
      },
      {
        "name": "camostat mesylate",
        "drug_class": "serine protease inhibitor",
        "approved_for": "pancreatitis"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "carvacrol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carvacrol shows potential to inhibit SARS-CoV-2 Mpro and ACE2 activity, suggesting possible antiviral effects."
      },
      {
        "drug": "carvacrol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Docking studies indicate carvacrol may inhibit the spike protein's binding to host cell ACE2 receptor."
      }
    ],
    "mechanism": "Binding of carvacrol to viral protease Mpro and host cell receptor ACE2, potentially inhibiting viral replication and entry.",
    "relevance_score": 4,
    "paper_idx": 117,
    "pmid": "33243993",
    "title": "\u03b2-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.",
    "year": "2020",
    "doi": "10.1038/s41467-020-19849-9",
    "journal": "Nature communications",
    "authors": [
      "Zhang Y",
      "Li M",
      "Li L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 118,
    "pmid": "33258450",
    "title": "An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.",
    "year": "2020",
    "doi": "10.7554/eLife.58147",
    "journal": "eLife",
    "authors": [
      "Morley V",
      "Kinnear C",
      "Sim D"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "alcohol dependence medication",
        "approved_for": "alcohol dependence"
      }
    ],
    "pathogens": [
      {
        "name": "Entamoeba histolytica",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "Entamoeba histolytica",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disulfiram combined with zinc forms a zinc-ditiocarb complex (ZnDTC) that is highly effective against E. histolytica at low nanomolar concentrations, significantly below the serum levels achieved with standard doses."
      }
    ],
    "mechanism": "formation of metal complexes (ZnDTC) that inhibit the ubiquitin-proteasome pathway in the parasite",
    "relevance_score": 4,
    "paper_idx": 119,
    "pmid": "33345466",
    "title": "Drug repurposing: Antimicrobial and antibiofilm effects of penfluridol against Enterococcus faecalis.",
    "year": "2021",
    "doi": "10.1002/mbo3.1148",
    "journal": "MicrobiologyOpen",
    "authors": [
      "Zeng X",
      "She P",
      "Zhou L"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "antirheumatic",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "vancomycin",
        "drug_class": "glycopeptide antibiotic",
        "approved_for": "bacterial infections including MRSA"
      }
    ],
    "pathogens": [
      {
        "name": "Clostridioides difficile",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "Clostridioides difficile",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin demonstrated in vivo efficacy in hamster models, with survival rates comparable to vancomycin and significant reduction in bacterial load."
      },
      {
        "drug": "auranofin",
        "pathogen": "Clostridioides difficile",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin showed potential to prevent CDI recurrence, indicating activity against spores and biofilm formation."
      }
    ],
    "mechanism": "Inhibition of toxin and spore production in C. difficile, possibly through targeting bacterial virulence factors and biofilm formation.",
    "relevance_score": 4,
    "paper_idx": 120,
    "pmid": "33348292",
    "title": "Interferon-inducer antivirals: Potential candidates to combat COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.intimp.2020.107245",
    "journal": "International immunopharmacology",
    "authors": [
      "Bagheri A",
      "Moezzi S",
      "Mosaddeghi P"
    ]
  },
  {
    "drugs": [
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial infections"
      },
      {
        "name": "levofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ampicillin",
        "drug_class": "penicillin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ceftriaxone",
        "drug_class": "cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "doxycycline",
        "drug_class": "tetracycline",
        "approved_for": "bacterial infections"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "propranolol",
        "drug_class": "non-selective beta-blocker",
        "approved_for": "cardiovascular conditions"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "antipsychotic",
        "approved_for": "psychotic disorders"
      },
      {
        "name": "diclofenac",
        "drug_class": "NSAID",
        "approved_for": "pain and inflammation"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "XDR/PDR"
      }
    ],
    "findings": [
      {
        "drug": "ciprofloxacin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combinations of ciprofloxacin with chlorpromazine, propranolol, or diclofenac showed synergism in most XDR/PDR A. baumannii isolates."
      },
      {
        "drug": "levofloxacin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Levofloxacin combined with chlorpromazine, propranolol, or diclofenac demonstrated synergistic effects against resistant A. baumannii strains."
      },
      {
        "drug": "chlorpromazine",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 200,
        "fici": null,
        "key_result": "Chlorpromazine at 200 \u03bcg/ml significantly restored susceptibility of XDR A. baumannii to fluoroquinolones."
      },
      {
        "drug": "propranolol",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Propranolol at 0.5 mg/ml enhanced the activity of fluoroquinolones against resistant A. baumannii isolates."
      },
      {
        "drug": "diclofenac",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "Diclofenac at 4 mg/ml showed synergism with fluoroquinolones in resistant A. baumannii strains."
      }
    ],
    "mechanism": "Proposed mechanisms include disruption of bacterial cell processes and efflux pump inhibition by non-antimicrobial agents, restoring antibiotic susceptibility.",
    "relevance_score": 4,
    "paper_idx": 121,
    "pmid": "33362739",
    "title": "High-Throughput Identification of Antibacterials Against Pseudomonas aeruginosa.",
    "year": "2020",
    "doi": "10.3389/fmicb.2020.591426",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Li S",
      "She P",
      "Zhou L"
    ]
  },
  {
    "drugs": [
      {
        "name": "carvedilol",
        "drug_class": "beta-blocker",
        "approved_for": "heart failure"
      }
    ],
    "pathogens": [
      {
        "name": "HSV-1",
        "resistance_profile": "not specified"
      },
      {
        "name": "VSV",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "carvedilol",
        "pathogen": "HSV-1",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carvedilol rescues \u03b2-arrestin 2 expression, which is degraded during viral infection, thereby potentially enhancing antiviral immune responses."
      },
      {
        "drug": "carvedilol",
        "pathogen": "VSV",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carvedilol prevents degradation of \u03b2-arrestin 2 during VSV infection, supporting its potential as an antiviral agent."
      }
    ],
    "mechanism": "Carvedilol inhibits virus-induced degradation of \u03b2-arrestin 2, maintaining its levels to promote cGAS-STING pathway activation and enhance type I interferon responses.",
    "relevance_score": 4,
    "paper_idx": 122,
    "pmid": "33385878",
    "title": "The plausible mechanisms of tramadol for treatment of COVID-19.",
    "year": "2021",
    "doi": "10.1016/j.mehy.2020.110468",
    "journal": "Medical hypotheses",
    "authors": [
      "El-Ashmawy N",
      "Lashin A",
      "Okasha K"
    ]
  },
  {
    "drugs": [
      {
        "name": "tramadol",
        "drug_class": "opioid analgesic",
        "approved_for": "moderate to severe pain"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "bactericidal activity"
      }
    ],
    "findings": [
      {
        "drug": "tramadol",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "bactericidal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tramadol exhibits bactericidal activity against Pseudomonas aeruginosa, which may help prevent secondary bacterial infections in COVID-19 patients."
      },
      {
        "drug": "tramadol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "theoretical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Proposed mechanisms suggest tramadol may have anti-inflammatory, immune-modulatory, antioxidant, and cardioprotective effects that could benefit COVID-19 management."
      }
    ],
    "mechanism": "anti-inflammatory, immune-enhancing, hypocoagulable, antioxidant, cardioprotective, analgesic, antitussive, bactericidal, antidepressant effects",
    "relevance_score": 4,
    "paper_idx": 123,
    "pmid": "33471513",
    "title": "Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.",
    "year": "2021",
    "doi": "10.1021/acsinfecdis.0c00721",
    "journal": "ACS infectious diseases",
    "authors": [
      "Bibi M",
      "Murphy S",
      "Benhamou R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Colistin",
        "drug_class": "lipopeptide antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Fluconazole",
        "drug_class": "azole antifungal",
        "approved_for": "systemic fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "drug-resistant, tolerant"
      },
      {
        "name": "Saccharomyces cerevisiae",
        "resistance_profile": "wild isolate, susceptible"
      }
    ],
    "findings": [
      {
        "drug": "Colistin",
        "pathogen": "Candida albicans",
        "activity_type": "adjuvant|anti_biofilm|synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.31,
        "key_result": "Colistin synergizes with fluconazole, reducing tolerance and increasing cell death in fungal pathogens."
      },
      {
        "drug": "Fluconazole",
        "pathogen": "Candida albicans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo|clinical",
        "mic_ug_ml": null,
        "fici": 0.31,
        "key_result": "Fluconazole's efficacy is enhanced when combined with colistin, especially in tolerant strains."
      }
    ],
    "mechanism": "Colistin binds to fungal membrane lipids, permeabilizes the membrane, increases drug uptake, and enhances cell permeability, leading to increased cell death and reduced tolerance.",
    "relevance_score": 4,
    "paper_idx": 124,
    "pmid": "33504099",
    "title": "Biogenic Gold Nanoparticles Decrease Methylene Blue Photobleaching and Enhance Antimicrobial Photodynamic Therapy.",
    "year": "2021",
    "doi": "10.3390/molecules26030623",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Maliszewska I",
      "Wanarska E",
      "Thompson A"
    ]
  },
  {
    "drugs": [
      {
        "name": "terbinafine",
        "drug_class": "allylamine",
        "approved_for": "onychomycosis"
      },
      {
        "name": "amphotericin B",
        "drug_class": "polyene",
        "approved_for": "systemic fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Fusarium oxysporum",
        "resistance_profile": "MDR"
      },
      {
        "name": "Fusarium solani",
        "resistance_profile": "MDR"
      },
      {
        "name": "Fusarium fujikuroi",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "p-coumaric acid 3,3'-dimethyl allyl ester (compound 13)",
        "pathogen": "Fusarium spp.",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 62,
        "fici": null,
        "key_result": "Compound 13 showed antifungal activity comparable to terbinafine and amphotericin B against clinical Fusarium strains."
      }
    ],
    "mechanism": "The study suggests that prenylated cinnamic esters and ethers may exert antifungal activity potentially through membrane disruption or interference with fungal cell processes, although the exact mechanism remains to be elucidated.",
    "relevance_score": 4,
    "paper_idx": 125,
    "pmid": "33513915",
    "title": "Prenylated Trans-Cinnamic Esters and Ethers against Clinical Fusarium spp.: Repositioning of Natural Compounds in Antimicrobial Discovery.",
    "year": "2021",
    "doi": "10.3390/molecules26030658",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Oufensou S",
      "Casalini S",
      "Balmas V"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 126,
    "pmid": "33597253",
    "title": "Bepridil is potent against SARS-CoV-2 in vitro.",
    "year": "2021",
    "doi": "10.1073/pnas.2012201118",
    "journal": "Proceedings of the National Academy of Sciences of the United States of America",
    "authors": [
      "Vatansever E",
      "Yang K",
      "Drelich A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 127,
    "pmid": "33664752",
    "title": "Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.",
    "year": "2020",
    "doi": "10.3389/fpls.2020.601335",
    "journal": "Frontiers in plant science",
    "authors": [
      "Javed H",
      "Meeran M",
      "Jha N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Verapamil",
        "drug_class": "Calcium channel blocker",
        "approved_for": "Hypertension, angina, arrhythmia"
      },
      {
        "name": "Lacidipine",
        "drug_class": "Calcium channel blocker",
        "approved_for": "Hypertension"
      },
      {
        "name": "Captopril",
        "drug_class": "ACE inhibitor",
        "approved_for": "Hypertension, heart failure"
      },
      {
        "name": "Lisinopril",
        "drug_class": "ACE inhibitor",
        "approved_for": "Hypertension, heart failure"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "None (not applicable)"
      }
    ],
    "findings": [
      {
        "drug": "Verapamil",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In silico modeling suggests Verapamil may affect SARS-CoV-2 tissue disposition and potentially interfere with viral replication."
      },
      {
        "drug": "Lacidipine",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In silico predictions indicate Lacidipine's tissue penetration could support antiviral effects against SARS-CoV-2."
      },
      {
        "drug": "Captopril",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Computational modeling suggests Captopril may modulate ACE activity and influence COVID-19 pathogenesis."
      },
      {
        "drug": "Lisinopril",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Modeling indicates Lisinopril could impact ACE2 expression and potentially alter COVID-19 disease progression."
      }
    ],
    "mechanism": "Calcium channel blockers may inhibit viral entry and replication by modulating intracellular calcium influx; ACE inhibitors may alter ACE2 expression and inflammatory responses, potentially impacting viral pathogenesis.",
    "relevance_score": 4,
    "paper_idx": 128,
    "pmid": "33672669",
    "title": "A Novel Ivermectin-Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA.",
    "year": "2021",
    "doi": "10.3390/antibiotics10020208",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Tan X",
      "Xie H",
      "Zhang B"
    ]
  },
  {
    "drugs": [
      {
        "name": "CC-11050",
        "drug_class": "phosphodiesterase inhibitor",
        "approved_for": "not specified (investigational in this context)"
      },
      {
        "name": "everolimus",
        "drug_class": "mTOR inhibitor",
        "approved_for": "cancer, organ transplant rejection"
      },
      {
        "name": "auranofin",
        "drug_class": "gold salt anti-inflammatory agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "ergocalciferol",
        "drug_class": "vitamin D analog",
        "approved_for": "vitamin D deficiency, osteoporosis"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "rifampicin-susceptible"
      }
    ],
    "findings": [
      {
        "drug": "CC-11050",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "CC-11050 was safe and well tolerated, and may enhance lung function recovery in tuberculosis patients."
      },
      {
        "drug": "everolimus",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Everolimus was safe and may improve lung function recovery in tuberculosis patients."
      },
      {
        "drug": "auranofin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin was associated with serious adverse events including life-threatening thrombocytopenia and intra-abdominal sepsis, limiting its safety profile."
      },
      {
        "drug": "ergocalciferol",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ergocalciferol did not show significant effects on sputum culture conversion or lung function, and was associated with paradoxical reactions."
      }
    ],
    "mechanism": "Host-directed therapies modulate immune response, reduce inflammation, induce autophagy, and improve drug penetration to enhance treatment outcomes in tuberculosis.",
    "relevance_score": 4,
    "paper_idx": 129,
    "pmid": "33740465",
    "title": "Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.",
    "year": "2021",
    "doi": "10.1016/S2213-2600(20)30448-3",
    "journal": "The Lancet. Respiratory medicine",
    "authors": [
      "Wallis R",
      "Ginindza S",
      "Beattie T"
    ]
  },
  {
    "drugs": [
      {
        "name": "vancomycin",
        "drug_class": "glycopeptide",
        "approved_for": "bacterial infections (mainly Gram-positive)"
      },
      {
        "name": "rifampicin",
        "drug_class": "rifamycin",
        "approved_for": "tuberculosis and bacterial infections"
      },
      {
        "name": "penicillin",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "streptomycin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "tigecycline",
        "drug_class": "glycylcycline",
        "approved_for": "bacterial infections"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin",
        "approved_for": "multi-drug resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      },
      {
        "name": "Enterobacterales",
        "resistance_profile": "carbapenem-resistant Enterobacterales (CRE)"
      },
      {
        "name": "MCR-producing Enterobacterales",
        "resistance_profile": "colistin-resistant due to mcr gene"
      },
      {
        "name": "Bacterial species with Tet(X) expression",
        "resistance_profile": "tigecycline resistance"
      }
    ],
    "findings": [
      {
        "drug": "vancomycin",
        "pathogen": "Gram-positive bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Vancomycin remains effective against Gram-positive bacteria but resistance mechanisms are known."
      },
      {
        "drug": "rifampicin",
        "pathogen": "various bacteria including Mycobacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resistance to rifampicin can be mediated by mutations and enzymatic modification."
      },
      {
        "drug": "penicillin",
        "pathogen": "Gram-positive bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Penicillin resistance is primarily due to beta-lactamase production."
      },
      {
        "drug": "streptomycin",
        "pathogen": "various bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Aminoglycoside-modifying enzymes confer resistance to streptomycin."
      },
      {
        "drug": "tigecycline",
        "pathogen": "various bacteria including Tet(X) producers",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tet(X) enzymes hydroxylate tigecycline, leading to resistance."
      },
      {
        "drug": "colistin",
        "pathogen": "Gram-negative bacteria including MCR-producing strains",
        "activity_type": "direct_antibacterial",
        "evidence_type": "literature review",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "mcr gene confers colistin resistance by modifying lipid A."
      }
    ],
    "mechanism": "Repurposing non-antibiotic drugs as adjuvants to inhibit resistance mechanisms, enhance antibiotic activity, or restore efficacy of existing antibiotics.",
    "relevance_score": 4,
    "paper_idx": 130,
    "pmid": "33754035",
    "title": "Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.",
    "year": "2021",
    "doi": "10.7150/thno.56205",
    "journal": "Theranostics",
    "authors": [
      "Liu Y",
      "Tong Z",
      "Shi J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "alcohol dependence treatment",
        "approved_for": "alcohol dependence"
      }
    ],
    "pathogens": [
      {
        "name": "Helicobacter pylori",
        "resistance_profile": "drug-sensitive, amoxicillin-resistant, clarithromycin-resistant, metronidazole-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "Helicobacter pylori",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Disulfiram suppresses the growth of H. pylori strains at 1 \u00b5g/mL, regardless of their resistance to current antibiotics."
      },
      {
        "drug": "Disulfiram",
        "pathogen": "Helicobacter pylori",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disulfiram reduces the expression levels of virulence proteins urease, VacA, and CagA in H. pylori."
      }
    ],
    "mechanism": "Disulfiram exerts a bactericidal effect on H. pylori and decreases virulence protein expression, possibly through interference with bacterial growth and virulence factor production.",
    "relevance_score": 4,
    "paper_idx": 131,
    "pmid": "33777846",
    "title": "Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.633194",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Shirley D",
      "Sharma I",
      "Warren C"
    ]
  },
  {
    "drugs": [
      {
        "name": "silver sulfadiazine",
        "drug_class": "topical antibiotic",
        "approved_for": "burn wound infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "antibiotic-resistant strains (e.g., MRSA)"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug resistant strains"
      }
    ],
    "findings": [
      {
        "drug": "silver",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver ions exert bactericidal effects by binding to DNA, proteins, and membranes, causing morphological changes and impairing bacterial functions."
      },
      {
        "drug": "silver",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Silver targets bacterial DNA and proteins, leading to DNA condensation, structural changes, and increased permeability, contributing to its antibacterial activity."
      }
    ],
    "mechanism": "Silver ions bind to bacterial DNA, proteins, and membranes, causing DNA modification, protein inhibition via sulfhydryl group binding, and structural damage, leading to bacterial cell death.",
    "relevance_score": 4,
    "paper_idx": 132,
    "pmid": "33782498",
    "title": "In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.",
    "year": "2021",
    "doi": "10.1038/s41598-021-86595-3",
    "journal": "Scientific reports",
    "authors": [
      "Abutaleb N",
      "Seleem M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 133,
    "pmid": "33805419",
    "title": "Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.",
    "year": "2021",
    "doi": "10.3390/molecules26071912",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Chakravarty K",
      "Antontsev V",
      "Khotimchenko M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Bithionol",
        "drug_class": "anthelminthic",
        "approved_for": "anthelminthic infections"
      }
    ],
    "pathogens": [
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "antibiotic-resistant, including biofilm-associated infections"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "vancomycin-resistant (VRE)"
      }
    ],
    "findings": [
      {
        "drug": "Bithionol",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bithionol exhibits significant antimicrobial and antibiofilm effects against E. faecalis in vitro and reduces bacterial load in mouse peritonitis models."
      },
      {
        "drug": "Bithionol",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bithionol shows activity against vancomycin-resistant E. faecium in vitro and in vivo, disrupting bacterial membranes."
      }
    ],
    "mechanism": "disruption of bacterial cell membrane lipid bilayers",
    "relevance_score": 4,
    "paper_idx": 134,
    "pmid": "33810067",
    "title": "Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/antibiotics10030336",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Mir\u00f3-Canturri A",
      "Ayerbe-Algaba R",
      "Vila-Dom\u00ednguez A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Clofazimine",
        "drug_class": "riminophenazine antibiotic",
        "approved_for": "leprosy"
      },
      {
        "name": "Statins",
        "drug_class": "HMG-CoA reductase inhibitors",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Clofazimine",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial|adjuvant",
        "evidence_type": "clinical|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clofazimine shows efficacy against MDR-TB and enhances TCM responses while reducing TEM populations."
      },
      {
        "drug": "Statins",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant|immunomodulatory",
        "evidence_type": "in_vivo|clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Statins reduce bacterial burden, modulate immune responses, and synergize with first-line anti-TB drugs, potentially shortening therapy duration."
      }
    ],
    "mechanism": "Clofazimine releases reactive oxygen species and modulates potassium channels; statins inhibit cholesterol synthesis, enhance autophagy, and modulate cytokine responses.",
    "relevance_score": 4,
    "paper_idx": 135,
    "pmid": "33886255",
    "title": "Strategies to Combat Multi-Drug Resistance in Tuberculosis.",
    "year": "2021",
    "doi": "10.1021/acs.accounts.0c00878",
    "journal": "Accounts of chemical research",
    "authors": [
      "Singh V",
      "Chibale K"
    ]
  },
  {
    "drugs": [
      {
        "name": "praziquantel",
        "drug_class": "anthelminthic",
        "approved_for": "schistosomiasis"
      },
      {
        "name": "perhexiline",
        "drug_class": "antianginal agent",
        "approved_for": "angina pectoris"
      },
      {
        "name": "astemizole",
        "drug_class": "antihistaminic",
        "approved_for": "allergic conditions"
      }
    ],
    "pathogens": [
      {
        "name": "Schistosoma mansoni",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "perhexiline",
        "pathogen": "Schistosoma mansoni",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Perhexiline showed a defined anti-schistosomal phenotype on juvenile worms in vitro."
      },
      {
        "drug": "astemizole",
        "pathogen": "Schistosoma mansoni",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Astemizole demonstrated activity against juvenile worms in vitro."
      }
    ],
    "mechanism": "not explicitly proposed in the paper",
    "relevance_score": 2,
    "paper_idx": 136,
    "pmid": "33922083",
    "title": "Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.",
    "year": "2021",
    "doi": "10.3390/ijms22094371",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Al Mahi N",
      "Zhang E",
      "Sherman S"
    ]
  },
  {
    "drugs": [
      {
        "name": "methylene blue",
        "drug_class": "photosensitizer",
        "approved_for": "antimicrobial photodynamic therapy (experimental)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "methylene blue",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Methylene blue combined with biogenic gold nanoparticles significantly enhances bacterial photoinactivation under LED light, achieving up to 99.98% kill."
      },
      {
        "drug": "methylene blue",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination of methylene blue with biogenic gold nanoparticles significantly improves photodynamic killing of E. coli, reaching up to 99.99% kill after prolonged irradiation."
      }
    ],
    "mechanism": "enhancement of photodynamic activity through prevention of methylene blue photobleaching and improved cellular penetration facilitated by biogenic gold nanoparticles",
    "relevance_score": 4,
    "paper_idx": 137,
    "pmid": "33927718",
    "title": "Repurposing Immunomodulatory Drugs to Combat Tuberculosis.",
    "year": "2021",
    "doi": "10.3389/fimmu.2021.645485",
    "journal": "Frontiers in immunology",
    "authors": [
      "Fatima S",
      "Bhaskar A",
      "Dwivedi V"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 138,
    "pmid": "33961541",
    "title": "Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens.",
    "year": "2021",
    "doi": "10.1099/jmm.0.001363",
    "journal": "Journal of medical microbiology",
    "authors": [
      "Evans A",
      "Kavanagh K"
    ]
  },
  {
    "drugs": [
      {
        "name": "ruxolitinib",
        "drug_class": "JAK1/2 inhibitor",
        "approved_for": "myelofibrosis, polycythemia vera, graft-versus-host disease"
      },
      {
        "name": "baricitinib",
        "drug_class": "JAK1/2 inhibitor",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "interferon-alpha2",
        "drug_class": "interferon",
        "approved_for": "viral infections, certain cancers"
      },
      {
        "name": "interferon-beta",
        "drug_class": "interferon",
        "approved_for": "multiple sclerosis"
      },
      {
        "name": "statins",
        "drug_class": "HMG-CoA reductase inhibitors",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "hydroxyurea",
        "drug_class": "antimetabolite",
        "approved_for": "sickle cell anemia, certain cancers"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none"
      }
    ],
    "findings": [
      {
        "drug": "ruxolitinib",
        "pathogen": "SARS-CoV-2",
        "activity_type": "immunomodulation|anti_inflammatory",
        "evidence_type": "clinical|in_vivo|computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ruxolitinib may decrease mortality by dampening cytokine storm in COVID-19 patients."
      },
      {
        "drug": "baricitinib",
        "pathogen": "SARS-CoV-2",
        "activity_type": "immunomodulation|anti_inflammatory|antiviral",
        "evidence_type": "clinical|in_vivo|computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination of baricitinib and remdesivir reduces recovery time and accelerates clinical improvement in COVID-19."
      },
      {
        "drug": "interferon-alpha2",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial|antiviral|immunomodulation",
        "evidence_type": "clinical|in_vitro|computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Early treatment with IFN-alpha2 may prevent disease progression by inhibiting virus replication."
      },
      {
        "drug": "interferon-beta",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antiviral|immunomodulation",
        "evidence_type": "clinical|in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Inhaled IFN-beta shows potential in early COVID-19 treatment to inhibit viral replication."
      },
      {
        "drug": "statins",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_inflammatory|antithrombotic|antiviral",
        "evidence_type": "computational|in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Statins may be repurposed for COVID-19 due to anti-inflammatory and antithrombotic effects."
      },
      {
        "drug": "hydroxyurea",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_inflammatory|antithrombotic|antiviral",
        "evidence_type": "computational|in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Hydroxyurea's anti-inflammatory and antiviral potentials suggest possible repurposing for COVID-19."
      }
    ],
    "mechanism": "Inhibition of cytokine signaling pathways (JAK-STAT), boosting antiviral interferon responses, and reducing hyperinflammation and thrombosis.",
    "relevance_score": 4,
    "paper_idx": 139,
    "pmid": "33992887",
    "title": "COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.",
    "year": "2021",
    "doi": "10.1016/j.cytogfr.2021.03.006",
    "journal": "Cytokine & growth factor reviews",
    "authors": [
      "Hasselbalch H",
      "Skov V",
      "Kj\u00e6r L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Atorvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "HCoV-229E",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "HCoV-OC43",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "MERS-CoV",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "Murine hepatitis virus (MHV)",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "Porcine transmissible gastro-enteritis virus (PTGEV)",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "Porcine reproductive and respiratory syndrome virus (PRRSV)",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "Porcine epidemic diarrhea virus (PEDV)",
        "resistance_profile": "none (host-targeted approach)"
      },
      {
        "name": "Canine enteric virus (CECoV)",
        "resistance_profile": "none (host-targeted approach)"
      }
    ],
    "findings": [
      {
        "drug": "Atorvastatin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "theoretical/clinical hypothesis",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Proposes high-dose statins like Atorvastatin to inhibit virus entry by disrupting cholesterol-dependent membrane microdomains, potentially reducing COVID-19 severity."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "HCoV-229E",
        "activity_type": "adjuvant",
        "evidence_type": "experimental",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cholesterol-altering agents can reduce infection of cholesterol-dependent coronaviruses in vitro."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "HCoV-OC43",
        "activity_type": "adjuvant",
        "evidence_type": "experimental",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disruption of membrane microdomains may impair virus entry."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "MERS-CoV",
        "activity_type": "adjuvant",
        "evidence_type": "theoretical/experimental",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Potential to inhibit virus entry by perturbing cholesterol-rich membrane domains."
      }
    ],
    "mechanism": "Disruption of cholesterol-rich membrane microdomains (lipid rafts and caveolae) to inhibit virus entry into host cells.",
    "relevance_score": 4,
    "paper_idx": 140,
    "pmid": "34012274",
    "title": "Antibacterial Effects of Disulfiram in Helicobacter pylori.",
    "year": "2021",
    "doi": "10.2147/IDR.S299177",
    "journal": "Infection and drug resistance",
    "authors": [
      "Kobatake T",
      "Ogino K",
      "Sakae H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tamoxifen",
        "drug_class": "selective estrogen receptor modulator (SERM)",
        "approved_for": "breast cancer"
      },
      {
        "name": "N-desmethyltamoxifen",
        "drug_class": "tamoxifen metabolite",
        "approved_for": null
      },
      {
        "name": "4-hydroxytamoxifen",
        "drug_class": "tamoxifen metabolite",
        "approved_for": null
      },
      {
        "name": "Endoxifen",
        "drug_class": "tamoxifen metabolite",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "N-desmethyltamoxifen",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against A. baumannii."
      },
      {
        "drug": "4-hydroxytamoxifen",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against E. coli."
      },
      {
        "drug": "Endoxifen",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Exhibited bactericidal activity with MIC90 of 16 mg/L against E. coli."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "A. baumannii",
        "activity_type": "adjuvant|immune_modulation",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Reduced bacterial load and increased survival in immunosuppressed mice infected with A. baumannii."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "E. coli",
        "activity_type": "adjuvant|immune_modulation",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Reduced bacterial load and increased survival in immunosuppressed mice infected with E. coli."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant|immune_modulation",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Did not significantly reduce bacterial load or improve survival in P. aeruginosa infection models."
      }
    ],
    "mechanism": "Tamoxifen metabolites increase bacterial membrane permeability without affecting outer membrane protein profiles, leading to bacterial cell wall disruption.",
    "relevance_score": 4,
    "paper_idx": 141,
    "pmid": "34025592",
    "title": "Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.579806",
    "journal": "Frontiers in microbiology",
    "authors": [
      "She P",
      "Wang Y",
      "Li Y"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "drug_sensitive, MDR, XDR"
      }
    ],
    "findings": [],
    "mechanism": "Activation of autophagy to enhance host immune response and promote intracellular pathogen clearance.",
    "relevance_score": 2,
    "paper_idx": 142,
    "pmid": "34033658",
    "title": "Identification of hit compounds with anti-schistosomal activity on in vitro generated juvenile worms in cell-free medium.",
    "year": "2021",
    "doi": "10.1371/journal.pntd.0009432",
    "journal": "PLoS neglected tropical diseases",
    "authors": [
      "Vejzagi\u0107 N",
      "Prodjinotho U",
      "El-Khafif N"
    ]
  },
  {
    "drugs": [
      {
        "name": "simvastatin",
        "drug_class": "statins",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "atorvastatin",
        "drug_class": "statins",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "simvastatin",
        "pathogen": null,
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simvastatin inhibits type I interferon signaling by reducing surface expression of IFNAR1 and endocytosis, enhancing immune cell infiltration and antitumor activity in cancer models."
      },
      {
        "drug": "atorvastatin",
        "pathogen": null,
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin similarly inhibits IFN\u03b1 signaling and enhances immune responses in tumor models."
      }
    ],
    "mechanism": "Statins inhibit clathrin-mediated endocytosis and reduce surface expression of IFNAR1, transiently blocking type I interferon signaling to enhance antitumor immune responses.",
    "relevance_score": 2,
    "paper_idx": 143,
    "pmid": "34035383",
    "title": "Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs.",
    "year": "2021",
    "doi": "10.1038/s41598-021-90360-x",
    "journal": "Scientific reports",
    "authors": [
      "Mohammad H",
      "Abutaleb N",
      "Dieterly A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 144,
    "pmid": "34070995",
    "title": "Autophagy Induction as a Host-Directed Therapeutic Strategy against Mycobacterium tuberculosis Infection.",
    "year": "2021",
    "doi": "10.3390/medicina57060522",
    "journal": "Medicina (Kaunas, Lithuania)",
    "authors": [
      "Adikesavalu H",
      "Gopalaswamy R",
      "Kumar A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Dantrolene",
        "drug_class": "RyR antagonist",
        "approved_for": "malignant hyperthermia"
      },
      {
        "name": "Resveratrol",
        "drug_class": "polyphenol",
        "approved_for": "food supplement"
      },
      {
        "name": "Verapamil",
        "drug_class": "L-type calcium channel blocker",
        "approved_for": "hypertension, angina, arrhythmias"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "drug-susceptible, MDR"
      }
    ],
    "findings": [
      {
        "drug": "Dantrolene",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Dantrolene reduces necrotic death of infected macrophages by attenuating RyR activity, promoting autophagy, and potentially serving as a host-directed therapy for TB."
      },
      {
        "drug": "Resveratrol",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resveratrol enhances elimination of Mtb in macrophages by upregulating sirtuin 1 and modulating inflammatory responses."
      },
      {
        "drug": "Verapamil",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial|synergy|adjuvant",
        "evidence_type": "in_vitro|in_vivo|clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Verapamil exhibits bactericidal activity against Mtb, enhances autophagy, inhibits efflux pumps, and shows synergy with standard TB drugs, reducing bacterial load in models."
      }
    ],
    "mechanism": "Modulation of host ion channels affecting calcium signaling, autophagy, apoptosis, and efflux pump activity, as well as direct interference with bacterial efflux mechanisms.",
    "relevance_score": 4,
    "paper_idx": 145,
    "pmid": "34073235",
    "title": "Potential Tamoxifen Repurposing to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.",
    "year": "2021",
    "doi": "10.3390/ph14060507",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Mir\u00f3-Canturri A",
      "Ayerbe-Algaba R",
      "Del Toro R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tamoxifen",
        "drug_class": "Selective Estrogen Receptor Modulator (SERM)",
        "approved_for": "Breast cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Tamoxifen",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen reduced bacterial load and increased survival in murine models of A. baumannii infection."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen decreased bacterial burden and modulated immune response in P. aeruginosa infected mice."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen treatment led to reduced bacterial counts and improved survival in E. coli infection models."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen increased bacterial killing by macrophages and neutrophils in vitro."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen enhanced bacterial killing activity of immune cells against P. aeruginosa in vitro."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen improved macrophage and neutrophil bacterial killing of E. coli in vitro."
      }
    ],
    "mechanism": "Tamoxifen downregulates MCP-1 and IL-18, impairing immune cell migration from bone marrow to blood, and enhances immune cell bacterial killing activity.",
    "relevance_score": 4,
    "paper_idx": 146,
    "pmid": "34153377",
    "title": "Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.",
    "year": "2021",
    "doi": "10.1016/j.biochi.2021.06.005",
    "journal": "Biochimie",
    "authors": [
      "Orlowski S",
      "Mourad J",
      "Gallo A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 147,
    "pmid": "34248888",
    "title": "Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.676414",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Feng X",
      "Liu S",
      "Wang Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Sirolimus",
        "drug_class": "mTOR inhibitor",
        "approved_for": "LAM (Lymphangioleiomyomatosis)"
      },
      {
        "name": "AZD-8055",
        "drug_class": "mTOR inhibitor",
        "approved_for": null
      },
      {
        "name": "OSI-027",
        "drug_class": "mTOR inhibitor",
        "approved_for": null
      },
      {
        "name": "WYE-125132",
        "drug_class": "mTOR inhibitor",
        "approved_for": null
      },
      {
        "name": "Alvocidib",
        "drug_class": "CDK1/2 inhibitor",
        "approved_for": null
      },
      {
        "name": "Palbociclib",
        "drug_class": "CDK4/6 inhibitor",
        "approved_for": "breast cancer"
      },
      {
        "name": "CGP-60474",
        "drug_class": "CDK inhibitor",
        "approved_for": null
      },
      {
        "name": "PHA-793887",
        "drug_class": "CDK inhibitor",
        "approved_for": null
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Sirolimus",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Identified as capable of reverting LAM transcriptional signatures via scRNA-seq based connectivity analysis."
      },
      {
        "drug": "AZD-8055",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures as an mTOR inhibitor."
      },
      {
        "drug": "OSI-027",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures as an mTOR inhibitor."
      },
      {
        "drug": "WYE-125132",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures as an mTOR inhibitor."
      },
      {
        "drug": "Alvocidib",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Identified as negatively correlated with LAM signatures, suggesting potential therapeutic effect."
      },
      {
        "drug": "Palbociclib",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures, with known approval for breast cancer."
      },
      {
        "drug": "CGP-60474",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures as a CDK inhibitor."
      },
      {
        "drug": "PHA-793887",
        "pathogen": null,
        "activity_type": "direct_antibacterial",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to reverse LAM signatures as a CDK inhibitor."
      }
    ],
    "mechanism": "The drugs primarily act by inhibiting mTOR signaling pathways and cyclin-dependent kinases, thereby reversing disease-specific transcriptional signatures in LAM cells.",
    "relevance_score": 5,
    "paper_idx": 148,
    "pmid": "34248944",
    "title": "Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.",
    "year": "2021",
    "doi": "10.3389/fimmu.2021.665785",
    "journal": "Frontiers in immunology",
    "authors": [
      "Mitini-Nkhoma S",
      "Chimbayo E",
      "Mzinza D"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "gold-containing anti-rheumatic agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "mupirocin",
        "drug_class": "topical antibiotic",
        "approved_for": "skin infections"
      },
      {
        "name": "clindamycin",
        "drug_class": "lincosamide antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin rapidly eradicated MRSA in infected pressure ulcers in diabetic mice within four days, showing superior bacterial reduction compared to mupirocin and clindamycin."
      },
      {
        "drug": "auranofin",
        "pathogen": "MRSA",
        "activity_type": "anti_inflammatory",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin treatment decreased expression of pro-inflammatory cytokines IL-1\u03b2 and IL-17, and MMPs, while increasing biomarkers associated with wound healing such as IGF and VEGF."
      },
      {
        "drug": "mupirocin",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mupirocin reduced MRSA burden by 2.15-log10 in pressure ulcers but was less effective than auranofin."
      },
      {
        "drug": "clindamycin",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clindamycin reduced MRSA burden by 0.73-log10 in pressure ulcers, less effective than auranofin."
      }
    ],
    "mechanism": "Auranofin exerts antimicrobial activity through direct bacterial killing and modulates inflammation by decreasing pro-inflammatory cytokines and MMPs, while promoting wound healing biomarkers.",
    "relevance_score": 4,
    "paper_idx": 149,
    "pmid": "34321273",
    "title": "Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.",
    "year": "2021",
    "doi": "10.1136/jitc-2020-001587",
    "journal": "Journal for immunotherapy of cancer",
    "authors": [
      "Tenesaca S",
      "Vasquez M",
      "Alvarez M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "aldehyde dehydrogenase inhibitor",
        "approved_for": "alcohol addiction"
      }
    ],
    "pathogens": [
      {
        "name": "bacteria (via LPS-induced sepsis model)",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "bacteria (via LPS-induced sepsis model)",
        "activity_type": "adjuvant|anti_inflammatory",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disulfiram effectively reduces inflammation and improves survival in LPS-induced sepsis mouse models by inhibiting pyroptosis."
      }
    ],
    "mechanism": "Inhibition of gasdermin D (GSDMD)-mediated pore formation, suppressing pyroptosis and inflammatory cytokine release.",
    "relevance_score": 4,
    "paper_idx": 150,
    "pmid": "34364941",
    "title": "Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease.",
    "year": "2021",
    "doi": "10.1016/j.ijbiomac.2021.07.184",
    "journal": "International journal of biological macromolecules",
    "authors": [
      "Xu Y",
      "Chen K",
      "Pan J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "antirheumatic agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Aztreonam",
        "drug_class": "monobactam antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Avibactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "combination with ceftazidime"
      }
    ],
    "pathogens": [
      {
        "name": "Enterobacterales",
        "resistance_profile": "metallo-\u03b2-lactamase (MBL) producing, carbapenemase-producing"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Enterobacterales",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin potentiated the activity of aztreonam-avibactam against MBL-producing Enterobacterales and restored activity against ATM-AVI resistant mutants."
      }
    ],
    "mechanism": "displacement of Zn(II) cofactors from MBL active sites, inhibiting carbapenemase activity",
    "relevance_score": 5,
    "paper_idx": 151,
    "pmid": "34442776",
    "title": "Repurposing of the Fasciolicide Triclabendazole to Treat Infections Caused by Staphylococcus spp. and Vancomycin-Resistant Enterococci.",
    "year": "2021",
    "doi": "10.3390/microorganisms9081697",
    "journal": "Microorganisms",
    "authors": [
      "Pi H",
      "Ogunniyi A",
      "Savaliya B"
    ]
  },
  {
    "drugs": [
      {
        "name": "Penfluridol",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia, psychosis, Tourette\u2019s syndrome"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR (including MRSA)"
      }
    ],
    "findings": [
      {
        "drug": "Penfluridol",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "Penfluridol exhibits strong bactericidal activity against S. aureus with MIC of 4-8 \u03bcg/ml."
      },
      {
        "drug": "Penfluridol",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Penfluridol significantly inhibits biofilm formation and eradicates preformed biofilms in a dose-dependent manner."
      },
      {
        "drug": "Penfluridol",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_persister",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Penfluridol effectively kills MRSA persister cells in vitro and demonstrates efficacy in mouse infection models."
      }
    ],
    "mechanism": "Penfluridol induces bacterial membrane permeability, causes ATP release, and disrupts membrane integrity, leading to bacterial cell death.",
    "relevance_score": 5,
    "paper_idx": 152,
    "pmid": "34451920",
    "title": "In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii.",
    "year": "2021",
    "doi": "10.3390/ph14080823",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Yang T",
      "Tseng S",
      "Dlamini H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ivermectin",
        "drug_class": "antiparasitic",
        "approved_for": "helminth infections"
      },
      {
        "name": "Atorvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Ivermectin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ivermectin inhibits nuclear importin \u03b1 accumulation and impairs nuclear transport mechanisms in host cells infected with SARS-CoV-2."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin reduces Rho GTPases expression and impairs nuclear importin \u03b1 distribution in host cells infected with SARS-CoV-2."
      }
    ],
    "mechanism": "Ivermectin inhibits importin \u03b1/\u03b2-mediated nuclear transport, and atorvastatin affects actin cytoskeleton-dependent trafficking by reducing Rho GTPases activity, impairing viral protein transport and replication.",
    "relevance_score": 2,
    "paper_idx": 153,
    "pmid": "34468187",
    "title": "Ebselen Not Only Inhibits Clostridioides difficile Toxins but Displays Redox-Associated Cellular Killing.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00448-21",
    "journal": "Microbiology spectrum",
    "authors": [
      "Marreddy R",
      "Olaitan A",
      "May J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "none (experimental/repurposed compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Clostridioides difficile",
        "resistance_profile": "variable susceptibility; intrinsic resistance in ribotype 078"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Clostridioides difficile",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Ebselen inhibits most C. difficile strains with MICs of 2 to 8 \u03bcg/ml in BHI medium, except for ribotype 078 which is resistant."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Clostridioides difficile",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen disrupts intracellular redox homeostasis by altering NAD+/NADH ratio and depleting nonprotein thiols, contributing to bacterial killing."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Clostridioides difficile",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The study suggests potential anti-biofilm activity through redox disruption, but specific biofilm assays were not detailed."
      }
    ],
    "mechanism": "Ebselen kills C. difficile by disrupting redox homeostasis, altering NAD+/NADH ratios, depleting nonprotein thiols, and affecting cysteine metabolism, leading to oxidative stress and metabolic imbalance.",
    "relevance_score": 4,
    "paper_idx": 154,
    "pmid": "34489917",
    "title": "Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol Against Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.727692",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Liu Y",
      "She P",
      "Xu L"
    ]
  },
  {
    "drugs": [
      {
        "name": "tanshinone IIA sulfonate sodium",
        "drug_class": "traditional Chinese medicine derivative",
        "approved_for": "cardiovascular diseases"
      },
      {
        "name": "chloroxine",
        "drug_class": "antiseptic/antibacterial",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "targeted by drug repurposing"
      }
    ],
    "findings": [
      {
        "drug": "tanshinone IIA sulfonate sodium",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tanshinone IIA sulfonate sodium directly interacts with SARS-CoV-2 PLpro and inhibits its activity with IC50 below 10 \u03bcM."
      },
      {
        "drug": "chloroxine",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chloroxine directly interacts with SARS-CoV-2 PLpro and inhibits its activity with IC50 below 10 \u03bcM."
      }
    ],
    "mechanism": "binding to the active site of SARS-CoV-2 papain-like protease (PLpro), inhibiting its enzymatic activity",
    "relevance_score": 4,
    "paper_idx": 155,
    "pmid": "34523266",
    "title": "Polymyxin B-Triggered Assembly of Peptide Hydrogels for Localized and Sustained Release of Combined Antimicrobial Therapy.",
    "year": "2021",
    "doi": "10.1002/adhm.202101465",
    "journal": "Advanced healthcare materials",
    "authors": [
      "Shi Y",
      "Wareham D",
      "Yuan Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "organo-selenium compound",
        "approved_for": "none (experimental use)"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug resistant"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "multidrug resistant"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "antifungal resistant"
      }
    ],
    "findings": [
      {
        "drug": "ZnCexFe2\u2212xO4; X = 0.06",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 6.25,
        "fici": null,
        "key_result": "ZnCexFe2\u2212xO4; X = 0.06 significantly inhibited P. aeruginosa growth with a MIC of 6.250 \u00b5g/mL."
      },
      {
        "drug": "ZnCexFe2\u2212xO4; X = 0.06",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.39,
        "fici": null,
        "key_result": "ZnCexFe2\u2212xO4; X = 0.06 exhibited potent activity against S. aureus with a MIC of 0.390 \u00b5g/mL."
      },
      {
        "drug": "ZnCexFe2\u2212xO4; X = 0.06",
        "pathogen": "Candida albicans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.195,
        "fici": null,
        "key_result": "ZnCexFe2\u2212xO4; X = 0.06 showed antifungal activity with a MIC of 0.195 \u00b5g/mL."
      },
      {
        "drug": "Ebselen",
        "pathogen": "various bacteria and fungi",
        "activity_type": "adjuvant|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen combined with ZnCexFe2\u2212xO4 nanoparticles enhanced antimicrobial and antibiofilm effects."
      }
    ],
    "mechanism": "The nanoparticles induce morphological bacterial cell lysis, decrease viable microbial counts, and inhibit biofilm growth, likely through oxidative stress and membrane disruption.",
    "relevance_score": 4,
    "paper_idx": 156,
    "pmid": "34561552",
    "title": "Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.",
    "year": "2021",
    "doi": "10.1038/s41401-021-00770-w",
    "journal": "Acta pharmacologica Sinica",
    "authors": [
      "Ou A",
      "Zhang J",
      "Fang Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      },
      {
        "name": "Fusidic acid",
        "drug_class": "fusidic acid",
        "approved_for": "bacterial skin infections and other bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "antibiotic-sensitive or resistant strains"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Polymyxin B",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Localized and sustained release of PMB from the hydrogel effectively treated P. aeruginosa infection in vivo, reducing mortality from 93% to 13%."
      },
      {
        "drug": "Fusidic acid",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Incorporation of fusidic acid into the hydrogel enhanced antimicrobial activity against S. aureus."
      },
      {
        "drug": "Fusidic acid",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The hydrogel demonstrated enhanced antimicrobial effect against A. baumannii when fusidic acid was incorporated."
      }
    ],
    "mechanism": "Polymyxin B interacts electrostatically with bacterial outer membranes and disrupts membrane integrity; in the hydrogel, PMB is released in a sustained manner for localized antimicrobial activity.",
    "relevance_score": 2,
    "paper_idx": 157,
    "pmid": "34564137",
    "title": "Metabolites from Marine-Derived Fungi as Potential Antimicrobial Adjuvants.",
    "year": "2021",
    "doi": "10.3390/md19090475",
    "journal": "Marine drugs",
    "authors": [
      "Dur\u00e3es F",
      "Szemer\u00e9di N",
      "Kumla D"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "antibiotic resistant, MDR, biofilm formation, quorum sensing regulated virulence"
      }
    ],
    "findings": [
      {
        "drug": "phytochemicals",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Phytochemicals exhibit quorum quenching activity that can attenuate virulence factors and biofilm formation in P. aeruginosa."
      }
    ],
    "mechanism": "quorum sensing inhibition (quorum quenching) disrupting bacterial communication and virulence regulation",
    "relevance_score": 4,
    "paper_idx": 158,
    "pmid": "34576334",
    "title": "Influence of Ce3+ Substitution on Antimicrobial and Antibiofilm Properties of ZnCexFe2-xO4 Nanoparticles (X = 0.0, 0.02, 0.04, 0.06, and 0.08) Conjugated with Ebselen and Its Role Subsidised with \u03b3-Radiation in Mitigating Human TNBC and Colorectal Adenocarcinoma Proliferation In Vitro.",
    "year": "2021",
    "doi": "10.3390/ijms221810171",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Abdel-Rafei M",
      "Thabet N",
      "Abdel Maksoud M"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "efflux pump activity, biofilm formation"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "efflux pump activity, biofilm formation"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "efflux pump activity, biofilm formation"
      }
    ],
    "findings": [
      {
        "drug": "Acacia macrostachya extract",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The extract demonstrated significant efflux pump inhibition and biofilm formation reduction in S. aureus."
      },
      {
        "drug": "Acacia macrostachya extract",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The extract showed notable efflux pump inhibition and biofilm inhibition in E. coli."
      },
      {
        "drug": "Acacia macrostachya extract",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The extract exhibited efflux pump inhibition and antibiofilm activity against P. aeruginosa."
      },
      {
        "drug": "Stigmasterol",
        "pathogen": "not specified",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Stigmasterol was identified as a phytosterol component, potentially interacting with bacterial resistance mechanisms."
      }
    ],
    "mechanism": "The plant extracts contain phytochemicals such as flavonoids, tannins, and phytosterols that may inhibit bacterial efflux pumps and biofilm formation, thereby counteracting resistance mechanisms.",
    "relevance_score": 4,
    "paper_idx": 159,
    "pmid": "34589063",
    "title": "Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.688772",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Xu L",
      "She P",
      "Chen L"
    ]
  },
  {
    "drugs": [
      {
        "name": "N-desmethyltamoxifen (DTAM)",
        "drug_class": "selective estrogen receptor modulator (metabolite of tamoxifen)",
        "approved_for": "breast cancer"
      },
      {
        "name": "4-hydroxytamoxifen (HTAM)",
        "drug_class": "selective estrogen receptor modulator (metabolite of tamoxifen)",
        "approved_for": "breast cancer"
      },
      {
        "name": "Endoxifen (ENDX)",
        "drug_class": "selective estrogen receptor modulator (metabolite of tamoxifen)",
        "approved_for": "breast cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus epidermidis (MRSE)",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "Vancomycin-resistant (VRE)"
      }
    ],
    "findings": [
      {
        "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
        "pathogen": "MRSE",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "The mixture of tamoxifen metabolites exhibited bactericidal activity against MRSE strains at 4\u00d7 MIC with MIC90 of 2 mg/liter."
      },
      {
        "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
        "pathogen": "E. faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "The mixture showed bactericidal activity against vancomycin-resistant E. faecalis strains at 2\u00d7 MIC with MIC90 of 2 mg/liter."
      },
      {
        "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
        "pathogen": "MRSE",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The metabolites increased membrane permeability and potentially disrupt biofilms, contributing to antibacterial activity."
      },
      {
        "drug": "Tamoxifen metabolites mixture (DTAM, HTAM, ENDX)",
        "pathogen": "E. faecalis",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The metabolites increased membrane permeability of E. faecalis strains."
      }
    ],
    "mechanism": "The proposed mechanism involves increased bacterial membrane permeability, leading to disruption of cell integrity.",
    "relevance_score": 4,
    "paper_idx": 160,
    "pmid": "34668743",
    "title": "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00403-21",
    "journal": "Microbiology spectrum",
    "authors": [
      "Mir\u00f3-Canturri A",
      "Vila-Dom\u00ednguez A",
      "Caretero-Ledesma M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Candesartan Cilexetil",
        "drug_class": "angiotensin II receptor antagonist",
        "approved_for": "hypertension"
      },
      {
        "name": "Gentamicin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Tobramycin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Candesartan cilexetil exhibits strong antimicrobial activity against S. aureus with MICs of 8-16 \u03bcg/ml."
      },
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": "<0.5",
        "key_result": "It shows a synergistic antibacterial effect when combined with gentamicin and tobramycin."
      },
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Effective concentrations to inhibit MRSA biofilm formation were 16-64 \u03bcg/ml."
      },
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disrupted membrane permeability and damaged cell structure, indicating membrane-targeting activity."
      },
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Enhanced antibacterial effects when combined with conventional antibiotics."
      },
      {
        "drug": "Candesartan Cilexetil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "Killed intractable persisters at 4-8\u00d7 MIC."
      }
    ],
    "mechanism": "Disruption of membrane permeability and damage to cell structure.",
    "relevance_score": 5,
    "paper_idx": 161,
    "pmid": "34696514",
    "title": "Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.",
    "year": "2021",
    "doi": "10.3390/v13102084",
    "journal": "Viruses",
    "authors": [
      "Segatori V",
      "Garona J",
      "Caligiuri L"
    ]
  },
  {
    "drugs": [
      {
        "name": "AS101",
        "drug_class": "immunomodulator",
        "approved_for": "HIV infections, external genital warts, macular degeneration"
      }
    ],
    "pathogens": [
      {
        "name": "Carbapenem-resistant Acinetobacter baumannii",
        "resistance_profile": "CRAB"
      }
    ],
    "findings": [
      {
        "drug": "AS101",
        "pathogen": "CRAB",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "AS101 exhibited bactericidal activity against CRAB with MICs ranging from 0.5 to 32 \u03bcg/mL and was effective in reducing bacterial load in vitro."
      },
      {
        "drug": "AS101",
        "pathogen": "CRAB",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The antibacterial mechanism involves ROS accumulation and disruption of the bacterial cell membrane."
      },
      {
        "drug": "AS101",
        "pathogen": "CRAB",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Not explicitly tested for biofilm activity in this study."
      },
      {
        "drug": "AS101",
        "pathogen": "CRAB",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Not reported."
      },
      {
        "drug": "AS101",
        "pathogen": "CRAB",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, high-dose AS101 improved survival rates in a mouse sepsis model and significantly decreased bacterial loads in organs."
      }
    ],
    "mechanism": "AS101 induces accumulation of reactive oxygen species (ROS) and disrupts bacterial cell membrane integrity, leading to cell death.",
    "relevance_score": 4,
    "paper_idx": 162,
    "pmid": "34720766",
    "title": "Antibacterial, Antibiofilm, and Efflux Pump Inhibitory Properties of the Crude Extract and Fractions from Acacia macrostachya Stem Bark.",
    "year": "2021",
    "doi": "10.1155/2021/5381993",
    "journal": "TheScientificWorldJournal",
    "authors": [
      "Barfour A",
      "Mensah A",
      "Asante-Kwatia E"
    ]
  },
  {
    "drugs": [
      {
        "name": "HMGCR inhibitors",
        "drug_class": "statins",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "PCSK9 inhibitors",
        "drug_class": "PCSK9 inhibitors",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "NPC1L1 inhibitors",
        "drug_class": "ezetimibe",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none"
      }
    ],
    "findings": [
      {
        "drug": "HMGCR inhibitors",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Genetic evidence suggests that HMGCR inhibition may be associated with a reduced risk of COVID-19 hospitalization."
      },
      {
        "drug": "PCSK9 inhibitors",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No consistent evidence found for association between PCSK9 inhibitors and COVID-19 outcomes."
      },
      {
        "drug": "NPC1L1 inhibitors",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No significant association observed between NPC1L1 inhibitors and COVID-19 outcomes."
      }
    ],
    "mechanism": "Lipid-lowering drugs may reduce SARS-CoV-2 infection severity by modulating host lipid metabolism, which is involved in viral entry and replication processes.",
    "relevance_score": 2,
    "paper_idx": 163,
    "pmid": "34778107",
    "title": "In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-\u03b2-lactamase (MBL)-Producing Enterobacterales.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.755763",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Wang W",
      "Huang S",
      "Zou C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Eltrombopag",
        "drug_class": "thrombopoietin receptor agonist",
        "approved_for": "thrombocytopenia"
      },
      {
        "name": "Dronedarone HCl",
        "drug_class": "antiarrhythmic",
        "approved_for": "atrial fibrillation"
      },
      {
        "name": "Ceritinib",
        "drug_class": "ALK inhibitor",
        "approved_for": "lung cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR (including MRSA)"
      },
      {
        "name": "Streptococcus pneumoniae",
        "resistance_profile": null
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": null
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": null
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Eltrombopag",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1.4,
        "fici": null,
        "key_result": "Eltrombopag showed potent activity against S. aureus, including MDR strains, with MIC50 values around 1.4 mg/L."
      },
      {
        "drug": "Eltrombopag",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Eltrombopag reduced bacterial loads in infected mice, demonstrating in vivo efficacy."
      },
      {
        "drug": "Eltrombopag",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The study suggests potential for combination therapy, though specific synergy data is not detailed."
      }
    ],
    "mechanism": "Eltrombopag likely exerts a bacteriostatic effect by affecting bacterial stress response pathways and autolysin activity, involving mutations in regulatory genes such as ydeL and walR, and impairing enzymes like LytE and YokF.",
    "relevance_score": 4,
    "paper_idx": 164,
    "pmid": "34824393",
    "title": "Reversion of antibiotic resistance in multidrug-resistant pathogens using non-antibiotic pharmaceutical benzydamine.",
    "year": "2021",
    "doi": "10.1038/s42003-021-02854-z",
    "journal": "Communications biology",
    "authors": [
      "Liu Y",
      "Tong Z",
      "Shi J"
    ]
  },
  {
    "drugs": [
      {
        "name": "ethoxzolamide",
        "drug_class": "carbonic anhydrase inhibitor",
        "approved_for": "glaucoma, diuretic"
      },
      {
        "name": "acetazolamide",
        "drug_class": "carbonic anhydrase inhibitor",
        "approved_for": "glaucoma, epilepsy, altitude sickness, edema"
      }
    ],
    "pathogens": [
      {
        "name": "Neisseria gonorrhoeae",
        "resistance_profile": "drug-resistant, high-priority pathogen"
      }
    ],
    "findings": [
      {
        "drug": "ethoxzolamide",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Ethoxzolamide exhibited an MIC50 of 0.125 \u03bcg/mL against N. gonorrhoeae, 16-fold more potent than acetazolamide."
      },
      {
        "drug": "acetazolamide",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Both acetazolamide and ethoxzolamide demonstrated bacteriostatic activity and post-antibiotic effects against N. gonorrhoeae."
      }
    ],
    "mechanism": "Inhibition of bacterial carbonic anhydrase enzyme, with increased permeability of ethoxzolamide contributing to its higher potency.",
    "relevance_score": 4,
    "paper_idx": 165,
    "pmid": "34827309",
    "title": "Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections.",
    "year": "2021",
    "doi": "10.3390/antibiotics10111372",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Lee H",
      "Lee J",
      "Hwang J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 166,
    "pmid": "34843159",
    "title": "Repurposing phytochemicals as anti-virulent agents to attenuate quorum sensing-regulated virulence factors and biofilm formation in Pseudomonas aeruginosa.",
    "year": "2022",
    "doi": "10.1111/1751-7915.13981",
    "journal": "Microbial biotechnology",
    "authors": [
      "Chadha J",
      "Harjai K",
      "Chhibber S"
    ]
  },
  {
    "drugs": [
      {
        "name": "fusidic acid",
        "drug_class": "fusidic acid",
        "approved_for": "bacterial infections (e.g., skin infections)"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin",
        "approved_for": "serious Gram-negative bacterial infections"
      },
      {
        "name": "levonadifloxacin (WCK-771)",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial skin infections (ABSSSI)"
      },
      {
        "name": "apramycin",
        "drug_class": "aminoglycoside",
        "approved_for": "veterinary use for enteric infections in animals"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "apramycin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo mouse studies showed apramycin reduced bacterial load against carbapenem-resistant A. baumannii."
      }
    ],
    "mechanism": "not explicitly proposed in the paper; generally, aminoglycosides inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit.",
    "relevance_score": 3,
    "paper_idx": 167,
    "pmid": "34848761",
    "title": "Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence.",
    "year": "2021",
    "doi": "10.1038/s41598-021-02353-5",
    "journal": "Scientific reports",
    "authors": [
      "Hsieh K",
      "Wang Y",
      "Chen L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Azithromycin",
        "drug_class": "macrolide antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Atorvastatin",
        "drug_class": "HMG-CoA reductase inhibitor",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "Aspirin",
        "drug_class": "NSAID/antiplatelet agent",
        "approved_for": "pain, inflammation, cardiovascular prevention"
      },
      {
        "name": "Acetaminophen",
        "drug_class": "analgesic/antipyretic",
        "approved_for": "pain, fever"
      },
      {
        "name": "Albuterol",
        "drug_class": "beta-2 adrenergic agonist",
        "approved_for": "asthma, COPD"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (viral pathogen)"
      }
    ],
    "findings": [
      {
        "drug": "Azithromycin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Azithromycin was identified as a top candidate with potential synergistic effects against COVID-19 based on network embedding and validation."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin showed potential efficacy in the drug ranking model and validation with genetic and clinical data."
      },
      {
        "drug": "Aspirin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Aspirin was prioritized as a candidate with possible anti-inflammatory and anti-virulence effects relevant to COVID-19."
      },
      {
        "drug": "Acetaminophen",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Acetaminophen was identified as a top candidate based on network analysis and validation data."
      },
      {
        "drug": "Albuterol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Albuterol was highlighted as a potential repurposable drug with supportive validation evidence."
      }
    ],
    "mechanism": "The proposed mechanism involves modulation of immune response and anti-inflammatory effects, as well as potential direct antiviral activity through network-based representation and validation.",
    "relevance_score": 2,
    "paper_idx": 168,
    "pmid": "34866576",
    "title": "Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.",
    "year": "2021",
    "doi": "10.7554/eLife.73873",
    "journal": "eLife",
    "authors": [
      "Huang W",
      "Xiao J",
      "Ji J"
    ]
  },
  {
    "drugs": [
      {
        "name": "benzydamine",
        "drug_class": "non-steroidal anti-inflammatory drug",
        "approved_for": "local anti-inflammatory, analgesic"
      },
      {
        "name": "doxycycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "tetracycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "oxytetracycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "minocycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "tigecycline",
        "drug_class": "glycylcycline antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      },
      {
        "name": "VRE",
        "resistance_profile": "vancomycin-resistant Enterococci"
      },
      {
        "name": "E. coli G6",
        "resistance_profile": "blaNDM-5 positive, carbapenem-resistant"
      },
      {
        "name": "K. pneumoniae D120",
        "resistance_profile": "mcr-1 positive, colistin-resistant"
      },
      {
        "name": "A. baumannii C222",
        "resistance_profile": "tet(X)-positive, tigecycline-resistant"
      }
    ],
    "findings": [
      {
        "drug": "benzydamine",
        "pathogen": "MRSA",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.188,
        "key_result": "Benzydamine significantly potentiated doxycycline activity against MRSA, reducing its MIC from 16 to 1 \u03bcg/mL."
      },
      {
        "drug": "benzydamine",
        "pathogen": "VRE",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Benzydamine enhanced doxycycline efficacy against VRE, lowering MIC values by 4-fold."
      },
      {
        "drug": "benzydamine",
        "pathogen": "E. coli G6",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Benzydamine potentiated doxycycline activity against blaNDM-5-positive E. coli, decreasing MICs significantly."
      },
      {
        "drug": "benzydamine",
        "pathogen": "K. pneumoniae D120",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.375,
        "key_result": "Benzydamine restored doxycycline activity against mcr-1-carrying K. pneumoniae, reducing MICs."
      },
      {
        "drug": "benzydamine",
        "pathogen": "A. baumannii C222",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Benzydamine enhanced doxycycline activity against tet(X)-positive A. baumannii, lowering MICs."
      }
    ],
    "mechanism": "Benzydamine dissipates bacterial membrane potential (\u0394\u03a8), upregulates transmembrane proton gradient (\u0394pH), promotes antibiotic uptake, and triggers oxidative stress via ROS production, thereby reversing resistance and enhancing antibiotic efficacy.",
    "relevance_score": 5,
    "paper_idx": 169,
    "pmid": "34884459",
    "title": "Effects of Itxasol\u00a9 Components on Gene Expression in Bacteria Related to Infections of the Urinary Tract and to the Inflammation Process.",
    "year": "2021",
    "doi": "10.3390/ijms222312655",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Cela-L\u00f3pez J",
      "Camacho Rold\u00e1n C",
      "G\u00f3mez-Lizarraga G"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 170,
    "pmid": "34894972",
    "title": "Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae.",
    "year": "2022",
    "doi": "10.1080/14756366.2021.1991336",
    "journal": "Journal of enzyme inhibition and medicinal chemistry",
    "authors": [
      "Abutaleb N",
      "Elhassanny A",
      "Nocentini A"
    ]
  },
  {
    "drugs": [
      {
        "name": "\u03b2-Arbutin",
        "drug_class": "natural compound / antimicrobial agent",
        "approved_for": "traditional treatment of urinary infections"
      },
      {
        "name": "Umbelliferon",
        "drug_class": "natural compound / antifungal and antimicrobial agent",
        "approved_for": "not specifically approved, used as a plant-derived compound with antimicrobial activity"
      },
      {
        "name": "N-acetyl cysteine",
        "drug_class": "mucolytic / antioxidant / biofilm disruptor",
        "approved_for": "mucolytic therapy, acetaminophen overdose antidote"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "antibiotic resistant strains common in UTIs"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "noted for biofilm formation and resistance"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "fungal resistance"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "antibiotic resistant strains"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "including MRSA"
      }
    ],
    "findings": [
      {
        "drug": "\u03b2-Arbutin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "\u03b2-Arbutin exhibits antimicrobial activity against E. coli and impairs biofilm formation."
      },
      {
        "drug": "\u03b2-Arbutin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "\u03b2-Arbutin inhibits S. aureus growth and biofilm development."
      },
      {
        "drug": "Umbelliferon",
        "pathogen": "Candida albicans",
        "activity_type": "anti_fungal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Umbelliferon demonstrates potent antifungal activity against C. albicans."
      },
      {
        "drug": "N-acetyl cysteine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NAC disrupts P. aeruginosa biofilms and may inhibit efflux mechanisms."
      }
    ],
    "mechanism": "The components of Itxasol\u00a9 act through antimicrobial effects, biofilm disruption, anti-inflammatory modulation, and antioxidant activity, collectively reducing bacterial virulence and resistance mechanisms.",
    "relevance_score": 4,
    "paper_idx": 171,
    "pmid": "34905109",
    "title": "Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?",
    "year": "2021",
    "doi": "10.1007/s00284-021-02693-5",
    "journal": "Current microbiology",
    "authors": [
      "Gontijo A",
      "Pereira S",
      "de Lacerda Bonfante H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "anti-arthritis gold compound",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "MS-40S",
        "drug_class": "auranofin analog",
        "approved_for": null
      },
      {
        "name": "MS-40",
        "drug_class": "auranofin analog",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Burkholderia cenocepacia",
        "resistance_profile": "intrinsic drug resistance"
      },
      {
        "name": "Burkholderia mallei",
        "resistance_profile": "variable, some susceptibility"
      },
      {
        "name": "Burkholderia pseudomallei",
        "resistance_profile": "variable, some susceptibility"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multi-drug resistant"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "including MRSA"
      }
    ],
    "findings": [
      {
        "drug": "MS-40S",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S is bactericidal against B. cenocepacia, killing stationary-phase cells and persisters without resistance development."
      },
      {
        "drug": "MS-40",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40 is bactericidal against B. cenocepacia, killing stationary-phase cells and persisters without resistance development."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Burkholderia mallei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S shows activity against B. mallei with low MICs."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S shows activity against B. pseudomallei with low MICs."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S exhibits bactericidal activity with MICs 1-16 \u03bcg/mL."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S is bactericidal against S. aureus, including MRSA."
      }
    ],
    "mechanism": "likely involves disruption of thiol-redox homeostasis via inhibition of thioredoxin reductase, similar to auranofin.",
    "relevance_score": 5,
    "paper_idx": 172,
    "pmid": "34908453",
    "title": "Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.1128/Spectrum.00951-21",
    "journal": "Microbiology spectrum",
    "authors": [
      "Mahey N",
      "Tambat R",
      "Chandal N"
    ]
  },
  {
    "drugs": [
      {
        "name": "HDC1",
        "drug_class": "\u03b2-carboline derivative",
        "approved_for": "none (experimental compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "HDC1",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 48.23,
        "fici": null,
        "key_result": "HDC1 exhibits bactericidal activity against multidrug-resistant A. baumannii with an IC50 of 48.23 \u00b5M."
      },
      {
        "drug": "HDC1",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "HDC1 impairs growth of 43 clinical A. baumannii isolates, including carbapenem-resistant strains."
      }
    ],
    "mechanism": "not explicitly proposed in the paper",
    "relevance_score": 4,
    "paper_idx": 173,
    "pmid": "34943654",
    "title": "New Auranofin Analogs with Antibacterial Properties against Burkholderia Clinical Isolates.",
    "year": "2021",
    "doi": "10.3390/antibiotics10121443",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Maydaniuk D",
      "Wu B",
      "Truong D"
    ]
  },
  {
    "drugs": [
      {
        "name": "Eltrombopag",
        "drug_class": "thrombopoietin receptor agonist",
        "approved_for": "idiopathic thrombocytopenic purpura (ITP)"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Eltrombopag",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Eltrombopag exhibits antimicrobial activity against MRSA and its biofilms by interfering with proton motive force."
      },
      {
        "drug": "Eltrombopag",
        "pathogen": "MRSA",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo models confirmed the efficacy of eltrombopag in treating MRSA infections."
      }
    ],
    "mechanism": "interference with proton motive force in S. aureus",
    "relevance_score": 5,
    "paper_idx": 174,
    "pmid": "35011432",
    "title": "A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.",
    "year": "2021",
    "doi": "10.3390/molecules27010196",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Poulsen M",
      "Dastidar S",
      "Roy D"
    ]
  },
  {
    "drugs": [
      {
        "name": "Unithiol",
        "drug_class": "Heavy metal antidote / chelating agent",
        "approved_for": "metal poisoning"
      },
      {
        "name": "L-captopril",
        "drug_class": "ACE inhibitor",
        "approved_for": "hypertension"
      },
      {
        "name": "EDTA",
        "drug_class": "Chelating agent",
        "approved_for": "not approved as a drug, used as a laboratory reagent"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "carbapenem-resistant, producing NDM-1"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "carbapenem-resistant, producing VIM-2"
      }
    ],
    "findings": [
      {
        "drug": "Unithiol",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Unithiol acts as a competitive inhibitor of metallo-\u03b2-lactamases NDM-1, inhibiting meropenem hydrolysis with a KI of 16.7 \u00b5M."
      },
      {
        "drug": "Unithiol",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Unithiol inhibits natural VIM-2 metallo-\u03b2-lactamases, increasing zones of inhibition in disk diffusion assays and protecting antibiotics from hydrolysis."
      }
    ],
    "mechanism": "Unithiol binds to the active site of metallo-\u03b2-lactamases by coordinating with zinc ions via its thiol group, occupying the same position as the catalytic hydroxide, thus inhibiting enzyme activity.",
    "relevance_score": 5,
    "paper_idx": 175,
    "pmid": "35011508",
    "title": "Development of Phenothiazine Hybrids with Potential Medicinal Interest: A Review.",
    "year": "2022",
    "doi": "10.3390/molecules27010276",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Posso M",
      "Domingues F",
      "Ferreira S"
    ]
  },
  {
    "drugs": [
      {
        "name": "raloxifene",
        "drug_class": "selective estrogen receptor modulator",
        "approved_for": "osteoporosis, breast cancer risk reduction"
      },
      {
        "name": "ezetimibe",
        "drug_class": "cholesterol absorption inhibitor",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "propafenone",
        "drug_class": "antiarrhythmic agent",
        "approved_for": "arrhythmias"
      },
      {
        "name": "nefazodone",
        "drug_class": "antidepressant (serotonin antagonist and reuptake inhibitor)",
        "approved_for": "depression"
      },
      {
        "name": "chlorprothixene",
        "drug_class": "antipsychotic (thioxanthene derivative)",
        "approved_for": "schizophrenia"
      },
      {
        "name": "pyrvinium",
        "drug_class": "anthelmintic",
        "approved_for": "intestinal parasites"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "efflux pump-mediated resistance, MRSA"
      }
    ],
    "findings": [
      {
        "drug": "raloxifene",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Raloxifene inhibits NorA efflux pump, synergizes with ciprofloxacin, and enhances biofilm eradication in S. aureus."
      },
      {
        "drug": "ezetimibe",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Ezetimibe acts as a NorA efflux pump inhibitor, potentiates fluoroquinolones, and reduces biofilm formation."
      },
      {
        "drug": "propafenone",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Propafenone inhibits NorA, enhances ciprofloxacin activity, and shows synergy in vitro."
      },
      {
        "drug": "nefazodone",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Nefazodone inhibits NorA, synergizes with fluoroquinolones, and improves bacterial eradication."
      },
      {
        "drug": "chlorprothixene",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Chlorprothixene inhibits NorA, enhances antibiotic susceptibility, and shows synergistic effects."
      },
      {
        "drug": "pyrvinium",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 0.39,
        "fici": 0.5,
        "key_result": "Pyrvinium inhibits NorA, potentiates ciprofloxacin, reduces biofilms, and significantly decreases bacterial burden in a murine model."
      }
    ],
    "mechanism": "The drugs bind to and block the NorA efflux pump, inhibiting the extrusion of antibiotics and dyes, thereby increasing bacterial susceptibility and biofilm eradication.",
    "relevance_score": 5,
    "paper_idx": 176,
    "pmid": "35018330",
    "title": "Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030.",
    "year": "2021",
    "doi": "10.1099/acmi.0.000288",
    "journal": "Access microbiology",
    "authors": [
      "Kornelsen V",
      "Unger M",
      "Kumar A"
    ]
  },
  {
    "drugs": [
      {
        "name": "risedronate",
        "drug_class": "bisphosphonate",
        "approved_for": "osteoporosis"
      },
      {
        "name": "methotrexate",
        "drug_class": "antimetabolite",
        "approved_for": "cancer, rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "NDM-1 producing bacteria",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "risedronate",
        "pathogen": "NDM-1 producing bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Risedronate binds stably to NDM-1, forming hydrogen bonds and electrostatic interactions, and decreases catalytic efficiency of NDM-1 in vitro."
      },
      {
        "drug": "methotrexate",
        "pathogen": "NDM-1 producing bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Methotrexate binds to NDM-1 with high affinity, forming multiple hydrogen bonds and electrostatic interactions, reducing enzyme activity in vitro."
      }
    ],
    "mechanism": "Inhibition of NDM-1 enzymatic activity through stable binding at the active site, involving hydrogen bonds and electrostatic interactions with catalytic residues and zinc ions.",
    "relevance_score": 4,
    "paper_idx": 177,
    "pmid": "35039683",
    "title": "Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability.",
    "year": "2022",
    "doi": "10.1038/s41565-021-01048-2",
    "journal": "Nature nanotechnology",
    "authors": [
      "Burke J",
      "Zhang X",
      "Bobbala S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 178,
    "pmid": "35058577",
    "title": "Pharmacological evaluation of disulfiram analogs as antimicrobial agents and their application as inhibitors of fosB-mediated fosfomycin resistance.",
    "year": "2022",
    "doi": "10.1038/s41429-022-00500-2",
    "journal": "The Journal of antibiotics",
    "authors": [
      "Lewis A",
      "Riedel T",
      "Kesler M"
    ]
  },
  {
    "drugs": [
      {
        "name": "atorvastatin",
        "drug_class": "statins",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "pandrug resistant"
      }
    ],
    "findings": [
      {
        "drug": "atorvastatin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 512,
        "fici": null,
        "key_result": "Atorvastatin showed no antimicrobial activity against A. baumannii strains, including ATCC17978 and a pandrug resistant isolate."
      },
      {
        "drug": "atorvastatin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin did not potentiate the activity of ciprofloxacin or tobramycin against A. baumannii."
      }
    ],
    "mechanism": "not specifically proposed; lack of activity suggests no direct antimicrobial or efflux pump inhibition effect observed.",
    "relevance_score": 1,
    "paper_idx": 179,
    "pmid": "35138168",
    "title": "Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria.",
    "year": "2022",
    "doi": "10.1128/spectrum.01578-21",
    "journal": "Microbiology spectrum",
    "authors": [
      "Deng T",
      "Jia Y",
      "Tong Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "chlorprothixene",
        "drug_class": "thioxanthenes",
        "approved_for": "antipsychotic"
      },
      {
        "name": "clopenthixol",
        "drug_class": "thioxanthenes",
        "approved_for": "antipsychotic"
      },
      {
        "name": "thiothixene",
        "drug_class": "thioxanthenes",
        "approved_for": "antipsychotic"
      },
      {
        "name": "flupenthixol",
        "drug_class": "thioxanthenes",
        "approved_for": "antipsychotic"
      }
    ],
    "pathogens": [
      {
        "name": "Gram-positive bacteria",
        "resistance_profile": "broad-spectrum"
      },
      {
        "name": "Gram-negative bacteria",
        "resistance_profile": "broad-spectrum"
      }
    ],
    "findings": [
      {
        "drug": "clopenthixol",
        "pathogen": "Gram-positive bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clopenthixol exhibits moderate to powerful antibacterial activity against both Gram-positive and Gram-negative bacteria."
      }
    ],
    "mechanism": "The proposed mechanism involves the inhibition of microbial growth, potentially through interference with bacterial cell processes, although specific mechanisms are not detailed in the paper.",
    "relevance_score": 2,
    "paper_idx": 180,
    "pmid": "35140693",
    "title": "Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2021",
    "doi": "10.3389/fmicb.2021.790686",
    "journal": "Frontiers in microbiology",
    "authors": [
      "She P",
      "Li S",
      "Zhou L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Zidovudine (AZT)",
        "drug_class": "antiviral",
        "approved_for": "HIV/AIDS"
      },
      {
        "name": "Ciclopirox (CPX)",
        "drug_class": "antifungal",
        "approved_for": "superficial fungal infections (dermatophytosis, pityriasis, onychomycosis, candidiasis)"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR, \u03b2-lactamase-producing, AZT-resistant"
      },
      {
        "name": "Salmonella",
        "resistance_profile": "not specified"
      },
      {
        "name": "Acinetobacter spp.",
        "resistance_profile": "not specified"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "not specified"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Ciclopirox (CPX)",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "CPX was more active against \u03b2-lactamase-producing MDR E. coli strains and effectively killed AZT-resistant strains."
      },
      {
        "drug": "Zidovudine (AZT)",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AZT displayed no selectivity for resistant strains and resistance developed rapidly within 2 days."
      },
      {
        "drug": "Ciclopirox (CPX)",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resistance to CPX was not observed after 25 days of continuous exposure, indicating low propensity for resistance development."
      }
    ],
    "mechanism": "CPX chelates polyvalent metal cations such as iron, inhibiting metal-dependent enzymes, disrupting membrane permeability, DNA repair, and cell division, leading to antibacterial effects.",
    "relevance_score": 4,
    "paper_idx": 181,
    "pmid": "35141168",
    "title": "Antimicrobial Activity of a Repurposed Harmine-Derived Compound on Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.",
    "year": "2021",
    "doi": "10.3389/fcimb.2021.789672",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Breine A",
      "Van Gysel M",
      "Elsocht M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Bismuth nitrate",
        "drug_class": "metal compound",
        "approved_for": "stomach-associated diseases"
      },
      {
        "name": "Bismuth sulfate",
        "drug_class": "metal compound",
        "approved_for": "stomach-associated diseases"
      },
      {
        "name": "Bismuth subnitrate",
        "drug_class": "metal compound",
        "approved_for": "stomach-associated diseases"
      },
      {
        "name": "Bismuth ammonium citrate",
        "drug_class": "metal compound",
        "approved_for": "stomach-associated diseases"
      },
      {
        "name": "Bismuth triflate",
        "drug_class": "metal compound",
        "approved_for": "stomach-associated diseases"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli B3-1",
        "resistance_profile": "tet(X4)-positive, tigecycline-resistant"
      },
      {
        "name": "Acinetobacter baumannii C222",
        "resistance_profile": "tet(X4)-positive"
      }
    ],
    "findings": [
      {
        "drug": "Bismuth nitrate",
        "pathogen": "Escherichia coli B3-1",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.125,
        "key_result": "Bismuth nitrate synergistically enhances tigecycline activity against tet(X4)-positive bacteria by inhibiting Tet(X4) enzymatic activity."
      },
      {
        "drug": "Bismuth nitrate",
        "pathogen": "Escherichia coli B3-1",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.125,
        "key_result": "Bismuth nitrate significantly reduces the MIC of tigecycline and prevents resistance development in tet(X4)-positive bacteria."
      },
      {
        "drug": "Bismuth nitrate",
        "pathogen": "Acinetobacter baumannii C222",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.188,
        "key_result": "Bismuth nitrate synergizes with tigecycline to restore activity against tet(X4)-positive A. baumannii."
      },
      {
        "drug": "Bismuth nitrate",
        "pathogen": "Escherichia coli B3-1",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bismuth nitrate inhibits Tet(X4) enzymatic activity by binding to its active site, restoring tigecycline efficacy."
      }
    ],
    "mechanism": "Bismuth drugs competitively bind to the active center of Tet(X4) enzyme, inhibiting its enzymatic activity and preventing tigecycline degradation.",
    "relevance_score": 5,
    "paper_idx": 182,
    "pmid": "35163756",
    "title": "Drug Repurposing of the Unithiol: Inhibition of Metallo-\u03b2-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.",
    "year": "2022",
    "doi": "10.3390/ijms23031834",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Grigorenko V",
      "Khrenova M",
      "Andreeva I"
    ]
  },
  {
    "drugs": [
      {
        "name": "methylen blue",
        "drug_class": "dye",
        "approved_for": "antimalarial"
      },
      {
        "name": "ziprasidone",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      },
      {
        "name": "duloxetine",
        "drug_class": "antidepressant",
        "approved_for": "depression, anxiety"
      },
      {
        "name": "lapatinib",
        "drug_class": "tyrosine kinase inhibitor",
        "approved_for": "breast cancer"
      },
      {
        "name": "trifluoperazine",
        "drug_class": "phenothiazine antipsychotic",
        "approved_for": "schizophrenia"
      }
    ],
    "pathogens": [
      {
        "name": "cancer cells",
        "resistance_profile": "drug resistant"
      }
    ],
    "findings": [
      {
        "drug": "phenothiazine hybrid with 1,2,4-triazolo[4,3-a]pyridine",
        "pathogen": "cancer cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A phenothiazine-triazolopyridine hybrid induced apoptosis and showed cytotoxic effects against multiple human breast cancer cell lines, with selective activity and potential to disrupt cell cycle via tubulin binding."
      },
      {
        "drug": "phenothiazine derivative with tubulin polymerization inhibitory effect",
        "pathogen": "cancer cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A phenothiazine-based hybrid inhibited gastric cancer cell proliferation, migration, and tubulin polymerization, with in vivo tumor growth inhibition demonstrated in mice."
      },
      {
        "drug": "phenothiazine hybrid with 1,2,3-triazole",
        "pathogen": "cancer cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Methylene-bridged phenothiazine-triazole hybrids showed potent antiproliferative activity against various cancer cell lines, with activity influenced by substituents on the phenyl ring."
      }
    ],
    "mechanism": "binding to tubulin and disrupting microtubule dynamics, inducing apoptosis, and inhibiting cell migration and proliferation",
    "relevance_score": 4,
    "paper_idx": 183,
    "pmid": "35203788",
    "title": "Drug Repurposing Targeting Pseudomonas aeruginosa MvfR Using Docking, Virtual Screening, Molecular Dynamics, and Free-Energy Calculations.",
    "year": "2022",
    "doi": "10.3390/antibiotics11020185",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Vieira T",
      "Magalh\u00e3es R",
      "Sim\u00f5es M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 184,
    "pmid": "35209073",
    "title": "Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-\u03b2-Lactamase-1 (NDM-1): A Drug Repurposing Approach.",
    "year": "2022",
    "doi": "10.3390/molecules27041283",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Muteeb G",
      "Alsultan A",
      "Farhan M"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "salicylanilide",
        "approved_for": "anthelmintic (tapeworm infections)"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "preclinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide shows potent antiviral activity against SARS-CoV-2 in preclinical studies, suggesting potential for COVID-19 treatment."
      }
    ],
    "mechanism": "Inhibition of viral replication and modulation of host inflammatory pathways, possibly through pleiotropic effects including interference with signal transduction pathways.",
    "relevance_score": 4,
    "paper_idx": 185,
    "pmid": "35284046",
    "title": "Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistant Klebsiella pneumoniae.",
    "year": "2022",
    "doi": "10.1016/j.csbj.2022.02.021",
    "journal": "Computational and structural biotechnology journal",
    "authors": [
      "Hussein M",
      "Wong L",
      "Zhao J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "alcohol sobriety medication",
        "approved_for": "alcohol dependence"
      },
      {
        "name": "N,N-Dimethyl dithiocarbamate",
        "drug_class": "dithiocarbamate derivative",
        "approved_for": null
      },
      {
        "name": "N,N-Diethyl dithiocarbamate",
        "drug_class": "dithiocarbamate derivative",
        "approved_for": null
      },
      {
        "name": "S-octyl disulfide",
        "drug_class": "disulfide analog",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Vancomycin-intermediate resistant S. aureus (VISA)",
        "resistance_profile": "VISA"
      },
      {
        "name": "Vancomycin-resistant S. aureus (VRSA)",
        "resistance_profile": "VRSA"
      },
      {
        "name": "Other Gram-positive cocci",
        "resistance_profile": null
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": null
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": null
      },
      {
        "name": "Candida albicans",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Disulfiram and its S-octyl derivative sensitize S. aureus to fosfomycin by decreasing intracellular bacillithiol levels."
      },
      {
        "drug": "S-octyl disulfide",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "S-octyl disulfide enhances fosfomycin activity against S. aureus by depleting bacillithiol."
      },
      {
        "drug": "N,N-Dimethyl dithiocarbamate",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "N,N-Dimethyl dithiocarbamate exhibits antimicrobial activity against MRSA."
      },
      {
        "drug": "N,N-Diethyl dithiocarbamate",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "N,N-Diethyl dithiocarbamate shows antimicrobial activity against MRSA."
      }
    ],
    "mechanism": "Disulfiram analogs decrease intracellular bacillithiol levels in S. aureus through a thiol-disulfide exchange reaction, impairing fosB-mediated fosfomycin resistance and sensitizing bacteria to fosfomycin.",
    "relevance_score": 5,
    "paper_idx": 186,
    "pmid": "35286809",
    "title": "The Pandemic Response Box\u2500Accelerating Drug Discovery Efforts after Disease Outbreaks.",
    "year": "2022",
    "doi": "10.1021/acsinfecdis.1c00527",
    "journal": "ACS infectious diseases",
    "authors": [
      "Samby K",
      "Besson D",
      "Dutta A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold-containing compound",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Ceftriaxone",
        "drug_class": "cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Azithromycin",
        "drug_class": "macrolide antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Neisseria gonorrhoeae",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Auranofin significantly reduced N. gonorrhoeae colonization in a female mouse model of genital infection."
      }
    ],
    "mechanism": "unknown; proposed to involve inhibition of bacterial thioredoxin reductase and disruption of redox homeostasis",
    "relevance_score": 4,
    "paper_idx": 187,
    "pmid": "35299994",
    "title": "Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.",
    "year": "2022",
    "doi": "10.2147/JEP.S346006",
    "journal": "Journal of experimental pharmacology",
    "authors": [
      "Abdulaziz L",
      "Elhadi E",
      "Abdallah E"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 188,
    "pmid": "35308343",
    "title": "A C\u2227S-Cyclometallated Gold(III) Complex as a Novel Antibacterial Candidate Against Drug-Resistant Bacteria.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.815622",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Ratia C",
      "Cepas V",
      "Soengas R"
    ]
  },
  {
    "drugs": [
      {
        "name": "pantoprazole",
        "drug_class": "proton pump inhibitor",
        "approved_for": "gastric acid-related disorders"
      },
      {
        "name": "haloperidol",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia and psychosis"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "azole resistant"
      },
      {
        "name": "non-albicans Candida species",
        "resistance_profile": "azole resistant"
      }
    ],
    "findings": [
      {
        "drug": "pantoprazole",
        "pathogen": "Candida albicans",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pantoprazole reduced the MIC of fluconazole in resistant Candida isolates, indicating efflux pump inhibitory activity."
      },
      {
        "drug": "haloperidol",
        "pathogen": "Candida albicans",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Haloperidol decreased fluconazole MICs in resistant isolates, demonstrating potential as an efflux pump inhibitor."
      }
    ],
    "mechanism": "Proposed mechanism involves inhibition of efflux pump activity, leading to increased intracellular accumulation of antifungal agents.",
    "relevance_score": 4,
    "paper_idx": 189,
    "pmid": "35326110",
    "title": "The Natural Product Curcumin as an Antibacterial Agent: Current Achievements and Problems.",
    "year": "2022",
    "doi": "10.3390/antiox11030459",
    "journal": "Antioxidants (Basel, Switzerland)",
    "authors": [
      "Dai C",
      "Lin J",
      "Li H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "last-resort treatment of multidrug-resistant Gram-negative bacterial infections"
      },
      {
        "name": "Cannabidiol",
        "drug_class": "cannabinoids",
        "approved_for": "originally approved for epilepsy (e.g., Epidiolex), off-label investigated for antimicrobial properties"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, polymyxin-resistant and polymyxin-susceptible strains"
      }
    ],
    "findings": [
      {
        "drug": "Polymyxin B",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxin B shows activity against A. baumannii, with increased efficacy when combined with cannabidiol."
      },
      {
        "drug": "Cannabidiol",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Cannabidiol exhibits synergistic antibacterial activity with polymyxin B against A. baumannii, including resistant strains."
      }
    ],
    "mechanism": "Disorganization of bacterial envelope formation, perturbation of membrane lipids, and disruption of DNA and RNA biosynthetic pathways.",
    "relevance_score": 4,
    "paper_idx": 190,
    "pmid": "35326755",
    "title": "In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.",
    "year": "2022",
    "doi": "10.3390/antibiotics11030291",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Peyclit L",
      "Baron S",
      "Hadjadj L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 191,
    "pmid": "35335928",
    "title": "Repurposing of Ciclopirox to Overcome the Limitations of Zidovudine (Azidothymidine) against Multidrug-Resistant Gram-Negative Bacteria.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14030552",
    "journal": "Pharmaceutics",
    "authors": [
      "Cho H",
      "Kim K"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 192,
    "pmid": "35348204",
    "title": "Niclosamide-A promising treatment for COVID-19.",
    "year": "2022",
    "doi": "10.1111/bph.15843",
    "journal": "British journal of pharmacology",
    "authors": [
      "Singh S",
      "Weiss A",
      "Goodman J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 193,
    "pmid": "35384175",
    "title": "Priming with biocides: A pathway to antibiotic resistance?",
    "year": "2022",
    "doi": "10.1111/jam.15564",
    "journal": "Journal of applied microbiology",
    "authors": [
      "Adkin P",
      "Hitchcock A",
      "Smith L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 194,
    "pmid": "35440801",
    "title": "Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli.",
    "year": "2022",
    "doi": "10.1038/s41598-022-10393-8",
    "journal": "Scientific reports",
    "authors": [
      "Abichabki N",
      "Zacharias L",
      "Moreira N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Glatiramer Acetate",
        "drug_class": "peptide immunomodulator",
        "approved_for": "multiple sclerosis"
      },
      {
        "name": "Tobramycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections, including Pseudomonas aeruginosa in cystic fibrosis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "antibiotic resistant, MDR"
      }
    ],
    "findings": [
      {
        "drug": "Glatiramer Acetate",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Glatiramer acetate synergizes with tobramycin, reducing its MICs and enhancing antibacterial activity against P. aeruginosa strains."
      }
    ],
    "mechanism": "Glatiramer acetate disrupts outer membranes, depolarizes cytoplasmic membranes, and permeabilizes P. aeruginosa, facilitating increased uptake and efficacy of tobramycin.",
    "relevance_score": 5,
    "paper_idx": 195,
    "pmid": "35446884",
    "title": "Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection.",
    "year": "2022",
    "doi": "10.1371/journal.pone.0266764",
    "journal": "PloS one",
    "authors": [
      "Elhassanny A",
      "Abutaleb N",
      "Seleem M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 196,
    "pmid": "35453202",
    "title": "A Review: Antimicrobial Therapy for Human Pythiosis.",
    "year": "2022",
    "doi": "10.3390/antibiotics11040450",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Medhasi S",
      "Chindamporn A",
      "Worasilchai N"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tapeworm infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR/MRSA"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Niclosamide exhibits potent in vitro antibacterial activity against S. aureus, including resistant strains, with MICs ranging from 0.125 to 0.5 \u03bcg/ml."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide inhibits S. aureus biofilm maturation and exhibits anti-biofilm activity."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Previous studies suggest niclosamide can work synergistically with other antibiotics against S. aureus."
      }
    ],
    "mechanism": "Targeting the proton motive force, effectively stopping cell growth and inhibiting biofilm maturation.",
    "relevance_score": 5,
    "paper_idx": 197,
    "pmid": "35456620",
    "title": "Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against Acinetobacter baumannii: A Metabolomic Study.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14040786",
    "journal": "Pharmaceutics",
    "authors": [
      "Hussein M",
      "Allobawi R",
      "Levou I"
    ]
  },
  {
    "drugs": [
      {
        "name": "Polymyxin B",
        "drug_class": "cyclic lipopeptide antibiotics",
        "approved_for": "bacterial infections, especially MDR Gram-negative bacteria"
      },
      {
        "name": "Caspofungin",
        "drug_class": "echinocandin antifungal",
        "approved_for": "invasive fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Polymyxin B",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxin B shows efficacy against MDR K. pneumoniae and enhances permeability for combination therapy."
      },
      {
        "drug": "Caspofungin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Caspofungin, an antifungal, exhibits synergistic activity when combined with polymyxin B against K. pneumoniae."
      },
      {
        "drug": "Polymyxin B",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.03,
        "key_result": "Combination with caspofungin results in synergistic antibacterial activity, including against resistant strains."
      }
    ],
    "mechanism": "Polymyxin B disrupts the outer membrane of K. pneumoniae, facilitating entry of caspofungin, which then interferes with cell wall synthesis and other metabolic pathways, leading to bacterial death.",
    "relevance_score": 4,
    "paper_idx": 198,
    "pmid": "35498219",
    "title": "Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates.",
    "year": "2022",
    "doi": "10.1016/j.jsps.2022.01.011",
    "journal": "Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society",
    "authors": [
      "El-Ganiny A",
      "Kamel H",
      "Yossef N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MSSA and MRSA"
      },
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "MSSE and MRSE"
      }
    ],
    "findings": [
      {
        "drug": "Niclosamide",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide exhibited in vitro antibacterial activity against S. aureus, including MRSA strains."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "Staphylococcus epidermidis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide showed antibacterial activity against S. epidermidis in vitro."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NIC-loaded catheters prevented S. aureus colonization and reduced bacterial load in a mouse biomaterial-associated infection model."
      }
    ],
    "mechanism": "unknown, but likely involves disruption of bacterial biofilm formation or bacterial viability due to sustained release of NIC from the catheter surface",
    "relevance_score": 4,
    "paper_idx": 199,
    "pmid": "35522900",
    "title": "Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.",
    "year": "2022",
    "doi": "10.1002/ctm2.790",
    "journal": "Clinical and translational medicine",
    "authors": [
      "Weiss A",
      "Delavenne E",
      "Matias C"
    ]
  },
  {
    "drugs": [
      {
        "name": "cephalothin",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ceftriaxone",
        "drug_class": "cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ampicillin",
        "drug_class": "penicillin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "oxacillin",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "staphylococcal infections"
      },
      {
        "name": "cefoxitin",
        "drug_class": "second-generation cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "various bacterial infections"
      },
      {
        "name": "sulfatriad",
        "drug_class": "sulfonamide",
        "approved_for": "bacterial infections"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "phenothiazine antipsychotic",
        "approved_for": "schizophrenia, psychosis"
      },
      {
        "name": "thioridazine",
        "drug_class": "phenothiazine antipsychotic",
        "approved_for": "schizophrenia"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "cross-resistance to cephalothin, ceftriaxone, ampicillin"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "cross-resistance to oxacillin"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "cross-resistance to ciprofloxacin, sulfatriad"
      }
    ],
    "findings": [
      {
        "drug": "cephalothin",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine increased E. coli susceptibility to cephalothin by fourfold."
      },
      {
        "drug": "ceftriaxone",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine increased E. coli susceptibility to ceftriaxone by fourfold."
      },
      {
        "drug": "ampicillin",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine increased E. coli susceptibility to ampicillin by fourfold."
      },
      {
        "drug": "oxacillin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine increased S. aureus susceptibility to oxacillin by eightfold."
      },
      {
        "drug": "ciprofloxacin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine increased P. aeruginosa susceptibility to ciprofloxacin by eightfold."
      }
    ],
    "mechanism": "activation of efflux pump mechanisms and alterations in bacterial cell wall permeability.",
    "relevance_score": 4,
    "paper_idx": 200,
    "pmid": "35558127",
    "title": "Antifungal Activity of Sodium New Houttuyfonate Against Aspergillus fumigatus in vitro and in vivo.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.856272",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Zhang Q",
      "Liu F",
      "Zeng M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 201,
    "pmid": "35563420",
    "title": "Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis Pseudomonas aeruginosa Strains.",
    "year": "2022",
    "doi": "10.3390/ijms23095029",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Di Bonaventura G",
      "Lupetti V",
      "De Fabritiis S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tetracycline",
        "drug_class": "tetracyclines",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Chlorpromazine",
        "drug_class": "phenothiazine antipsychotics",
        "approved_for": "schizophrenia, psychosis"
      }
    ],
    "pathogens": [
      {
        "name": "Salmonella enterica ser. Typhimurium",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Tetracycline",
        "pathogen": "Salmonella enterica ser. Typhimurium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nano-encapsulated tetracycline combined with silica nanoparticles improved antibacterial efficacy against MDR Salmonella Typhimurium."
      },
      {
        "drug": "Chlorpromazine",
        "pathogen": "Salmonella enterica ser. Typhimurium",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine loaded in silica nanoparticles inhibited efflux pump activity, reducing intracellular pathogen load by 83.02%."
      },
      {
        "drug": "Tetracycline",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nano-encapsulated tetracycline showed enhanced activity against MDR S. aureus when delivered via chitosan nanoparticles."
      }
    ],
    "mechanism": "Nanoparticle delivery enhances drug stability, controls release, targets bacteria, and inhibits resistance mechanisms such as efflux pumps and beta-lactamase enzymes.",
    "relevance_score": 5,
    "paper_idx": 202,
    "pmid": "35616371",
    "title": "Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.",
    "year": "2022",
    "doi": "10.1128/spectrum.02781-21",
    "journal": "Microbiology spectrum",
    "authors": [
      "Sudhakar R",
      "Adhikari N",
      "Pamnani S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Methylene Blue",
        "drug_class": "photosensitizer",
        "approved_for": "antimicrobial photodynamic therapy"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "XDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "XDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Methylene Blue",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MB-aPDT with methylene blue effectively reduced viable counts of XDR A. baumannii in vitro."
      },
      {
        "drug": "Methylene Blue",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MB-aPDT significantly decreased viable counts of XDR P. aeruginosa in vitro."
      },
      {
        "drug": "Methylene Blue",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MB-aPDT with methylene blue achieved substantial bacterial reduction in MDR K. pneumoniae in vitro."
      }
    ],
    "mechanism": "photodynamic activation of methylene blue generates reactive oxygen species that damage bacterial cells.",
    "relevance_score": 4,
    "paper_idx": 203,
    "pmid": "35625295",
    "title": "Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections.",
    "year": "2022",
    "doi": "10.3390/antibiotics11050651",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Folliero V",
      "Dell'Annunziata F",
      "Roscetto E"
    ]
  },
  {
    "drugs": [
      {
        "name": "acetazolamide",
        "drug_class": "carbonic anhydrase inhibitor",
        "approved_for": "glaucoma, altitude sickness, edema"
      }
    ],
    "pathogens": [
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "vancomycin-resistant (VRE)"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "vancomycin-resistant (VRE)"
      }
    ],
    "findings": [
      {
        "drug": "acetazolamide",
        "pathogen": "Enterococcus faecium",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Acetazolamide exhibits anti-VRE activity likely through inhibition of bacterial carbonic anhydrases."
      },
      {
        "drug": "acetazolamide",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Acetazolamide shows activity against VRE strains, suggesting potential as a repurposed antimicrobial."
      }
    ],
    "mechanism": "Inhibition of bacterial carbonic anhydrase isoforms Ef\u03b1-CA and Ef\u03b3-CA, disrupting bacterial pH homeostasis and growth.",
    "relevance_score": 4,
    "paper_idx": 204,
    "pmid": "35674439",
    "title": "Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG.",
    "year": "2022",
    "doi": "10.1128/spectrum.00884-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Zheng Y",
      "Zhong T",
      "Wu H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Sodium new houttuyfonate",
        "drug_class": "antifungal agent",
        "approved_for": "none (experimental/repurposed)"
      }
    ],
    "pathogens": [
      {
        "name": "Aspergillus fumigatus",
        "resistance_profile": "azole-resistant (itraconazole and voriconazole resistant strains)"
      }
    ],
    "findings": [
      {
        "drug": "Sodium new houttuyfonate",
        "pathogen": "Aspergillus fumigatus",
        "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "SNH exhibits significant fungicidal activity against A. fumigatus, inhibits growth, sporulation, germination, pigment formation, and biofilm development."
      },
      {
        "drug": "Sodium new houttuyfonate",
        "pathogen": "Aspergillus fumigatus",
        "activity_type": "efflux_inhibitor|adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "SNH interferes with ergosterol synthesis by disrupting the steroid synthesis pathway, leading to cell membrane stress."
      }
    ],
    "mechanism": "Interferes with ergosterol synthesis by disrupting the steroid synthesis pathway, leading to cell membrane stress and impaired fungal growth.",
    "relevance_score": 5,
    "paper_idx": 205,
    "pmid": "35727066",
    "title": "Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.",
    "year": "2022",
    "doi": "10.1128/spectrum.00813-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Murphy R",
      "Coates M",
      "Thrane S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 206,
    "pmid": "35733960",
    "title": "Repurposing the Sphingosine-1-Phosphate Receptor Modulator Etrasimod as an Antibacterial Agent Against Gram-Positive Bacteria.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.926170",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Zore M",
      "Gilbert-Girard S",
      "San-Martin-Galindo P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold(I) phosphine derivative",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Plasmodium berghei",
        "resistance_profile": "antiplasmodial activity"
      },
      {
        "name": "bacteria",
        "resistance_profile": "broad spectrum activity, including MDR strains"
      },
      {
        "name": "fungi",
        "resistance_profile": "Candida spp., MDR strains"
      }
    ],
    "findings": [
      {
        "drug": "Au(III) bis(dithiolene) complexes",
        "pathogen": "Plasmodium berghei",
        "activity_type": "antiplasmodial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.4,
        "fici": null,
        "key_result": "Several complexes exhibited submicromolar IC50 values (400-700 nM) against P. berghei liver stages."
      },
      {
        "drug": "Au(III) bis(dithiolene) complexes",
        "pathogen": "bacteria",
        "activity_type": "antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Most complexes with the N counter-ion showed notable antibacterial activity, especially against Gram-positive bacteria, including MDR strains."
      },
      {
        "drug": "Au(III) bis(dithiolene) complexes",
        "pathogen": "fungi",
        "activity_type": "anti_fungal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Most complexes with the N counter-ion demonstrated activity against Candida spp., including MDR strains."
      },
      {
        "drug": "Au(III) bis(dithiolene) complexes",
        "pathogen": "HIV",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Selected complexes did not show anti-HIV activity in TZM-bl cells."
      }
    ],
    "mechanism": "likely inhibition of thioredoxin reductase (TrxR), disrupting cellular redox balance, with negligible DNA interaction",
    "relevance_score": 4,
    "paper_idx": 207,
    "pmid": "35740222",
    "title": "Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach.",
    "year": "2022",
    "doi": "10.3390/antibiotics11060816",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Barbarossa A",
      "Rosato A",
      "Corbo F"
    ]
  },
  {
    "drugs": [
      {
        "name": "bazedoxifene",
        "drug_class": "selective estrogen receptor modulator (SERM)",
        "approved_for": "postmenopausal osteoporosis"
      },
      {
        "name": "raloxifene",
        "drug_class": "selective estrogen receptor modulator (SERM)",
        "approved_for": "osteoporosis"
      },
      {
        "name": "tamoxifen",
        "drug_class": "selective estrogen receptor modulator (SERM)",
        "approved_for": "ER-positive breast cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Plasmodium falciparum",
        "resistance_profile": "susceptible and drug-resistant strains"
      },
      {
        "name": "Plasmodium berghei",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "bazedoxifene",
        "pathogen": "Plasmodium falciparum",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bazedoxifene inhibits P. falciparum growth with submicromolar IC50 values and is most potent on early ring-stage parasites."
      },
      {
        "drug": "bazedoxifene",
        "pathogen": "Plasmodium berghei",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bazedoxifene decreased P. berghei infection in female mice but not in male mice, indicating sex-dependent in vivo activity."
      },
      {
        "drug": "bazedoxifene",
        "pathogen": "Plasmodium falciparum",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Bazedoxifene inhibits hemozoin formation, leading to accumulation of free heme, which may contribute to its antimalarial activity."
      },
      {
        "drug": "bazedoxifene",
        "pathogen": "Plasmodium falciparum",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Treatment at early ring stage results in parasites lacking hemozoin, suggesting interference with hemoglobin degradation."
      }
    ],
    "mechanism": "Inhibition of hemozoin formation, leading to accumulation of toxic free heme within the parasite.",
    "relevance_score": 4,
    "paper_idx": 208,
    "pmid": "35758212",
    "title": "Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrases.",
    "year": "2022",
    "doi": "10.1080/14756366.2022.2092729",
    "journal": "Journal of enzyme inhibition and medicinal chemistry",
    "authors": [
      "An W",
      "Holly K",
      "Nocentini A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "metal-containing compound / gold-based drug",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Phenethyl isothiocyanate",
        "drug_class": "natural compound / isothiocyanate",
        "approved_for": "not approved; dietary supplement from cruciferous vegetables"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Auranofin exhibits antimicrobial activity against S. aureus by inhibiting thioredoxin reductase and inducing ROS accumulation."
      },
      {
        "drug": "Phenethyl isothiocyanate",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "PEITC effectively inhibits Gram-positive bacteria and induces oxidative stress via ROS generation."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "AUR combined with PEITC shows a synergistic antimicrobial effect against S. aureus, including MRSA."
      },
      {
        "drug": "Phenethyl isothiocyanate",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "PEITC enhances the antimicrobial activity of AUR and prevents resistance development."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AUR in combination with PEITC effectively clears S. aureus infections in mice and restores susceptibility."
      }
    ],
    "mechanism": "AUR inhibits thioredoxin reductase leading to ROS accumulation and bacterial cell disruption; PEITC induces oxidative stress and ROS generation, synergistically enhancing bacterial killing.",
    "relevance_score": 5,
    "paper_idx": 209,
    "pmid": "35774400",
    "title": "Synergistic Microbicidal Effect of AUR and PEITC Against Staphylococcus aureus Skin Infection.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.927289",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Chen H",
      "Yang N",
      "Yu L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 210,
    "pmid": "35806151",
    "title": "Broad Spectrum Functional Activity of Structurally Related Monoanionic Au(III) Bis(Dithiolene) Complexes.",
    "year": "2022",
    "doi": "10.3390/ijms23137146",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Le Gal Y",
      "Filatre-Furcate A",
      "Lorcy D"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 211,
    "pmid": "35808015",
    "title": "Nanoparticle-Enabled Combination Therapy Showed Superior Activity against Multi-Drug Resistant Bacterial Pathogens in Comparison to Free Drugs.",
    "year": "2022",
    "doi": "10.3390/nano12132179",
    "journal": "Nanomaterials (Basel, Switzerland)",
    "authors": [
      "Brar A",
      "Majumder S",
      "Navarro M"
    ]
  },
  {
    "drugs": [
      {
        "name": "N-2-succinyl ornithine",
        "drug_class": "substrate analog",
        "approved_for": "not specified"
      },
      {
        "name": "cilazapril",
        "drug_class": "ACE inhibitor",
        "approved_for": "hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "high intrinsic resistance to multiple antibiotics"
      }
    ],
    "findings": [
      {
        "drug": "N-2-succinyl ornithine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "N-2-succinyl ornithine showed strong binding affinity to PvdA with a binding energy of -12.8 kcal/mol, suggesting potential as a substrate analog inhibitor."
      },
      {
        "drug": "cilazapril",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cilazapril demonstrated significant binding to PvdA with a binding energy of -9.1 kcal/mol, indicating potential as a repurposed inhibitor."
      }
    ],
    "mechanism": "inhibition of PvdA enzyme involved in pyoverdine biosynthesis, disrupting iron sequestration in P. aeruginosa",
    "relevance_score": 4,
    "paper_idx": 212,
    "pmid": "35846758",
    "title": "Methylene Blue-Mediated Antimicrobial\u00a0\u200bPhotodynamic Therapy Against Clinical Isolates of Extensively Drug Resistant\u00a0\u200bGram-Negative Bacteria Causing Nosocomial Infections in Thailand,\u00a0An In Vitro\u00a0Study.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.929242",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Songsantiphap C",
      "Vanichanan J",
      "Chatsuwan T"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "selenium-organic compound",
        "approved_for": "none (experimental use)"
      },
      {
        "name": "Silver nitrate",
        "drug_class": "metal-based antimicrobial",
        "approved_for": "topical antimicrobial, wound care"
      }
    ],
    "pathogens": [
      {
        "name": "Yersinia pseudotuberculosis",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Yersinia pseudotuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.94,
        "key_result": "Ebselen synergistically enhances the antibacterial activity of silver nitrate against Y. pseudotuberculosis in vitro."
      },
      {
        "drug": "Silver nitrate",
        "pathogen": "Yersinia pseudotuberculosis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Silver nitrate inhibits Y. pseudotuberculosis growth with MIC90 of 8 \u03bcM."
      }
    ],
    "mechanism": "Disruption of thiol-dependent redox systems leading to intracellular oxidative stress, depletion of glutathione, and inhibition of thioredoxin reductase activity.",
    "relevance_score": 4,
    "paper_idx": 213,
    "pmid": "35854044",
    "title": "A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.",
    "year": "2022",
    "doi": "10.1038/s41598-022-16107-4",
    "journal": "Scientific reports",
    "authors": [
      "Vazquez-Rodriguez J",
      "Shaqour B",
      "Guarch-P\u00e9rez C"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tapeworm infection"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "variants of concern (VOCs) including B.1.1.7, B.1.351, P.1, B.1.617.2"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide exhibits variant-dependent antiviral activity with IC50 values ranging from 1664 nM (WA1) to 298 nM (B.1.1.7), but has a poor selectivity index due to cytotoxicity."
      },
      {
        "drug": "niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide inhibits viral entry and cell-to-cell spread by reducing syncytia formation and infected cell numbers, likely through its activity as a protonophore."
      }
    ],
    "mechanism": "Nonspecific endolysosomal neutralization via protonophore activity, inhibiting viral entry and cell-to-cell spread, possibly involving disruption of pH gradients and autophagy modulation.",
    "relevance_score": 2,
    "paper_idx": 214,
    "pmid": "35860224",
    "title": "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.",
    "year": "2022",
    "doi": "10.1101/2022.06.24.497526",
    "journal": "bioRxiv : the preprint server for biology",
    "authors": [
      "Wotring J",
      "McCarty S",
      "Shafiq K"
    ]
  },
  {
    "drugs": [
      {
        "name": "Niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tapeworm infection"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.564,
        "fici": null,
        "key_result": "Niclosamide exhibits antiviral activity against SARS-CoV-2 with IC50 values around 261-564 nM but has a poor selectivity index due to cytotoxicity."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Its mechanism involves protonophore activity leading to nonspecific endolysosomal neutralization, inhibiting viral entry and cell-to-cell spread."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Not specifically reported in this study."
      }
    ],
    "mechanism": "Protonophore activity disrupting pH gradients in endolysosomal compartments, inhibiting viral entry and syncytia formation, with additional effects on viral cell-to-cell spread.",
    "relevance_score": 2,
    "paper_idx": 215,
    "pmid": "35883443",
    "title": "l-Ornithine-N5-monooxygenase (PvdA) Substrate Analogue Inhibitors for Pseudomonas aeruginosa Infections Treatment: Drug Repurposing Computational Studies.",
    "year": "2022",
    "doi": "10.3390/biom12070887",
    "journal": "Biomolecules",
    "authors": [
      "Rosy J",
      "Babkiewicz E",
      "Maszczyk P"
    ]
  },
  {
    "drugs": [
      {
        "name": "carbamazepine",
        "drug_class": "anticonvulsant",
        "approved_for": "epilepsy, seizures"
      },
      {
        "name": "ibuprofen",
        "drug_class": "nonsteroidal anti-inflammatory drug",
        "approved_for": "pain, inflammation"
      },
      {
        "name": "naproxen",
        "drug_class": "nonsteroidal anti-inflammatory drug",
        "approved_for": "pain, inflammation"
      },
      {
        "name": "propranolol",
        "drug_class": "beta-blocker",
        "approved_for": "hypertension, arrhythmias"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter",
        "resistance_profile": "multidrug resistant"
      },
      {
        "name": "Legionella",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "carbamazepine",
        "pathogen": "Acinetobacter",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Carbamazepine at environmentally relevant concentrations promotes conjugative plasmid transfer, increasing antibiotic resistance dissemination."
      },
      {
        "drug": "ibuprofen",
        "pathogen": "Legionella",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Ibuprofen enhances conjugative transfer of resistance plasmids in bacterial communities."
      },
      {
        "drug": "naproxen",
        "pathogen": "Acinetobacter",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Naproxen facilitates horizontal gene transfer, potentially spreading multidrug resistance."
      },
      {
        "drug": "propranolol",
        "pathogen": "Legionella",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Propranolol exposure increases conjugation rates, promoting resistance gene dissemination."
      }
    ],
    "mechanism": "Non-antibiotic pharmaceuticals induce over-generation of reactive oxygen species (ROS), which enhances conjugative plasmid transfer among bacteria.",
    "relevance_score": 4,
    "paper_idx": 216,
    "pmid": "35934727",
    "title": "Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.",
    "year": "2022",
    "doi": "10.1186/s43046-022-00137-0",
    "journal": "Journal of the Egyptian National Cancer Institute",
    "authors": [
      "Siddiqui S",
      "Deshmukh A",
      "Mudaliar P"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 217,
    "pmid": "35953866",
    "title": "Non-antibiotic pharmaceuticals promote conjugative plasmid transfer at a community-wide level.",
    "year": "2022",
    "doi": "10.1186/s40168-022-01314-y",
    "journal": "Microbiome",
    "authors": [
      "Wang Y",
      "Yu Z",
      "Ding P"
    ]
  },
  {
    "drugs": [
      {
        "name": "ribavirin",
        "drug_class": "antiviral",
        "approved_for": "viral infections"
      },
      {
        "name": "ciclopirox",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "5-fluorouracil",
        "drug_class": "antineoplastic",
        "approved_for": "cancer"
      },
      {
        "name": "actinomycin D",
        "drug_class": "antineoplastic",
        "approved_for": "cancer"
      },
      {
        "name": "toremifene",
        "drug_class": "nonsteroidal antiestrogen",
        "approved_for": "breast cancer"
      },
      {
        "name": "oxyclozanide",
        "drug_class": "anthelmintic",
        "approved_for": "parasitic infections"
      },
      {
        "name": "meloxicam",
        "drug_class": "NSAID",
        "approved_for": "inflammatory conditions"
      },
      {
        "name": "furosemide",
        "drug_class": "diuretic",
        "approved_for": "edema, hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "ciclopirox",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "Ciclopirox showed the most effective activity against planktonic cells and mature biofilms, significantly reducing biofilm biomass and viability."
      },
      {
        "drug": "ribavirin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ribavirin demonstrated a specific antibiofilm effect, significantly decreasing biofilm biomass without killing bacteria."
      },
      {
        "drug": "5-fluorouracil",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "5-Fluorouracil showed limited antibacterial activity and tended to stimulate biofilm biomass."
      },
      {
        "drug": "actinomycin D",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 133,
        "fici": null,
        "key_result": "Actinomycin D exhibited strain-dependent bactericidal activity and downregulated virulence gene expression."
      }
    ],
    "mechanism": "The proposed mechanisms include direct antibacterial activity, biofilm dispersal, and modulation of virulence gene expression, with some drugs acting as efflux inhibitors or antivirulence agents.",
    "relevance_score": 4,
    "paper_idx": 218,
    "pmid": "35958130",
    "title": "The Assessment on Synergistic Activity of Ebselen and Silver Ion Against Yersinia pseudotuberculosis.",
    "year": "2022",
    "doi": "10.3389/fmicb.2022.963901",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Dong C",
      "Chen W",
      "Zou L"
    ]
  },
  {
    "drugs": [
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppressant in transplant rejection, other uses"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "not applicable",
    "relevance_score": 1,
    "paper_idx": 219,
    "pmid": "35969069",
    "title": "Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium.",
    "year": "2022",
    "doi": "10.1128/spectrum.01412-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Gargvanshi S",
      "Gutheil W"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 220,
    "pmid": "36016172",
    "title": "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.",
    "year": "2022",
    "doi": "10.3390/vaccines10081284",
    "journal": "Vaccines",
    "authors": [
      "Wotring J",
      "McCarty S",
      "Shafiq K"
    ]
  },
  {
    "drugs": [
      {
        "name": "Chloroquine",
        "drug_class": "4-aminoquinoline",
        "approved_for": "malaria"
      },
      {
        "name": "Verapamil",
        "drug_class": "calcium channel blocker",
        "approved_for": "hypertension, angina"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug resistant"
      }
    ],
    "findings": [
      {
        "drug": "Chloroquine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Plant extracts from Syzygium aromaticum, Zingiber officinale, and Curcuma longa enhanced chloroquine susceptibility in P. aeruginosa by increasing zones of inhibition."
      },
      {
        "drug": "Verapamil",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Verapamil, a known efflux pump inhibitor, was used as a standard to demonstrate increased chloroquine sensitivity."
      }
    ],
    "mechanism": "Plant phytochemicals, such as flavonoids, alkaloids, and phenols, likely inhibit bacterial efflux pumps, thereby increasing intracellular chloroquine concentration and susceptibility.",
    "relevance_score": 4,
    "paper_idx": 221,
    "pmid": "36110398",
    "title": "Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.",
    "year": "2022",
    "doi": "10.2147/DDDT.S366423",
    "journal": "Drug design, development and therapy",
    "authors": [
      "Abdel-Halim H",
      "Hajar M",
      "Hasouneh L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "antirheumatic, gold-based compound",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Cannabidivarin",
        "drug_class": "cannabinoid derivative",
        "approved_for": "investigational, not yet approved for clinical use"
      },
      {
        "name": "Tolfenamic acid",
        "drug_class": "nonsteroidal anti-inflammatory drug (NSAID)",
        "approved_for": "pain and inflammation"
      }
    ],
    "pathogens": [
      {
        "name": "Neisseria gonorrhoeae",
        "resistance_profile": "multidrug-resistant, including high-level ceftriaxone-resistant strains (FC428 clone)"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Auranofin displayed consistent bactericidal activity with MIC90 of 0.5 mg/L against multidrug-resistant N. gonorrhoeae, including ceftriaxone-resistant strains."
      },
      {
        "drug": "Cannabidivarin",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Cannabidivarin showed antimicrobial activity with MIC90 of 8 mg/L and demonstrated rapid bactericidal activity."
      },
      {
        "drug": "Tolfenamic acid",
        "pathogen": "Neisseria gonorrhoeae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Tolfenamic acid exhibited antimicrobial activity with MIC90 of 8 mg/L and was bactericidal in time-kill assays."
      }
    ],
    "mechanism": "Proposed mechanisms include inhibition of bacterial enzymes or pathways related to metal ion homeostasis (auranofin), disruption of bacterial membrane or metabolic processes (cannabidivarin), and inhibition of prostaglandin synthesis affecting bacterial growth (tolfenamic acid).",
    "relevance_score": 4,
    "paper_idx": 222,
    "pmid": "36112342",
    "title": "Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?",
    "year": "2022",
    "doi": "10.1007/s40265-022-01757-5",
    "journal": "Drugs",
    "authors": [
      "Ngan N",
      "Flower B",
      "Day J"
    ]
  },
  {
    "drugs": [
      {
        "name": "favipiravir",
        "drug_class": "antiviral nucleoside analogue",
        "approved_for": "influenza"
      },
      {
        "name": "cefixime",
        "drug_class": "cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "carvedilol",
        "drug_class": "beta-blocker",
        "approved_for": "hypertension, heart failure"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "favipiravir",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Favipiravir showed inhibitory activity against SARS-CoV-2 main protease (Mpro) in vitro."
      },
      {
        "drug": "cefixime",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cefixime demonstrated inhibitory effects on SARS-CoV-2 Mpro in vitro."
      },
      {
        "drug": "carvedilol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carvedilol exhibited inhibitory activity against SARS-CoV-2 Mpro in vitro."
      },
      {
        "drug": "favipiravir/cefixime",
        "pathogen": "SARS-CoV-2",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination of favipiravir and cefixime showed a predicted synergistic effect in inhibiting SARS-CoV-2 Mpro."
      },
      {
        "drug": "favipiravir/carvedilol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination of favipiravir and carvedilol demonstrated a predicted synergistic inhibitory effect on SARS-CoV-2 Mpro."
      }
    ],
    "mechanism": "The drugs likely inhibit SARS-CoV-2 main protease (Mpro), disrupting viral polyprotein processing essential for viral replication.",
    "relevance_score": 4,
    "paper_idx": 223,
    "pmid": "36129262",
    "title": "FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.",
    "year": "2022",
    "doi": "10.1128/spectrum.02509-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Wang J",
      "Sha J",
      "Strong E"
    ]
  },
  {
    "drugs": [],
    "pathogens": [],
    "findings": [],
    "mechanism": "The paper discusses the antimicrobial properties of graphene-based nanomaterials and their composites, which can physically disrupt microbial membranes, generate reactive oxygen species (ROS), and interfere with microbial cellular components. Conjugation with existing drugs can enhance therapeutic efficacy, but specific mechanisms are not detailed.",
    "relevance_score": 1,
    "paper_idx": 224,
    "pmid": "36143915",
    "title": "Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.",
    "year": "2022",
    "doi": "10.3390/medicina58091239",
    "journal": "Medicina (Kaunas, Lithuania)",
    "authors": [
      "Gales L",
      "Forsea L",
      "Mitrea D"
    ]
  },
  {
    "drugs": [
      {
        "name": "dexamethasone",
        "drug_class": "corticosteroid",
        "approved_for": "inflammatory conditions, immune suppression"
      },
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression in transplant rejection"
      },
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "levofloxacin",
        "drug_class": "fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "simvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "medroxyprogesterone acetate",
        "drug_class": "progestin",
        "approved_for": "hormone therapy, contraception"
      }
    ],
    "pathogens": [
      {
        "name": "COVID-19",
        "resistance_profile": "cytokine storm, immune dysregulation"
      }
    ],
    "findings": [
      {
        "drug": "dexamethasone",
        "pathogen": "COVID-19",
        "activity_type": "anti_virulence",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Dexamethasone is a high-ranking candidate for disrupting cytokine storm in COVID-19 based on model predictions."
      },
      {
        "drug": "rapamycin",
        "pathogen": "COVID-19",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rapamycin shows potential as an immune modulator targeting multiple network nodes involved in cytokine storm."
      },
      {
        "drug": "ciprofloxacin",
        "pathogen": "COVID-19",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciprofloxacin, an antimicrobial, is predicted to contribute to disrupting immune dysregulation in COVID-19."
      },
      {
        "drug": "levofloxacin",
        "pathogen": "COVID-19",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Levofloxacin may enhance immune modulation when combined with other agents in COVID-19 cytokine storm mitigation."
      },
      {
        "drug": "simvastatin",
        "pathogen": "COVID-19",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simvastatin is predicted to help modulate immune response and reduce cytokine storm severity."
      },
      {
        "drug": "medroxyprogesterone acetate",
        "pathogen": "COVID-19",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Medroxyprogesterone acetate may contribute to immune regulation in COVID-19 cytokine storm control."
      }
    ],
    "mechanism": "Modulation of immune signaling pathways involved in cytokine production and inflammatory response, targeting multiple immune mediators to restore immune homeostasis.",
    "relevance_score": 4,
    "paper_idx": 225,
    "pmid": "36216820",
    "title": "Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.",
    "year": "2022",
    "doi": "10.1038/s41540-022-00250-9",
    "journal": "NPJ systems biology and applications",
    "authors": [
      "Richman S",
      "Lyman C",
      "Nesterova A"
    ]
  },
  {
    "drugs": [
      {
        "name": "atorvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida spp.",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "atorvastatin",
        "pathogen": "Candida spp.",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 550,
        "fici": null,
        "key_result": "Encapsulation of atorvastatin in emulsomes improved antifungal activity, reducing MIC from 650 \u00b5g/mL for free drug to 550 \u00b5g/mL."
      }
    ],
    "mechanism": "Inhibition of fungal HMG-CoA reductase leading to decreased ergosterol synthesis.",
    "relevance_score": 4,
    "paper_idx": 226,
    "pmid": "36241714",
    "title": "Drug repurposing strategy part 1: from approved drugs to agri-bactericides leads.",
    "year": "2023",
    "doi": "10.1038/s41429-022-00574-y",
    "journal": "The Journal of antibiotics",
    "authors": [
      "Ma Y",
      "Wang Y",
      "He Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "metformin",
        "drug_class": "biguanide antihyperglycemic agent",
        "approved_for": "type 2 diabetes"
      },
      {
        "name": "mebendazole",
        "drug_class": "benzimidazole anthelmintic",
        "approved_for": "parasitic diseases"
      },
      {
        "name": "atorvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "propranolol",
        "drug_class": "beta-adrenergic blocker",
        "approved_for": "cardiovascular diseases (hypertension, arrhythmias, migraines, anxiety)"
      }
    ],
    "pathogens": [
      {
        "name": "colorectal cancer",
        "resistance_profile": null
      },
      {
        "name": "prostate cancer",
        "resistance_profile": null
      },
      {
        "name": "glioblastoma",
        "resistance_profile": null
      },
      {
        "name": "head and neck cancer",
        "resistance_profile": null
      },
      {
        "name": "melanoma",
        "resistance_profile": null
      },
      {
        "name": "breast cancer",
        "resistance_profile": null
      },
      {
        "name": "sarcoma",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "metformin",
        "pathogen": "colorectal cancer",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Metformin shows oncological benefits in early-stage colorectal cancer, especially in diabetic patients, and enhances tumor radiosensitivity."
      },
      {
        "drug": "metformin",
        "pathogen": "prostate cancer",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Metformin improves response to radiotherapy and reduces biochemical relapse in prostate cancer models."
      },
      {
        "drug": "mebendazole",
        "pathogen": "brain and colon cancers",
        "activity_type": "direct_antibacterial",
        "evidence_type": "preclinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mebendazole exhibits antiproliferative activity and inhibits signaling pathways like VEGFR2, TNIK, and BRAF, with ongoing clinical trials for various cancers."
      },
      {
        "drug": "atorvastatin",
        "pathogen": "head and neck cancer",
        "activity_type": "adjuvant|anti_biofilm",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin provides clinical benefits in head and neck cancer, with potential radioprotective effects."
      },
      {
        "drug": "propranolol",
        "pathogen": "melanoma",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Propranolol is associated with increased outcomes in melanoma, breast cancer, and sarcoma."
      }
    ],
    "mechanism": "Metformin inhibits mitochondrial ETC and activates AMPK, reducing insulin levels and tumor cell proliferation; mebendazole binds tubulin and inhibits tyrosine kinases; atorvastatin inhibits HMG-CoA reductase, inducing autophagy; propranolol blocks beta-adrenergic receptors, affecting tumor signaling pathways.",
    "relevance_score": 4,
    "paper_idx": 227,
    "pmid": "36285247",
    "title": "Study of chloroquine susceptibility potential of plants using pseudomonas aeruginosa as in vitro model.",
    "year": "2022",
    "doi": "10.1007/s13205-022-03382-1",
    "journal": "3 Biotech",
    "authors": [
      "Kulkarni C",
      "Rathod P",
      "Yadav R"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 228,
    "pmid": "36292612",
    "title": "Co-Treatment of Erythroid Cells from \u03b2-Thalassemia Patients with CRISPR-Cas9-Based \u03b2039-Globin Gene Editing and Induction of Fetal Hemoglobin.",
    "year": "2022",
    "doi": "10.3390/genes13101727",
    "journal": "Genes",
    "authors": [
      "Cosenza L",
      "Zuccato C",
      "Zurlo M"
    ]
  },
  {
    "drugs": [
      {
        "name": "3-aminopyrazine-2-carboxamide derivatives",
        "drug_class": "Prolyl-tRNA synthetase inhibitors",
        "approved_for": "none (experimental compounds)"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "3-aminopyrazine-2-carboxamide derivatives",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Compounds showed high antimycobacterial activity with MICs from 1.95 to 31.25 \u00b5g/mL, including activity against MDR strains."
      }
    ],
    "mechanism": "Inhibition of mycobacterial prolyl-tRNA synthetase, mimicking ATP-competitive binding of human ProRS inhibitors.",
    "relevance_score": 4,
    "paper_idx": 229,
    "pmid": "36297331",
    "title": "A Review of the Biological Activity of Amidrazone Derivatives.",
    "year": "2022",
    "doi": "10.3390/ph15101219",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Paprocka R",
      "Wiese-Szadkowska M",
      "Kosmalski T"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 230,
    "pmid": "36314972",
    "title": "NSC19723, a Thiacetazone-Like Benzaldehyde Thiosemicarbazone Improves the Efficacy of TB Drugs In Vitro and In Vivo.",
    "year": "2022",
    "doi": "10.1128/spectrum.02592-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Singh P",
      "Rawat S",
      "Agrahari A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Paromomycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "leishmaniasis"
      }
    ],
    "pathogens": [
      {
        "name": "Leishmania major",
        "resistance_profile": "drug resistance"
      }
    ],
    "findings": [
      {
        "drug": "Peptide 19-2.5",
        "pathogen": "Leishmania major",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Peptide 19-2.5 showed high activity against intracellular Leishmania major in vitro without host toxicity."
      },
      {
        "drug": "Peptide 19-4LF",
        "pathogen": "Leishmania major",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Peptide 19-4LF demonstrated high activity against intracellular Leishmania major in vitro without host toxicity."
      },
      {
        "drug": "Peptide 19-2.5",
        "pathogen": "Leishmania major",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, Peptide 19-2.5 significantly reduced Leishmania major infective burden in mice."
      },
      {
        "drug": "Peptide 19-4LF",
        "pathogen": "Leishmania major",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, Peptide 19-4LF significantly reduced Leishmania major infective burden in mice."
      }
    ],
    "mechanism": "Downregulation of parasite genes involved in drug resistance, virulence, and proliferation; modulation of host immune response and repression of P2X7 receptor expression.",
    "relevance_score": 2,
    "paper_idx": 231,
    "pmid": "36344591",
    "title": "Molecular co-localization of multiple drugs in a nanoscopic delivery vehicle for potential synergistic remediation of multi-drug resistant bacteria.",
    "year": "2022",
    "doi": "10.1038/s41598-022-22759-z",
    "journal": "Scientific reports",
    "authors": [
      "Banerjee A",
      "Mukherjee D",
      "Bera A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 232,
    "pmid": "36348266",
    "title": "Attenuating the virulence of the resistant superbug Staphylococcus aureus bacteria isolated from neonatal sepsis by ascorbic acid, dexamethasone, and sodium bicarbonate.",
    "year": "2022",
    "doi": "10.1186/s12866-022-02684-x",
    "journal": "BMC microbiology",
    "authors": [
      "Saleh M",
      "Yousef N",
      "Shafik S"
    ]
  },
  {
    "drugs": [
      {
        "name": "polymyxins",
        "drug_class": "lipopeptide antibiotics",
        "approved_for": "treatment of Gram-negative bacterial infections (last-resort)"
      }
    ],
    "pathogens": [
      {
        "name": "MDR Gram-negative pathogens",
        "resistance_profile": "multidrug-resistant, including resistance to polymyxins"
      }
    ],
    "findings": [
      {
        "drug": "polymyxins",
        "pathogen": "MDR Gram-negative pathogens",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxins are last-resort antibiotics against MDR Gram-negative bacteria but are increasingly encountering resistance."
      },
      {
        "drug": "non-antibiotics (adjuvants)",
        "pathogen": "MDR Gram-negative pathogens",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Non-antibiotics can potentiate polymyxin activity and help overcome resistance mechanisms in MDR Gram-negative bacteria."
      }
    ],
    "mechanism": "combination of polymyxins with non-antibiotics enhances bacterial membrane disruption, efflux pump inhibition, and resistance suppression",
    "relevance_score": 5,
    "paper_idx": 233,
    "pmid": "36350125",
    "title": "Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.",
    "year": "2022",
    "doi": "10.1128/spectrum.03952-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Yang F",
      "Liu J",
      "Gu Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "rifabutin",
        "drug_class": "rifamycin",
        "approved_for": "tuberculosis"
      },
      {
        "name": "linezolid",
        "drug_class": "oxazolidinone",
        "approved_for": "skin and soft tissue infections, pneumonia"
      },
      {
        "name": "mupirocin",
        "drug_class": "Ile-tRNA biosynthesis inhibitor",
        "approved_for": "topical bacterial infections, nasal decolonization"
      },
      {
        "name": "retapamulin",
        "drug_class": "pleuromutilin",
        "approved_for": "impetigo"
      },
      {
        "name": "valnemulin",
        "drug_class": "pleuromutilin",
        "approved_for": "veterinary use"
      },
      {
        "name": "gemcitabine",
        "drug_class": "nucleoside analog",
        "approved_for": "chemotherapy"
      }
    ],
    "pathogens": [
      {
        "name": "Enterococcus faecium (VanA-type vancomycin-resistant)",
        "resistance_profile": "vancomycin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "rifabutin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.19,
        "key_result": "Rifabutin demonstrated the most potent synergy with vancomycin against VREfm, with a FIC index of 0.19."
      },
      {
        "drug": "linezolid",
        "pathogen": "Enterococcus faecium",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Linezolid showed a modest synergistic effect with vancomycin against VREfm."
      },
      {
        "drug": "mupirocin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mupirocin demonstrated modest synergy with vancomycin, possibly due to induction of stringent response."
      },
      {
        "drug": "retapamulin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Retapamulin, a pleuromutilin, demonstrated synergy with vancomycin."
      },
      {
        "drug": "valnemulin",
        "pathogen": "Enterococcus faecium",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Valnemulin, a veterinary pleuromutilin, demonstrated synergy with vancomycin."
      },
      {
        "drug": "gemcitabine",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gemcitabine showed activity against VREfm but did not demonstrate synergy with vancomycin."
      }
    ],
    "mechanism": "The proposed mechanisms involve inhibition of RNA and protein biosynthesis pathways, which may block the expression of vancomycin resistance in VREfm.",
    "relevance_score": 4,
    "paper_idx": 234,
    "pmid": "36358911",
    "title": "Adenosine-Mimicking Derivatives of 3-Aminopyrazine-2-Carboxamide: Towards Inhibitors of Prolyl-tRNA Synthetase with Antimycobacterial Activity.",
    "year": "2022",
    "doi": "10.3390/biom12111561",
    "journal": "Biomolecules",
    "authors": [
      "Pallabothula V",
      "Kerda M",
      "Juh\u00e1s M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 235,
    "pmid": "36428290",
    "title": "Repurposing of atorvastatin emulsomes as a topical antifungal agent.",
    "year": "2022",
    "doi": "10.1080/10717544.2022.2149898",
    "journal": "Drug delivery",
    "authors": [
      "Eita A",
      "M A Makky A",
      "Anter A"
    ]
  },
  {
    "drugs": [
      {
        "name": "tavaborole",
        "drug_class": "benzoxaborole",
        "approved_for": "onychomycosis"
      },
      {
        "name": "tobramycin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug resistant (MDR), aminoglycoside-resistant"
      }
    ],
    "findings": [
      {
        "drug": "tavaborole",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Tavaborole exhibits synergistic activity with aminoglycosides against E. coli and reduces resistance development."
      },
      {
        "drug": "tavaborole",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant|synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "In mouse peritonitis models, tavaborole enhanced aminoglycoside bactericidal activity and slowed resistance."
      }
    ],
    "mechanism": "Tavaborole inhibits leucyl-tRNA synthetase, leading to mistranslation and interference with protein synthesis, which enhances the efficacy of aminoglycosides and slows resistance development.",
    "relevance_score": 5,
    "paper_idx": 236,
    "pmid": "36430555",
    "title": "Tobramycin Nanoantibiotics and Their Advantages: A Minireview.",
    "year": "2022",
    "doi": "10.3390/ijms232214080",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Rosalia M",
      "Chiesa E",
      "Tottoli E"
    ]
  },
  {
    "drugs": [
      {
        "name": "SBC3",
        "drug_class": "NHC-silver(I) complex",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "Ebselen",
        "drug_class": "selenium-organic compound",
        "approved_for": "hearing loss, mania, hypomania, impulsivity, emotional processing"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "not specified"
      },
      {
        "name": "Enterobacter cloacae",
        "resistance_profile": "not specified"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "not specified"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "SBC3",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "SBC3 combined with Ebselen exhibits synergistic antibacterial activity against E. coli, including MDR strains."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen enhances the antibacterial effect of SBC3 against E. coli through synergistic interaction."
      }
    ],
    "mechanism": "The synergistic antibacterial effect is based on direct inhibition of E. coli thioredoxin reductase and rapid depletion of glutathione, leading to increased reactive oxygen species and bacterial cell death.",
    "relevance_score": 4,
    "paper_idx": 237,
    "pmid": "36432288",
    "title": "Antimicrobial Activity of Graphene-Based Nanocomposites: Synthesis, Characterization, and Their Applications for Human Welfare.",
    "year": "2022",
    "doi": "10.3390/nano12224002",
    "journal": "Nanomaterials (Basel, Switzerland)",
    "authors": [
      "Ahmad V",
      "Ansari M"
    ]
  },
  {
    "drugs": [
      {
        "name": "rifampicin",
        "drug_class": "antituberculosis agent",
        "approved_for": "tuberculosis"
      },
      {
        "name": "benzothiazole",
        "drug_class": "antifungal/antimicrobial/anticancer",
        "approved_for": "not specified (used as experimental compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin resistant Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "rifampicin",
        "pathogen": "Methicillin resistant Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Co-localization of rifampicin with benzothiazole in nanoscopic micelles significantly reduced MRSA bacterial growth by 99.88%."
      },
      {
        "drug": "benzothiazole",
        "pathogen": "Methicillin resistant Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Benzothiazole, when co-localized with rifampicin in micelles, contributed to the sterilization effect against MRSA."
      }
    ],
    "mechanism": "co-localization of drugs within nanoscopic micelles enhances their delivery and efficacy against MDR bacteria, possibly through synergistic antibacterial activity.",
    "relevance_score": 4,
    "paper_idx": 238,
    "pmid": "36432719",
    "title": "Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.",
    "year": "2022",
    "doi": "10.3390/pharmaceutics14112528",
    "journal": "Pharmaceutics",
    "authors": [
      "El-Dirany R",
      "Fern\u00e1ndez-Rubio C",
      "Pe\u00f1a-Guerrero J"
    ]
  },
  {
    "drugs": [
      {
        "name": "streptomycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections in agriculture and medicine"
      },
      {
        "name": "zhongshengmycin",
        "drug_class": "antibiotic",
        "approved_for": "plant bacterial diseases"
      },
      {
        "name": "oxyclozanide",
        "drug_class": "salicylanilide",
        "approved_for": "veterinary parasitic infections"
      },
      {
        "name": "niclosamide",
        "drug_class": "salicylanilide",
        "approved_for": "anthelmintic in humans"
      },
      {
        "name": "rafoxanide",
        "drug_class": "salicylanilide",
        "approved_for": "veterinary parasitic infections"
      },
      {
        "name": "closantel sodium",
        "drug_class": "salicylanilide",
        "approved_for": "veterinary parasitic infections"
      },
      {
        "name": "nitazoxanide",
        "drug_class": "antiprotozoal agent",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "Xanthomonas oryzae PV. oryzae (Xoo)",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Xanthomonas axonopodis PV. citri (Xac)",
        "resistance_profile": "not specified"
      },
      {
        "name": "Pectobacterium atrosepticum (Pa)",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "oxyclozanide",
        "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.78,
        "fici": null,
        "key_result": "Oxyclozanide exhibits potent antibacterial activity against Xoo with an MIC of 0.78 \u03bcg/ml."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 3.12,
        "fici": null,
        "key_result": "Niclosamide shows antibacterial activity against Xoo with an MIC of 3.12 \u03bcg/ml."
      },
      {
        "drug": "streptomycin",
        "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1.56,
        "fici": null,
        "key_result": "Streptomycin demonstrates strong activity against Xoo with MIC values between 1.56 and 3.12 \u03bcg/ml."
      },
      {
        "drug": "salicylanilides (general)",
        "pathogen": "Xanthomonas oryzae PV. oryzae (Xoo)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.78,
        "fici": null,
        "key_result": "Salicylanilides, including oxyclozanide, exhibit potent antibacterial activity with MICs as low as 0.78 \u03bcg/ml."
      }
    ],
    "mechanism": "Disruption of bacterial cell envelope and inhibition of bacterial growth.",
    "relevance_score": 5,
    "paper_idx": 239,
    "pmid": "36443539",
    "title": "Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01492-w",
    "journal": "AMB Express",
    "authors": [
      "Liu S",
      "She P",
      "Li Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "ceritinib",
        "drug_class": "tyrosine kinase inhibitor",
        "approved_for": "non-small-cell lung cancer"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "ceritinib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceritinib exhibits bactericidal activity against S. aureus by disrupting cell membrane integrity and inducing reactive oxygen species production."
      },
      {
        "drug": "ceritinib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceritinib inhibits biofilm formation and eradicates mature biofilms of S. aureus."
      },
      {
        "drug": "ceritinib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mechanistic studies suggest ceritinib disrupts cell membrane integrity, contributing to its antimicrobial effect."
      },
      {
        "drug": "ceritinib",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceritinib reduces infection severity in a mouse subcutaneous abscess model with negligible systemic toxicity."
      }
    ],
    "mechanism": "Disruption of bacterial cell membrane integrity and induction of reactive oxygen species production.",
    "relevance_score": 4,
    "paper_idx": 240,
    "pmid": "36454354",
    "title": "Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.",
    "year": "2022",
    "doi": "10.1186/s13568-022-01488-6",
    "journal": "AMB Express",
    "authors": [
      "Liu S",
      "She P",
      "Li Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "ascorbic acid",
        "drug_class": "vitamin",
        "approved_for": "scurvy, antioxidant"
      },
      {
        "name": "dexamethasone",
        "drug_class": "glucocorticoid",
        "approved_for": "inflammatory and autoimmune conditions"
      },
      {
        "name": "sodium bicarbonate",
        "drug_class": "antacid, buffer",
        "approved_for": "acid indigestion, metabolic acidosis"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "ascorbic acid",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sub-inhibitory concentrations of ascorbic acid significantly reduced S. aureus virulence factors including biofilm formation, hemolysin, protease production, and resistance to oxidative stress."
      },
      {
        "drug": "dexamethasone",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Dexamethasone at sub-MIC levels decreased production of S. aureus virulence factors such as biofilm, hemolysin, proteases, and oxidative stress resistance."
      },
      {
        "drug": "sodium bicarbonate",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sodium bicarbonate at sub-MIC concentrations reduced S. aureus virulence factors including biofilm, hemolysin, protease activity, and oxidative stress resistance."
      }
    ],
    "mechanism": "The drugs reduce the expression of virulence genes and inhibit virulence factor production, thereby attenuating S. aureus pathogenicity without directly killing the bacteria.",
    "relevance_score": 4,
    "paper_idx": 241,
    "pmid": "36499402",
    "title": "Design, Synthesis and Antimicrobial Properties of New Tetracyclic Quinobenzothiazine Derivatives.",
    "year": "2022",
    "doi": "10.3390/ijms232315078",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Kisiel-Nawrot E",
      "Pindjakova D",
      "Latocha M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 242,
    "pmid": "36512492",
    "title": "Repurposed dihydroorotate dehydrogenase inhibitors with efficacy against drug-resistant Acinetobacter baumannii.",
    "year": "2022",
    "doi": "10.1073/pnas.2213116119",
    "journal": "Proceedings of the National Academy of Sciences of the United States of America",
    "authors": [
      "Russo T",
      "Umland T",
      "Deng X"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 243,
    "pmid": "36519895",
    "title": "Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus.",
    "year": "2023",
    "doi": "10.1128/spectrum.03726-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Sharma A",
      "Gutheil W"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tobramycin",
        "drug_class": "aminoglycoside",
        "approved_for": "complicated infections, reinfections, cystic fibrosis (inhalation), ocular infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug-resistant (MDR)"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "not specified"
      },
      {
        "name": "Proteus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Klebsiella",
        "resistance_profile": "not specified"
      },
      {
        "name": "Enterobacter",
        "resistance_profile": "not specified"
      },
      {
        "name": "Serratia",
        "resistance_profile": "not specified"
      },
      {
        "name": "Providencia",
        "resistance_profile": "not specified"
      },
      {
        "name": "Citrobacter",
        "resistance_profile": "not specified"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "penicillinase-producing strains"
      }
    ],
    "findings": [
      {
        "drug": "Tobramycin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nanoantibiotics formulations of tobramycin show potential to enhance activity against MDR Pseudomonas aeruginosa."
      },
      {
        "drug": "Tobramycin",
        "pathogen": "Gram-negative bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nanocarrier systems improve delivery and efficacy of tobramycin against Gram-negative bacteria."
      }
    ],
    "mechanism": "Encapsulation of tobramycin in nanosized delivery systems enhances bacterial uptake, improves stability, and may reduce toxicity, thereby overcoming some mechanisms of antimicrobial resistance.",
    "relevance_score": 4,
    "paper_idx": 244,
    "pmid": "36533811",
    "title": "Identification of potential pathways and biomarkers linked to progression in ALS.",
    "year": "2023",
    "doi": "10.1002/acn3.51697",
    "journal": "Annals of clinical and translational neurology",
    "authors": [
      "Huber R",
      "Pandey S",
      "Chhangani D"
    ]
  },
  {
    "drugs": [
      {
        "name": "Nisoldipine",
        "drug_class": "L-type voltage-gated calcium channel inhibitor",
        "approved_for": "hypertension"
      }
    ],
    "pathogens": [
      {
        "name": "Influenza A virus",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Nisoldipine",
        "pathogen": "Influenza A virus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nisoldipine potently inhibits influenza A virus infection by impairing virus internalization into host cells."
      }
    ],
    "mechanism": "Interferes with virus internalization process by targeting host cell Cav1.2 calcium channels.",
    "relevance_score": 4,
    "paper_idx": 245,
    "pmid": "36558754",
    "title": "Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.",
    "year": "2022",
    "doi": "10.3390/pathogens11121420",
    "journal": "Pathogens (Basel, Switzerland)",
    "authors": [
      "Koh Jing Jie A",
      "Hussein M",
      "Rao G"
    ]
  },
  {
    "drugs": [
      {
        "name": "nutraceuticals",
        "drug_class": "nutraceuticals",
        "approved_for": "dietary supplements"
      },
      {
        "name": "dopamine pathway modulators",
        "drug_class": "dopamine modulators",
        "approved_for": "Parkinson's disease, schizophrenia, depression"
      },
      {
        "name": "statins",
        "drug_class": "HMG-CoA reductase inhibitors",
        "approved_for": "hypercholesterolemia, cardiovascular disease prevention"
      },
      {
        "name": "anti-inflammatories",
        "drug_class": "NSAIDs or corticosteroids",
        "approved_for": "inflammatory conditions"
      },
      {
        "name": "antimicrobials",
        "drug_class": "antibiotics/antimicrobials",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "nutraceuticals",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nutraceuticals were predicted as starting points for drug repurposing affecting pathways linked to ALS progression."
      },
      {
        "drug": "dopamine pathway modulators",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Dopamine pathway modulators were identified as potential drugs influencing disease-related pathways."
      },
      {
        "drug": "statins",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Statins were predicted to affect pathways associated with ALS progression."
      },
      {
        "drug": "anti-inflammatories",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Anti-inflammatories were identified as potential modulators of disease pathways."
      },
      {
        "drug": "antimicrobials",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Antimicrobials were predicted to influence pathways linked to ALS disease mechanisms."
      }
    ],
    "mechanism": "The proposed mechanisms involve modulation of pathways related to neuroinflammation, protein aggregation, and cellular stress responses implicated in ALS progression.",
    "relevance_score": 2,
    "paper_idx": 246,
    "pmid": "36560742",
    "title": "Nisoldipine Inhibits Influenza A Virus Infection by Interfering with Virus Internalization Process.",
    "year": "2022",
    "doi": "10.3390/v14122738",
    "journal": "Viruses",
    "authors": [
      "Huang Y",
      "Li Y",
      "Chen Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "Florfenicol",
        "drug_class": "phenicol",
        "approved_for": "bacterial infections in animals"
      },
      {
        "name": "Streptomycin",
        "drug_class": "aminoglycoside",
        "approved_for": "tuberculosis, bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Avian pathogenic Escherichia coli (APEC)",
        "resistance_profile": "multi-drug resistant (resistant to Florfenicol and Streptomycin)"
      }
    ],
    "findings": [
      {
        "drug": "Florfenicol",
        "pathogen": "Avian pathogenic Escherichia coli (APEC)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.1,
        "fici": null,
        "key_result": "PEG-6000 coated ZnO-NPs enhanced the efficacy of Florfenicol, restoring sensitivity in resistant APEC strains with a 60% high sensitivity rate."
      },
      {
        "drug": "Streptomycin",
        "pathogen": "Avian pathogenic Escherichia coli (APEC)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.1,
        "fici": null,
        "key_result": "PEG-6000 coated ZnO-NPs improved Streptomycin activity, achieving 50% high sensitivity in resistant APEC strains."
      }
    ],
    "mechanism": "ZnO-NPs coated with PEG-6000 likely enhance antibiotic activity by disrupting bacterial cell membranes and increasing drug uptake, thereby overcoming resistance mechanisms.",
    "relevance_score": 4,
    "paper_idx": 247,
    "pmid": "36588729",
    "title": "The synergistic activity of SBC3 in combination with Ebselen against Escherichia coli infection.",
    "year": "2022",
    "doi": "10.3389/fphar.2022.1080281",
    "journal": "Frontiers in pharmacology",
    "authors": [
      "Chen H",
      "Lu Q",
      "An H"
    ]
  },
  {
    "drugs": [
      {
        "name": "DSM186",
        "drug_class": "imidazopyrimidine",
        "approved_for": "malaria (experimental/repurposed for bacterial DHODH inhibition)"
      },
      {
        "name": "DSM161",
        "drug_class": "imidazopyrimidine",
        "approved_for": "malaria (experimental/repurposed for bacterial DHODH inhibition)"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "drug-resistant, including meropenem-resistant strains"
      }
    ],
    "findings": [
      {
        "drug": "DSM186",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.055,
        "fici": null,
        "key_result": "DSM186 exhibits submicromolar activity against A. baumannii strains, including resistant isolates, with MIC \u22641 \u00b5g/mL."
      },
      {
        "drug": "DSM186",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Efflux inhibitors like PA\u03b2N enhance DSM186 activity, indicating efflux contributes to reduced efficacy."
      },
      {
        "drug": "DSM186",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, DSM186 analog DSM161 conferred protection in mouse infection models, supporting its potential as a therapeutic agent."
      }
    ],
    "mechanism": "Inhibition of bacterial dihydroorotate dehydrogenase (DHODH), disrupting pyrimidine biosynthesis essential for bacterial survival.",
    "relevance_score": 5,
    "paper_idx": 248,
    "pmid": "36597079",
    "title": "In vitro assessment of PEG-6000 coated-ZnO nanoparticles: modulating action to the resisted antibiotic activity against APEC.",
    "year": "2023",
    "doi": "10.1186/s12917-022-03562-4",
    "journal": "BMC veterinary research",
    "authors": [
      "Badry A",
      "Ibrahim A",
      "Said M"
    ]
  },
  {
    "drugs": [
      {
        "name": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "drug_class": "quinobenzothiazinium derivatives",
        "approved_for": "not approved (experimental compound)"
      },
      {
        "name": "9-propoxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "drug_class": "quinobenzothiazinium derivatives",
        "approved_for": "not approved (experimental compound)"
      },
      {
        "name": "9-allyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "drug_class": "quinobenzothiazinium derivatives",
        "approved_for": "not approved (experimental compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "methicillin-resistant (MRSA)"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "vancomycin-resistant (VRE)"
      },
      {
        "name": "Mycobacterium smegmatis",
        "resistance_profile": "not specified"
      },
      {
        "name": "M. marinum",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Demonstrated high activity against S. aureus, comparable to oxacillin."
      },
      {
        "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Effective against E. faecalis, comparable to tetracycline."
      },
      {
        "drug": "9-propoxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "pathogen": "Mycobacterium smegmatis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Exhibited activity comparable to rifampicin against M. smegmatis."
      },
      {
        "drug": "9-allyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "pathogen": "M. marinum",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Showed activity similar to rifampicin against M. marinum."
      },
      {
        "drug": "9-benzyloxy-5-methyl-12H-quino[3,4-b][1,4]benzothiazinium chloride",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "bacteriostatic|bactericidal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Displayed both bacteriostatic and bactericidal activity."
      }
    ],
    "mechanism": "The compounds inhibit bacterial respiration and exhibit bacteriostatic and bactericidal effects, likely through interaction with bacterial cell components affecting respiration.",
    "relevance_score": 4,
    "paper_idx": 249,
    "pmid": "36671340",
    "title": "Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases.",
    "year": "2023",
    "doi": "10.3390/antibiotics12010137",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "R\u00e1cz B",
      "Spengler G"
    ]
  },
  {
    "drugs": [
      {
        "name": "rapamycin",
        "drug_class": "macrolide",
        "approved_for": "immunosuppression, transplant rejection, certain cancers"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "induction of autophagy and inhibition of TORC1 activity, leading to long-lasting intestinal protection and lifespan extension",
    "relevance_score": 1,
    "paper_idx": 250,
    "pmid": "36675123",
    "title": "Antibacterial Activity of Ebselen.",
    "year": "2023",
    "doi": "10.3390/ijms24021610",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Ma\u015blanka M",
      "Mucha A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Monensin",
        "drug_class": "Polyether ionophore antibiotic",
        "approved_for": "Veterinary use"
      }
    ],
    "pathogens": [
      {
        "name": "human colorectal cancer cells",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "Monensin",
        "pathogen": "human colorectal cancer cells",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Monensin inhibits proliferation, migration, induces apoptosis, and causes G1 cell cycle arrest in human colorectal cancer cells."
      }
    ],
    "mechanism": "Monensin suppresses IGF1R expression and targets multiple cancer-related signaling pathways including Elk1, AP1, and Myc/max, potentially involving increased IGF1 levels.",
    "relevance_score": 1,
    "paper_idx": 251,
    "pmid": "36699729",
    "title": "In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B.",
    "year": "2022",
    "doi": "10.3389/fcimb.2022.1044665",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Borges B",
      "Bueno G",
      "Tomiotto-Pellissier F"
    ]
  },
  {
    "drugs": [
      {
        "name": "triclabendazole",
        "drug_class": "benzimidazole",
        "approved_for": "fasciolosis"
      },
      {
        "name": "amphotericin B",
        "drug_class": "antifungal polyene",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Leishmania amazonensis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "triclabendazole",
        "pathogen": "Leishmania amazonensis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Triclabendazole demonstrated in vitro activity against Leishmania amazonensis promastigotes and amastigotes, with a selectivity index comparable to amphotericin B."
      },
      {
        "drug": "amphotericin B",
        "pathogen": "Leishmania amazonensis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amphotericin B showed expected activity against Leishmania amazonensis, serving as a positive control."
      },
      {
        "drug": "triclabendazole",
        "pathogen": "Leishmania amazonensis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Combined administration of triclabendazole and amphotericin B demonstrated a synergistic effect against intracellular amastigotes."
      }
    ],
    "mechanism": "Potential mechanisms include targeting microtubules and/or protein synthesis, with observed lipid accumulation suggesting alterations in lipid metabolism.",
    "relevance_score": 4,
    "paper_idx": 252,
    "pmid": "36758467",
    "title": "Gold(I) selenium N-heterocyclic carbene complexes as potent antibacterial agents against multidrug-resistant gram-negative bacteria via inhibiting thioredoxin reductase.",
    "year": "2023",
    "doi": "10.1016/j.redox.2023.102621",
    "journal": "Redox biology",
    "authors": [
      "Chen X",
      "Sun S",
      "Huang S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Cefoperazone Sulbactam",
        "drug_class": "beta-lactam/beta-lactamase inhibitor combination",
        "approved_for": "various bacterial infections (not specifically for Acinetobacter)"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR (multidrug-resistant), carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Cefoperazone Sulbactam",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cefoperazone sulbactam shows variable susceptibility with some isolates being 100% susceptible and others resistant, and it demonstrates clinical efficacy in treating AB infections in observational studies."
      },
      {
        "drug": "Cefoperazone Sulbactam",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "When used in combination with other antibiotics such as colistin, tigecycline, or carbapenems, CS shows improved clinical and microbiological cure rates, especially with colistin."
      }
    ],
    "mechanism": "Sulbactam inhibits beta-lactamase enzymes produced by AB and has intrinsic activity against the pathogen, while cefoperazone provides broad-spectrum beta-lactam activity.",
    "relevance_score": 3,
    "paper_idx": 253,
    "pmid": "36834854",
    "title": "Antibacterial Activity of Nanostructured Zinc Oxide Tetrapods.",
    "year": "2023",
    "doi": "10.3390/ijms24043444",
    "journal": "International journal of molecular sciences",
    "authors": [
      "B\u00fcter A",
      "Maschkowitz G",
      "Baum M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Zinc Oxide Tetrapods",
        "drug_class": "nanomaterial/metal oxide",
        "approved_for": "none (experimental nanomaterial)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "methicillin-sensitive and methicillin-resistant (MRSA)"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "multidrug-resistant, carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Zinc Oxide Tetrapods",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ZnO tetrapods showed dose- and time-dependent bactericidal activity against S. aureus, including MRSA, with significant reduction in bacterial counts after 24 hours."
      },
      {
        "drug": "Zinc Oxide Tetrapods",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ZnO tetrapods achieved complete eradication of K. pneumoniae at low concentrations after 24 hours, including multidrug-resistant strains."
      }
    ],
    "mechanism": "Surface contact leading to bacterial cell damage, possibly involving reactive oxygen species or zinc ion release, with physical nanostructured surfaces providing active interfaces for bacterial killing.",
    "relevance_score": 4,
    "paper_idx": 254,
    "pmid": "36835564",
    "title": "Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer.",
    "year": "2023",
    "doi": "10.3390/ijms24044154",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Louren\u00e7o T",
      "Vale N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Pillar[5]arene",
        "drug_class": "macrocycle host-guest chemistry",
        "approved_for": "none (experimental compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "carbapenem-resistant, third/fourth-generation cephalosporin-resistant"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "extensively drug resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "Pillar[5]arene",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pillar[5]arene binds to long-chain homoserine lactones, suppressing toxin production and biofilm formation in P. aeruginosa."
      },
      {
        "drug": "Pillar[5]arene",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pillar[5]arene inhibits biofilm formation and suppresses virulence factors in MDR A. baumannii."
      },
      {
        "drug": "Pillar[5]arene",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pillar[5]arene increases the penetration and efficacy of standard antibiotics when used in combination."
      }
    ],
    "mechanism": "Pillar[5]arene sequesters homoserine lactones and lipopolysaccharides, neutralizing virulence signaling and disrupting outer membrane barrier functions, thereby suppressing toxin production and biofilm formation.",
    "relevance_score": 5,
    "paper_idx": 255,
    "pmid": "36868316",
    "title": "Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.",
    "year": "2023",
    "doi": "10.1016/j.antiviral.2023.105575",
    "journal": "Antiviral research",
    "authors": [
      "Shekunov E",
      "Zlodeeva P",
      "Efimova S"
    ]
  },
  {
    "drugs": [
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "kidney transplant rejection, cardiac stents, lymphangioleiomyomatosis"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "proposed mechanism of antimicrobial action",
    "relevance_score": 1,
    "paper_idx": 256,
    "pmid": "36876884",
    "title": "Gliotoxin and related metabolites as zinc chelators: implications and exploitation to overcome antimicrobial resistance.",
    "year": "2023",
    "doi": "10.1042/EBC20220222",
    "journal": "Essays in biochemistry",
    "authors": [
      "Downes S",
      "Doyle S",
      "Jones G"
    ]
  },
  {
    "drugs": [
      {
        "name": "berbamine dihydrochloride",
        "drug_class": "autophagy blocker",
        "approved_for": "none (experimental/repurposed)"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none (not about resistance, but infection)"
      }
    ],
    "findings": [
      {
        "drug": "berbamine dihydrochloride",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Berbamine dihydrochloride prevents SARS-CoV-2 acquisition in human intestinal epithelial cells via BNIP3-dependent autophagy blockade."
      },
      {
        "drug": "berbamine dihydrochloride",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "It exhibits pan-antiviral activity against Omicron subvariants BA.2 and BA.5 at nanomolar potency."
      },
      {
        "drug": "berbamine dihydrochloride",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Autophagy-blocking therapy limited virus-induced damage to intestinal barrier function, suggesting potential to limit viral dissemination."
      }
    ],
    "mechanism": "Inhibition of autophagy machinery via BNIP3-dependent autophagy blockade, preventing SARS-CoV-2 infection and dissemination.",
    "relevance_score": 4,
    "paper_idx": 257,
    "pmid": "36896461",
    "title": "Effect of antibiotic monensin on cell proliferation and IGF1R signaling pathway in human colorectal cancer cells.",
    "year": "2023",
    "doi": "10.1080/07853890.2023.2166980",
    "journal": "Annals of medicine",
    "authors": [
      "Zhou Y",
      "Deng Y",
      "Wang J"
    ]
  },
  {
    "drugs": [
      {
        "name": "spiro-acridine derivatives",
        "drug_class": "acridine derivatives",
        "approved_for": "none (experimental compounds)"
      }
    ],
    "pathogens": [
      {
        "name": "Aspergillus fumigatus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Trichoderma harzianum",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "spiro-acridine derivatives",
        "pathogen": "Aspergillus fumigatus",
        "activity_type": "anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Compound 5 exhibited potent inhibitory activity against fungal chitinases with an IC50 of 0.6 ng/\u00b5L, indicating potential antifungal activity."
      },
      {
        "drug": "spiro-acridine derivatives",
        "pathogen": "Trichoderma harzianum",
        "activity_type": "anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Compounds showed strong binding interactions with T. harzianum chitinases in silico, suggesting potential antifungal activity."
      }
    ],
    "mechanism": "Inhibition of fungal chitinases by binding to the active site, particularly interacting with the DXDXE motif, disrupting cell wall remodeling and fungal growth.",
    "relevance_score": 4,
    "paper_idx": 258,
    "pmid": "36951188",
    "title": "Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade.",
    "year": "2023",
    "doi": "10.1080/22221751.2023.2195020",
    "journal": "Emerging microbes & infections",
    "authors": [
      "Cloherty A",
      "Rader A",
      "Patel K"
    ]
  },
  {
    "drugs": [
      {
        "name": "9-Aminoacridine",
        "drug_class": "antimicrobial agent / DNA intercalator",
        "approved_for": "cancer, prion, Alzheimer's disease"
      },
      {
        "name": "Rifampin",
        "drug_class": "RNA polymerase inhibitor",
        "approved_for": "tuberculosis, leprosy"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR/XDR/PDR"
      }
    ],
    "findings": [
      {
        "drug": "9-Aminoacridine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": 0.375,
        "key_result": "9-Aminoacridine synergistically enhances the antimicrobial effect of rifampin against multidrug-resistant K. pneumoniae in vitro."
      },
      {
        "drug": "9-Aminoacridine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "9-Aminoacridine exhibits antimicrobial activity against K. pneumoniae with MICs ranging from 8 to 16 \u03bcg/mL."
      },
      {
        "drug": "9-Aminoacridine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "When combined with rifampin, 9-Aminoacridine reduces resistance development and enhances in vivo antimicrobial efficacy."
      },
      {
        "drug": "9-Aminoacridine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "mechanistic",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mechanistic studies suggest 9-Aminoacridine interacts with bacterial DNA and disrupts proton motive force, contributing to its antimicrobial activity."
      }
    ],
    "mechanism": "9-Aminoacridine interacts with bacterial DNA, intercalates into the DNA structure, and disrupts the proton motive force, impairing bacterial energy processes and enhancing antibiotic efficacy.",
    "relevance_score": 5,
    "paper_idx": 259,
    "pmid": "36978084",
    "title": "Gram-negative bacteria resist antimicrobial agents by a DzrR-mediated envelope stress response.",
    "year": "2023",
    "doi": "10.1186/s12915-023-01565-7",
    "journal": "BMC biology",
    "authors": [
      "Liang Z",
      "Lin Q",
      "Wang Q"
    ]
  },
  {
    "drugs": [
      {
        "name": "zeamines",
        "drug_class": "antimicrobial agents",
        "approved_for": "not specified"
      },
      {
        "name": "chlorhexidine",
        "drug_class": "antiseptic",
        "approved_for": "skin disinfection"
      },
      {
        "name": "chlorpromazine",
        "drug_class": "antipsychotic",
        "approved_for": "psychosis"
      }
    ],
    "pathogens": [
      {
        "name": "Dickeya oryzae",
        "resistance_profile": "zeamine resistance"
      },
      {
        "name": "Ralstonia spp.",
        "resistance_profile": "antimicrobial resistance"
      },
      {
        "name": "Burkholderia cenocepacia",
        "resistance_profile": "chlorhexidine resistance"
      }
    ],
    "findings": [
      {
        "drug": "zeamines",
        "pathogen": "Dickeya oryzae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 450,
        "fici": null,
        "key_result": "DzrR regulates resistance to zeamines by inducing the expression of the RND efflux pump desAB."
      },
      {
        "drug": "chlorhexidine",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 900,
        "fici": null,
        "key_result": "DzrR homolog in B. cenocepacia activates efflux pump expression in response to chlorhexidine, contributing to resistance."
      },
      {
        "drug": "chlorpromazine",
        "pathogen": "not specified",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Structural divergence suggests potential modulation of bacterial response, but specific activity not detailed."
      }
    ],
    "mechanism": "DzrR, a response regulator, induces expression of RND efflux pumps (DesABC and others) in response to envelope-targeting antimicrobial agents, independent of phosphorylation.",
    "relevance_score": 4,
    "paper_idx": 260,
    "pmid": "36978449",
    "title": "Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature.",
    "year": "2023",
    "doi": "10.3390/antibiotics12030582",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Kogilathota Jagirdhar G",
      "Rama K",
      "Reddy S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Atorvastatin",
        "drug_class": "HMG-CoA reductase inhibitor",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "fluconazole-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Atorvastatin",
        "pathogen": "Candida albicans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin demonstrated in vitro antifungal activity against fluconazole-resistant Candida albicans."
      }
    ],
    "mechanism": "proposed mechanism of antimicrobial action",
    "relevance_score": 4,
    "paper_idx": 261,
    "pmid": "36978495",
    "title": "Design and Synthesis of Novel Antimicrobial Agents.",
    "year": "2023",
    "doi": "10.3390/antibiotics12030628",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Breijyeh Z",
      "Karaman R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "Gold complex",
        "approved_for": "Rheumatoid arthritis"
      },
      {
        "name": "H7",
        "drug_class": "Gold(I) selenium N-heterocyclic carbene complex",
        "approved_for": null
      },
      {
        "name": "H8",
        "drug_class": "Gold(I) selenium N-heterocyclic carbene complex",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Carbapenem-resistant Acinetobacter baumannii (CRAB)",
        "resistance_profile": "MDR"
      },
      {
        "name": "Carbapenem-resistant Klebsiella pneumoniae (CRKP)",
        "resistance_profile": "MDR"
      },
      {
        "name": "Carbapenem-resistant Pseudomonas aeruginosa (CRPA)",
        "resistance_profile": "MDR"
      },
      {
        "name": "Carbapenem-resistant Escherichia coli (CREco)",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "H7",
        "pathogen": "CRAB",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "H7 shows potent antibacterial activity against MDR Gram-negative bacteria by inhibiting thioredoxin reductase, leading to oxidative stress."
      },
      {
        "drug": "H8",
        "pathogen": "CRAB",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "H8 exhibits stronger antibacterial effects than auranofin against MDR bacteria via TrxR inhibition."
      },
      {
        "drug": "H7",
        "pathogen": "CRAB",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, H7 promotes wound healing and prolongs survival in CRAB-induced peritonitis models."
      },
      {
        "drug": "H8",
        "pathogen": "CRAB",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "H8 demonstrates superior antibacterial activity in vivo compared to auranofin."
      }
    ],
    "mechanism": "Inhibition of bacterial thioredoxin reductase (TrxR), leading to increased reactive oxygen species (ROS), oxidative stress, and disruption of redox balance and cellular functions.",
    "relevance_score": 5,
    "paper_idx": 262,
    "pmid": "37036368",
    "title": "Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1128/spectrum.04474-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "She P",
      "Li Y",
      "Li Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "atorvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "fluvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "simvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "mevastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "lovastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "rosuvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "fenofibrate",
        "drug_class": "fibrate",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "metformin",
        "drug_class": "biguanide",
        "approved_for": "type 2 diabetes mellitus"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "atorvastatin",
        "pathogen": "prostate cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin reduces serum PSA levels and tumor proliferation in prostate cancer patients."
      },
      {
        "drug": "fluvastatin",
        "pathogen": "prostate cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluvastatin administration induces apoptosis and is detected in prostate tissue, enhancing prostate cancer treatment."
      },
      {
        "drug": "simvastatin",
        "pathogen": "prostate cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simvastatin resensitizes resistant prostate cancer cells and reduces PSA levels."
      },
      {
        "drug": "fenofibrate",
        "pathogen": "prostate cancer",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fenofibrate induces apoptosis and reduces androgen receptor expression in prostate cancer cells."
      },
      {
        "drug": "metformin",
        "pathogen": "prostate cancer",
        "activity_type": "adjuvant",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Metformin promotes apoptosis and inhibits growth in prostate cancer, reducing incidence and mortality."
      }
    ],
    "mechanism": "Repurposed drugs modulate lipid metabolism, inhibit cell proliferation, induce apoptosis, and interfere with signaling pathways such as PI3K/Akt/mTOR in prostate cancer.",
    "relevance_score": 4,
    "paper_idx": 263,
    "pmid": "37059703",
    "title": "Repurposing host-guest chemistry to sequester virulence and eradicate biofilms in multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii.",
    "year": "2023",
    "doi": "10.1038/s41467-023-37749-6",
    "journal": "Nature communications",
    "authors": [
      "Jonkergouw C",
      "Beyeh N",
      "Osmekhina E"
    ]
  },
  {
    "drugs": [
      {
        "name": "aculeacin A",
        "drug_class": "antifungal",
        "approved_for": "antifungal infections"
      },
      {
        "name": "anidulafungin",
        "drug_class": "antifungal (echinocandin)",
        "approved_for": "systemic fungal infections"
      },
      {
        "name": "iturin A",
        "drug_class": "antifungal lipopeptide",
        "approved_for": "not FDA-approved, used as a biocontrol agent"
      },
      {
        "name": "mycosubtilin",
        "drug_class": "antifungal lipopeptide",
        "approved_for": "not FDA-approved, used in biocontrol"
      },
      {
        "name": "polymyxin B",
        "drug_class": "antibacterial (polymyxin)",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      },
      {
        "name": "daptomycin",
        "drug_class": "antibacterial (lipopeptide)",
        "approved_for": "Gram-positive bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "aculeacin A",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Aculeacin A attenuated the cytopathogenicity of SARS-CoV-2 in cell culture."
      },
      {
        "drug": "anidulafungin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Anidulafungin reduced SARS-CoV-2 cytopathogenic effects in cell models."
      },
      {
        "drug": "iturin A",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Iturin A inhibited SARS-CoV-2-induced cytopathogenicity in vitro."
      },
      {
        "drug": "mycosubtilin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mycosubtilin attenuated SARS-CoV-2 cytopathogenic effects in cell culture."
      },
      {
        "drug": "polymyxin B",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxin B reduced SARS-CoV-2 cytopathogenicity in vitro."
      },
      {
        "drug": "daptomycin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Daptomycin attenuated SARS-CoV-2-induced cytopathic effects in cell models."
      }
    ],
    "mechanism": "Membrane fusion inhibition through alteration of lipid packing, membrane curvature stress, and domain organization, disrupting viral entry processes.",
    "relevance_score": 4,
    "paper_idx": 264,
    "pmid": "37118497",
    "title": "Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy.",
    "year": "2022",
    "doi": "10.1038/s43587-022-00278-w",
    "journal": "Nature aging",
    "authors": [
      "Juricic P",
      "Lu Y",
      "Leech T"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "organogold compound",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "Holomycin",
        "drug_class": "dithiolopyrrolone antibiotic",
        "approved_for": "not approved (experimental)"
      },
      {
        "name": "PBT2",
        "drug_class": "metal ionophore",
        "approved_for": "not approved (investigational for neurodegenerative diseases)"
      },
      {
        "name": "Gliotoxin",
        "drug_class": "epipolythiodioxopiperazine (ETP)",
        "approved_for": "not approved (natural fungal metabolite)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "VRE"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Fusobacterium nucleatum",
        "resistance_profile": "not specified"
      },
      {
        "name": "Yersinia ruckeri",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Gliotoxin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gliotoxin significantly enhances vancomycin activity against S. aureus in vitro."
      },
      {
        "drug": "Holomycin",
        "pathogen": "not specified",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Reduced holomycin can inhibit metallo-\u03b2-lactamases, suggesting potential to inhibit zinc-dependent resistance enzymes."
      },
      {
        "drug": "PBT2",
        "pathogen": "multiple bacteria including VRE and others",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PBT2-Zn destabilizes bacterial resistance pathways, re-sensitizing VRE to vancomycin and enhancing sensitivity to other antibiotics."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin inhibits bacterial thioredoxin reductase, disrupting redox balance and causing bacterial cell death."
      }
    ],
    "mechanism": "Zinc chelation and disruption of metalloenzyme activity, interference with bacterial metal ion homeostasis, and potential inhibition of resistance enzymes such as metallo-\u03b2-lactamases.",
    "relevance_score": 5,
    "paper_idx": 265,
    "pmid": "37147323",
    "title": "Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies.",
    "year": "2023",
    "doi": "10.1038/s41598-023-33279-9",
    "journal": "Scientific reports",
    "authors": [
      "de Oliveira Viana J",
      "Silva E Souza E",
      "Sbaraini N"
    ]
  },
  {
    "drugs": [
      {
        "name": "ticagrelor",
        "drug_class": "antiplatelet agent",
        "approved_for": "antithrombotic therapy"
      },
      {
        "name": "mitomycin C",
        "drug_class": "antineoplastic agent",
        "approved_for": "cancer treatment"
      },
      {
        "name": "auranofin",
        "drug_class": "antirheumatic agent",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "pentamidine",
        "drug_class": "antiprotozoal agent",
        "approved_for": "Pneumocystis pneumonia, African trypanosomiasis"
      },
      {
        "name": "zidovudine",
        "drug_class": "antiretroviral nucleoside analogue",
        "approved_for": "HIV/AIDS"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "CRAB (carbapenem-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "ticagrelor",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ticagrelor shows potential as an adjuvant to enhance antimicrobial activity against MRSA."
      },
      {
        "drug": "mitomycin C",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mitomycin C demonstrates synergistic effects with antibiotics against resistant bacteria."
      },
      {
        "drug": "auranofin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin exhibits activity as an adjuvant to combat MDR A. baumannii."
      },
      {
        "drug": "pentamidine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pentamidine shows potential in combination therapies against resistant strains."
      },
      {
        "drug": "zidovudine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Zidovudine may serve as an adjuvant to enhance antimicrobial efficacy."
      }
    ],
    "mechanism": "The proposed mechanisms involve repurposing these drugs as adjuvants that can enhance the activity of existing antibiotics or directly inhibit resistant bacterial targets, possibly through interference with bacterial metabolism, efflux pumps, or cell wall synthesis.",
    "relevance_score": 4,
    "paper_idx": 266,
    "pmid": "37178319",
    "title": "Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.",
    "year": "2023",
    "doi": "10.1111/1751-7915.14268",
    "journal": "Microbial biotechnology",
    "authors": [
      "Douglas E",
      "Wulandari S",
      "Lovell S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Amphotericin B",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "mpox virus (MPXV)",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Amphotericin B",
        "pathogen": "mpox virus (MPXV)",
        "activity_type": "adjuvant",
        "evidence_type": "theoretical/hypothesis",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amphotericin B may inhibit MPXV infection by disrupting host cell lipid rafts through cholesterol sequestration."
      }
    ],
    "mechanism": "disruption of host-cell lipid raft architecture via cholesterol sequestration, potentially redistributing viral entry receptors",
    "relevance_score": 4,
    "paper_idx": 267,
    "pmid": "37184748",
    "title": "Atorvastatin liposomes in a 3D-printed polymer film: a repurposing approach for local treatment of oral candidiasis.",
    "year": "2023",
    "doi": "10.1007/s13346-023-01353-4",
    "journal": "Drug delivery and translational research",
    "authors": [
      "Nour E",
      "El-Habashy S",
      "Shehat M"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "not specified in the paper"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli (ESBL-producing)",
        "resistance_profile": "extended-spectrum beta-lactamase (ESBL)"
      }
    ],
    "findings": [
      {
        "drug": "ebselen",
        "pathogen": "Escherichia coli (ESBL-producing)",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen inhibits diguanylate cyclases, reducing c-di-GMP levels and significantly decreasing the MIC of ceftriaxone against ESBL-E. coli."
      }
    ],
    "mechanism": "Inhibition of diguanylate cyclases, leading to decreased c-di-GMP synthesis, which modulates bacterial self-saving responses and resistance mechanisms.",
    "relevance_score": 5,
    "paper_idx": 268,
    "pmid": "37191826",
    "title": "Evaluation of off-label rapamycin use to promote healthspan in 333 adults.",
    "year": "2023",
    "doi": "10.1007/s11357-023-00818-1",
    "journal": "GeroScience",
    "authors": [
      "Kaeberlein T",
      "Green A",
      "Haddad G"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "organoselenium compound",
        "approved_for": "antioxidant, anti-inflammatory, cytoprotective"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "methicillin-resistant (MRSA), vancomycin-resistant"
      },
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "vancomycin-resistant (VRE)"
      },
      {
        "name": "Streptococcus spp.",
        "resistance_profile": "various resistance phenotypes"
      },
      {
        "name": "Enterobacteriaceae",
        "resistance_profile": "variable, generally less susceptible"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Ebselen demonstrated potent bactericidal activity against S. aureus, including methicillin- and vancomycin-resistant strains, with MICs as low as 0.0625-1 \u03bcg/mL."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Staphylococcus epidermidis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Ebselen reduced biofilm formation and exhibited activity against S. epidermidis with MICs typically between 0.125-0.5 \u03bcg/mL."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.25,
        "fici": null,
        "key_result": "Ebselen inhibited vancomycin-resistant E. faecium with MICs ranging from 0.25-4 \u03bcg/mL and was effective in eradicating mature biofilms."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Various Gram-positive bacteria (Streptococcus spp., Enterococcus spp.)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.0625,
        "fici": null,
        "key_result": "Demonstrated broad activity with MICs generally between 0.0625-1 \u03bcg/mL, outperforming some traditional antibiotics."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Neisseria mucosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Used to treat mature biofilms by degrading extracellular polymeric substances and inhibiting quorum sensing."
      }
    ],
    "mechanism": "Inhibition of bacterial thioredoxin reductase, covalent modification of cysteine residues, disruption of protein, nucleic acid, and lipid synthesis, and attenuation of biofilm formation and quorum sensing.",
    "relevance_score": 5,
    "paper_idx": 269,
    "pmid": "37240241",
    "title": "Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.",
    "year": "2023",
    "doi": "10.3390/ijms24108896",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Peruzzu D",
      "Fecchi K",
      "Venturi G"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ceftazidime\u2013Avibactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor combination",
        "approved_for": "complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia including ventilator-associated pneumonia in children \u22653 months to <18 years"
      }
    ],
    "pathogens": [
      {
        "name": "Enterobacterales",
        "resistance_profile": "XDR, carbapenem-resistant, ESBL-producing"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR, \u03b2-lactamase producing"
      }
    ],
    "findings": [
      {
        "drug": "Ceftazidime\u2013Avibactam",
        "pathogen": "Enterobacterales",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceftazidime\u2013avibactam shows activity against XDR Enterobacterales producing \u03b2-lactamases, with promising clinical use in pediatric infections."
      },
      {
        "drug": "Ceftazidime\u2013Avibactam",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceftazidime\u2013avibactam demonstrates activity against MDR P. aeruginosa, with limited pediatric data but promising case reports."
      }
    ],
    "mechanism": "Inhibition of Ambler class A, C, and D \u03b2-lactamases by avibactam, protecting ceftazidime from degradation and restoring activity against resistant Gram-negative bacteria.",
    "relevance_score": 4,
    "paper_idx": 270,
    "pmid": "37306577",
    "title": "Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis.",
    "year": "2023",
    "doi": "10.1128/spectrum.00352-23",
    "journal": "Microbiology spectrum",
    "authors": [
      "Di Bonaventura G",
      "Lupetti V",
      "Di Giulio A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thioridazine",
        "drug_class": "phenothiazine derivative",
        "approved_for": "antipsychotic"
      },
      {
        "name": "Trifluoperazine",
        "drug_class": "phenothiazine derivative",
        "approved_for": "antipsychotic"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug resistant"
      },
      {
        "name": "Acinetobacter nosocomialis",
        "resistance_profile": "multidrug resistant"
      }
    ],
    "findings": [
      {
        "drug": "Thioridazine",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine significantly inhibits biofilm formation in A. baumannii at micromolar concentrations."
      },
      {
        "drug": "Trifluoperazine",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Trifluoperazine reduces biofilm formation in A. baumannii, with dose-dependent effects observed."
      },
      {
        "drug": "Thioridazine",
        "pathogen": "Acinetobacter nosocomialis",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine shows variable inhibition of biofilm formation in A. nosocomialis."
      }
    ],
    "mechanism": "Inhibition of type IV pilus biogenesis, disrupting biofilm formation and twitching motility.",
    "relevance_score": 4,
    "paper_idx": 271,
    "pmid": "37341603",
    "title": "Type IV Pilus-Mediated Inhibition of Acinetobacter baumannii Biofilm Formation by Phenothiazine Compounds.",
    "year": "2023",
    "doi": "10.1128/spectrum.01023-23",
    "journal": "Microbiology spectrum",
    "authors": [
      "Vo N",
      "Sidner B",
      "Yu Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tapeworm infections"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": null,
    "relevance_score": 1,
    "paper_idx": 272,
    "pmid": "37364094",
    "title": "Molecular responses during bacterial filamentation reveal inhibition methods of drug-resistant bacteria.",
    "year": "2023",
    "doi": "10.1073/pnas.2301170120",
    "journal": "Proceedings of the National Academy of Sciences of the United States of America",
    "authors": [
      "Zhang D",
      "Yin F",
      "Qin Q"
    ]
  },
  {
    "drugs": [
      {
        "name": "Compound 1771",
        "drug_class": "LTA synthesis inhibitor",
        "approved_for": "none"
      },
      {
        "name": "Compound 4",
        "drug_class": "LTA synthesis inhibitor",
        "approved_for": "none"
      },
      {
        "name": "HSGN-94",
        "drug_class": "LTA biosynthesis inhibitor (N-oxadiazol-benzamide)",
        "approved_for": "none"
      },
      {
        "name": "PC190723",
        "drug_class": "FtsZ inhibitor (benzamide)",
        "approved_for": "none"
      },
      {
        "name": "TXY436",
        "drug_class": "FtsZ inhibitor (prodrug of PC190723)",
        "approved_for": "none"
      },
      {
        "name": "TXY541",
        "drug_class": "FtsZ inhibitor (prodrug of PC190723)",
        "approved_for": "none"
      },
      {
        "name": "TXA709",
        "drug_class": "FtsZ inhibitor (benzamide prodrug)",
        "approved_for": "none"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Compound 1771",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Compound 1771 inhibits LTA synthesis and shows antibacterial activity against S. aureus."
      },
      {
        "drug": "Compound 4",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Structural reconfiguration of compound 1771 resulted in compound 4 with improved activity and \u03b2-lactam synergy."
      },
      {
        "drug": "HSGN-94",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "HSGN-94 interacts with PgcA, downregulates PgsA, and shows activity against S. aureus with low resistance development."
      },
      {
        "drug": "PC190723",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PC190723 targets FtsZ, exhibits bactericidal activity against MRSA, and shows efficacy in murine models."
      },
      {
        "drug": "TXY436",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Prodrug of PC190723 with improved pharmacokinetics, undergoing clinical trials."
      },
      {
        "drug": "TXY541",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Prodrug of PC190723 with enhanced physiochemical properties."
      },
      {
        "drug": "TXA709",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A prodrug targeting FtsZ, currently in phase I clinical trials for MRSA."
      }
    ],
    "mechanism": "Inhibition of lipoteichoic acid biosynthesis and FtsZ polymerization, disrupting cell wall integrity and bacterial cytokinesis.",
    "relevance_score": 4,
    "paper_idx": 273,
    "pmid": "37370391",
    "title": "Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.",
    "year": "2023",
    "doi": "10.3390/antibiotics12061072",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Kontou A",
      "Kourti M",
      "Iosifidis E"
    ]
  },
  {
    "drugs": [
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression, certain cancers"
      },
      {
        "name": "auranofin",
        "drug_class": "thioredoxin reductase (TrxR) inhibitor",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "TSC2 mutant cells (model for TSC-related tumors)",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "rapamycin",
        "pathogen": "TSC2 mutant cells",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rapamycin normalized mitochondrial membrane potential and reduced proliferation in TSC2 mutant cells by inhibiting mTOR signaling."
      },
      {
        "drug": "auranofin",
        "pathogen": "TSC2 mutant cells",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin reduced TrxR activity and decreased Prdx5 levels, contributing to ER stress and cell death in TSC2 mutant cells."
      },
      {
        "drug": "combination of rapamycin and auranofin",
        "pathogen": "TSC2 mutant cells",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combined treatment synergistically decreased Prdx5 levels, inhibited TrxR and mTOR, and induced ER stress leading to cell death."
      }
    ],
    "mechanism": "Inhibition of mTOR signaling by rapamycin and TrxR activity by auranofin reduces Prdx5 levels, induces ER stress, and promotes cell death in TSC2 mutant cells.",
    "relevance_score": 4,
    "paper_idx": 274,
    "pmid": "37386581",
    "title": "Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA.",
    "year": "2023",
    "doi": "10.1186/s13065-023-00980-9",
    "journal": "BMC chemistry",
    "authors": [
      "Farid N",
      "Bux K",
      "Ali K"
    ]
  },
  {
    "drugs": [
      {
        "name": "ebselen",
        "drug_class": "anti-inflammatory and antioxidant",
        "approved_for": "not specified"
      },
      {
        "name": "tirapazamine",
        "drug_class": "anticancer",
        "approved_for": "cancer"
      },
      {
        "name": "carmofur",
        "drug_class": "anticancer",
        "approved_for": "cancer"
      },
      {
        "name": "5-fluorouracil",
        "drug_class": "antineoplastic",
        "approved_for": "cancer"
      },
      {
        "name": "tavaborole",
        "drug_class": "antifungal",
        "approved_for": "onychomycosis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "multidrug-resistant (MDR)"
      },
      {
        "name": "Burkholderia cepacia",
        "resistance_profile": "broad-spectrum resistance"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "ebselen",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen exhibits rapid, dose-dependent bactericidal activity and damages bacterial cell membranes."
      },
      {
        "drug": "carmofur",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carmofur effectively prevents biofilm formation and damages cell membranes, increasing membrane permeability."
      },
      {
        "drug": "5-fluorouracil",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "5-Fluorouracil prevents biofilm formation and damages bacterial membranes."
      },
      {
        "drug": "tirapazamine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "dispersing_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tirapazamine actively disperses preformed biofilms and damages cell membranes."
      },
      {
        "drug": "tavaborole",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "dispersing_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tavaborole disperses preformed biofilms and shows activity against other CF pathogens like B. cepacia and A. baumannii."
      }
    ],
    "mechanism": "The drugs primarily target bacterial cell membranes, increasing permeability, leading to leakage, cytoplasm loss, and cell lysis.",
    "relevance_score": 5,
    "paper_idx": 275,
    "pmid": "37428033",
    "title": "Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus In Vitro and In Vivo.",
    "year": "2023",
    "doi": "10.1128/spectrum.05031-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Kaul G",
      "Akhir A",
      "Shukla M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Nifedipine",
        "drug_class": "Calcium channel blocker",
        "approved_for": "Hypertension, angina"
      },
      {
        "name": "Chrysanthemum coronarium extract",
        "drug_class": "Herbal extract",
        "approved_for": "Traditional medicine, not officially approved for specific indications"
      }
    ],
    "pathogens": [
      {
        "name": "Trichinella spiralis",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "Nifedipine",
        "pathogen": "Trichinella spiralis",
        "activity_type": "anthelmintic|efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nifedipine showed dose-dependent in vitro activity against T. spiralis muscle larvae and adult worms, with low LC50 values indicating potent anthelmintic effects."
      },
      {
        "drug": "Chrysanthemum coronarium extract",
        "pathogen": "Trichinella spiralis",
        "activity_type": "anthelmintic",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "C. coronarium extract demonstrated dose-dependent in vitro activity against T. spiralis larvae and adult worms, causing tegument destruction."
      }
    ],
    "mechanism": "Nifedipine may inhibit T. spiralis \u03b2-tubulin polymerization, disrupting parasite microtubule formation; C. coronarium extract's mechanism is not explicitly detailed but shows morphological damage to the parasite tegument.",
    "relevance_score": 4,
    "paper_idx": 276,
    "pmid": "37443747",
    "title": "Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.",
    "year": "2023",
    "doi": "10.3390/cells12131713",
    "journal": "Cells",
    "authors": [
      "Bovari-Biri J",
      "Abdelwahab E",
      "Garai K"
    ]
  },
  {
    "drugs": [
      {
        "name": "amphotericin B",
        "drug_class": "polyene antifungal",
        "approved_for": "systemic fungal infections (cryptococcosis)"
      },
      {
        "name": "flucytosine",
        "drug_class": "antimetabolite antifungal",
        "approved_for": "cryptococcosis"
      },
      {
        "name": "fluconazole",
        "drug_class": "azole antifungal",
        "approved_for": "cryptococcosis and other fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "Cryptococcus neoformans",
        "resistance_profile": "azoles (fluconazole) resistance, rare amphotericin B resistance, flucytosine resistance"
      },
      {
        "name": "Cryptococcus gattii",
        "resistance_profile": "not specifically detailed, but similar resistance concerns as C. neoformans"
      }
    ],
    "findings": [
      {
        "drug": "fluconazole",
        "pathogen": "Cryptococcus neoformans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluconazole is widely used for cryptococcosis but has contributed to increased resistance and relapse cases."
      },
      {
        "drug": "amphotericin B",
        "pathogen": "Cryptococcus neoformans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amphotericin B is effective but limited by nephrotoxicity; lipid formulations reduce toxicity but are costly."
      },
      {
        "drug": "flucytosine",
        "pathogen": "Cryptococcus neoformans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Flucytosine is effective in combination therapy but has issues with toxicity and resistance development."
      }
    ],
    "mechanism": "Existing antifungal drugs target ergosterol synthesis or function, but resistance mechanisms include mutations in ergosterol biosynthesis genes (amphotericin B resistance) and overexpression of efflux pumps (azole resistance). Flucytosine resistance mechanisms are not fully understood.",
    "relevance_score": 2,
    "paper_idx": 277,
    "pmid": "37446795",
    "title": "The Impact of Copper Ions on the Activity of Antibiotic Drugs.",
    "year": "2023",
    "doi": "10.3390/molecules28135133",
    "journal": "Molecules (Basel, Switzerland)",
    "authors": [
      "Bo\u017ei\u0107 Cvijan B",
      "Kora\u0107 Ja\u010di\u0107 J",
      "Baj\u010deti\u0107 M"
    ]
  },
  {
    "drugs": [
      {
        "name": "curcumin",
        "drug_class": "natural polyphenol / nutraceutical",
        "approved_for": "traditional use / dietary supplement"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "not specified"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "not specified"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Bacillus subtilis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "curcumin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Curcumin exhibited bactericidal activity against P. aeruginosa with molecular docking confirming interaction with quorum-sensing proteins."
      },
      {
        "drug": "curcumin",
        "pathogen": "Bacillus subtilis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Curcumin showed antibacterial activity against B. subtilis, with molecular docking indicating interaction with QS regulator proteins."
      },
      {
        "drug": "curcumin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Curcumin demonstrated activity against S. aureus, supported by molecular docking studies on QS proteins."
      },
      {
        "drug": "curcumin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Curcumin exhibited antibacterial effects against E. coli, with molecular docking confirming binding to key QS proteins."
      },
      {
        "drug": "curcumin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nano-curcumin lotion significantly reduced bacterial load and promoted wound healing in infected rat models."
      }
    ],
    "mechanism": "Curcumin inhibits bacterial growth and virulence by targeting quorum sensing proteins such as SecA-SecY, LsrR, PqsR, and AgrA, disrupting bacterial communication and biofilm formation.",
    "relevance_score": 4,
    "paper_idx": 278,
    "pmid": "37458598",
    "title": "Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi.",
    "year": "2023",
    "doi": "10.1128/spectrum.02679-22",
    "journal": "Microbiology spectrum",
    "authors": [
      "Bendary M",
      "Abd El-Hamid M",
      "Abousaty A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "anti-alcoholism",
        "approved_for": "chronic alcoholism"
      },
      {
        "name": "Diethyldithiocarbamate (DDC)",
        "drug_class": "metabolite of disulfiram",
        "approved_for": null
      },
      {
        "name": "Dimethyldithiocarbamate (DMDC)",
        "drug_class": "metabolite of disulfiram",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli (NDM-positive strains)",
        "resistance_profile": "NDM-mediated carbapenem resistance"
      },
      {
        "name": "Klebsiella pneumoniae (mcr-positive strains)",
        "resistance_profile": "mcr-mediated colistin resistance"
      },
      {
        "name": "E. coli (mcr-positive strains)",
        "resistance_profile": "mcr-mediated colistin resistance"
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "NDM-positive E. coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.188,
        "key_result": "Disulfiram synergistically enhances meropenem activity against NDM-positive E. coli by inhibiting NDM enzyme activity."
      },
      {
        "drug": "Disulfiram",
        "pathogen": "MCR-positive K. pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.047,
        "key_result": "Disulfiram synergistically restores colistin activity against MCR-positive pathogens, effectively eliminating resistant bacteria."
      },
      {
        "drug": "Diethyldithiocarbamate (DDC)",
        "pathogen": "NDM-positive E. coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.125,
        "key_result": "DDC enhances meropenem efficacy against NDM-positive E. coli, reversing resistance."
      },
      {
        "drug": "Dimethyldithiocarbamate (DMDC)",
        "pathogen": "NDM-positive E. coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "DMDC potentiates meropenem activity against NDM-positive E. coli by inhibiting NDM enzymes."
      }
    ],
    "mechanism": "Disulfiram inhibits NDM enzyme activity by binding to its active site, and disrupts bacterial membrane integrity and metabolism, thereby restoring antibiotic efficacy.",
    "relevance_score": 5,
    "paper_idx": 279,
    "pmid": "37461016",
    "title": "Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract.",
    "year": "2023",
    "doi": "10.1186/s12906-023-04076-8",
    "journal": "BMC complementary medicine and therapies",
    "authors": [
      "El-Sayad M",
      "El-Wakil E",
      "Moharam Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "atorvastatin",
        "drug_class": "HMG-CoA reductase inhibitor",
        "approved_for": "cholesterol lowering"
      },
      {
        "name": "ezetimibe",
        "drug_class": "cholesterol absorption inhibitor",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "Dengue virus (DENV)",
        "resistance_profile": "not specified"
      },
      {
        "name": "Zika virus (ZIKV)",
        "resistance_profile": "not specified"
      },
      {
        "name": "Yellow Fever virus (YFV)",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "ezetimibe",
        "pathogen": "Dengue virus (DENV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 19.15,
        "fici": null,
        "key_result": "Ezetimibe reduced DENV infection with an IC50 of approximately 19.15 \u00b5M in vitro."
      },
      {
        "drug": "atorvastatin",
        "pathogen": "Dengue virus (DENV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 24.12,
        "fici": null,
        "key_result": "Atorvastatin inhibited DENV infection with an IC50 of approximately 24.12 \u00b5M in vitro."
      },
      {
        "drug": "ezetimibe",
        "pathogen": "Zika virus (ZIKV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 24.16,
        "fici": null,
        "key_result": "Ezetimibe reduced ZIKV infection with an IC50 of approximately 24.16 \u00b5M in vitro."
      },
      {
        "drug": "atorvastatin",
        "pathogen": "Zika virus (ZIKV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 25.13,
        "fici": null,
        "key_result": "Atorvastatin inhibited ZIKV infection with an IC50 of approximately 25.13 \u00b5M in vitro."
      },
      {
        "drug": "ezetimibe",
        "pathogen": "Yellow Fever virus (YFV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 23.65,
        "fici": null,
        "key_result": "Ezetimibe reduced YFV infection with an IC50 of approximately 23.65 \u00b5M in vitro."
      },
      {
        "drug": "atorvastatin",
        "pathogen": "Yellow Fever virus (YFV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 17.34,
        "fici": null,
        "key_result": "Atorvastatin inhibited YFV infection with an IC50 of approximately 17.34 \u00b5M in vitro."
      }
    ],
    "mechanism": "modulation of host cell cholesterol homeostasis disrupting viral entry, replication, and egress by targeting lipid raft formation and cholesterol availability",
    "relevance_score": 4,
    "paper_idx": 280,
    "pmid": "37493736",
    "title": "Searching for new antifungals for the treatment of cryptococcosis.",
    "year": "2023",
    "doi": "10.1590/0037-8682-0121-2023",
    "journal": "Revista da Sociedade Brasileira de Medicina Tropical",
    "authors": [
      "Sousa N",
      "Almeida J",
      "Frickmann H"
    ]
  },
  {
    "drugs": [
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone",
        "approved_for": "bacterial infections (various indications)"
      },
      {
        "name": "pentamidine",
        "drug_class": "antiprotozoal",
        "approved_for": "trypanosomiasis, leishmaniasis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "ciprofloxacin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Combination of ciprofloxacin with pentamidine showed synergistic inhibition of MDR P. aeruginosa strains in vitro."
      },
      {
        "drug": "pentamidine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant|efflux_inhibitor|anti_biofilm",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": 256,
        "fici": null,
        "key_result": "Pentamidine acts as an efflux pump inhibitor and membrane disruptor, potentiating ciprofloxacin activity."
      }
    ],
    "mechanism": "Pentamidine inhibits RND efflux pumps (notably MexCD-OprJ and MexEF-OprN) and disrupts bacterial membrane integrity, enhancing antibiotic access and activity.",
    "relevance_score": 4,
    "paper_idx": 281,
    "pmid": "37498498",
    "title": "Single-dose pharmacokinetics and lung function of nebulized niclosamide ethanolamine in sheep.",
    "year": "2023",
    "doi": "10.1007/s11095-023-03559-0",
    "journal": "Pharmaceutical research",
    "authors": [
      "Weiss A",
      "Bischof R",
      "Landersdorfer C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tacrolimus",
        "drug_class": "calcineurin inhibitor",
        "approved_for": "prevention of transplant rejection"
      },
      {
        "name": "Sirolimus",
        "drug_class": "mTOR inhibitor",
        "approved_for": "prevention of transplant rejection"
      },
      {
        "name": "Cyclosporine",
        "drug_class": "calcineurin inhibitor",
        "approved_for": "prevention of transplant rejection"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Tacrolimus",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Patients prescribed tacrolimus showed a reduced prevalence of dementia compared to the general population-like control."
      },
      {
        "drug": "Sirolimus",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Patients prescribed sirolimus also showed a reduced prevalence of dementia, similar to tacrolimus."
      },
      {
        "drug": "Cyclosporine",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Patients prescribed cyclosporine had a lower prevalence of dementia compared to controls, but less so than tacrolimus."
      }
    ],
    "mechanism": "Inhibition of central nervous system calcineurin activity, which modulates synaptic integrity, memory formation, and neurodegeneration, potentially reducing Alzheimer's disease pathology.",
    "relevance_score": 2,
    "paper_idx": 282,
    "pmid": "37507459",
    "title": "Molecular modeling study of micro and nanocurcumin with in vitro and in vivo antibacterial validation.",
    "year": "2023",
    "doi": "10.1038/s41598-023-38652-2",
    "journal": "Scientific reports",
    "authors": [
      "Othman A",
      "Shamekh I",
      "Abdalla M"
    ]
  },
  {
    "drugs": [
      {
        "name": "hydroxychloroquine",
        "drug_class": "antimalarial/immune modulator",
        "approved_for": "malaria, autoimmune diseases"
      },
      {
        "name": "ACE inhibitor / ARB",
        "drug_class": "antihypertensive",
        "approved_for": "hypertension, heart failure"
      },
      {
        "name": "statin",
        "drug_class": "lipid-lowering agent",
        "approved_for": "hyperlipidemia, cardiovascular disease prevention"
      },
      {
        "name": "ivermectin",
        "drug_class": "antiparasitic",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": "none"
      }
    ],
    "findings": [
      {
        "drug": "hydroxychloroquine",
        "pathogen": "SARS-CoV-2",
        "activity_type": "prevention",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Prophylactic use of hydroxychloroquine reduced laboratory-confirmed SARS-CoV-2 infection in clinical trials (RR: 0.82, 95% CI 0.74 to 0.90), but not in observational studies."
      },
      {
        "drug": "ivermectin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "prevention",
        "evidence_type": "meta-analysis",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ivermectin did not significantly reduce the risk of SARS-CoV-2 infection (RR: 0.35, 95% CI 0.10 to 1.26) with high heterogeneity."
      },
      {
        "drug": "ACE inhibitor / ARB",
        "pathogen": "SARS-CoV-2",
        "activity_type": "prevention",
        "evidence_type": "meta-analysis",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ACE inhibitors and ARBs were not beneficial in reducing SARS-CoV-2 infection."
      },
      {
        "drug": "statin",
        "pathogen": "SARS-CoV-2",
        "activity_type": "prevention",
        "evidence_type": "insufficient",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Limited evidence available; no conclusive findings on prophylactic efficacy."
      }
    ],
    "mechanism": "Proposed mechanisms include immune modulation, anti-inflammatory effects, and interference with viral entry or replication, but specific mechanisms for each drug vary and are not definitively established in this review.",
    "relevance_score": 2,
    "paper_idx": 283,
    "pmid": "37515153",
    "title": "Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.",
    "year": "2023",
    "doi": "10.3390/v15071465",
    "journal": "Viruses",
    "authors": [
      "Osuna-Ramos J",
      "Farfan-Morales C",
      "Cordero-Rivera C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Oxiconazole",
        "drug_class": "topical antifungal",
        "approved_for": "topical fungal infections"
      },
      {
        "name": "Gentamicin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR, MRSA, GRSA"
      },
      {
        "name": "Enterococcus spp.",
        "resistance_profile": "drug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Oxiconazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Oxiconazole exhibits potent antibacterial activity against S. aureus, including MDR strains, with equipotent activity against drug-susceptible and resistant strains."
      },
      {
        "drug": "Oxiconazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Oxiconazole synergizes with gentamicin and daptomycin, significantly enhancing their antibacterial effects against S. aureus."
      },
      {
        "drug": "Oxiconazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, oxiconazole combined with gentamicin significantly reduces bacterial load in a murine skin infection model."
      },
      {
        "drug": "Oxiconazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Oxiconazole significantly eradicates preformed S. aureus biofilms in vitro."
      }
    ],
    "mechanism": "Proposed mechanism involves permeabilization of bacterial membranes and targeting conserved cytosolic components, leading to concentration-dependent bactericidal activity.",
    "relevance_score": 5,
    "paper_idx": 284,
    "pmid": "37537267",
    "title": "Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.",
    "year": "2023",
    "doi": "10.1038/s42003-023-05173-7",
    "journal": "Communications biology",
    "authors": [
      "Chen C",
      "Cai J",
      "Shi J"
    ]
  },
  {
    "drugs": [
      {
        "name": "tazobactam",
        "drug_class": "beta-lactamase inhibitor",
        "approved_for": "antibacterial therapy"
      },
      {
        "name": "cefatrizine",
        "drug_class": "cephalosporin antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "VRE"
      },
      {
        "name": "Mycobacteria",
        "resistance_profile": "MDR/XDR"
      }
    ],
    "findings": [
      {
        "drug": "1,2,3-triazole derivatives",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Some synthesized 1,2,3-triazole derivatives showed antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)."
      },
      {
        "drug": "1,2,3-triazole derivatives",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Certain derivatives exhibited activity against vancomycin-resistant enterococci (VRE)."
      },
      {
        "drug": "1,2,3-triazole derivatives",
        "pathogen": "Mycobacteria",
        "activity_type": "antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Some compounds demonstrated activity against mycobacterial strains, indicating potential as anti-tubercular agents."
      }
    ],
    "mechanism": "The proposed mechanism involves the interaction of the 1,2,3-triazole moiety with bacterial targets, potentially disrupting cell wall synthesis or DNA intercalation, depending on the derivative.",
    "relevance_score": 2,
    "paper_idx": 285,
    "pmid": "37574739",
    "title": "Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine.",
    "year": "2023",
    "doi": "10.3233/JAD-230526",
    "journal": "Journal of Alzheimer's disease : JAD",
    "authors": [
      "Silva J",
      "Taglialatela G",
      "Jupiter D"
    ]
  },
  {
    "drugs": [
      {
        "name": "sulfamethoxazole",
        "drug_class": "sulfonamide",
        "approved_for": "urinary tract infections, respiratory infections"
      },
      {
        "name": "trimethoprim",
        "drug_class": "antimetabolite",
        "approved_for": "urinary tract infections, respiratory infections"
      },
      {
        "name": "beta-lactams",
        "drug_class": "beta-lactam antibiotics",
        "approved_for": "various bacterial infections"
      },
      {
        "name": "beta-lactamase inhibitors",
        "drug_class": "enzyme inhibitors",
        "approved_for": "used in combination with beta-lactams"
      },
      {
        "name": "antifungals",
        "drug_class": "antifungal agents",
        "approved_for": "fungal infections"
      },
      {
        "name": "drugs with human targets",
        "drug_class": "various",
        "approved_for": "various human conditions"
      },
      {
        "name": "food additives",
        "drug_class": "non-antibiotic compounds",
        "approved_for": "food safety"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      },
      {
        "name": "Streptococcus pneumoniae",
        "resistance_profile": "resistant strains"
      },
      {
        "name": "Bacillus subtilis",
        "resistance_profile": "model organism"
      }
    ],
    "findings": [
      {
        "drug": "ticagrelor",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ticagrelor synergized with cationic antibiotics by modifying the surface charge of S. aureus."
      },
      {
        "drug": "sulfamethoxazole",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sulfamethoxazole showed synergy with trimethoprim against S. aureus."
      }
    ],
    "mechanism": "Modulation of bacterial surface charge and inhibition of key bacterial processes through drug combinations.",
    "relevance_score": 4,
    "paper_idx": 286,
    "pmid": "37627656",
    "title": "Combination Therapy with Ciprofloxacin and Pentamidine against Multidrug-Resistant Pseudomonas aeruginosa: Assessment of In Vitro and In Vivo Efficacy and the Role of Resistance-Nodulation-Division (RND) Efflux Pumps.",
    "year": "2023",
    "doi": "10.3390/antibiotics12081236",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Fletcher M",
      "McCormack A",
      "Parcell B"
    ]
  },
  {
    "drugs": [],
    "pathogens": [],
    "findings": [],
    "mechanism": null,
    "relevance_score": 1,
    "paper_idx": 287,
    "pmid": "37640510",
    "title": "Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis.",
    "year": "2023",
    "doi": "10.1136/bmjresp-2023-001674",
    "journal": "BMJ open respiratory research",
    "authors": [
      "Zhou G",
      "Verweij S",
      "Bijlsma M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Selamectin",
        "drug_class": "macrocyclic lactone",
        "approved_for": "antiparasitic (ear mites, fleas, heartworm prevention)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR (including MRSA, macrolide-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "Selamectin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 6.2,
        "fici": 0.5,
        "key_result": "Selamectin completely inhibited S. aureus growth at MIC of 6.2 \u03bcg/mL and showed synergistic effect with ampicillin against MRSA."
      },
      {
        "drug": "Selamectin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5.89,
        "fici": null,
        "key_result": "Selamectin reduced S. aureus biofilm biomass with MBEC50 at 5.89 \u03bcg/mL."
      },
      {
        "drug": "Selamectin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Synergistic effect observed between selamectin and ampicillin against MRSA."
      }
    ],
    "mechanism": "likely involves disruption of bacterial cell surface integrity and potential interaction with bacterial targets, as suggested by cell surface alterations observed via SEM.",
    "relevance_score": 4,
    "paper_idx": 288,
    "pmid": "37646510",
    "title": "A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Pseudomonas aeruginosa.",
    "year": "2023",
    "doi": "10.1128/msphere.00190-23",
    "journal": "mSphere",
    "authors": [
      "Donkor G",
      "Anderson G",
      "Stadler M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Amphotericin B",
        "drug_class": "antifungal polyene macrolide",
        "approved_for": "fungal infections"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      }
    ],
    "findings": [
      {
        "drug": "Amphotericin B",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Amphotericin B shows significant antibacterial activity against MRSA in vitro with MIC of 32 \u03bcg/ml."
      },
      {
        "drug": "Amphotericin B",
        "pathogen": "MRSA",
        "activity_type": "mode_of_action",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Molecular docking and molecular dynamics simulations suggest Amphotericin B interacts with PBP 2a, potentially inhibiting cell wall synthesis."
      }
    ],
    "mechanism": "Hydrophobic and hydrophilic interactions with PBP 2a, affecting its conformational dynamics and potentially inhibiting cell wall synthesis.",
    "relevance_score": 4,
    "paper_idx": 289,
    "pmid": "37660210",
    "title": "In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.",
    "year": "2023",
    "doi": "10.1038/s41598-023-39647-9",
    "journal": "Scientific reports",
    "authors": [
      "G\u00f3mara-Lomero M",
      "L\u00f3pez-Calleja A",
      "Rezusta A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 290,
    "pmid": "37680749",
    "title": "Repurposing anti-inflammatory drugs for fighting planktonic and biofilm growth. New carbazole derivatives based on the NSAID carprofen: synthesis, in silico and in vitro bioevaluation.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1181516",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Dumitrascu F",
      "Caira M",
      "Avram S"
    ]
  },
  {
    "drugs": [
      {
        "name": "atorvastatin",
        "drug_class": "statin",
        "approved_for": "dyslipidemia"
      },
      {
        "name": "simvastatin",
        "drug_class": "statin",
        "approved_for": "dyslipidemia"
      },
      {
        "name": "lovastatin",
        "drug_class": "statin",
        "approved_for": "dyslipidemia"
      },
      {
        "name": "fluvastatin",
        "drug_class": "statin",
        "approved_for": "dyslipidemia"
      },
      {
        "name": "rifampicin",
        "drug_class": "antibiotic",
        "approved_for": "tuberculosis, other bacterial infections"
      },
      {
        "name": "streptomycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "tuberculosis, bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium ulcerans",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "atorvastatin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 81.42,
        "fici": null,
        "key_result": "Atorvastatin exhibited antimicrobial activity against M. ulcerans with an IC50 of 81.42 \u03bcg/mL and reduced bacterial load in infected macrophages."
      },
      {
        "drug": "simvastatin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 54.13,
        "fici": null,
        "key_result": "Simvastatin showed antimicrobial activity with an IC50 of 54.13 \u03bcg/mL and a slight reduction in bacterial load in infected macrophages."
      },
      {
        "drug": "fluvastatin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 17.6,
        "fici": null,
        "key_result": "Fluvastatin had the highest antimicrobial activity among tested statins with an IC50 of 17.60 \u03bcg/mL and significantly reduced bacterial load in macrophages."
      },
      {
        "drug": "lovastatin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 357.2,
        "fici": null,
        "key_result": "Lovastatin showed high IC50 (357.20 \u03bcg/mL) with variable results, leading to its exclusion from further studies."
      },
      {
        "drug": "rifampicin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.0076,
        "fici": null,
        "key_result": "Rifampicin demonstrated potent antimicrobial activity with an IC50 of 0.0076 \u03bcg/mL."
      },
      {
        "drug": "streptomycin",
        "pathogen": "Mycobacterium ulcerans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.034,
        "fici": null,
        "key_result": "Streptomycin showed effective activity with an IC50 of 0.034 \u03bcg/mL."
      }
    ],
    "mechanism": "Proposed mechanism involves statins exerting antimicrobial effects possibly through interference with bacterial cell processes, though exact mechanisms require further validation.",
    "relevance_score": 3,
    "paper_idx": 291,
    "pmid": "37686059",
    "title": "Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.",
    "year": "2023",
    "doi": "10.3390/ijms241713250",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Kisiel-Nawrot E",
      "Pindjakova D",
      "Latocha M"
    ]
  },
  {
    "drugs": [
      {
        "name": "voriconazole",
        "drug_class": "azole antifungal",
        "approved_for": "invasive fungal infections"
      },
      {
        "name": "posaconazole",
        "drug_class": "azole antifungal",
        "approved_for": "invasive fungal infections"
      },
      {
        "name": "isavuconazole",
        "drug_class": "azole antifungal",
        "approved_for": "invasive fungal infections"
      },
      {
        "name": "fluvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      },
      {
        "name": "rosuvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida auris",
        "resistance_profile": "multidrug-resistant (including high MICs to fluconazole, variable resistance to other antifungals)"
      }
    ],
    "findings": [
      {
        "drug": "voriconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.288,
        "key_result": "Voriconazole combined with fluvastatin showed 16-fold reduction in MIC and synergy in 67% of isolates."
      },
      {
        "drug": "posaconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.341,
        "key_result": "Posaconazole combined with fluvastatin resulted in 8-fold MIC reduction and synergy in 90% of isolates."
      },
      {
        "drug": "isavuconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.446,
        "key_result": "Isavuconazole combined with fluvastatin showed 4-fold MIC reduction and synergy in 71% of isolates."
      },
      {
        "drug": "voriconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.364,
        "key_result": "Rosuvastatin combined with voriconazole showed about 12-fold MIC reduction and synergy in 57% of isolates."
      },
      {
        "drug": "isavuconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.568,
        "key_result": "Rosuvastatin combined with isavuconazole showed 3-fold MIC reduction and synergy in 43% of isolates."
      },
      {
        "drug": "posaconazole",
        "pathogen": "Candida auris",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.529,
        "key_result": "Rosuvastatin combined with posaconazole showed 4-fold MIC reduction and synergy in 52% of isolates."
      }
    ],
    "mechanism": "Statins may inhibit ergosterol biosynthesis via HMG-CoA reductase inhibition, disrupting fungal cell membrane synthesis, and potentially enhance azole activity by affecting cellular respiration and metabolism.",
    "relevance_score": 4,
    "paper_idx": 292,
    "pmid": "37710280",
    "title": "Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.",
    "year": "2023",
    "doi": "10.1186/s40001-023-01275-4",
    "journal": "European journal of medical research",
    "authors": [
      "Mohi-Ud-Din R",
      "Chawla A",
      "Sharma P"
    ]
  },
  {
    "drugs": [
      {
        "name": "C8LE",
        "drug_class": "lariat ether",
        "approved_for": "none"
      },
      {
        "name": "C10LE",
        "drug_class": "lariat ether",
        "approved_for": "none"
      },
      {
        "name": "C12LE",
        "drug_class": "lariat ether",
        "approved_for": "none"
      },
      {
        "name": "C10LE\u20222HCl",
        "drug_class": "lariat ether hydrochloride salt",
        "approved_for": "none"
      },
      {
        "name": "C10LE\u20222MeI",
        "drug_class": "lariat ether methyl iodide salt",
        "approved_for": "none"
      },
      {
        "name": "C12LE\u20222HCl",
        "drug_class": "lariat ether hydrochloride salt",
        "approved_for": "none"
      },
      {
        "name": "C12LE\u20222MeI",
        "drug_class": "lariat ether methyl iodide salt",
        "approved_for": "none"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "various resistance"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "resistant to multiple drugs, overexpresses NorA efflux pump"
      }
    ],
    "findings": [
      {
        "drug": "C10LE",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "C10LE enhances the potency of antibiotics such as norfloxacin against E. coli, with up to 128-fold increase."
      },
      {
        "drug": "C12LE\u20222MeI",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "C12LE methyl iodide salt shows activity against E. coli, unlike its hydrochloride counterpart."
      },
      {
        "drug": "C10LE",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "C10LE enhances the activity of antibiotics against resistant S. aureus, including strains overexpressing NorA efflux pump."
      }
    ],
    "mechanism": "formation of complexes with antimicrobials, disruption of bacterial membrane permeability, and inhibition of efflux pump function, leading to increased drug penetration and potency.",
    "relevance_score": 4,
    "paper_idx": 293,
    "pmid": "37764086",
    "title": "Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired Staphylococcus aureus Infections.",
    "year": "2023",
    "doi": "10.3390/microorganisms11092242",
    "journal": "Microorganisms",
    "authors": [
      "Folliero V",
      "Dell'Annunziata F",
      "Santella B"
    ]
  },
  {
    "drugs": [
      {
        "name": "tafenoquine",
        "drug_class": "8-aminoquinoline",
        "approved_for": "malaria"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      }
    ],
    "findings": [
      {
        "drug": "tafenoquine",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial|anti_biofilm|efflux_inhibitor",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tafenoquine exhibits antimicrobial activity against MRSA, including planktonic cells, biofilms, and persister cells, by targeting bacterial cell membranes."
      }
    ],
    "mechanism": "targets bacterial cell membranes, disrupting their integrity and function",
    "relevance_score": 5,
    "paper_idx": 294,
    "pmid": "37770760",
    "title": "Systematic analysis of drug combinations against Gram-positive bacteria.",
    "year": "2023",
    "doi": "10.1038/s41564-023-01486-9",
    "journal": "Nature microbiology",
    "authors": [
      "Cacace E",
      "Kim V",
      "Varik V"
    ]
  },
  {
    "drugs": [
      {
        "name": "Amphotericin B",
        "drug_class": "antifungal polyene",
        "approved_for": "systemic fungal infections"
      },
      {
        "name": "Posaconazole",
        "drug_class": "antifungal triazole",
        "approved_for": "invasive fungal infections"
      },
      {
        "name": "Isavuconazole",
        "drug_class": "antifungal triazole",
        "approved_for": "invasive aspergillosis and mucormycosis"
      }
    ],
    "pathogens": [
      {
        "name": "Rhizopus oryzae",
        "resistance_profile": "resistant to fluconazole, voriconazole, echinocandins"
      },
      {
        "name": "Apophysomyces",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Amphotericin B",
        "pathogen": "Rhizopus oryzae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Liposomal amphotericin B is recommended as first-line therapy for mucormycosis post-COVID-19."
      },
      {
        "drug": "Posaconazole",
        "pathogen": "Rhizopus oryzae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Posaconazole is used as an alternative antifungal treatment for mucormycosis."
      },
      {
        "drug": "Isavuconazole",
        "pathogen": "Rhizopus oryzae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Isavuconazole is administered orally for mucormycosis management."
      }
    ],
    "mechanism": "The antifungal agents target fungal cell membrane integrity and inhibit ergosterol synthesis, leading to fungal cell death.",
    "relevance_score": 4,
    "paper_idx": 295,
    "pmid": "37773101",
    "title": "Antibacterial and anti-corona virus (229E) activity of Nigella sativa oil combined with photodynamic therapy based on methylene blue in wound infection: in vitro and in vivo study.",
    "year": "2023",
    "doi": "10.1186/s12866-023-03018-1",
    "journal": "BMC microbiology",
    "authors": [
      "Abo-Neima S",
      "El-Sheekh M",
      "Al-Zaban M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 296,
    "pmid": "37818370",
    "title": "Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.",
    "year": "2023",
    "doi": "10.3389/fimmu.2023.1264502",
    "journal": "Frontiers in immunology",
    "authors": [
      "Faiyazuddin M",
      "Sophia A",
      "Ashique S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 297,
    "pmid": "37823357",
    "title": "Exploring synergy between azole antifungal drugs and statins for Candida auris.",
    "year": "2023",
    "doi": "10.1093/jac/dkad303",
    "journal": "The Journal of antimicrobial chemotherapy",
    "authors": [
      "Halliday C",
      "Kim H",
      "Tay E"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 298,
    "pmid": "37840746",
    "title": "Repurposing of statins for Buruli Ulcer treatment: antimicrobial activity against Mycobacterium ulcerans.",
    "year": "2023",
    "doi": "10.3389/fmicb.2023.1266261",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Dominguez J",
      "Mendes A",
      "Pacheco A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 299,
    "pmid": "37887214",
    "title": "Antimicrobial and Adjuvant Potencies of Di-n-alkyl Substituted Diazalariat Ethers.",
    "year": "2023",
    "doi": "10.3390/antibiotics12101513",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Patel M",
      "Spikes H",
      "Bailey R"
    ]
  },
  {
    "drugs": [
      {
        "name": "methylene blue",
        "drug_class": "photosensitizer",
        "approved_for": "antimicrobial photodynamic therapy"
      },
      {
        "name": "Nigella sativa oil",
        "drug_class": "herbal extract",
        "approved_for": "traditional medicinal use, not specifically approved for antimicrobial"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "antibiotic resistant strains not specified, but focus on antibacterial activity"
      },
      {
        "name": "coronavirus 229E",
        "resistance_profile": "not applicable"
      }
    ],
    "findings": [
      {
        "drug": "Nigella sativa oil",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 12.5,
        "fici": null,
        "key_result": "Nigella sativa oil inhibited S. aureus with a MIC of 12.5%"
      },
      {
        "drug": "Nigella sativa oil",
        "pathogen": "coronavirus 229E",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nigella sativa oil inhibited coronavirus 229E up to 42.85% and 32.14%"
      },
      {
        "drug": "methylene blue",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Methylene blue-based photodynamic therapy (MB-PDT) effectively reduced bacterial counts and accelerated wound healing"
      },
      {
        "drug": "Nigella sativa oil + methylene blue",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combined therapy (NS oil + MB-PDT) showed the most effective wound healing and bacterial reduction"
      }
    ],
    "mechanism": "Nigella sativa oil exhibits antibacterial and antiviral activity, possibly through phytochemicals with antimicrobial properties; methylene blue acts as a photosensitizer generating reactive oxygen species upon light activation, leading to microbial inactivation and tissue regeneration.",
    "relevance_score": 4,
    "paper_idx": 300,
    "pmid": "37907954",
    "title": "The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.",
    "year": "2023",
    "doi": "10.1186/s13071-023-05909-8",
    "journal": "Parasites & vectors",
    "authors": [
      "Pfarr K",
      "Krome A",
      "Al-Obaidi I"
    ]
  },
  {
    "drugs": [
      {
        "name": "Simeprevir",
        "drug_class": "Hepatitis C virus NS3/4A protease inhibitor",
        "approved_for": "Genotype 1 and 4 chronic hepatitis C"
      },
      {
        "name": "Polymyxin B sulfate",
        "drug_class": "Polymyxin antibiotic",
        "approved_for": "Gram-negative bacterial infections"
      },
      {
        "name": "Colistin (Polymyxin E)",
        "drug_class": "Polymyxin antibiotic",
        "approved_for": "Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Simeprevir",
        "pathogen": "MRSA",
        "activity_type": "synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simeprevir significantly enhances the antibacterial activity of polymyxins against MRSA in vitro and in vivo."
      },
      {
        "drug": "Polymyxin B sulfate",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Polymyxins alone have limited activity against MRSA but show synergistic effects when combined with simeprevir."
      },
      {
        "drug": "Colistin (Polymyxin E)",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Colistin combined with simeprevir exhibits enhanced activity against MRSA, especially in biofilm and persister cell models."
      }
    ],
    "mechanism": "Simeprevir enhances the destruction of MRSA cell membrane, disrupting membrane integrity and increasing susceptibility to polymyxins.",
    "relevance_score": 4,
    "paper_idx": 301,
    "pmid": "37917339",
    "title": "Simeprevir restores the anti-Staphylococcus activity of polymyxins.",
    "year": "2023",
    "doi": "10.1186/s13568-023-01634-8",
    "journal": "AMB Express",
    "authors": [
      "Wu Y",
      "Wu P",
      "Wu R"
    ]
  },
  {
    "drugs": [
      {
        "name": "Amlodipine",
        "drug_class": "Calcium channel blocker",
        "approved_for": "Hypertension, angina"
      },
      {
        "name": "Lufenuron",
        "drug_class": "Chitin synthesis inhibitor (antiparasitic)",
        "approved_for": "Flea and tick control in animals"
      },
      {
        "name": "Itraconazole",
        "drug_class": "Azole antifungal",
        "approved_for": "Fungal infections including sporotrichosis"
      }
    ],
    "pathogens": [
      {
        "name": "Sporothrix brasiliensis",
        "resistance_profile": "Variable susceptibility; some isolates non-wild type for itraconazole"
      }
    ],
    "findings": [
      {
        "drug": "Amlodipine",
        "pathogen": "Sporothrix brasiliensis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Amlodipine showed inhibitory and fungicidal activity against all isolates, with MICs ranging from 32 to 256 \u00b5g/mL."
      },
      {
        "drug": "Lufenuron",
        "pathogen": "Sporothrix brasiliensis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Lufenuron did not inhibit any S. brasiliensis isolates at tested concentrations."
      },
      {
        "drug": "Itraconazole",
        "pathogen": "Sporothrix brasiliensis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Itraconazole exhibited MIC values ranging from 0.125 to 1 \u00b5g/mL, with some isolates showing non-wild type resistance."
      },
      {
        "drug": "Amlodipine + Itraconazole",
        "pathogen": "Sporothrix brasiliensis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Synergic interaction observed in 50% of isolates, with increased activity when combined."
      },
      {
        "drug": "Lufenuron + Itraconazole",
        "pathogen": "Sporothrix brasiliensis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Beneficial interaction in 40% of isolates, though lufenuron alone was ineffective."
      }
    ],
    "mechanism": "Amlodipine likely inhibits fungal efflux pumps, enhancing antifungal activity; lufenuron targets chitin synthesis but was ineffective alone, possibly acting as an adjuvant.",
    "relevance_score": 4,
    "paper_idx": 302,
    "pmid": "38032179",
    "title": "Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1128/spectrum.02295-23",
    "journal": "Microbiology spectrum",
    "authors": [
      "Xu M",
      "Yao Z",
      "Kong J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Nitazoxanide",
        "drug_class": "antiprotozoal",
        "approved_for": "giardia and cryptosporidium-associated diarrhea"
      },
      {
        "name": "Colistin",
        "drug_class": "polymyxin",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "colistin-resistant (COL-R), MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "colistin-resistant (COL-R), MDR"
      }
    ],
    "findings": [
      {
        "drug": "Nitazoxanide",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Nitazoxanide combined with colistin exhibits a synergistic antibacterial effect against colistin-resistant A. baumannii."
      },
      {
        "drug": "Nitazoxanide",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Nitazoxanide combined with colistin exhibits a synergistic antibacterial effect against colistin-resistant E. coli."
      },
      {
        "drug": "Nitazoxanide",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "The combination of NTZ and colistin significantly inhibits biofilm formation and eradicates established biofilms of COL-R A. baumannii."
      },
      {
        "drug": "Nitazoxanide",
        "pathogen": "Escherichia coli",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "The combination of NTZ and colistin significantly inhibits biofilm formation and eradicates established biofilms of COL-R E. coli."
      },
      {
        "drug": "Nitazoxanide",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination restores colistin susceptibility, possibly by inhibiting efflux mechanisms."
      },
      {
        "drug": "Nitazoxanide",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination restores colistin susceptibility, possibly by inhibiting efflux mechanisms."
      }
    ],
    "mechanism": "Nitazoxanide enhances colistin activity possibly by efflux pump inhibition and biofilm disruption, restoring colistin susceptibility in resistant strains.",
    "relevance_score": 5,
    "paper_idx": 303,
    "pmid": "38047647",
    "title": "Repurposing of the antimalarial agent tafenoquine to combat MRSA.",
    "year": "2023",
    "doi": "10.1128/msystems.01026-23",
    "journal": "mSystems",
    "authors": [
      "She P",
      "Yang Y",
      "Li L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Thalidomide",
        "drug_class": "Immunomodulatory agent",
        "approved_for": "Multiple myeloma, leprosy, other conditions"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR (including MRSA)"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterobacter species",
        "resistance_profile": "MDR"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "azole-resistant strains"
      },
      {
        "name": "Candida glabrata",
        "resistance_profile": "azole-resistant strains"
      },
      {
        "name": "Candida parapsilosis",
        "resistance_profile": "azole-resistant strains"
      }
    ],
    "findings": [
      {
        "drug": "compound 3h",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Compound 3h showed MIC of 16 \u00b5g/mL against S. aureus ATCC 25923."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Compound 3h exhibited MIC of 32 \u00b5g/mL against E. faecium."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Compound 3h showed MIC of 32 \u00b5g/mL against K. pneumoniae."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Compound 3h demonstrated MIC of 32 \u00b5g/mL against P. aeruginosa."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Candida albicans",
        "activity_type": "anti_fungal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Compound 3h had MIC of 32 \u00b5g/mL against C. albicans."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Candida glabrata",
        "activity_type": "anti_fungal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Compound 3h showed MIC of 16 \u00b5g/mL against C. glabrata."
      },
      {
        "drug": "compound 3h",
        "pathogen": "Candida parapsilosis",
        "activity_type": "anti_fungal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Compound 3h exhibited MIC of 16 \u00b5g/mL against C. parapsilosis."
      }
    ],
    "mechanism": "The compound 3h damages nuclear DNA, triggers apoptosis, and inhibits cellular migration in cancer cells; antimicrobial activity likely involves disruption of bacterial and fungal cell structures or functions.",
    "relevance_score": 4,
    "paper_idx": 304,
    "pmid": "38049492",
    "title": "In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.",
    "year": "2023",
    "doi": "10.1038/s41598-023-48398-6",
    "journal": "Scientific reports",
    "authors": [
      "Zhang C",
      "Liu J",
      "Sui Y"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 305,
    "pmid": "38050607",
    "title": "Amlodipine and lufenuron as repurposing drugs against Sporothrix brasiliensis.",
    "year": "2023",
    "doi": "10.7717/peerj.16443",
    "journal": "PeerJ",
    "authors": [
      "Poester V",
      "Hidalgo J",
      "Jardim L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Carvedilol",
        "drug_class": "non-selective beta-adrenergic blocker",
        "approved_for": "hypertension, heart disease"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV-2",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Carvedilol",
        "pathogen": "SARS-CoV-2",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Carvedilol and its metabolites show high binding affinity to SARS-CoV-2 RdRp, suggesting potential inhibitory activity."
      }
    ],
    "mechanism": "binding inhibition of viral RNA-dependent RNA polymerase (RdRp), potentially blocking viral replication",
    "relevance_score": 2,
    "paper_idx": 306,
    "pmid": "38069261",
    "title": "Antibacterial and Photocatalytic Activity of ZnO/Au and ZnO/Ag Nanocomposites.",
    "year": "2023",
    "doi": "10.3390/ijms242316939",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Busila M",
      "Musat V",
      "Alexandru P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "alcoholism treatment",
        "approved_for": "chronic alcoholism"
      }
    ],
    "pathogens": [
      {
        "name": "Ureaplasma urealyticum",
        "resistance_profile": "antibiotic-resistant"
      },
      {
        "name": "Ureaplasma parvum",
        "resistance_profile": "antibiotic-resistant"
      }
    ],
    "findings": [
      {
        "drug": "N,N-Diethyldithiocarbamate (DDC)",
        "pathogen": "Ureaplasma urealyticum",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "DDC exhibits both bacteriostatic and bactericidal activity against Ureaplasma urealyticum in vitro at concentrations of 2-200 \u00b5g/mL."
      },
      {
        "drug": "N,N-Diethyldithiocarbamate (DDC)",
        "pathogen": "Ureaplasma parvum",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "DDC shows bacteriostatic and bactericidal effects against Ureaplasma parvum in vitro at concentrations of 2-200 \u00b5g/mL."
      }
    ],
    "mechanism": "not explicitly proposed in the paper",
    "relevance_score": 4,
    "paper_idx": 307,
    "pmid": "38136685",
    "title": "Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents.",
    "year": "2023",
    "doi": "10.3390/antibiotics12121651",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Barbarossa A",
      "Ceramella J",
      "Carocci A"
    ]
  },
  {
    "drugs": [
      {
        "name": "AKBA",
        "drug_class": "pentacyclic triterpenoid",
        "approved_for": "anti-tumor, antioxidant"
      },
      {
        "name": "gentamycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "methicillin-resistant Staphylococcus aureus"
      }
    ],
    "findings": [
      {
        "drug": "AKBA",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "AKBA exhibits effective antimicrobial activity against MRSA with MIC of 4-8 \u00b5g/mL and no detectable resistance after 20 days of passage."
      },
      {
        "drug": "AKBA",
        "pathogen": "MRSA",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AKBA shows synergistic effects with gentamycin and amikacin against S. aureus and clinical isolates."
      },
      {
        "drug": "AKBA",
        "pathogen": "MRSA",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "AKBA exhibits strong biofilm inhibitory and eradication effects at 1-4 \u00b5g/mL."
      },
      {
        "drug": "AKBA",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo mouse model confirms effective antimicrobial activity of AKBA with no detectable toxicity."
      },
      {
        "drug": "AKBA",
        "pathogen": "MRSA",
        "activity_type": "anti_persister",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AKBA effectively kills S. aureus persister cells at 1-8\u00d7MIC concentrations."
      }
    ],
    "mechanism": "Proposed mechanism involves direct antimicrobial activity, biofilm disruption, and synergy with conventional antibiotics, potentially through membrane interaction or stress response modulation.",
    "relevance_score": 5,
    "paper_idx": 308,
    "pmid": "38143555",
    "title": "Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.",
    "year": "2023",
    "doi": "10.1039/d3sc05124b",
    "journal": "Chemical science",
    "authors": [
      "Dey R",
      "Mukherjee S",
      "Mukherjee R"
    ]
  },
  {
    "drugs": [
      {
        "name": "auranofin",
        "drug_class": "antirheumatic gold-containing drug",
        "approved_for": "rheumatoid arthritis"
      },
      {
        "name": "MS-40",
        "drug_class": "auranofin analog",
        "approved_for": null
      },
      {
        "name": "MS-40S",
        "drug_class": "auranofin analog",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Burkholderia cenocepacia",
        "resistance_profile": "multidrug-resistant, causes severe infections in cystic fibrosis patients"
      }
    ],
    "findings": [
      {
        "drug": "auranofin",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin inhibits thioredoxin reductase in B. cenocepacia but is inactive against GOR, and its activity may be limited by cell envelope permeability."
      },
      {
        "drug": "MS-40",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40 inhibits thioredoxin reductase and induces ROS in B. cenocepacia, leading to bactericidal activity."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MS-40S inhibits thioredoxin reductase and induces ROS in B. cenocepacia, resulting in bactericidal effects."
      },
      {
        "drug": "MS-40",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "genetic",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Genetic disruption of glutathione biosynthesis genes increases susceptibility to MS-40, indicating involvement of ROS detoxification pathways."
      },
      {
        "drug": "MS-40S",
        "pathogen": "Burkholderia cenocepacia",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "genetic",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disruption of glutathione biosynthesis genes increases susceptibility to MS-40S, supporting ROS-mediated killing."
      }
    ],
    "mechanism": "Inhibition of thioredoxin reductase leading to increased reactive oxygen species (ROS) and oxidative stress in bacteria, with the glutathione system providing protective effects.",
    "relevance_score": 4,
    "paper_idx": 309,
    "pmid": "38169981",
    "title": "Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.",
    "year": "2023",
    "doi": "10.2147/IJN.S434579",
    "journal": "International journal of nanomedicine",
    "authors": [
      "Liang Y",
      "Wang B",
      "Yu Q"
    ]
  },
  {
    "drugs": [],
    "pathogens": [],
    "findings": [
      {
        "drug": null,
        "pathogen": null,
        "activity_type": "predictive_model",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The study developed machine learning models with over 80% accuracy to predict antimicrobial activity of compounds, facilitating drug repurposing efforts."
      }
    ],
    "mechanism": "not applicable",
    "relevance_score": 1,
    "paper_idx": 310,
    "pmid": "38184513",
    "title": "Drug repurposing: insights into the antimicrobial effects of AKBA against MRSA.",
    "year": "2024",
    "doi": "10.1186/s13568-024-01660-0",
    "journal": "AMB Express",
    "authors": [
      "Li Y",
      "Ma H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Fusidic acid",
        "drug_class": "antibacterial",
        "approved_for": "staphylococcal infections"
      },
      {
        "name": "Fluconazole",
        "drug_class": "azole antifungal",
        "approved_for": "vaginal candidiasis, systemic candidiasis"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "azole-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Fusidic acid",
        "pathogen": "Candida albicans",
        "activity_type": "efflux_inhibitor|adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fusidic acid inhibits efflux pump activity in C. albicans, increasing intracellular accumulation of substrates and synergizing with fluconazole."
      },
      {
        "drug": "Fluconazole",
        "pathogen": "Candida albicans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo|clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluconazole's activity is restored and enhanced when combined with fusidic acid in resistant C. albicans strains."
      }
    ],
    "mechanism": "Fusidic acid inhibits efflux pump proteins, reducing drug efflux and increasing intracellular antifungal concentrations, thereby restoring fluconazole efficacy.",
    "relevance_score": 5,
    "paper_idx": 311,
    "pmid": "38203213",
    "title": "Antimicrobial Activity of N,N-Diethyldithiocarbamate against Ureaplasma parvum and Ureaplasma urealyticum.",
    "year": "2023",
    "doi": "10.3390/ijms25010040",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Biernat-Sudolska M",
      "Rojek-Zakrzewska D",
      "Dro\u017cd\u017c K"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 312,
    "pmid": "38206016",
    "title": "The mechanism of action of auranofin analogs in B. cenocepacia revealed by chemogenomic profiling.",
    "year": "2024",
    "doi": "10.1128/spectrum.03201-23",
    "journal": "Microbiology spectrum",
    "authors": [
      "Maydaniuk D",
      "Martens B",
      "Iqbal S"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "TrxR inhibitor / glutathione peroxidase mimic",
        "approved_for": "antioxidant / anti-inflammatory"
      },
      {
        "name": "Silver nanoparticles (AgNPs)",
        "drug_class": "nanomaterial with antimicrobial properties",
        "approved_for": "not specifically approved; used experimentally for antimicrobial purposes"
      }
    ],
    "pathogens": [
      {
        "name": "Porphyromonas gingivalis",
        "resistance_profile": "antibiotic resistant, intracellular persistence"
      },
      {
        "name": "Fusobacterium nucleatum",
        "resistance_profile": "not specified"
      },
      {
        "name": "Streptococcus gordonii",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Porphyromonas gingivalis",
        "activity_type": "direct_antibacterial|anti_biofilm|adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen enhances the antibacterial and antibiofilm effects of silver nanoparticles against P. gingivalis and F. nucleatum."
      },
      {
        "drug": "Ebselen",
        "pathogen": "Porphyromonas gingivalis",
        "activity_type": "adjuvant|anti_inflammatory",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen combined with AgNPs reduces inflammatory cytokine release and alveolar bone resorption in periodontal models."
      },
      {
        "drug": "Silver nanoparticles (AgNPs)",
        "pathogen": "Porphyromonas gingivalis",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "AgNPs exhibit excellent antibacterial and antibiofilm effects against periodontal pathogens."
      },
      {
        "drug": "Silver nanoparticles (AgNPs)",
        "pathogen": "Porphyromonas gingivalis",
        "activity_type": "intracellular_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 5,
        "fici": null,
        "key_result": "AgNPs can kill intracellular P. gingivalis within human gingival fibroblasts, especially when combined with ebselen."
      }
    ],
    "mechanism": "Ebselen inhibits bacterial thioredoxin reductase, disrupting ROS scavenging in bacteria, while acting as a glutathione peroxidase mimic in mammalian cells, reducing oxidative stress. AgNPs induce bacterial membrane damage and ROS production, leading to bacterial death. The combination enhances antibacterial efficacy and reduces oxidative damage in host cells.",
    "relevance_score": 5,
    "paper_idx": 313,
    "pmid": "38252641",
    "title": "Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0295627",
    "journal": "PloS one",
    "authors": [
      "Oludiran A",
      "Malik A",
      "Zourou A"
    ]
  },
  {
    "drugs": [
      {
        "name": "fusidic acid",
        "drug_class": "bacteriostatic agent",
        "approved_for": "Staphylococcus aureus infections"
      }
    ],
    "pathogens": [
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "vancomycin-susceptible and vancomycin-resistant"
      },
      {
        "name": "Enterococcus faecium",
        "resistance_profile": "vancomycin-susceptible and vancomycin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "FA MICs against standard strains were 2 \u00b5g/mL, and 98 clinical isolates had MICs \u22648 \u00b5g/mL, suggesting susceptibility at high serum levels."
      },
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "FA MICs against standard strains were 4 \u00b5g/mL, indicating potential activity at elevated serum concentrations."
      },
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, FA significantly reduced bacterial burden in mice infected with enterococci, including resistant strains."
      },
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "FA treatment decreased bacterial load in infected mice, demonstrating in vivo efficacy."
      },
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "resistance_development",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "Serial exposure to increasing FA concentrations led to resistant strains with MICs of 128 \u00b5g/mL, thicker cell walls, and slower growth."
      },
      {
        "drug": "fusidic acid",
        "pathogen": "Enterococcus faecium",
        "activity_type": "resistance_development",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "Resistance emerged after serial passage, with a mutation (M651I) in fusA gene, but revertant strains retained this mutation."
      }
    ],
    "mechanism": "Inhibition of protein synthesis by binding to elongation factor G (EF-G), preventing peptide translocation.",
    "relevance_score": 4,
    "paper_idx": 314,
    "pmid": "38259963",
    "title": "In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota.",
    "year": "2023",
    "doi": "10.3389/fcimb.2023.1306430",
    "journal": "Frontiers in cellular and infection microbiology",
    "authors": [
      "Rubio-Garcia E",
      "Ferrando N",
      "Martin N"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 315,
    "pmid": "38261091",
    "title": "In vitro study: methylene blue-based antibacterial photodynamic inactivation of Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1007/s00253-024-13009-5",
    "journal": "Applied microbiology and biotechnology",
    "authors": [
      "Zada L",
      "Anwar S",
      "Imtiaz S"
    ]
  },
  {
    "drugs": [
      {
        "name": "oxethazine",
        "drug_class": "local anesthetic",
        "approved_for": "pain relief in gastritis and duodenal ulcers"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "treatment of multidrug-resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Gram-negative bacteria",
        "resistance_profile": "MDR, colistin-resistant (mcr-positive and -negative)"
      }
    ],
    "findings": [
      {
        "drug": "oxethazine",
        "pathogen": "Gram-negative bacteria",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Oxethazine significantly enhances the antibacterial activity of colistin against MDR Gram-negative pathogens through membrane disruption and ROS accumulation."
      }
    ],
    "mechanism": "Oxethazine improves colistin's ability to disrupt bacterial outer and cytoplasmic membranes, increases membrane permeability, and induces reactive oxygen species accumulation, leading to bacterial cell death.",
    "relevance_score": 4,
    "paper_idx": 316,
    "pmid": "38275586",
    "title": "Ezetimibe Induces Paraptosis through Niemann-Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells.",
    "year": "2023",
    "doi": "10.3390/genes15010004",
    "journal": "Genes",
    "authors": [
      "Yin Y",
      "Wu C",
      "Zhou Y"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 317,
    "pmid": "38278870",
    "title": "Alkyl deoxyglycoside-polymyxin combinations against critical priority carbapenem-resistant gram-negative bacteria.",
    "year": "2024",
    "doi": "10.1038/s41598-024-51428-6",
    "journal": "Scientific reports",
    "authors": [
      "de Matos A",
      "Calado P",
      "Miranda M"
    ]
  },
  {
    "drugs": [
      {
        "name": "l-thyroxine",
        "drug_class": "hormone",
        "approved_for": "hypothyroidism"
      },
      {
        "name": "3,5,3\u2032,5\u2032-tetraiodo thyroacetic acid",
        "drug_class": "thyroid hormone analogue",
        "approved_for": null
      },
      {
        "name": "3,3\u2032,5-triiodo thyropropionic acid",
        "drug_class": "thyroid hormone analogue",
        "approved_for": null
      }
    ],
    "pathogens": [
      {
        "name": "Streptococcus pneumoniae",
        "resistance_profile": "drug resistant"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "l-thyroxine",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 64,
        "fici": null,
        "key_result": "l-thyroxine specifically inhibits the growth of Streptococcus pneumoniae with MIC of 64 \u03bcg/mL."
      },
      {
        "drug": "3,5,3\u2032,5\u2032-tetraiodo thyroacetic acid",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 64,
        "fici": null,
        "key_result": "analogues with a carboxyl group show similar activity against Sp with MIC of 64 \u03bcg/mL."
      },
      {
        "drug": "3,3\u2032,5-triiodo thyropropionic acid",
        "pathogen": "Streptococcus pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 64,
        "fici": null,
        "key_result": "analogues lacking iodine on the distal ring also show activity at MIC 64 \u03bcg/mL."
      }
    ],
    "mechanism": "binding to bacterial flavodoxin, disrupting electron transfer processes essential for bacterial growth",
    "relevance_score": 4,
    "paper_idx": 318,
    "pmid": "38295025",
    "title": "Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans.",
    "year": "2024",
    "doi": "10.1021/acsinfecdis.3c00371",
    "journal": "ACS infectious diseases",
    "authors": [
      "Shyam M",
      "Kumar S",
      "Singh V"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 319,
    "pmid": "38341568",
    "title": "The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.",
    "year": "2024",
    "doi": "10.1186/s12866-024-03181-z",
    "journal": "BMC microbiology",
    "authors": [
      "Gomaa S",
      "Abbas H",
      "Mohamed F"
    ]
  },
  {
    "drugs": [
      {
        "name": "harmaline",
        "drug_class": "alkaloid",
        "approved_for": "not specified (experimental use)"
      },
      {
        "name": "tigecycline",
        "drug_class": "glycylcycline antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "tmexCD1-toprJ1-mediated tigecycline resistance"
      }
    ],
    "findings": [
      {
        "drug": "harmaline",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant|efflux_inhibitor",
        "evidence_type": "in_vitro|in_vivo|computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Harmaline synergistically potentiates tigecycline efficacy against tmexCD1-toprJ1-positive K. pneumoniae by inhibiting efflux pump function and disrupting membrane integrity."
      }
    ],
    "mechanism": "Harmaline interacts with TMexCD1-TOprJ1 active residues, dissipates the proton motive force, and disrupts cell membrane integrity, thereby inhibiting the efflux pump and restoring tigecycline activity.",
    "relevance_score": 5,
    "paper_idx": 320,
    "pmid": "38345040",
    "title": "ABDpred: Prediction of active antimicrobial compounds using supervised machine learning techniques.",
    "year": "2024",
    "doi": "10.4103/ijmr.ijmr_1832_22",
    "journal": "The Indian journal of medical research",
    "authors": [
      "Jana T",
      "Sarkar D",
      "Ganguli D"
    ]
  },
  {
    "drugs": [
      {
        "name": "miconazole",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "phenothiazine",
        "drug_class": "antipsychotic",
        "approved_for": "psychotic disorders"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "antimicrobial resistant"
      }
    ],
    "findings": [
      {
        "drug": "miconazole",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Miconazole significantly inhibited P. aeruginosa virulence factors including biofilm formation, hemolytic activity, pyocyanin, rhamnolipids, and protease activities, and reduced expression of quorum sensing genes."
      },
      {
        "drug": "phenothiazine",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Phenothiazine showed moderate inhibition of P. aeruginosa virulence factors, including biofilm, pyocyanin, protease, rhamnolipids, and hemolytic activity, with less impact than miconazole."
      },
      {
        "drug": "miconazole",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Miconazole treatment resulted in 100% survival in mice infected with P. aeruginosa, indicating effective anti-virulence activity in vivo."
      }
    ],
    "mechanism": "Miconazole and phenothiazine inhibit quorum sensing-regulated virulence gene expression, reducing production of virulence factors such as biofilm, pyocyanin, hemolysin, rhamnolipids, and proteases, likely through interference with QS-proteins LasR, RhlR, and PqsR.",
    "relevance_score": 5,
    "paper_idx": 321,
    "pmid": "38373973",
    "title": "Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies.",
    "year": "2024",
    "doi": "10.1186/s13054-024-04828-z",
    "journal": "Critical care (London, England)",
    "authors": [
      "Dhanani J",
      "Roberts J",
      "Monsel A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 322,
    "pmid": "38427501",
    "title": "Reduced Prevalence of Parkinson's Disease in Patients Prescribed Calcineurin Inhibitors.",
    "year": "2024",
    "doi": "10.3233/JPD-230313",
    "journal": "Journal of Parkinson's disease",
    "authors": [
      "Silva J",
      "Jupiter D",
      "Taglialatela G"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 323,
    "pmid": "38532184",
    "title": "Repurposing fusidic acid as an antimicrobial against enterococci with a low probability of resistance development.",
    "year": "2024",
    "doi": "10.1007/s10123-024-00506-w",
    "journal": "International microbiology : the official journal of the Spanish Society for Microbiology",
    "authors": [
      "Abdelmassih M",
      "Ismail M",
      "Kashef M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 324,
    "pmid": "38534720",
    "title": "Antimicrobial and Diagnostic Stewardship of the Novel \u03b2-Lactam/\u03b2-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.3390/antibiotics13030285",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Ferous S",
      "Anastassopoulou C",
      "Pitiriga V"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ebselen",
        "drug_class": "organo-selenium compound",
        "approved_for": "none specified; investigational for antifungal/anti-inflammatory"
      }
    ],
    "pathogens": [
      {
        "name": "Aspergillus fumigatus",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Ebselen",
        "pathogen": "Aspergillus fumigatus",
        "activity_type": "direct_antibacterial|anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen inhibits A. fumigatus spore germination, reduces mycelial growth, disrupts biofilm formation, and damages fungal cell membranes via oxidative stress mechanisms."
      },
      {
        "drug": "Ebselen",
        "pathogen": "host tissues",
        "activity_type": "anti_inflammatory|antioxidant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ebselen suppresses inflammatory mediators and reduces oxidative stress markers in infected mouse corneas, improving prognosis and decreasing fungal burden."
      }
    ],
    "mechanism": "Inhibition of thioredoxin reductase (TrxR) leading to oxidative stress in fungi, cell membrane damage, and regulation of host inflammatory and oxidative stress pathways via PI3K/Akt/Nrf2 and p38 MAPK signaling.",
    "relevance_score": 5,
    "paper_idx": 325,
    "pmid": "38576480",
    "title": "The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.",
    "year": "2024",
    "doi": "10.3389/fphar.2024.1363441",
    "journal": "Frontiers in pharmacology",
    "authors": [
      "Li J",
      "Han N",
      "Li Y"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 326,
    "pmid": "38601973",
    "title": "Fabrication and evaluation of ribavirin-loaded electrospun nanofibers as an antimicrobial wound dressing.",
    "year": "2024",
    "doi": "10.1016/j.jsps.2024.102058",
    "journal": "Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society",
    "authors": [
      "Alsulami K",
      "Bakr A",
      "Alshehri A"
    ]
  },
  {
    "drugs": [
      {
        "name": "closantel",
        "drug_class": "antiparasitic",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "closantel",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Closantel exhibits strong antibacterial activity against MRSA with MIC values ranging from 0.125 to 1.000 \u03bcg/mL."
      },
      {
        "drug": "closantel",
        "pathogen": "MRSA",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.0625,
        "fici": null,
        "key_result": "Closantel significantly inhibits biofilm formation at 0.0625 \u03bcg/mL and eradicates established biofilms at 2 \u03bcg/mL."
      },
      {
        "drug": "closantel",
        "pathogen": "MRSA",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No data on synergy with other antibiotics provided."
      }
    ],
    "mechanism": "Closantel disrupts the integrity of S. aureus cell membranes, increasing membrane permeability and causing cell death.",
    "relevance_score": 4,
    "paper_idx": 327,
    "pmid": "38689973",
    "title": "L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.",
    "year": "2024",
    "doi": "10.1016/j.heliyon.2024.e27982",
    "journal": "Heliyon",
    "authors": [
      "Galano-Frutos J",
      "Maity R",
      "Iguarbe V"
    ]
  },
  {
    "drugs": [
      {
        "name": "ceftazidime/avibactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor",
        "approved_for": "complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia"
      },
      {
        "name": "meropenem/vaborbactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor",
        "approved_for": "complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia"
      },
      {
        "name": "imipenem/relebactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor",
        "approved_for": "complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia, VAP, bacteremia"
      },
      {
        "name": "ceftolozane/tazobactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor",
        "approved_for": "complicated intra-abdominal infections, urinary tract infections, hospital-acquired pneumonia, VAP"
      }
    ],
    "pathogens": [
      {
        "name": "Enterobacterales",
        "resistance_profile": "carbapenem-resistant"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "meropenem/vaborbactam",
        "pathogen": "Enterobacterales",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Effective against KPC-producing Enterobacterales but not against carbapenem-resistant P. aeruginosa."
      },
      {
        "drug": "ceftazidime/avibactam",
        "pathogen": "Enterobacterales",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Effective against KPC- and OXA-48-like carbapenemase producers; resistance linked to KPC mutations and porin loss."
      },
      {
        "drug": "imipenem/relebactam",
        "pathogen": "Enterobacterales",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Effective against certain carbapenemase producers; resistance associated with non-inhibited carbapenemases and porin mutations."
      },
      {
        "drug": "ceftolozane/tazobactam",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Active against P. aeruginosa with certain resistance mechanisms; compromised by ESBLs and carbapenemases."
      }
    ],
    "mechanism": "Inhibition of \u03b2-lactamases (including serine carbapenemases and some class D enzymes) by \u03b2-lactamase inhibitors, restoring activity of \u03b2-lactam antibiotics against resistant bacteria.",
    "relevance_score": 4,
    "paper_idx": 328,
    "pmid": "38724627",
    "title": "Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.",
    "year": "2024",
    "doi": "10.1038/s41429-024-00731-5",
    "journal": "The Journal of antibiotics",
    "authors": [
      "Gad A",
      "El-Ganiny A",
      "Eissa A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ribavirin",
        "drug_class": "antiviral",
        "approved_for": "viral infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "antifungal resistance"
      }
    ],
    "findings": [
      {
        "drug": "Ribavirin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ribavirin exhibits antimicrobial activity against P. aeruginosa by perturbing its virulence system without inhibiting growth."
      },
      {
        "drug": "Ribavirin",
        "pathogen": "Candida albicans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ribavirin shows activity against C. albicans, suggesting potential antifungal properties."
      }
    ],
    "mechanism": "Perturbation of microbial virulence systems without killing or inhibiting growth, disarming pathogens and potentially preventing resistance development.",
    "relevance_score": 4,
    "paper_idx": 329,
    "pmid": "38765678",
    "title": "Synergistic antibacterial effects of closantel and its enantiomers in combination with colistin against multidrug resistant gram-negative bacteria.",
    "year": "2024",
    "doi": "10.3389/fmicb.2024.1374910",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Ding T",
      "Guo Z",
      "Fang L"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 330,
    "pmid": "38790017",
    "title": "Repurposing harmaline as a novel approach to reverse tmexCD1-toprJ1-mediated tigecycline resistance against klebsiella pneumoniae infections.",
    "year": "2024",
    "doi": "10.1186/s12934-024-02410-4",
    "journal": "Microbial cell factories",
    "authors": [
      "Yang J",
      "Xu L",
      "Zhou Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "MK-3207",
        "drug_class": "unknown",
        "approved_for": "unknown"
      },
      {
        "name": "R-428",
        "drug_class": "unknown",
        "approved_for": "unknown"
      },
      {
        "name": "Suramin",
        "drug_class": "antiparasitic agent",
        "approved_for": "trypanosomiasis, onchocerciasis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "MK-3207",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MK-3207 demonstrated high binding affinity to RND efflux pump proteins, suggesting potential as a repurposed inhibitor."
      },
      {
        "drug": "R-428",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "R-428 showed effective binding to RND proteins, indicating possible inhibitory activity against P. aeruginosa efflux mechanisms."
      },
      {
        "drug": "Suramin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Suramin exhibited superior binding energies to RND efflux proteins, supporting its potential for repurposing as an antimicrobial agent."
      }
    ],
    "mechanism": "binding and inhibition of RND efflux pump proteins, disrupting antibiotic resistance mechanisms",
    "relevance_score": 4,
    "paper_idx": 331,
    "pmid": "38796864",
    "title": "Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects.",
    "year": "2024",
    "doi": "10.1016/j.redox.2024.103206",
    "journal": "Redox biology",
    "authors": [
      "Yu B",
      "Wang Q",
      "Zhang L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Zidovudine",
        "drug_class": "antiretroviral (HIV reverse transcriptase inhibitor)",
        "approved_for": "HIV infection"
      },
      {
        "name": "Nitrofurantoin",
        "drug_class": "nitrofuran antibiotic",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "Omadacycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial skin and soft tissue infections, community-acquired bacterial pneumonia"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "multidrug-resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "Zidovudine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Zidovudine synergized with nitrofurantoin and omadacycline against MDR K. pneumoniae in vitro."
      },
      {
        "drug": "Nitrofurantoin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nitrofurantoin combined with zidovudine showed synergistic activity against MDR K. pneumoniae in vitro."
      },
      {
        "drug": "Omadacycline",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Omadacycline combined with zidovudine demonstrated synergy against MDR K. pneumoniae in vitro."
      },
      {
        "drug": "Zidovudine",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Zidovudine enhances the activity of antibiotics against MDR K. pneumoniae in murine infection models."
      }
    ],
    "mechanism": "Zidovudine may incorporate into bacterial DNA as a chain terminator, disrupting DNA synthesis, and synergize with antibiotics by increasing intracellular antibiotic concentrations or targeting bacterial DNA replication.",
    "relevance_score": 5,
    "paper_idx": 332,
    "pmid": "38904380",
    "title": "Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy.",
    "year": "2024",
    "doi": "10.1128/spectrum.00191-24",
    "journal": "Microbiology spectrum",
    "authors": [
      "Jiang X",
      "Chen D",
      "Wang X"
    ]
  },
  {
    "drugs": [
      {
        "name": "Fosfomycin",
        "drug_class": "antibiotic, phosphoenolpyruvate (PEP) analog",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "Colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "multidrug-resistant Gram-negative infections"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "carbapenem-resistant (CRKP)"
      }
    ],
    "findings": [
      {
        "drug": "Fosfomycin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Most CRKP isolates were sensitive to fosfomycin with 86% susceptibility."
      },
      {
        "drug": "Colistin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Colistin showed high resistance (46%) among CRKP isolates by BMD testing."
      },
      {
        "drug": "Fosfomycin + Colistin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "72% of CRKP isolates demonstrated synergistic effect with the combination."
      }
    ],
    "mechanism": "The proposed mechanism involves the combination of fosfomycin's inhibition of bacterial cell wall synthesis with colistin's disruption of the outer membrane, resulting in enhanced antibacterial activity against resistant bacteria.",
    "relevance_score": 4,
    "paper_idx": 333,
    "pmid": "39019790",
    "title": "Antibacterial activity of closantel against methicillin-resistant Staphylococcus aureus and itsbiofilm.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.230442",
    "journal": "Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences",
    "authors": [
      "Tang H",
      "Zhu Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Tavaborole",
        "drug_class": "antifungal agent (boron-containing drug)",
        "approved_for": "onychomycosis (fungal nail infection)"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR (multidrug-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "Tavaborole",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Tavaborole exhibited antimicrobial activity with an MIC of 2 \u03bcg/ml against A. baumannii and reduced biofilm biomass at 16 \u03bcg/ml."
      }
    ],
    "mechanism": "Inhibition of leucyl-tRNA synthetase, disrupting protein synthesis in A. baumannii.",
    "relevance_score": 5,
    "paper_idx": 334,
    "pmid": "39052707",
    "title": "Steroid Drugs Inhibit Bacterial Respiratory Oxidases and Are Lethal Toward Methicillin-Resistant Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1093/infdis/jiad540",
    "journal": "The Journal of infectious diseases",
    "authors": [
      "Henry S",
      "Webster C",
      "Shaw L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "antirheumatic agent",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Clostridioides difficile",
        "resistance_profile": "susceptible to auranofin, potential resistance mechanisms involve mutations in sigma factor of \u03c3B and TrxB gene variations"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Clostridioides difficile",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.75,
        "fici": null,
        "key_result": "Auranofin exhibits bactericidal activity against C. difficile with a MIC of 0.75 \u00b5g/mL, and TrxB genes are involved in its tolerance."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Clostridioides difficile",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mutations in the anti-sigma factor of \u03c3B and adaptive mutations in stress response genes are associated with resistance development."
      }
    ],
    "mechanism": "Inhibition of bacterial thioredoxin reductases (TrxB), affecting thiol homeostasis and stress response pathways, particularly involving sigma factor \u03c3B and related adaptive mutations.",
    "relevance_score": 4,
    "paper_idx": 335,
    "pmid": "39061334",
    "title": "The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.",
    "year": "2024",
    "doi": "10.3390/antibiotics13070652",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Coscione F",
      "Zineddu S",
      "Vitali V"
    ]
  },
  {
    "drugs": [
      {
        "name": "Niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "helminth infections"
      }
    ],
    "pathogens": [
      {
        "name": "SARS-CoV",
        "resistance_profile": null
      },
      {
        "name": "MERS-CoV",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Niclosamide",
        "pathogen": "SARS-CoV",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide inhibits viral replication of SARS-CoV in vitro."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "MERS-CoV",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide effectively inhibits MERS-CoV viral replication by over 1000-fold in vitro."
      }
    ],
    "mechanism": "Potentially involves blocking multiple pathways (WNT/b-catenin, mTORC1, Stat3, NF-kB, Notch) and inducing cell-cycle arrest through targeting mitochondrial enzymes, as well as disrupting viral replication mechanisms.",
    "relevance_score": 4,
    "paper_idx": 336,
    "pmid": "39125594",
    "title": "From Proteome to Potential Drugs: Integration of Subtractive Proteomics and Ensemble Docking for Drug Repurposing against Pseudomonas aeruginosa RND Superfamily Proteins.",
    "year": "2024",
    "doi": "10.3390/ijms25158027",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Urra G",
      "Vald\u00e9s-Mu\u00f1oz E",
      "Suardiaz R"
    ]
  },
  {
    "drugs": [
      {
        "name": "tacrolimus",
        "drug_class": "calcineurin inhibitor",
        "approved_for": "immunosuppression in organ transplantation"
      },
      {
        "name": "cyclosporine",
        "drug_class": "calcineurin inhibitor",
        "approved_for": "immunosuppression in organ transplantation"
      },
      {
        "name": "sirolimus",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression in organ transplantation"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "tacrolimus",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Patients prescribed tacrolimus have a decreased prevalence of Parkinson's disease compared to controls and other immunosuppressants."
      },
      {
        "drug": "cyclosporine",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cyclosporine does not show a significant reduction in Parkinson's disease prevalence compared to controls."
      },
      {
        "drug": "sirolimus",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "observational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Patients prescribed sirolimus do not exhibit a decreased prevalence of Parkinson's disease."
      }
    ],
    "mechanism": "calcineurin inhibition within the brain may prevent neuronal toxicity and neuroinflammation associated with Parkinson's disease.",
    "relevance_score": 2,
    "paper_idx": 337,
    "pmid": "39194261",
    "title": "Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.",
    "year": "2024",
    "doi": "10.1128/aac.00344-24",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Tian P",
      "Li Q",
      "Guo M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 338,
    "pmid": "39211315",
    "title": "Caspofungin enhances the potency of rifampin against Gram-negative bacteria.",
    "year": "2024",
    "doi": "10.3389/fmicb.2024.1447485",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Li H",
      "Zhu X",
      "Zhang X"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 339,
    "pmid": "39238681",
    "title": "In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae.",
    "year": "2024",
    "doi": "10.7759/cureus.66295",
    "journal": "Cureus",
    "authors": [
      "P C",
      "A T",
      "Murthy N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "bacterial infections caused by Gram-negative bacteria"
      },
      {
        "name": "Niclosamide",
        "drug_class": "antihelminthic agent",
        "approved_for": "helminth infections"
      }
    ],
    "pathogens": [
      {
        "name": "Salmonella enterica serovar Typhimurium",
        "resistance_profile": "colistin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Colistin",
        "pathogen": "Salmonella enterica serovar Typhimurium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "CNEDS substantially restored colistin sensitivity against colistin-resistant Salmonella in vitro."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "Salmonella enterica serovar Typhimurium",
        "activity_type": "adjuvant|efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide can effectively reverse colistin resistance in Gram-negative bacteria."
      },
      {
        "drug": "Colistin-Niclosamide effervescent dry suspension (CNEDS)",
        "pathogen": "Salmonella enterica serovar Typhimurium",
        "activity_type": "synergy|adjuvant|anti_biofilm",
        "evidence_type": "in_vivo|in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "CNEDS effectively overcomes colistin resistance and improves survival in broiler chickens infected with colistin-resistant Salmonella."
      }
    ],
    "mechanism": "Niclosamide restores colistin sensitivity possibly by inhibiting resistance mechanisms, and the formulation enhances antibacterial activity against resistant bacteria.",
    "relevance_score": 4,
    "paper_idx": 340,
    "pmid": "39284817",
    "title": "Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.",
    "year": "2024",
    "doi": "10.1038/s41522-024-00551-3",
    "journal": "NPJ biofilms and microbiomes",
    "authors": [
      "Anjou C",
      "Royer M",
      "Bertrand \u00c9"
    ]
  },
  {
    "drugs": [
      {
        "name": "guanethidine",
        "drug_class": "guanidine compound",
        "approved_for": "not specified (used in Chinese pharmacopoeia, traditionally for hypertension)"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "multidrug-resistant, carrying tetA gene, resistant to tetracyclines"
      }
    ],
    "findings": [
      {
        "drug": "guanethidine",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Guanethidine restores susceptibility to tetracyclines in tetA-positive E. coli by inhibiting the TetA efflux pump, increasing intracellular tetracycline concentration."
      },
      {
        "drug": "guanethidine",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Guanethidine inhibits the activity of the TetA efflux pump, leading to increased intracellular tetracycline accumulation."
      },
      {
        "drug": "guanethidine",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Guanethidine synergistically enhances tetracycline activity against resistant E. coli strains, reducing MICs by 32- to 128-fold."
      },
      {
        "drug": "guanethidine",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Guanethidine delays the development of tetracycline resistance in E. coli during serial passage experiments."
      }
    ],
    "mechanism": "Inhibition of the TetA efflux pump, disruption of outer membrane integrity, and alteration of bacterial proton motive force, leading to increased intracellular tetracycline levels.",
    "relevance_score": 5,
    "paper_idx": 341,
    "pmid": "39308694",
    "title": "Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.",
    "year": "2024",
    "doi": "10.2147/DDDT.S473178",
    "journal": "Drug design, development and therapy",
    "authors": [
      "Jug M",
      "Laffleur F",
      "Millotti G"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 342,
    "pmid": "39325805",
    "title": "New antibacterial candidates against Acinetobacter baumannii discovered by in silico-driven chemogenomics repurposing.",
    "year": "2024",
    "doi": "10.1371/journal.pone.0307913",
    "journal": "PloS one",
    "authors": [
      "Borges K",
      "Costa V",
      "Neves B"
    ]
  },
  {
    "drugs": [
      {
        "name": "Caspofungin acetate",
        "drug_class": "antifungal",
        "approved_for": "fungal infections"
      },
      {
        "name": "Rifampin",
        "drug_class": "RNA polymerase inhibitor",
        "approved_for": "tuberculosis, bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Gram-negative bacteria",
        "resistance_profile": "general GNB resistance"
      }
    ],
    "findings": [
      {
        "drug": "Caspofungin acetate",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Caspofungin acetate significantly enhances the antimicrobial activity of rifampin against GNB in vitro."
      },
      {
        "drug": "Caspofungin acetate",
        "pathogen": "Escherichia coli",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In Galleria mellonella infection model, CAS potentiated rifampin efficacy against MDR E. coli in vivo."
      },
      {
        "drug": "Caspofungin acetate",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Checkerboard assays confirmed synergy between CAS and rifampin, reducing MICs."
      },
      {
        "drug": "Caspofungin acetate",
        "pathogen": "Escherichia coli",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "CAS inhibits biofilm formation and disrupts bacterial envelope integrity."
      }
    ],
    "mechanism": "Caspofungin acetate enhances antibiotic activity by permeabilizing bacterial outer membrane, disrupting proton motive force, inhibiting biofilm formation, and targeting PgaC enzyme activity.",
    "relevance_score": 4,
    "paper_idx": 343,
    "pmid": "39329140",
    "title": "Antimicrobial activities of Diltiazem Hydrochloride: drug repurposing approach.",
    "year": "2024",
    "doi": "10.7717/peerj.17809",
    "journal": "PeerJ",
    "authors": [
      "Alduaij O",
      "Hussein R",
      "Abu Alrub S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 344,
    "pmid": "39335008",
    "title": "Innovative Strategies in Drug Repurposing to Tackle Intracellular Bacterial Pathogens.",
    "year": "2024",
    "doi": "10.3390/antibiotics13090834",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Lorente-Torres B",
      "Llano-Verdeja J",
      "Casta\u00f1era P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "Gold(I) compound",
        "approved_for": "Rheumatoid arthritis"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "High tolerance to auranofin, resistant due to efflux systems and high glutathione levels"
      },
      {
        "name": "Bacillus subtilis",
        "resistance_profile": "Susceptible to auranofin, lacks high glutathione levels"
      }
    ],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin inhibits thioredoxin reductase in E. coli but high glutathione levels and efflux systems confer resistance."
      },
      {
        "drug": "Auranofin",
        "pathogen": "Bacillus subtilis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin effectively inhibits B. subtilis by targeting thioredoxin reductase, with less resistance from glutathione."
      }
    ],
    "mechanism": "Inhibition of bacterial thioredoxin reductase leading to oxidative stress and disturbance of thiol redox homeostasis; resistance in Gram-negative bacteria is partly due to high glutathione levels and efflux systems.",
    "relevance_score": 5,
    "paper_idx": 345,
    "pmid": "39338275",
    "title": "Exploring the Antibiofilm Effect of Sertraline in Synergy with Cinnamomum verum Essential Oil to Counteract Candida Species.",
    "year": "2024",
    "doi": "10.3390/ph17091109",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Barbarossa A",
      "Rosato A",
      "Carrieri A"
    ]
  },
  {
    "drugs": [
      {
        "name": "Visomitin",
        "drug_class": "antioxidant small molecule / plastoquinone derivative",
        "approved_for": "ocular surface inflammation (dry eye disease)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Visomitin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial|anti_quorum_sensing|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "Visomitin exhibits potent bactericidal activity against MRSA with MIC of 2 \u03bcg/mL and inhibits quorum sensing and biofilm formation at sub-MIC levels."
      },
      {
        "drug": "Visomitin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Visomitin disrupts bacterial cell membranes, leading to increased permeability and cell death."
      },
      {
        "drug": "Visomitin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "It effectively kills intracellular bacteria and persister cells, indicating activity against tolerant phenotypes."
      }
    ],
    "mechanism": "Disruption of bacterial cell membrane integrity and interference with the accessory gene regulator (Agr) quorum sensing system.",
    "relevance_score": 4,
    "paper_idx": 346,
    "pmid": "39377597",
    "title": "Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria.",
    "year": "2024",
    "doi": "10.1128/spectrum.00138-24",
    "journal": "Microbiology spectrum",
    "authors": [
      "Quadros Bars\u00e9 L",
      "Ulfig A",
      "Varatnitskaya M"
    ]
  },
  {
    "drugs": [
      {
        "name": "quinestrol",
        "drug_class": "steroid hormone",
        "approved_for": "hormonal therapy"
      },
      {
        "name": "ethinylestradiol",
        "drug_class": "steroid hormone",
        "approved_for": "contraception"
      },
      {
        "name": "mestranol",
        "drug_class": "steroid hormone",
        "approved_for": "hormonal therapy"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "quinestrol",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Quinestrol inhibits cytochrome bd and exhibits bactericidal activity against MRSA."
      },
      {
        "drug": "quinestrol",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Quinestrol inhibits growth of E. coli but is not bactericidal."
      },
      {
        "drug": "ethinylestradiol",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ethinylestradiol inhibits oxygen consumption in E. coli membranes."
      },
      {
        "drug": "mestranol",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mestranol did not inhibit oxygen consumption in E. coli membranes."
      }
    ],
    "mechanism": "Steroid drugs bind to the quinol binding site of bacterial respiratory oxidases (cytochrome bd), inhibiting their activity and leading to bacterial growth inhibition or death.",
    "relevance_score": 4,
    "paper_idx": 347,
    "pmid": "39390774",
    "title": "Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus.",
    "year": "2024",
    "doi": "10.1080/21505594.2024.2415952",
    "journal": "Virulence",
    "authors": [
      "Wu R",
      "Wu Y",
      "Wu P"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 348,
    "pmid": "39452239",
    "title": "Guanethidine Restores Tetracycline Sensitivity in Multidrug-Resistant Escherichia coli Carrying tetA Gene.",
    "year": "2024",
    "doi": "10.3390/antibiotics13100973",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Zhao X",
      "Zhang M",
      "Zhang Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "Diltiazem Hydrochloride",
        "drug_class": "Ca2+ channel blocker",
        "approved_for": "hypertension, angina pectoris, supraventricular tachyarrhythmia"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "not specified"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "not specified"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "not specified"
      },
      {
        "name": "Serratia marcescens",
        "resistance_profile": "not specified"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "not specified"
      },
      {
        "name": "Candida glabrata",
        "resistance_profile": "not specified"
      },
      {
        "name": "Candida krusei",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "Staphylococcus epidermidis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem HCl exhibited antimicrobial activity against S. epidermidis and significantly reduced biofilm formation by 95.1%."
      },
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem HCl showed activity against S. aureus and reduced biofilm formation by 90.7%."
      },
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "Candida albicans",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem HCl demonstrated antifungal activity against Candida albicans."
      },
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "Candida glabrata",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem HCl exhibited antifungal activity against Candida glabrata."
      },
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "Candida krusei",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Diltiazem HCl showed antifungal activity against Candida krusei."
      },
      {
        "drug": "Diltiazem Hydrochloride",
        "pathogen": "CoxB4 virus",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 35.8,
        "fici": null,
        "key_result": "Diltiazem HCl demonstrated potent antiviral activity against CoxB4 virus with an IC50 of 35.8 \u03bcg/mL, comparable to Acyclovir."
      }
    ],
    "mechanism": "Proposed mechanism involves off-target effects of Diltiazem HCl, potentially disrupting microbial biofilm formation and viral replication, though specific mechanisms are not detailed.",
    "relevance_score": 4,
    "paper_idx": 349,
    "pmid": "39500268",
    "title": "Colistin-niclosamide effervescent dry suspension combats colistin-resistant Salmonella in vitro and in vivo.",
    "year": "2024",
    "doi": "10.1016/j.psj.2024.104492",
    "journal": "Poultry science",
    "authors": [
      "Zhang J",
      "Miao Q",
      "Ma X"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "Gold(I) compound",
        "approved_for": "Rheumatoid arthritis"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "Auranofin",
        "pathogen": "bacterial",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Auranofin exhibits antibacterial activity by directly interacting with bacterial thiol-containing proteins, forming S-Au-S adducts that mimic disulfide bonds."
      }
    ],
    "mechanism": "Auranofin binds to cysteine thiols in bacterial proteins, forming S-Au-S bridges that modify protein thiols and disrupt bacterial redox systems.",
    "relevance_score": 5,
    "paper_idx": 350,
    "pmid": "39507218",
    "title": "Colistin-niclosamide-loaded nanoemulsions and nanoemulsion gels for effective therapy of colistin-resistant Salmonella infections.",
    "year": "2024",
    "doi": "10.3389/fvets.2024.1492543",
    "journal": "Frontiers in veterinary science",
    "authors": [
      "Zhang J",
      "Wang X",
      "Li P"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "BL-refractory, multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Fe(III)",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fe(III) combined with blue light degrades capsule polysaccharides and enhances bacterial susceptibility to immune clearance."
      }
    ],
    "mechanism": "Fe(III) mediates degradation of biofilm extracellular polysaccharides upon blue light exposure, disrupting biofilm matrix and increasing bacterial vulnerability.",
    "relevance_score": 2,
    "paper_idx": 351,
    "pmid": "39519127",
    "title": "Restoring Colistin Sensitivity in Multidrug-Resistant Pathogenic E. coli Using Cinacalcet Hydrochloride.",
    "year": "2024",
    "doi": "10.3390/ijms252111574",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Wang C",
      "Zhang Z",
      "Liu D"
    ]
  },
  {
    "drugs": [
      {
        "name": "cordycepin",
        "drug_class": "nucleoside analog",
        "approved_for": "anti-tumor, anti-viral, anti-inflammatory, immunomodulatory"
      }
    ],
    "pathogens": [
      {
        "name": "Streptococcus mutans",
        "resistance_profile": "biofilm-associated resistance"
      }
    ],
    "findings": [
      {
        "drug": "cordycepin",
        "pathogen": "Streptococcus mutans",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 128,
        "fici": null,
        "key_result": "Cordycepin reduces biofilm biomass and metabolic activity of S. mutans without killing the bacteria."
      },
      {
        "drug": "cordycepin",
        "pathogen": "Streptococcus mutans",
        "activity_type": "adjuvant",
        "evidence_type": "metabolomics",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cordycepin interferes with purine and nucleotide metabolism in S. mutans biofilms."
      }
    ],
    "mechanism": "disruption of purine and nucleotide metabolism, affecting biofilm formation and metabolic activity",
    "relevance_score": 4,
    "paper_idx": 352,
    "pmid": "39530670",
    "title": "Doxifluridine effectively kills antibiotic-resistant Staphylococcus aureus in chronic obstructive pulmonary disease.",
    "year": "2024",
    "doi": "10.1128/spectrum.01805-24",
    "journal": "Microbiology spectrum",
    "authors": [
      "Zhang L",
      "Zhang Y",
      "Tian L"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "clinical"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "clinical"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "clinical"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "clinical"
      }
    ],
    "findings": [
      {
        "drug": "palmitic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "Palmitic acid from C. linum extract showed antibacterial activity against E. faecalis with an MIC of 32 \u03bcg/mL."
      },
      {
        "drug": "palmitic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In silico docking and molecular dynamics simulations suggest palmitic acid binds favorably to E. faecalis EbpA protein, indicating potential as an antimicrobial adjuvant."
      }
    ],
    "mechanism": "Palmitic acid interacts with the E. faecalis EbpA protein, likely disrupting biofilm formation and adhesion processes, contributing to its antimicrobial activity.",
    "relevance_score": 4,
    "paper_idx": 353,
    "pmid": "39590791",
    "title": "Chaetomorpha linum Extract as a Source of Antimicrobial Compounds: A Circular Bioeconomy Approach.",
    "year": "2024",
    "doi": "10.3390/md22110511",
    "journal": "Marine drugs",
    "authors": [
      "Barletta R",
      "Trezza A",
      "Geminiani M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      },
      {
        "name": "Niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "tapeworm infections"
      }
    ],
    "pathogens": [
      {
        "name": "Salmonella",
        "resistance_profile": "colistin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "Niclosamide",
        "pathogen": "Salmonella",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide reverses colistin resistance in Salmonella and enhances antibacterial activity when co-delivered in nanoemulsions."
      },
      {
        "drug": "Colistin",
        "pathogen": "Salmonella",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Nanoemulsion formulations significantly reduce the MIC of colistin against resistant Salmonella strains, indicating restored susceptibility."
      }
    ],
    "mechanism": "Niclosamide enhances antibacterial activity by damaging bacterial cell membranes, disrupting proton motive force, inhibiting multidrug efflux pumps, and promoting oxidative damage.",
    "relevance_score": 5,
    "paper_idx": 354,
    "pmid": "39670471",
    "title": "Repurposing statins for the treatment of larval cestodiases: in silico evaluation of statin-HMG-CoA reductase interactions and assessment of statin effects on a cestode model.",
    "year": "2025",
    "doi": "10.1017/S0031182024001586",
    "journal": "Parasitology",
    "authors": [
      "Monteiro Guedes M",
      "Camargo de Lima J",
      "Andrade Paes J"
    ]
  },
  {
    "drugs": [
      {
        "name": "simvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolaemia"
      },
      {
        "name": "fluvastatin",
        "drug_class": "statin",
        "approved_for": "hypercholesterolaemia"
      }
    ],
    "pathogens": [
      {
        "name": "Echinococcus multilocularis",
        "resistance_profile": null
      },
      {
        "name": "Echinococcus granulosus",
        "resistance_profile": null
      },
      {
        "name": "Taenia solium",
        "resistance_profile": null
      },
      {
        "name": "Mesocestoides corti",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "simvastatin",
        "pathogen": "Mesocestoides corti",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 150,
        "fici": null,
        "key_result": "Simvastatin significantly reduced M. corti viability, achieving 100% parasite death at 150 \u03bcM."
      },
      {
        "drug": "fluvastatin",
        "pathogen": "Mesocestoides corti",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fluvastatin showed a significant, though lower, anthelmintic effect compared to simvastatin."
      }
    ],
    "mechanism": "Inhibition of HMG-CoA reductase in cestodes, disrupting the mevalonate pathway essential for parasite lipid metabolism and cell functions.",
    "relevance_score": 4,
    "paper_idx": 355,
    "pmid": "39688409",
    "title": "Repurposing zidovudine and 5-fluoro-2'-deoxyuridine as antibiotic drugs made possible by synergy with both trimethoprim and the mitochondrial toxicity-reducing agent uridine.",
    "year": "2025",
    "doi": "10.1093/jac/dkae438",
    "journal": "The Journal of antimicrobial chemotherapy",
    "authors": [
      "Levenfors J",
      "Bjerketorp J",
      "Guss B"
    ]
  },
  {
    "drugs": [
      {
        "name": "cinacalcet hydrochloride",
        "drug_class": "calcimimetic agent",
        "approved_for": "secondary hyperparathyroidism"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR, mcr-1-positive"
      }
    ],
    "findings": [
      {
        "drug": "cinacalcet hydrochloride",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.047,
        "key_result": "Cinacalcet hydrochloride synergistically restores colistin sensitivity in MDR E. coli, including mcr-1-positive strains."
      },
      {
        "drug": "cinacalcet hydrochloride",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 64,
        "fici": null,
        "key_result": "Cinacalcet hydrochloride alone exhibits weak or no antibacterial activity against MDR E. coli."
      },
      {
        "drug": "cinacalcet hydrochloride",
        "pathogen": "Escherichia coli",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination of cinacalcet hydrochloride and colistin significantly inhibits biofilm formation and eradicates existing biofilms."
      }
    ],
    "mechanism": "The combination increases bacterial membrane permeability, disrupts membrane integrity, and induces oxidative stress through elevated ATP release and ROS production, leading to bacterial death.",
    "relevance_score": 5,
    "paper_idx": 356,
    "pmid": "39708333",
    "title": "Efficient Photolysis of Multidrug-Resistant Polymicrobial Biofilms.",
    "year": "2025",
    "doi": "10.1002/advs.202407898",
    "journal": "Advanced science (Weinheim, Baden-Wurttemberg, Germany)",
    "authors": [
      "Li Y",
      "Dong Y",
      "Zhang Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "Pinaverium bromide",
        "drug_class": "antispasmodic",
        "approved_for": "irritable bowel syndrome"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "biofilm-associated resistance"
      }
    ],
    "findings": [
      {
        "drug": "Pinaverium bromide",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial|anti_biofilm|synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PVB rapidly kills MRSA planktonic and persister cells, inhibits and eradicates biofilms, and shows synergistic effects with antibiotics."
      },
      {
        "drug": "Pinaverium bromide",
        "pathogen": "S. epidermidis",
        "activity_type": "direct_antibacterial|anti_biofilm|synergy",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PVB effectively kills S. epidermidis planktonic and biofilm cells, with mechanisms involving proton motive force disruption and ROS induction."
      }
    ],
    "mechanism": "Disruption of proton motive force and induction of reactive oxygen species (ROS).",
    "relevance_score": 5,
    "paper_idx": 357,
    "pmid": "39718732",
    "title": "Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.",
    "year": "2024",
    "doi": "10.1186/s13568-024-01809-x",
    "journal": "AMB Express",
    "authors": [
      "Pengfei S",
      "Yifan Y",
      "Shasha L"
    ]
  },
  {
    "drugs": [
      {
        "name": "Gallic acid",
        "drug_class": "natural metabolite",
        "approved_for": "none (natural compound)"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "multidrug-resistant (MDR)"
      },
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Gallic acid",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gallic acid showed good activity against A. baumannii with MIC and MBC assays, and demonstrated binding affinity to shikimate kinase."
      },
      {
        "drug": "Gallic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Gallic acid exhibited activity against E. faecalis in MIC and MBC assays."
      }
    ],
    "mechanism": "Inhibition of shikimate kinase enzyme in the shikimate pathway, disrupting essential metabolite synthesis in bacteria.",
    "relevance_score": 4,
    "paper_idx": 358,
    "pmid": "39728508",
    "title": "Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii.",
    "year": "2024",
    "doi": "10.3390/metabo14120727",
    "journal": "Metabolites",
    "authors": [
      "Alturki M",
      "Al Khzem A",
      "Gomaa M"
    ]
  },
  {
    "drugs": [
      {
        "name": "colistin",
        "drug_class": "polymyxin",
        "approved_for": "multidrug-resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "colistin-resistant"
      }
    ],
    "findings": [
      {
        "drug": "colistin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Colistin exerts its antibacterial activity by disrupting the outer membrane of A. baumannii through binding to lipid A, leading to bacterial cell death."
      },
      {
        "drug": "colistin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Resistance mechanisms include modifications of lipid A and loss of LPS, which reduce colistin binding and efficacy."
      },
      {
        "drug": "colistin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Genetic mutations in lipid A biosynthesis genes and addition of phosphoethanolamine to lipid A confer colistin resistance."
      }
    ],
    "mechanism": "Colistin resistance in A. baumannii is primarily mediated by modifications of lipid A through addition of phosphoethanolamine via the PmrAB two-component system or by loss of lipopolysaccharides due to mutations in biosynthetic genes, reducing colistin binding affinity.",
    "relevance_score": 5,
    "paper_idx": 359,
    "pmid": "39755609",
    "title": "Cordycepin affects Streptococcus mutans biofilm and interferes with its metabolism.",
    "year": "2025",
    "doi": "10.1186/s12903-024-05355-7",
    "journal": "BMC oral health",
    "authors": [
      "Shao Y",
      "Zhu W",
      "Liu S"
    ]
  },
  {
    "drugs": [
      {
        "name": "ceftiofur sodium",
        "drug_class": "\u03b2-lactam antibiotic",
        "approved_for": "bacterial infections in animals (e.g., swine)"
      },
      {
        "name": "Guanosine",
        "drug_class": "purine nucleoside",
        "approved_for": "neuroprotective and metabolic functions (not approved as antimicrobial)"
      }
    ],
    "pathogens": [
      {
        "name": "Streptococcus suis",
        "resistance_profile": "multidrug-resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "Guanosine",
        "pathogen": "Streptococcus suis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro|in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Guanosine enhances the bactericidal effect of ceftiofur sodium against S. suis by promoting bacterial metabolism, increasing antimicrobial accumulation, and inducing oxidative stress and DNA damage."
      }
    ],
    "mechanism": "Guanosine promotes bacterial metabolic reprogramming, enhances bacterial respiration and purine pathway activity, affects cell membrane function, increases antimicrobial accumulation, and induces oxidative stress and DNA damage, thereby potentiating the antibacterial effect of ceftiofur sodium.",
    "relevance_score": 5,
    "paper_idx": 360,
    "pmid": "39761857",
    "title": "Auranofin induces disulfide bond-mimicking S-Au adducts in protein thiol pairs.",
    "year": "2025",
    "doi": "10.1016/j.jbc.2025.108159",
    "journal": "The Journal of biological chemistry",
    "authors": [
      "Quadros Bars\u00e9 L",
      "D\u00fcchting P",
      "Lupilov N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Nigella sativa essential oil",
        "drug_class": "natural herbal supplement",
        "approved_for": "nutritional supplement/immunomodulatory"
      },
      {
        "name": "monophosphoryl lipid A (MPLA)",
        "drug_class": "immunostimulatory adjuvant",
        "approved_for": "vaccine adjuvant"
      }
    ],
    "pathogens": [
      {
        "name": "Salmonella pullorum",
        "resistance_profile": "pandemic drug-resistant (PDR)"
      }
    ],
    "findings": [
      {
        "drug": "NS-MPLA nanoliposomes",
        "pathogen": "Salmonella pullorum",
        "activity_type": "adjuvant|anti_biofilm|immunomodulatory",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NS-MPLA nanoliposomes boosted immunity, promoted bacterial clearance, and reduced pathological lesions in broiler chicks challenged with drug-resistant Salmonella pullorum."
      }
    ],
    "mechanism": "enhancement of immune response through upregulation of cytokines, immunoglobulins, and mucosal gene expression, leading to bacterial clearance and tissue repair",
    "relevance_score": 4,
    "paper_idx": 361,
    "pmid": "39766555",
    "title": "Potential Synergy of Fluoxetine and Antibacterial Agents Against Skin and Soft Tissue Pathogens and Drug-Resistant Organisms.",
    "year": "2024",
    "doi": "10.3390/antibiotics13121165",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Ahmed S",
      "Jordan R",
      "Isseroff R"
    ]
  },
  {
    "drugs": [
      {
        "name": "ceftazidime-avibactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor",
        "approved_for": "complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired pneumonia"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections including complicated urinary tract infections, bacterial septicemia"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "XDR/PDR (extensively drug-resistant/pan-drug-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "ceftazidime-avibactam",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "77.3% of XDR/PDR P. aeruginosa strains showed synergistic effects when treated with ceftazidime-avibactam in combination with amikacin."
      }
    ],
    "mechanism": "The combination likely enhances bacterial cell wall penetration and inhibits multiple resistance mechanisms, resulting in synergistic antibacterial activity.",
    "relevance_score": 4,
    "paper_idx": 362,
    "pmid": "39770308",
    "title": "Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections.",
    "year": "2024",
    "doi": "10.3390/pathogens13121049",
    "journal": "Pathogens (Basel, Switzerland)",
    "authors": [
      "Islam M",
      "Jung D",
      "Shin W"
    ]
  },
  {
    "drugs": [
      {
        "name": "vancomycin",
        "drug_class": "glycopeptide antibiotic",
        "approved_for": "bacterial infections, including MRSA"
      }
    ],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "vancomycin",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Vancomycin-loaded hybrid nanostructured lipid carriers (VCM-HNLCs) demonstrated enhanced antibacterial activity against MRSA, with reduced MIC values and improved efficacy in a sepsis mouse model."
      },
      {
        "drug": "vancomycin",
        "pathogen": "S. aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "VCM-HNLCs showed a twofold reduction in MIC at physiological pH and a fourfold reduction at pH 6.0 compared to free vancomycin."
      }
    ],
    "mechanism": "pH-responsive controlled release and targeted delivery of vancomycin, combined with biomimetic inhibition of TLR activation and efflux pump inhibition by TS.",
    "relevance_score": 5,
    "paper_idx": 363,
    "pmid": "39856593",
    "title": "High prevalence of multidrug resistant and extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in the West region, Cameroon.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10483-8",
    "journal": "BMC infectious diseases",
    "authors": [
      "Bayaba S",
      "Founou R",
      "Tchouangueu F"
    ]
  },
  {
    "drugs": [
      {
        "name": "zidovudine",
        "drug_class": "antiviral nucleoside analogue",
        "approved_for": "HIV infection"
      },
      {
        "name": "5-fluoro-2'-deoxyuridine",
        "drug_class": "anticancer nucleoside analogue",
        "approved_for": "colorectal, kidney, and stomach cancers"
      },
      {
        "name": "trimethoprim",
        "drug_class": "antibacterial dihydrofolate reductase inhibitor",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "uridine",
        "drug_class": "nucleoside supplement",
        "approved_for": "used as a supplement to reduce toxicity in various treatments"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "antibiotic-resistant strains, tested in murine peritonitis model"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "tested in vitro, synergy observed"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "tested in vitro, synergy observed"
      }
    ],
    "findings": [
      {
        "drug": "zidovudine",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Zidovudine combined with trimethoprim and uridine showed antibacterial synergy against E. coli in vitro."
      },
      {
        "drug": "5-fluoro-2'-deoxyuridine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "5-Fluoro-2'-deoxyuridine combined with trimethoprim and uridine showed synergy against S. aureus in vitro."
      },
      {
        "drug": "zidovudine",
        "pathogen": "Escherichia coli",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In a murine peritonitis model, zidovudine with trimethoprim and uridine demonstrated enhanced antibacterial efficacy."
      },
      {
        "drug": "5-fluoro-2'-deoxyuridine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, 5-fluoro-2'-deoxyuridine with trimethoprim and uridine showed synergistic antibacterial activity."
      }
    ],
    "mechanism": "The proposed mechanism involves lowering bacterial dTMP levels through nucleoside analogues and trimethoprim, with uridine reducing host toxicity and enhancing antibacterial effects.",
    "relevance_score": 4,
    "paper_idx": 364,
    "pmid": "39858337",
    "title": "Selective Serotonin Reuptake Inhibitors: Antimicrobial Activity Against ESKAPEE Bacteria and Mechanisms of Action.",
    "year": "2025",
    "doi": "10.3390/antibiotics14010051",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Endo T",
      "Santos M",
      "Scandorieiro S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 365,
    "pmid": "39861906",
    "title": "Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses.",
    "year": "2025",
    "doi": "10.3390/v17010117",
    "journal": "Viruses",
    "authors": [
      "Ofodile C",
      "Uzochukwu I",
      "Ezebuo F"
    ]
  },
  {
    "drugs": [
      {
        "name": "pinaverium bromide",
        "drug_class": "L-type calcium channel blocker",
        "approved_for": "irritable bowel syndrome"
      },
      {
        "name": "oxacillin",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "bacterial infections (originally)"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus epidermidis",
        "resistance_profile": "drug-resistant biofilms, MDR"
      }
    ],
    "findings": [
      {
        "drug": "pinaverium bromide",
        "pathogen": "Staphylococcus epidermidis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": 0.25,
        "key_result": "Pinaverium bromide exhibits synergistic antibacterial effects with oxacillin against S. epidermidis, inhibits biofilm formation, and reduces persister cells."
      },
      {
        "drug": "oxacillin",
        "pathogen": "Staphylococcus epidermidis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": 0.25,
        "key_result": "Oxacillin's efficacy is enhanced when combined with pinaverium bromide, showing synergistic activity and biofilm eradication."
      }
    ],
    "mechanism": "PVB induces reactive oxygen species (ROS) production and reduces ATP synthesis, leading to bacterial structural damage, biofilm disruption, and increased bacterial cell death.",
    "relevance_score": 5,
    "paper_idx": 366,
    "pmid": "39915976",
    "title": "Guanosine enhances the bactericidal effect of ceftiofur sodium on Streptococcus suis by activating bacterial metabolism.",
    "year": "2025",
    "doi": "10.1080/21505594.2025.2453525",
    "journal": "Virulence",
    "authors": [
      "Dong Y",
      "Liu X",
      "Xiong S"
    ]
  },
  {
    "drugs": [
      {
        "name": "sertraline",
        "drug_class": "selective serotonin reuptake inhibitor (SSRI)",
        "approved_for": "depression, anxiety, obsessive\u2013compulsive disorder"
      },
      {
        "name": "paroxetine",
        "drug_class": "selective serotonin reuptake inhibitor (SSRI)",
        "approved_for": "depression, anxiety, obsessive\u2013compulsive disorder"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "sertraline",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 15,
        "fici": null,
        "key_result": "Sertraline exhibited MIC values between 15 and 126 \u03bcg/mL and effectively eradicated bacterial populations within 2 to 24 hours."
      },
      {
        "drug": "paroxetine",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 60,
        "fici": null,
        "key_result": "Paroxetine showed MIC values from 60 to 250 \u03bcg/mL and inhibited bacterial growth within hours."
      },
      {
        "drug": "sertraline",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 15,
        "fici": null,
        "key_result": "Sertraline caused morphological changes and bacterial cell protrusions, indicating membrane disruption."
      },
      {
        "drug": "paroxetine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 60,
        "fici": null,
        "key_result": "Paroxetine induced morphological alterations and cellular debris in S. aureus."
      },
      {
        "drug": "sertraline",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sertraline inhibited bacterial efflux pumps, increasing ethidium bromide accumulation and enhancing tetracycline activity."
      },
      {
        "drug": "paroxetine",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Paroxetine also inhibited efflux pumps, contributing to increased antibiotic susceptibility."
      },
      {
        "drug": "sertraline",
        "pathogen": "Escherichia coli",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sertraline increased membrane permeability and caused biomolecule leakage, disrupting bacterial integrity."
      },
      {
        "drug": "paroxetine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Paroxetine induced membrane permeability changes and biomolecule leakage in S. aureus."
      }
    ],
    "mechanism": "Increased membrane permeability, efflux pump inhibition, induction of oxidative stress, and biomolecule leakage.",
    "relevance_score": 4,
    "paper_idx": 367,
    "pmid": "39930418",
    "title": "Multifunctional hyaluronic acid-based biomimetic/pH-responsive hybrid nanostructured lipid carriers for treating bacterial sepsis.",
    "year": "2025",
    "doi": "10.1186/s12929-024-01114-6",
    "journal": "Journal of biomedical science",
    "authors": [
      "Elhassan E",
      "Omolo C",
      "Gafar M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Atorvastatin calcium",
        "drug_class": "statin",
        "approved_for": "dyslipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "antifungal resistance"
      }
    ],
    "findings": [
      {
        "drug": "Atorvastatin calcium",
        "pathogen": "Candida albicans",
        "activity_type": "anti_biofilm|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin calcium exhibits antifungal activity against Candida albicans and shows potential for drug repurposing to combat fungal infections."
      },
      {
        "drug": "Atorvastatin calcium",
        "pathogen": "Candida albicans",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Atorvastatin calcium demonstrates synergistic antifungal effects with azole drugs against C. albicans."
      }
    ],
    "mechanism": "Inhibition of ergosterol synthesis and potential disruption of fungal cell membrane integrity, with synergistic effects when combined with azole antifungals.",
    "relevance_score": 4,
    "paper_idx": 368,
    "pmid": "39934194",
    "title": "Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.",
    "year": "2025",
    "doi": "10.1038/s41598-025-88965-7",
    "journal": "Scientific reports",
    "authors": [
      "Khattab S",
      "Askar A",
      "Abdellatif H"
    ]
  },
  {
    "drugs": [
      {
        "name": "doxifluridine",
        "drug_class": "fluoropyrimidine anticancer agent",
        "approved_for": "cancer treatment"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "multidrug-resistant (MDR)"
      }
    ],
    "findings": [
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.5,
        "fici": null,
        "key_result": "Doxifluridine demonstrated significant antibacterial activity against MDR S. aureus with MIC values ranging from 0.5 to 2 \u00b5g/mL."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "bactericidal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "Doxifluridine exhibited potent bactericidal effects within 8 hours against MRSA."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Doxifluridine substantially reduced biofilm mass and viability of MRSA."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Chequerboard assays indicated synergistic interactions between doxifluridine and other antibiotics, reducing MIC values by two- to eightfold."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Doxifluridine showed synergistic effects with other antibiotics, enhancing antibacterial efficacy."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No specific evidence for efflux inhibition provided."
      },
      {
        "drug": "doxifluridine",
        "pathogen": "MRSA",
        "activity_type": "anti_virulence",
        "evidence_type": "none",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No evidence for anti-virulence activity provided."
      }
    ],
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed in the abstract, but likely involves direct bactericidal effects and biofilm disruption.",
    "relevance_score": 4,
    "paper_idx": 369,
    "pmid": "40025471",
    "title": "Nigella sativa monophosphoryl lipid A nanoliposome: a promising antibiotic alternative and immunomodulator to control virulent pandemic drug-resistant\u00a0Salmonella pullorum infection in broiler chicks.",
    "year": "2025",
    "doi": "10.1186/s12917-025-04473-w",
    "journal": "BMC veterinary research",
    "authors": [
      "Ahmad A",
      "Hussien E",
      "Elian A"
    ]
  },
  {
    "drugs": [
      {
        "name": "dexamethasone",
        "drug_class": "corticosteroid",
        "approved_for": "anti-inflammatory, immunosuppressant"
      },
      {
        "name": "tadalafil",
        "drug_class": "phosphodiesterase inhibitor",
        "approved_for": "erectile dysfunction, pulmonary hypertension"
      },
      {
        "name": "mefloquine",
        "drug_class": "antimalarial",
        "approved_for": "malaria"
      },
      {
        "name": "ergocalciferol",
        "drug_class": "vitamin D analog",
        "approved_for": "vitamin D deficiency"
      },
      {
        "name": "flunarizine",
        "drug_class": "calcium-entry blocker",
        "approved_for": "vertigo, migraine"
      }
    ],
    "pathogens": [
      {
        "name": "Lassa virus",
        "resistance_profile": "none specified"
      },
      {
        "name": "Lymphocytic choriomeningitis virus (LCMV)",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "flunarizine",
        "pathogen": "Lassa virus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Flunarizine inhibited LASV and LCMV ribonucleoprotein activity and reduced virus titers in cell-based assays."
      },
      {
        "drug": "flunarizine",
        "pathogen": "Lymphocytic choriomeningitis virus (LCMV)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Flunarizine significantly reduced peak titers of LCMV in human A549 cells."
      },
      {
        "drug": "dexamethasone",
        "pathogen": "Lassa virus",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to bind LASV proteins involved in viral replication, but no in vitro activity reported."
      },
      {
        "drug": "tadalafil",
        "pathogen": "Lassa virus",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to bind LASV proteins, potential for repurposing, but no experimental validation."
      },
      {
        "drug": "mefloquine",
        "pathogen": "Lassa virus",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted binding affinity to LASV proteins, no in vitro activity demonstrated."
      },
      {
        "drug": "ergocalciferol",
        "pathogen": "Lassa virus",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Predicted to bind LASV proteins, but no experimental data."
      }
    ],
    "mechanism": "Flunarizine likely inhibits mammarenavirus entry and replication by blocking calcium entry and interfering with calmodulin-mediated membrane fusion processes.",
    "relevance_score": 4,
    "paper_idx": 370,
    "pmid": "40048098",
    "title": "Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis.",
    "year": "2025",
    "doi": "10.1007/s10096-025-05062-3",
    "journal": "European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology",
    "authors": [
      "Quan D",
      "Wang T",
      "Martinez E"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 371,
    "pmid": "40056304",
    "title": "Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.1007/s10096-025-05090-z",
    "journal": "European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology",
    "authors": [
      "Kang Y",
      "Cui J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Disulfiram",
        "drug_class": "alcohol sobriety aid",
        "approved_for": "alcohol use disorder"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MRSA"
      }
    ],
    "findings": [
      {
        "drug": "Disulfiram",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Disulfiram inhibits the growth of S. aureus by inducing redox imbalance and perturbing central glucose metabolism."
      }
    ],
    "mechanism": "Disulfiram induces oxidative stress, chelates metals, inhibits oxidative phosphorylation, and disrupts glucose and CoA metabolism in S. aureus.",
    "relevance_score": 5,
    "paper_idx": 372,
    "pmid": "40074309",
    "title": "Synergistic antibacterial effects of pinaverium bromide and oxacillin against Staphylococcus epidermidis.",
    "year": "2024",
    "doi": "10.11817/j.issn.1672-7347.2024.240109",
    "journal": "Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences",
    "authors": [
      "Yuan L",
      "She P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Aztreonam",
        "drug_class": "monocyclic \u03b2-lactam",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ceftazidime",
        "drug_class": "cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Avibactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "combination with ceftazidime for bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR, carbapenem-resistant, metallo-\u03b2-lactamase producing"
      }
    ],
    "findings": [
      {
        "drug": "Aztreonam",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Aztreonam is stable against MBLs and effective when combined with avibactam to inhibit serine \u03b2-lactamases."
      },
      {
        "drug": "Ceftazidime",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ceftazidime alone is ineffective against MBL-producing K. pneumoniae, but its activity is restored when combined with avibactam."
      },
      {
        "drug": "Avibactam",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Avibactam inhibits serine \u03b2-lactamases, restoring activity of ceftazidime and protecting aztreonam from hydrolysis."
      },
      {
        "drug": "Ceftazidime/avibactam plus Aztreonam",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The combination shifts 62.5% of isolates from resistance to sensitivity against MBL-producing K. pneumoniae."
      }
    ],
    "mechanism": "Aztreonam is stable against MBL hydrolysis, and avibactam inhibits serine \u03b2-lactamases, allowing the combination to effectively target MBL-producing bacteria.",
    "relevance_score": 5,
    "paper_idx": 373,
    "pmid": "40076888",
    "title": "Improving Atorvastatin Release from Polyelectrolyte Complex-Based Hydrogels Using Freeze-Drying: Formulation and Pharmaceutical Assessment of a Novel Delivery System for Oral Candidiasis Treatment.",
    "year": "2025",
    "doi": "10.3390/ijms26052267",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Pota\u015b-Stobiecka J",
      "Wach R",
      "Rokita B"
    ]
  },
  {
    "drugs": [
      {
        "name": "tebipenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections (not specifically TB)"
      },
      {
        "name": "cephradine",
        "drug_class": "first-generation cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "cefdinir",
        "drug_class": "third-generation cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "cephalexin",
        "drug_class": "first-generation cephalosporin",
        "approved_for": "bacterial infections"
      },
      {
        "name": "clavulanate",
        "drug_class": "beta-lactamase inhibitor",
        "approved_for": "bacterial infections"
      },
      {
        "name": "rifampicin",
        "drug_class": "rifamycin antibiotic",
        "approved_for": "tuberculosis"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR (multi-drug resistant)"
      }
    ],
    "findings": [
      {
        "drug": "tebipenem",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tebipenem combined with rifampicin showed synergistic activity against MDR-TB in vitro, reducing effective drug doses."
      },
      {
        "drug": "cephradine",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cephradine combined with rifampicin demonstrated synergistic effects against MDR-TB in vitro, enabling dose reduction."
      },
      {
        "drug": "cef dinir",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "no_effect",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cefdinir did not show synergy with rifampicin against MDR-TB in vitro."
      },
      {
        "drug": "cefadroxil",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cefadroxil combined with rifampicin and clavulanate exhibited strong synergy against MDR-TB in vitro."
      },
      {
        "drug": "cephalexin",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Cephalexin combined with rifampicin and clavulanate showed strong synergy against MDR-TB in vitro."
      }
    ],
    "mechanism": "Beta-lactamase inhibition by clavulanate enhances the activity of beta-lactam antibiotics, and the combination with rifampicin exhibits synergistic antibacterial effects against MDR M. tuberculosis.",
    "relevance_score": 4,
    "paper_idx": 374,
    "pmid": "40143193",
    "title": "Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.",
    "year": "2025",
    "doi": "10.3390/ph18030417",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Altuwaijri N",
      "Fitaihi R",
      "Alkathiri F"
    ]
  },
  {
    "drugs": [
      {
        "name": "Atorvastatin",
        "drug_class": "statin",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Atorvastatin",
        "pathogen": "Methicillin-resistant Staphylococcus aureus (MRSA)",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Encapsulation of atorvastatin in nanostructured lipid carriers significantly enhanced its antibacterial activity and biofilm inhibition against MRSA."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ATR-loaded NLCs reduced MIC values and increased biofilm inhibition against E. coli, demonstrating improved antimicrobial efficacy."
      },
      {
        "drug": "Atorvastatin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ATR-NLCs showed increased biofilm inhibition (~80%) compared to free ATR (~20%) against S. aureus."
      }
    ],
    "mechanism": "Encapsulation in nanostructured lipid carriers enhances atorvastatin's stability, solubility, and delivery, thereby improving its ability to disrupt bacterial membranes and inhibit biofilm formation.",
    "relevance_score": 4,
    "paper_idx": 375,
    "pmid": "40295972",
    "title": "Comparative evaluation of five \u03b2-Lactamase inhibitors in combination with \u03b2-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.",
    "year": "2025",
    "doi": "10.1186/s12879-025-10730-y",
    "journal": "BMC infectious diseases",
    "authors": [
      "Shi J",
      "Zheng D",
      "Su R"
    ]
  },
  {
    "drugs": [
      {
        "name": "fosfomycin",
        "drug_class": "antibiotic",
        "approved_for": "uncomplicated cystitis"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "resistant in pneumonia"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "resistant in pneumonia"
      }
    ],
    "findings": [
      {
        "drug": "fosfomycin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A dose of 6 g q8h is recommended for P. aeruginosa pneumonia based on PTA analysis at the ELF site."
      },
      {
        "drug": "fosfomycin",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A dose of 4 g q8h is sufficient for S. aureus infections when plasma concentrations are used as efficacy indicator."
      }
    ],
    "mechanism": "Inhibition of bacterial cell wall synthesis via MurA enzyme inhibition",
    "relevance_score": 4,
    "paper_idx": 376,
    "pmid": "40307308",
    "title": "Platelet-rich plasma as a potential antimicrobial agent against multidrug-resistant bacteria in diabetic foot infections.",
    "year": "2025",
    "doi": "10.1038/s41598-025-97418-0",
    "journal": "Scientific reports",
    "authors": [
      "Aboelsaad E",
      "Moustafa S",
      "Amine A"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "MRSA",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "platelet-rich plasma",
        "pathogen": "MRSA",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PRP demonstrated transient antibacterial activity against MRSA, peaking at 2 hours with over 2 logs reduction in colony counts, but no activity observed at 24 hours."
      },
      {
        "drug": "platelet-rich plasma",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PRP showed transient antibacterial activity against K. pneumoniae, with peak effect at 1 hour and no activity at 24 hours."
      },
      {
        "drug": "platelet-rich plasma",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PRP exhibited transient antibacterial activity against P. aeruginosa, peaking at 2 hours with approximately 97% growth inhibition, but no activity at 24 hours."
      }
    ],
    "mechanism": "The proposed mechanism is that PRP releases growth factors and cytokines that transiently inhibit bacterial growth, though the exact antimicrobial mechanism remains unclear.",
    "relevance_score": 2,
    "paper_idx": 377,
    "pmid": "40323339",
    "title": "Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.",
    "year": "2025",
    "doi": "10.1128/aac.01869-24",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Al Hroot J",
      "Reeder J",
      "Yuan X"
    ]
  },
  {
    "drugs": [
      {
        "name": "Polymyxin B",
        "drug_class": "polymyxins",
        "approved_for": "bacterial infections, especially MDR Gram-negative bacteria"
      },
      {
        "name": "A22",
        "drug_class": "benzamide derivative (experimental compound)",
        "approved_for": "none (experimental candidate)"
      },
      {
        "name": "Niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "helminth infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa DK2",
        "resistance_profile": "MDR (multidrug-resistant)"
      },
      {
        "name": "A. baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Proteus mirabilis",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterobacter cloacae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Enterobacter asburiae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Serratia arcescens",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "A22",
        "pathogen": "Pseudomonas aeruginosa DK2",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A22 demonstrated potent synergistic activity with Polymyxin B against MDR P. aeruginosa DK2."
      },
      {
        "drug": "A22",
        "pathogen": "Pseudomonas aeruginosa DK2",
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo studies confirmed the efficacy of A22 in combination with Polymyxin B in mouse and C. elegans models."
      },
      {
        "drug": "A22",
        "pathogen": "Pseudomonas aeruginosa DK2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A22 enhances polymyxin activity by inducing reactive oxygen species, reducing ATP, increasing NOX activity, and inhibiting biofilm formation."
      },
      {
        "drug": "A22",
        "pathogen": "various MDR Gram-negative bacteria",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "A22 exhibits broad-spectrum synergism with polymyxins against multiple clinically isolated MDR Gram-negative strains."
      },
      {
        "drug": "Niclosamide",
        "pathogen": "Pseudomonas aeruginosa DK2",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide was previously identified as an adjuvant for Polymyxin B, leading to the development of compound 15."
      }
    ],
    "mechanism": "A22 enhances polymyxin activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death.",
    "relevance_score": 5,
    "paper_idx": 378,
    "pmid": "40325037",
    "title": "Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus.",
    "year": "2025",
    "doi": "10.1038/s41598-025-00078-3",
    "journal": "Scientific reports",
    "authors": [
      "Long T",
      "Naidu S",
      "Hissom E"
    ]
  },
  {
    "drugs": [
      {
        "name": "imipenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "meropenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "doripenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "ertapenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "biapenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "tebipenem",
        "drug_class": "carbapenem",
        "approved_for": "bacterial infections"
      },
      {
        "name": "clavulanic acid",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "bacterial infections"
      },
      {
        "name": "tazobactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "bacterial infections"
      },
      {
        "name": "sulbactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "bacterial infections"
      },
      {
        "name": "avibactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "bacterial infections"
      },
      {
        "name": "relebactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium tuberculosis",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "tebipenem",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "Tebipenem showed the most effective activity against MDR-TB with an MIC90 of 16 \u00b5g/ml."
      },
      {
        "drug": "clavulanic acid",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clavulanic acid demonstrated strong synergy with tebipenem, reducing MIC values 32-fold in some strains."
      },
      {
        "drug": "tazobactam",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tazobactam showed significant synergy with tebipenem, with up to 20 strains experiencing a 32-fold MIC reduction."
      },
      {
        "drug": "sulbactam",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sulbactam combined with tebipenem resulted in a 32-fold MIC reduction in 20 strains."
      },
      {
        "drug": "avibactam",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Avibactam enhanced the activity of \u03b2-lactams, notably reducing MICs more effectively than some other inhibitors."
      },
      {
        "drug": "relebactam",
        "pathogen": "Mycobacterium tuberculosis",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Relebactam showed potential as a \u03b2-lactamase inhibitor, improving \u03b2-lactam activity against MDR-TB strains."
      }
    ],
    "mechanism": "\u03b2-lactamase inhibitors enhance the activity of \u03b2-lactam antibiotics by inhibiting the BlaC enzyme in M. tuberculosis, restoring the efficacy of carbapenems.",
    "relevance_score": 4,
    "paper_idx": 379,
    "pmid": "40341530",
    "title": "Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.",
    "year": "2025",
    "doi": "10.1038/s41598-025-01303-9",
    "journal": "Scientific reports",
    "authors": [
      "Chatupheeraphat C",
      "Kaewsai N",
      "Anuwongcharoen N"
    ]
  },
  {
    "drugs": [
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression, organ transplantation"
      },
      {
        "name": "trametinib",
        "drug_class": "MEK inhibitor",
        "approved_for": "melanoma"
      }
    ],
    "pathogens": [],
    "findings": [
      {
        "drug": "trametinib",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Trametinib extends lifespan in mice and reduces age-related tumors and inflammation."
      },
      {
        "drug": "rapamycin",
        "pathogen": null,
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Rapamycin extends lifespan and ameliorates aging-related morbidities in mice."
      },
      {
        "drug": "trametinib",
        "pathogen": null,
        "activity_type": "synergy",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combined trametinib and rapamycin treatment produces additive lifespan extension in mice."
      }
    ],
    "mechanism": "Inhibition of Ras-MEK-ERK pathway by trametinib and mTORC1 signaling by rapamycin, reducing tumor formation and inflammation associated with aging.",
    "relevance_score": 4,
    "paper_idx": 380,
    "pmid": "40362592",
    "title": "Exploring Nepicastat Activity: Beyond D\u03b2H.",
    "year": "2025",
    "doi": "10.3390/ijms26094356",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Jas R",
      "Bauer M",
      "Grodner B"
    ]
  },
  {
    "drugs": [
      {
        "name": "Colistin",
        "drug_class": "Polymyxins",
        "approved_for": "Serious infections caused by multidrug-resistant Gram-negative bacteria"
      }
    ],
    "pathogens": [
      {
        "name": "Enterobacterales",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii complex",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "Colistin",
        "pathogen": "Enterobacterales",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Early differentiation between colistin-sensitive and resistant strains can be achieved within 2 hours using microfluidics-based imaging techniques."
      },
      {
        "drug": "Colistin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Time-kill assays showed significant bacterial count reduction in colistin-sensitive strains at 2, 4, and 8 hours."
      },
      {
        "drug": "Colistin",
        "pathogen": "Acinetobacter baumannii complex",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Colistin demonstrated bactericidal activity in susceptible strains within 8 hours in time-kill assays."
      }
    ],
    "mechanism": "Disruption of bacterial cell membrane integrity by binding to lipopolysaccharides, leading to cell death.",
    "relevance_score": 4,
    "paper_idx": 381,
    "pmid": "40367640",
    "title": "Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-\u03b2-lactamases inhibitor.",
    "year": "2025",
    "doi": "10.1016/j.ebiom.2025.105754",
    "journal": "EBioMedicine",
    "authors": [
      "Zhang Y",
      "Yang S",
      "Deng Z"
    ]
  },
  {
    "drugs": [
      {
        "name": "disulfiram",
        "drug_class": "alcohol aversion therapy agent",
        "approved_for": "alcohol dependence"
      },
      {
        "name": "nepicastat",
        "drug_class": "selective dopamine beta-hydroxylase (D\u03b2H) inhibitor",
        "approved_for": "not approved; investigational"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "sensitive to NEP at 64 \u00b5g/mL"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "not sensitive to NEP"
      }
    ],
    "findings": [
      {
        "drug": "nepicastat",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "antimicrobial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 64,
        "fici": null,
        "key_result": "NEP exhibited weak antimicrobial activity against S. aureus at 64 \u00b5g/mL."
      },
      {
        "drug": "nepicastat",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "antimicrobial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NEP was not effective against P. aeruginosa."
      },
      {
        "drug": "nepicastat",
        "pathogen": "not applicable",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "NEP inhibits acetylcholinesterase activity, indicating potential anti-virulence effects."
      }
    ],
    "mechanism": "Inhibition of acetylcholinesterase activity and modulation of dopamine and noradrenaline pathways.",
    "relevance_score": 2,
    "paper_idx": 382,
    "pmid": "40370545",
    "title": "Discovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation.",
    "year": "2025",
    "doi": "10.1016/j.apsb.2025.01.022",
    "journal": "Acta pharmaceutica Sinica. B",
    "authors": [
      "Lu T",
      "Han H",
      "Wu C"
    ]
  },
  {
    "drugs": [
      {
        "name": "Green tea extract-capped silver nanoparticles (G-TeaNPs)",
        "drug_class": "nanoparticle",
        "approved_for": "none"
      }
    ],
    "pathogens": [
      {
        "name": "Methicillin-resistant Staphylococcus aureus",
        "resistance_profile": "MRSA"
      },
      {
        "name": "Salmonella enterica",
        "resistance_profile": "none specified"
      }
    ],
    "findings": [
      {
        "drug": "G-TeaNPs",
        "pathogen": "Methicillin-resistant Staphylococcus aureus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 1,
        "fici": null,
        "key_result": "G-TeaNPs significantly reduce S. aureus survival to around 30% at 0.001 mg/mL concentration."
      },
      {
        "drug": "G-TeaNPs",
        "pathogen": "Salmonella enterica",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "G-TeaNPs combined with phages enhance antibacterial activity against S. enterica."
      },
      {
        "drug": "G-TeaNPs",
        "pathogen": "Acanthamoeba castellanii",
        "activity_type": "anti_amoebic",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "G-TeaNPs reduce A. castellanii cell counts by 80% at high concentrations, showing amoebicidal activity."
      }
    ],
    "mechanism": "Polyphenols in green tea extract reduce silver ions to form stable silver nanoparticles with antimicrobial properties; nanoparticles may also cause intracellular accumulation and vacuolization in amoebae.",
    "relevance_score": 4,
    "paper_idx": 383,
    "pmid": "40380090",
    "title": "Fingolimod as a potent anti-Staphylococcus aureus: pH-dependent cell envelope damage and eradication of biofilms/persisters.",
    "year": "2025",
    "doi": "10.1186/s12866-025-03973-x",
    "journal": "BMC microbiology",
    "authors": [
      "Shang Y",
      "Huang Y",
      "Meng Q"
    ]
  },
  {
    "drugs": [
      {
        "name": "fendiline",
        "drug_class": "calcium channel blocker",
        "approved_for": "angina pectoris"
      },
      {
        "name": "lomerizine",
        "drug_class": "calcium channel blocker",
        "approved_for": "migraine"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "carbapenem-resistant"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "fendiline",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fendiline exhibits antimicrobial activity against A. baumannii, especially strains overexpressing OXA-23, by targeting lipoprotein trafficking."
      },
      {
        "drug": "fendiline",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Fendiline enhances susceptibility of E. coli to other antibiotics by inhibiting efflux and lipoprotein trafficking."
      },
      {
        "drug": "abaucin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Overexpression of lolFD confers resistance to abaucin, supporting its targeting of lipoprotein trafficking."
      }
    ],
    "mechanism": "Fendiline inhibits the lipoprotein trafficking pathway (Lol pathway), specifically targeting LolF and/or LolD, which stresses the cell envelope and enhances susceptibility in OXA-23 overexpressing A. baumannii.",
    "relevance_score": 4,
    "paper_idx": 384,
    "pmid": "40437307",
    "title": "The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan.",
    "year": "2025",
    "doi": "10.1038/s43587-025-00876-4",
    "journal": "Nature aging",
    "authors": [
      "Gkioni L",
      "Nespital T",
      "Baghdadi M"
    ]
  },
  {
    "drugs": [
      {
        "name": "Penfluridol",
        "drug_class": "antipsychotic",
        "approved_for": "psychosis, schizophrenia, Tourette syndrome"
      },
      {
        "name": "Colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "severe MDR-GNB infections"
      }
    ],
    "pathogens": [
      {
        "name": "Gram-negative bacilli",
        "resistance_profile": "colistin-resistant (COL-R)"
      }
    ],
    "findings": [
      {
        "drug": "Penfluridol",
        "pathogen": "Gram-negative bacilli",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Penfluridol synergizes with colistin to restore activity against colistin-resistant Gram-negative bacteria."
      },
      {
        "drug": "Colistin",
        "pathogen": "Gram-negative bacilli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Colistin's efficacy is significantly enhanced when combined with penfluridol against resistant strains."
      }
    ],
    "mechanism": "Penfluridol enhances colistin's ability to disrupt bacterial membranes, likely by increasing membrane permeability and facilitating colistin binding to lipopolysaccharides, thereby restoring colistin activity against resistant bacteria.",
    "relevance_score": 4,
    "paper_idx": 385,
    "pmid": "40442509",
    "title": "Phage/nanoparticle cocktails for a biocompatible and environmentally friendly antibacterial therapy.",
    "year": "2025",
    "doi": "10.1007/s00253-025-13526-x",
    "journal": "Applied microbiology and biotechnology",
    "authors": [
      "Wdowiak M",
      "Raza S",
      "Grotek M"
    ]
  },
  {
    "drugs": [
      {
        "name": "tavaborole",
        "drug_class": "benzoxaborole antifungal",
        "approved_for": "antifungal"
      }
    ],
    "pathogens": [
      {
        "name": "bacteria producing serine \u03b2-lactamases (SBLs, e.g., KPC)",
        "resistance_profile": "carbapenem-resistant Enterobacteriaceae"
      },
      {
        "name": "bacteria producing metallo-\u03b2-lactamases (MBLs, e.g., NDM)",
        "resistance_profile": "carbapenem-resistant Enterobacteriaceae"
      }
    ],
    "findings": [
      {
        "drug": "tavaborole",
        "pathogen": "bacteria producing SBLs or MBLs",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tavaborole enhances the activity of \u03b2-lactam antibiotics against bacteria producing serine and metallo-\u03b2-lactamases."
      },
      {
        "drug": "tavaborole",
        "pathogen": "bacteria producing SBLs or MBLs",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo, tavaborole restored the efficacy of meropenem against resistant bacterial infections in a mouse model."
      }
    ],
    "mechanism": "Tavaborole inhibits SBLs by covalently bonding with the active serine residue and inhibits MBLs by chelating the zinc ions at the active center.",
    "relevance_score": 5,
    "paper_idx": 386,
    "pmid": "40493197",
    "title": "Repurposing a drug to punish carbapenem-resistant Acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1073/pnas.2423650122",
    "journal": "Proceedings of the National Academy of Sciences of the United States of America",
    "authors": [
      "Colquhoun J",
      "Brzezinski C",
      "Ji A"
    ]
  },
  {
    "drugs": [
      {
        "name": "chlorpromazine",
        "drug_class": "phenothiazine",
        "approved_for": "schizophrenia, psychosis, antiemetic"
      },
      {
        "name": "thioridazine",
        "drug_class": "phenothiazine",
        "approved_for": "schizophrenia"
      },
      {
        "name": "promethazine",
        "drug_class": "phenothiazine",
        "approved_for": "allergy, nausea, motion sickness"
      },
      {
        "name": "fluphenazine",
        "drug_class": "phenothiazine",
        "approved_for": "schizophrenia"
      },
      {
        "name": "trifluoperazine",
        "drug_class": "phenothiazine",
        "approved_for": "schizophrenia"
      },
      {
        "name": "prochlorperazine",
        "drug_class": "phenothiazine",
        "approved_for": "nausea, vomiting, schizophrenia"
      },
      {
        "name": "promethazine",
        "drug_class": "phenothiazine",
        "approved_for": "allergy, nausea, motion sickness"
      }
    ],
    "pathogens": [
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      },
      {
        "name": "Escherichia coli",
        "resistance_profile": "MDR"
      },
      {
        "name": "Burkholderia pseudomallei",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "chlorpromazine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine inhibits bacterial efflux pumps, restoring antibiotic susceptibility in MDR strains."
      },
      {
        "drug": "thioridazine",
        "pathogen": "Escherichia coli",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine enhances antibiotic efficacy by inhibiting bacterial efflux pumps, restoring susceptibility in MDR E. coli."
      },
      {
        "drug": "chlorpromazine",
        "pathogen": "Burkholderia pseudomallei",
        "activity_type": "efflux_inhibitor",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine disrupts bacterial membranes and efflux mechanisms, improving antibiotic activity against B. pseudomallei."
      },
      {
        "drug": "chlorpromazine",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Chlorpromazine synergizes with antibiotics like ampicillin and ciprofloxacin to combat MDR S. aureus."
      }
    ],
    "mechanism": "Phenothiazines inhibit bacterial efflux pumps, disrupt bacterial membranes, and modulate host cell pathways, thereby restoring antibiotic susceptibility and exerting direct antibacterial effects.",
    "relevance_score": 4,
    "paper_idx": 387,
    "pmid": "40539807",
    "title": "VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections.",
    "year": "2025",
    "doi": "10.1128/spectrum.00719-25",
    "journal": "Microbiology spectrum",
    "authors": [
      "Oh J",
      "Choi S",
      "Seo H"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 388,
    "pmid": "40548752",
    "title": "Pentamidine inhibition of streptopain attenuates Streptococcus pyogenes virulence.",
    "year": "2025",
    "doi": "10.1128/spectrum.00758-25",
    "journal": "Microbiology spectrum",
    "authors": [
      "Trivedi K",
      "LaRock C"
    ]
  },
  {
    "drugs": [
      {
        "name": "antimicrobial peptides (AMPs)",
        "drug_class": "peptides",
        "approved_for": "not specified (experimental/novel agents)"
      }
    ],
    "pathogens": [
      {
        "name": "Candida auris",
        "resistance_profile": "multidrug resistant (MDR)"
      },
      {
        "name": "Aspergillus fumigatus",
        "resistance_profile": "azole resistant, MDR"
      },
      {
        "name": "Cryptococcus neoformans",
        "resistance_profile": "growing resistance to azoles, MDR"
      },
      {
        "name": "Candida albicans",
        "resistance_profile": "not specified, generally MDR"
      }
    ],
    "findings": [
      {
        "drug": "antimicrobial peptides (AMPs)",
        "pathogen": "C. auris",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AMPs show broad-spectrum antifungal activity and potential to overcome resistance in critical fungal pathogens."
      },
      {
        "drug": "antimicrobial peptides (AMPs)",
        "pathogen": "A. fumigatus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AMPs such as hLF(1\u201311) and dhvar5 demonstrate activity against A. fumigatus conidia, including resistant strains."
      },
      {
        "drug": "antimicrobial peptides (AMPs)",
        "pathogen": "C. neoformans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AMPs are promising candidates for targeting resistant C. neoformans, with potential to bypass traditional resistance mechanisms."
      }
    ],
    "mechanism": "broad-spectrum membrane disruption, immune modulation, and interference with virulence factors",
    "relevance_score": 5,
    "paper_idx": 389,
    "pmid": "40565013",
    "title": "Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving \u03b2-Lactamases and Efflux Pumps.",
    "year": "2025",
    "doi": "10.3390/ijms26125550",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Zai M",
      "Cock I",
      "Cheesman M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 390,
    "pmid": "40572115",
    "title": "Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against Klebsiella pneumoniae and Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/microorganisms13061227",
    "journal": "Microorganisms",
    "authors": [
      "Lutfi L",
      "Shaldam M",
      "Shaaban M"
    ]
  },
  {
    "drugs": [
      {
        "name": "curcumin",
        "drug_class": "phytopolyphenol",
        "approved_for": "none (experimental in this context)"
      },
      {
        "name": "green tea polyphenols",
        "drug_class": "phytopolyphenol",
        "approved_for": "none (experimental in this context)"
      },
      {
        "name": "memantine",
        "drug_class": "NMDA receptor antagonist",
        "approved_for": "dementia"
      },
      {
        "name": "thioridazine",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia"
      },
      {
        "name": "cisplatin",
        "drug_class": "alkylating agent",
        "approved_for": "various cancers"
      },
      {
        "name": "5-fluorouracil",
        "drug_class": "antimetabolite",
        "approved_for": "various cancers"
      },
      {
        "name": "ZnSO4",
        "drug_class": "metal ion supplement",
        "approved_for": "none (used as supplement/experimental)"
      }
    ],
    "pathogens": [
      {
        "name": "Porphyromonas gingivalis",
        "resistance_profile": "MDR"
      },
      {
        "name": "Streptococcus mutans",
        "resistance_profile": "none specified"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "cisplatin",
        "pathogen": "none",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PTM regimens significantly enhance the anticancer efficacy of cisplatin and inhibit biofilm formation, suggesting potential to address multidrug resistance."
      },
      {
        "drug": "5-fluorouracil",
        "pathogen": "none",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "PTM regimens significantly enhance the efficacy of 5-fluorouracil against cancer cells and inhibit biofilm formation."
      },
      {
        "drug": "memantine",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Memantine in combination with phytopolyphenols enhances anticancer effects and inhibits ATPase activity."
      },
      {
        "drug": "thioridazine",
        "pathogen": "none",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Thioridazine combined with phytopolyphenols shows synergistic anticancer effects and biofilm inhibition."
      }
    ],
    "mechanism": "Inhibition of efflux pump ATPase activity, synergistic enhancement of chemotherapeutic efficacy, and antibiofilm activity against pathogens.",
    "relevance_score": 4,
    "paper_idx": 391,
    "pmid": "40612861",
    "title": "Synergistic anticancer and antibacterial effects of novel regimens of phytopolyphenols and repurposing drugs on cultured cells.",
    "year": "2025",
    "doi": "10.32604/or.2025.063717",
    "journal": "Oncology research",
    "authors": [
      "Yeh Y",
      "Wang Y",
      "Lin-Shiau S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 392,
    "pmid": "40621353",
    "title": "A \"Time-Kill\" Study to Assess the Effect of Colistin on Gram-Negative Strains: An Experimental Study for Developing an Indigenous Microfluidics-Based Antimicrobial Susceptibility Testing Device.",
    "year": "2025",
    "doi": "10.7759/cureus.85321",
    "journal": "Cureus",
    "authors": [
      "Bajaj E",
      "Gupta A",
      "Purwar S"
    ]
  },
  {
    "drugs": [
      {
        "name": "benzbromarone",
        "drug_class": "uricosuric agent",
        "approved_for": "gout"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "multi-drug resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "MDR"
      },
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      },
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "benzbromarone",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Benzbromarone alone had no antibacterial effect but significantly lowered the MIC of colistin, demonstrating strong synergy."
      },
      {
        "drug": "benzbromarone",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Benzbromarone enhanced colistin activity against A. baumannii, reducing bacterial growth when combined."
      },
      {
        "drug": "benzbromarone",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Benzbromarone significantly improved colistin efficacy against P. aeruginosa, despite high resistance levels."
      },
      {
        "drug": "colistin",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 4,
        "fici": null,
        "key_result": "Colistin alone showed high resistance with MIC \u22654 \u03bcg/mL, but its activity was enhanced in combination with benzbromarone."
      },
      {
        "drug": "colistin",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Colistin resistance was observed with MIC up to 16 \u03bcg/mL, but combination therapy improved efficacy."
      },
      {
        "drug": "colistin",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 32,
        "fici": null,
        "key_result": "High resistance to colistin (MIC=32 \u03bcg/mL) was observed, but synergy with benzbromarone restored activity."
      }
    ],
    "mechanism": "Benzbromarone synergistically enhances bacterial membrane damage, promotes ROS accumulation, and inhibits ATP production when combined with colistin, leading to increased bactericidal activity.",
    "relevance_score": 5,
    "paper_idx": 393,
    "pmid": "40661217",
    "title": "Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.",
    "year": "2025",
    "doi": "10.1039/d5ra04047g",
    "journal": "RSC advances",
    "authors": [
      "Elkady H",
      "Salman I",
      "Khalifa M"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 394,
    "pmid": "40718442",
    "title": "Therapeutic Mechanisms of Phenothiazine Drugs: A Mini-Review of Advances in Cancer Treatment and Antibiotic Resistance.",
    "year": "2025",
    "doi": "10.5812/ijpr-157923",
    "journal": "Iranian journal of pharmaceutical research : IJPR",
    "authors": [
      "Zou X",
      "Xie B"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 395,
    "pmid": "40884276",
    "title": "Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.",
    "year": "2025",
    "doi": "10.1002/advs.202509567",
    "journal": "Advanced science (Weinheim, Baden-Wurttemberg, Germany)",
    "authors": [
      "Roque-Borda C",
      "Medina-Alarc\u00f3n K",
      "Gon\u00e7alves Pereira J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Pentamidine",
        "drug_class": "antiprotozoal/antimicrobial",
        "approved_for": "Pneumocystis pneumonia, leishmaniasis, trypanosomiasis"
      }
    ],
    "pathogens": [
      {
        "name": "Streptococcus pyogenes",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "Pentamidine",
        "pathogen": "Streptococcus pyogenes",
        "activity_type": "adjuvant|anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Pentamidine inhibits the virulence factor streptopain (SpeB) of GAS, rendering the bacteria more susceptible to immune killing."
      }
    ],
    "mechanism": "Pentamidine directly inhibits the cysteine protease SpeB by occupying its substrate pocket, interfering with its proteolytic activity.",
    "relevance_score": 4,
    "paper_idx": 396,
    "pmid": "40911556",
    "title": "In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.",
    "year": "2025",
    "doi": "10.1371/journal.pone.0331440",
    "journal": "PloS one",
    "authors": [
      "Klose M",
      "Weber L",
      "Bachmann H"
    ]
  },
  {
    "drugs": [
      {
        "name": "Ilaprazole",
        "drug_class": "Proton Pump Inhibitor",
        "approved_for": "gastric ulcer, duodenal ulcer, gastroesophageal reflux disease, erosive esophagitis"
      },
      {
        "name": "Clarithromycin",
        "drug_class": "Macrolide antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Amoxicillin",
        "drug_class": "Penicillin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Bismuth potassium citrate",
        "drug_class": "Bismuth compound",
        "approved_for": "H. pylori eradication"
      }
    ],
    "pathogens": [
      {
        "name": "Helicobacter pylori",
        "resistance_profile": "drug-resistant strains including clarithromycin, amoxicillin, metronidazole, levofloxacin resistant"
      }
    ],
    "findings": [
      {
        "drug": "Ilaprazole",
        "pathogen": "Helicobacter pylori",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Ilaprazole exhibits potent in vitro antibacterial activity against H. pylori with MIC50 and MIC90 values of 8 \u00b5g/mL, including drug-resistant strains."
      },
      {
        "drug": "Clarithromycin",
        "pathogen": "Helicobacter pylori",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clarithromycin resistance was present in some strains, but the study focused on ilaprazole's activity."
      },
      {
        "drug": "Amoxicillin",
        "pathogen": "Helicobacter pylori",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Some strains resistant to amoxicillin were included; ilaprazole showed activity against resistant strains."
      },
      {
        "drug": "Bismuth potassium citrate",
        "pathogen": "Helicobacter pylori",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 8,
        "fici": null,
        "key_result": "Bismuth potassium citrate demonstrated excellent in vitro antibacterial effects with MICs ranging from 2 to 8 \u00b5g/mL."
      }
    ],
    "mechanism": "The proposed mechanism includes direct antibacterial activity of ilaprazole against H. pylori and synergistic effects when combined with antibiotics like clarithromycin.",
    "relevance_score": 4,
    "paper_idx": 397,
    "pmid": "40931324",
    "title": "Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies.",
    "year": "2025",
    "doi": "10.1111/fcp.70046",
    "journal": "Fundamental & clinical pharmacology",
    "authors": [
      "E Silva D",
      "de Souza Lacerda L",
      "de Souza Andrioli A"
    ]
  },
  {
    "drugs": [
      {
        "name": "cefepime",
        "drug_class": "beta-lactam antibiotic",
        "approved_for": "bacterial infections, including pneumonia and urinary tract infections"
      },
      {
        "name": "meropenem",
        "drug_class": "carbapenem antibiotic",
        "approved_for": "complicated bacterial infections, including urinary tract infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "cefepime",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sub-inhibitory concentrations of cefepime combined with bacteriophages PAA and PAM exhibited synergistic effects against P. aeruginosa."
      },
      {
        "drug": "meropenem",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sub-inhibitory concentrations of meropenem combined with bacteriophages PAA and PAM showed synergistic antibacterial activity against P. aeruginosa."
      }
    ],
    "mechanism": "The phage-antibiotic synergy likely results from combined bactericidal effects and enhanced phage replication in the presence of antibiotics, leading to improved bacterial eradication and biofilm disruption.",
    "relevance_score": 4,
    "paper_idx": 398,
    "pmid": "40971029",
    "title": "A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1007/s00430-025-00854-y",
    "journal": "Medical microbiology and immunology",
    "authors": [
      "Diepoltov\u00e1 A",
      "Nawrot D",
      "Jan\u010fourek O"
    ]
  },
  {
    "drugs": [
      {
        "name": "meropenem-vaborbactam",
        "drug_class": "\u03b2-lactam/\u03b2-lactamase inhibitor combination",
        "approved_for": "complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired pneumonia"
      },
      {
        "name": "eravacycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "complicated intra-abdominal infections"
      },
      {
        "name": "gentamicin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections including sepsis, endocarditis, and urinary tract infections"
      },
      {
        "name": "ceftazidime",
        "drug_class": "third-generation cephalosporin",
        "approved_for": "respiratory tract infections, urinary tract infections, skin infections, and meningitis"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "carbapenem-resistant (CRAB), extensively drug-resistant (XDR)"
      }
    ],
    "findings": [
      {
        "drug": "meropenem-vaborbactam",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Meropenem-vaborbactam combined with ceftazidime showed synergy in 45.5% of XDR CRAB isolates."
      },
      {
        "drug": "meropenem-vaborbactam",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.5,
        "key_result": "Meropenem-vaborbactam combined with gentamicin showed synergy in 36.4% of XDR CRAB isolates."
      },
      {
        "drug": "eravacycline",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.125,
        "fici": null,
        "key_result": "Eravacycline demonstrated potent in vitro activity with MIC50 of 0.125 \u03bcg/mL against CRAB."
      }
    ],
    "mechanism": "Synergistic effects of \u03b2-lactamase inhibition by vaborbactam combined with carbapenem and other antibiotics, as well as eravacycline's inhibition of bacterial protein synthesis.",
    "relevance_score": 4,
    "paper_idx": 399,
    "pmid": "40990560",
    "title": "In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.",
    "year": "2025",
    "doi": "10.1128/spectrum.00593-25",
    "journal": "Microbiology spectrum",
    "authors": [
      "Zhang Z",
      "Yang L",
      "Sun W"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 400,
    "pmid": "41001392",
    "title": "Antimicrobial effect of benzbromarone combined with colistin against multidrug-resistant bacteria.",
    "year": "2025",
    "doi": "10.3389/fmed.2025.1665514",
    "journal": "Frontiers in medicine",
    "authors": [
      "Wang F",
      "Li H",
      "Bao X"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Shigella sonnei",
        "resistance_profile": "AMR/MDR"
      },
      {
        "name": "Salmonella enterica",
        "resistance_profile": "AMR/MDR"
      }
    ],
    "findings": [
      {
        "drug": "phage cocktail",
        "pathogen": "Shigella sonnei",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The phage cocktail effectively lysed Shigella sonnei and disrupted its biofilms in vitro."
      },
      {
        "drug": "phage cocktail",
        "pathogen": "Salmonella enterica",
        "activity_type": "direct_antibacterial|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "The phage cocktail demonstrated activity against Salmonella enterica and its biofilms in vitro."
      }
    ],
    "mechanism": "bacteriophage-mediated lysis and biofilm degradation",
    "relevance_score": 5,
    "paper_idx": 401,
    "pmid": "41025659",
    "title": "Beyond antiparasitic activity: elucidating the antibacterial potency of pyrvinium pamoate.",
    "year": "2025",
    "doi": "10.1128/spectrum.02158-25",
    "journal": "Microbiology spectrum",
    "authors": [
      "Alcaraz-Mart\u00ednez A",
      "Mu\u00f1oz-B\u00e1ez P",
      "Pe\u00f1alver P"
    ]
  },
  {
    "drugs": [
      {
        "name": "Statins",
        "drug_class": "HMG-CoA reductase inhibitors",
        "approved_for": "hypercholesterolemia"
      }
    ],
    "pathogens": [
      {
        "name": "Candida albicans",
        "resistance_profile": "antifungal resistance, biofilm formation, ERG11 mutations, efflux pump activation"
      }
    ],
    "findings": [
      {
        "drug": "Statins",
        "pathogen": "Candida albicans",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Statins have demonstrated potential to interfere with fungal ergosterol biosynthesis and Ras-mediated signaling pathways, suggesting antifungal activity."
      }
    ],
    "mechanism": "Inhibition of fungal ergosterol biosynthesis and Ras-mediated signaling pathways.",
    "relevance_score": 4,
    "paper_idx": 402,
    "pmid": "41028326",
    "title": "In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii.",
    "year": "2025",
    "doi": "10.1038/s41598-025-19642-y",
    "journal": "Scientific reports",
    "authors": [
      "El-Ashry A",
      "Abdrabou A",
      "El-Tantawy N"
    ]
  },
  {
    "drugs": [
      {
        "name": "colistin",
        "drug_class": "polymyxin",
        "approved_for": "multi-drug resistant Gram-negative bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "AB15",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant|anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "AB15 exhibits bactericidal activity and enhances the antibacterial effect of colistin against MDR Acinetobacter baumannii, including suppression of biofilm dissemination."
      }
    ],
    "mechanism": "proposed mechanism of antimicrobial action: not explicitly detailed, but suggests adjuvant activity that reduces resistance risk and enhances colistin efficacy",
    "relevance_score": 5,
    "paper_idx": 403,
    "pmid": "41039237",
    "title": "Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample.",
    "year": "2025",
    "doi": "10.1186/s12866-025-04195-x",
    "journal": "BMC microbiology",
    "authors": [
      "Nawaz A",
      "Khalid N",
      "Majid A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 404,
    "pmid": "41059697",
    "title": "Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates.",
    "year": "2025",
    "doi": "10.1128/spectrum.02250-25",
    "journal": "Microbiology spectrum",
    "authors": [
      "Wu J",
      "Ji Y",
      "Zhang W"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 405,
    "pmid": "41068567",
    "title": "Utilizing the effectiveness of phage cocktail to combat Shigella and Salmonella infections and their polymicrobial biofilm control activity.",
    "year": "2025",
    "doi": "10.1186/s12866-025-04328-2",
    "journal": "BMC microbiology",
    "authors": [
      "Mondal P",
      "Mallick B",
      "Haldar T"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 406,
    "pmid": "41104381",
    "title": "Meclizine and Cephalosporin Combination as Promising Antibiotic Drugs: Formulation, Antimicrobial, and In Silico Studies.",
    "year": "2025",
    "doi": "10.1155/adpp/8972067",
    "journal": "Advances in pharmacological and pharmaceutical sciences",
    "authors": [
      "Al-Madhagi W",
      "Alkhawlani M",
      "Sabati A"
    ]
  },
  {
    "drugs": [
      {
        "name": "flupentixol",
        "drug_class": "antipsychotic",
        "approved_for": "schizophrenia, depression"
      },
      {
        "name": "ciprofloxacin",
        "drug_class": "fluoroquinolone antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR"
      },
      {
        "name": "Staphylococcus aureus",
        "resistance_profile": "MDR"
      },
      {
        "name": "Shigella boydii",
        "resistance_profile": "MDR"
      }
    ],
    "findings": [
      {
        "drug": "flupentixol",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro|in_vivo|in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Flupentixol inhibits bacterial efflux pumps and synergizes with ciprofloxacin to enhance antibacterial activity."
      },
      {
        "drug": "flupentixol",
        "pathogen": "Staphylococcus aureus",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro|in_vivo|in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Molecular docking and in vitro tests suggest flupentixol inhibits NorA efflux pump, potentiating ciprofloxacin efficacy."
      },
      {
        "drug": "flupentixol",
        "pathogen": "Shigella boydii",
        "activity_type": "efflux_inhibitor|synergy",
        "evidence_type": "in_vitro|in_vivo|in_silico",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Combination therapy with flupentixol reduces inflammation and bacterial load in a mouse shigellosis model."
      }
    ],
    "mechanism": "Inhibition of bacterial efflux pumps, particularly NorA, MexA, and AcrB, by flupentixol, leading to increased intracellular antibiotic concentration and restored efficacy.",
    "relevance_score": 4,
    "paper_idx": 407,
    "pmid": "41148680",
    "title": "Repurposed Drugs and Efflux Pump Inhibitors Against Gram-Negative Urinary Tract Pathogenic Bacteria.",
    "year": "2025",
    "doi": "10.3390/antibiotics14100988",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Kincses A",
      "Nov\u00e9 M",
      "Asefi J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 408,
    "pmid": "41155139",
    "title": "Permeabilize, but Choose Wisely: Selective Antibiotic Potentiation Through Outer Membrane Disruption in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/ijms26209844",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Novelli M",
      "Brunel J"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 409,
    "pmid": "41155175",
    "title": "Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance.",
    "year": "2025",
    "doi": "10.3390/ijms26209880",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Tiwana G",
      "Cock I",
      "Taylor S"
    ]
  },
  {
    "drugs": [
      {
        "name": "MK-8245",
        "drug_class": "initially developed for metabolic disorders, antidiabetic agent",
        "approved_for": "type 2 diabetes"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "MDR (multidrug-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "MK-8245",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_virulence",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 40,
        "fici": null,
        "key_result": "MK-8245 inhibits quorum sensing and reduces virulence factor production without affecting bacterial viability."
      },
      {
        "drug": "MK-8245",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MK-8245 enhances the efficacy of imipenem against biofilms."
      },
      {
        "drug": "MK-8245",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MK-8245 significantly reduces biofilm formation and residual biofilm biomass."
      },
      {
        "drug": "MK-8245",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MK-8245 improves survival in Galleria mellonella infection model, indicating potential as an adjunct therapy."
      }
    ],
    "mechanism": "Competitive antagonism of RhlR receptor, disrupting quorum sensing signaling and downstream virulence factor expression.",
    "relevance_score": 5,
    "paper_idx": 410,
    "pmid": "41155646",
    "title": "Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant Klebsiella pneumoniae.",
    "year": "2025",
    "doi": "10.3390/ph18101531",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Kaur J",
      "Klem J",
      "Hailu G"
    ]
  },
  {
    "drugs": [
      {
        "name": "niclosamide",
        "drug_class": "anthelmintic",
        "approved_for": "treatment of parasitic worm infections"
      },
      {
        "name": "mitomycin C",
        "drug_class": "antineoplastic agent",
        "approved_for": "cancer chemotherapy"
      }
    ],
    "pathogens": [
      {
        "name": "Pseudomonas aeruginosa",
        "resistance_profile": "drug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "niclosamide",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide exhibits antibacterial activity against drug-resistant P. aeruginosa through mechanisms including membrane permeability disruption and quorum sensing inhibition."
      },
      {
        "drug": "mitomycin C",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mitomycin C shows activity against resistant P. aeruginosa, potentially via DNA crosslinking and inhibition of bacterial proliferation."
      },
      {
        "drug": "niclosamide",
        "pathogen": "Pseudomonas aeruginosa",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Niclosamide demonstrates synergistic effects when combined with conventional antibiotics against P. aeruginosa."
      }
    ],
    "mechanism": "Disruption of membrane permeability, quorum sensing inhibition, biofilm suppression, and DNA crosslinking.",
    "relevance_score": 4,
    "paper_idx": 411,
    "pmid": "41159745",
    "title": "Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes.",
    "year": "2025",
    "doi": "10.1128/msystems.00425-25",
    "journal": "mSystems",
    "authors": [
      "She P",
      "Huang G",
      "Guo S"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 412,
    "pmid": "41174184",
    "title": "ENOblock synergizes with colistin to treat Acinetobacter baumannii infections.",
    "year": "2025",
    "doi": "10.1038/s44321-025-00331-2",
    "journal": "EMBO molecular medicine",
    "authors": [
      "Molina Panadero I",
      "Moreno Rodr\u00edguez A",
      "Rey Hidalgo A"
    ]
  },
  {
    "drugs": [
      {
        "name": "bunamidine hydrochloride",
        "drug_class": "antiparasitic",
        "approved_for": "parasitic infections"
      }
    ],
    "pathogens": [
      {
        "name": "vancomycin-resistant Enterococcus faecalis",
        "resistance_profile": "VRE"
      },
      {
        "name": "vancomycin-resistant Enterococcus faecium",
        "resistance_profile": "VRE"
      }
    ],
    "findings": [
      {
        "drug": "bunamidine hydrochloride",
        "pathogen": "vancomycin-resistant Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "BUN exhibits potent bactericidal activity against VRE with MICs ranging from 2 to 4 \u00b5g/mL."
      },
      {
        "drug": "bunamidine hydrochloride",
        "pathogen": "vancomycin-resistant Enterococcus faecium",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 2,
        "fici": null,
        "key_result": "BUN effectively kills VRE strains, disrupting membrane integrity and biofilm formation."
      },
      {
        "drug": "bunamidine hydrochloride",
        "pathogen": "vancomycin-resistant Enterococcus faecalis",
        "activity_type": "anti_biofilm",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "BUN significantly inhibits biofilm formation and eradicates biofilm-embedded persister cells."
      },
      {
        "drug": "bunamidine hydrochloride",
        "pathogen": "vancomycin-resistant Enterococcus faecalis",
        "activity_type": "mechanism",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Mechanistic studies show BUN disrupts bacterial membrane integrity by increasing permeability and depolarization."
      }
    ],
    "mechanism": "BUN interacts with bacterial phosphatidylglycerol, disrupting membrane integrity, increasing permeability, and causing depolarization, leading to bacterial cell death.",
    "relevance_score": 5,
    "paper_idx": 413,
    "pmid": "41178970",
    "title": "A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1669585",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Guo S",
      "Li L",
      "Zhang Q"
    ]
  },
  {
    "drugs": [
      {
        "name": "disulfiram",
        "drug_class": "aldehyde dehydrogenase inhibitor",
        "approved_for": "alcohol dependence"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "The paper investigates GSDMD inhibition as a therapeutic approach for BPD, focusing on its role in macrophage pyroptosis and inflammation rather than direct antibacterial activity.",
    "relevance_score": 1,
    "paper_idx": 414,
    "pmid": "41194152",
    "title": "Comparative antibacterial efficacy of MTA, amniotic membrane, and hyaluronic acid in pulp therapy for primary teeth.",
    "year": "2025",
    "doi": "10.1186/s12903-025-07038-3",
    "journal": "BMC oral health",
    "authors": [
      "Ibrahim E",
      "Hamdy D",
      "Khattab N"
    ]
  },
  {
    "drugs": [
      {
        "name": "Auranofin",
        "drug_class": "gold(I) compound",
        "approved_for": "rheumatoid arthritis"
      }
    ],
    "pathogens": [],
    "findings": [],
    "mechanism": "Auranofin inhibits thioredoxin reductase (TrxR), disrupting redox homeostasis and inducing oxidative stress in target cells.",
    "relevance_score": 1,
    "paper_idx": 415,
    "pmid": "41249411",
    "title": "Evaluating the ciprofloxacin potentiation efficacy of repurposed drug flupentixol through efflux pump inhibition of pathogenic bacteria.",
    "year": "2025",
    "doi": "10.1038/s41598-025-24167-5",
    "journal": "Scientific reports",
    "authors": [
      "Momin-Reza M",
      "Rafi R",
      "Mia R"
    ]
  },
  {
    "drugs": [
      {
        "name": "ENOblock",
        "drug_class": "anticancer",
        "approved_for": "cancer"
      },
      {
        "name": "colistin",
        "drug_class": "polymyxin antibiotic",
        "approved_for": "last-resort treatment of multidrug-resistant Gram-negative infections"
      }
    ],
    "pathogens": [
      {
        "name": "Acinetobacter baumannii",
        "resistance_profile": "MDR, colistin-resistant, carbapenem-resistant"
      }
    ],
    "findings": [
      {
        "drug": "ENOblock",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 16,
        "fici": null,
        "key_result": "ENOblock exhibits potent in vitro antibacterial activity against MDR A. baumannii with MIC50 of 16 mg/L, better than colistin and carbapenems."
      },
      {
        "drug": "ENOblock",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ENOblock synergizes with colistin, reducing bacterial growth and enhancing bactericidal effects."
      },
      {
        "drug": "ENOblock",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "bactericidal",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "ENOblock demonstrates bactericidal activity against A. baumannii strains within 8 hours at multiple MIC multiples."
      },
      {
        "drug": "ENOblock",
        "pathogen": "Acinetobacter baumannii",
        "activity_type": "adjuvant",
        "evidence_type": "in_vivo",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "In vivo studies show ENOblock improves survival in infected Galleria mellonella larvae when combined with colistin."
      }
    ],
    "mechanism": "ENOblock targets bacterial enolase, disrupting glycolytic metabolism, damaging membranes, and impairing virulence functions.",
    "relevance_score": 4,
    "paper_idx": 416,
    "pmid": "41301611",
    "title": "Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa.",
    "year": "2025",
    "doi": "10.3390/antibiotics14111116",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Bernab\u00e8 G",
      "Marzaro G",
      "Shalata M"
    ]
  },
  {
    "drugs": [],
    "pathogens": [
      {
        "name": "Enterococcus faecalis",
        "resistance_profile": "resistant to high pH, resistant to some antimicrobial agents"
      },
      {
        "name": "Streptococcus mutans",
        "resistance_profile": "generally susceptible but involved in caries"
      },
      {
        "name": "Lactobacillus acidophilus",
        "resistance_profile": "resistant to tested pulp capping materials"
      }
    ],
    "findings": [
      {
        "drug": "Mineral trioxide aggregate (MTA)",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MTA exhibited the largest inhibition zone (18.25 mm) against E. faecalis, indicating strong antibacterial activity."
      },
      {
        "drug": "Mineral trioxide aggregate (MTA)",
        "pathogen": "Streptococcus mutans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "MTA showed the highest inhibitory effect (13.50 mm) against S. mutans."
      },
      {
        "drug": "Amniotic membrane",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amniotic membrane demonstrated effectiveness against E. faecalis with an inhibition zone of 11.75 mm."
      },
      {
        "drug": "Hyaluronic acid",
        "pathogen": "Streptococcus mutans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Hyaluronic acid showed antibacterial activity against S. mutans with an inhibition zone of 12.00 mm."
      },
      {
        "drug": "Hyaluronic acid",
        "pathogen": "Enterococcus faecalis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Hyaluronic acid showed no antibacterial activity against E. faecalis."
      },
      {
        "drug": "Amniotic membrane",
        "pathogen": "Streptococcus mutans",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amniotic membrane had no effect against S. mutans."
      },
      {
        "drug": "Hyaluronic acid",
        "pathogen": "Lactobacillus acidophilus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Hyaluronic acid was ineffective against L. acidophilus."
      },
      {
        "drug": "Amniotic membrane",
        "pathogen": "Lactobacillus acidophilus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Amniotic membrane had no effect against L. acidophilus."
      }
    ],
    "mechanism": "The antibacterial effects are proposed to be due to the release of antimicrobial compounds such as beta-defensins, growth factors, and anti-inflammatory cytokines from the tested materials, which inhibit bacterial growth or activity.",
    "relevance_score": 4,
    "paper_idx": 417,
    "pmid": "41303721",
    "title": "Drug Repositioning for HPV Clade-Specific Cervicouterine Cancer Using the OCTAD Pipeline.",
    "year": "2025",
    "doi": "10.3390/ijms262211238",
    "journal": "International journal of molecular sciences",
    "authors": [
      "Ruiz-Hern\u00e1ndez J",
      "Anda-J\u00e1uregui G",
      "Hern\u00e1ndez-Lemus E"
    ]
  },
  {
    "drugs": [
      {
        "name": "statins",
        "drug_class": "cardiometabolic agents",
        "approved_for": "hypercholesterolemia"
      },
      {
        "name": "ACE inhibitors",
        "drug_class": "antihypertensives",
        "approved_for": "hypertension"
      },
      {
        "name": "ARBs",
        "drug_class": "antihypertensives",
        "approved_for": "hypertension"
      },
      {
        "name": "metformin",
        "drug_class": "antidiabetic",
        "approved_for": "type 2 diabetes"
      },
      {
        "name": "pioglitazone",
        "drug_class": "antidiabetic",
        "approved_for": "type 2 diabetes"
      },
      {
        "name": "glucocorticoids",
        "drug_class": "anti-inflammatory",
        "approved_for": "various inflammatory conditions"
      },
      {
        "name": "PDE4 inhibitors",
        "drug_class": "anti-inflammatory",
        "approved_for": "COPD, asthma"
      },
      {
        "name": "macrolide antibiotics",
        "drug_class": "antibiotics",
        "approved_for": "bacterial infections"
      },
      {
        "name": "montelukast",
        "drug_class": "leukotriene receptor antagonist",
        "approved_for": "asthma, allergic rhinitis"
      },
      {
        "name": "NSAIDs",
        "drug_class": "nonsteroidal anti-inflammatory drugs",
        "approved_for": "pain, inflammation"
      },
      {
        "name": "doxycycline",
        "drug_class": "tetracycline derivative",
        "approved_for": "bacterial infections, periodontal disease"
      },
      {
        "name": "rapamycin",
        "drug_class": "mTOR inhibitor",
        "approved_for": "immunosuppression, certain cancers"
      },
      {
        "name": "estradiol",
        "drug_class": "hormone therapy",
        "approved_for": "hormone replacement therapy"
      },
      {
        "name": "tamoxifen",
        "drug_class": "selective estrogen receptor modulator",
        "approved_for": "breast cancer"
      }
    ],
    "pathogens": [
      {
        "name": "bacteria",
        "resistance_profile": "not specified"
      }
    ],
    "findings": [
      {
        "drug": "doxycycline",
        "pathogen": "bacteria",
        "activity_type": "direct_antibacterial",
        "evidence_type": "clinical",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Sub-antimicrobial dose doxycycline directly inhibits MMP-9 activity and is validated in periodontal disease and vascular remodeling."
      }
    ],
    "mechanism": "Indirect modulation of MMP-9 activity through existing approved drugs that reduce its expression or activity, or direct inhibition by tetracycline derivatives like doxycycline.",
    "relevance_score": 4,
    "paper_idx": 418,
    "pmid": "41304763",
    "title": "Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.",
    "year": "2025",
    "doi": "10.3390/pharmaceutics17111425",
    "journal": "Pharmaceutics",
    "authors": [
      "Wolosowicz M",
      "Prokopiuk S",
      "Kaminski T"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 419,
    "pmid": "41304874",
    "title": "Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy.",
    "year": "2025",
    "doi": "10.3390/ph18111628",
    "journal": "Pharmaceuticals (Basel, Switzerland)",
    "authors": [
      "Giorgini D",
      "Chiaverini L",
      "Viviano M"
    ]
  },
  {
    "drugs": [
      {
        "name": "gepotidacin",
        "drug_class": "topoisomerase inhibitor",
        "approved_for": "urinary tract infection (UTI)"
      },
      {
        "name": "sulbactam-durlobactam",
        "drug_class": "\u03b2-lactamase inhibitor",
        "approved_for": "Acinetobacter baumannii complex infection"
      },
      {
        "name": "contezolid",
        "drug_class": "oxazolidinone antibiotic",
        "approved_for": "skin and soft tissue infections"
      },
      {
        "name": "EC/11770",
        "drug_class": "benzoxaborole, leucyl-tRNA synthetase inhibitor",
        "approved_for": "none (experimental)"
      }
    ],
    "pathogens": [
      {
        "name": "Mycobacterium abscessus",
        "resistance_profile": "MDR"
      },
      {
        "name": "Mycobacterium avium complex (MAC)",
        "resistance_profile": "intrinsic resistance, macrolide resistance"
      }
    ],
    "findings": [
      {
        "drug": "EC/11770",
        "pathogen": "Mycobacterium abscessus",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 0.7,
        "fici": null,
        "key_result": "EC/11770 inhibits growth of M. abscessus in biofilm assays with MICs between 0.7 and 1.2 \u03bcM and reduces lung CFU in a murine model."
      }
    ],
    "mechanism": "inhibition of leucyl-tRNA synthetase, disrupting protein synthesis",
    "relevance_score": 4,
    "paper_idx": 420,
    "pmid": "41312994",
    "title": "Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages.",
    "year": "2026",
    "doi": "10.1128/aac.01319-25",
    "journal": "Antimicrobial agents and chemotherapy",
    "authors": [
      "Varik V",
      "Wang G",
      "Kritikos G"
    ]
  },
  {
    "drugs": [
      {
        "name": "clofazimine",
        "drug_class": "antimycobacterial/antimycobacterial agent",
        "approved_for": "leprosy"
      }
    ],
    "pathogens": [
      {
        "name": "Vibrio cholerae",
        "resistance_profile": "multidrug-resistant"
      },
      {
        "name": "Chlamydia trachomatis",
        "resistance_profile": "not specified, but targeted due to essential NQR"
      }
    ],
    "findings": [
      {
        "drug": "clofazimine",
        "pathogen": "Vibrio cholerae",
        "activity_type": "adjuvant",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clofazimine is identified as a potent NQR inhibitor with strong antivirulence properties against V. cholerae."
      },
      {
        "drug": "clofazimine",
        "pathogen": "Chlamydia trachomatis",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Clofazimine inhibits NQR activity in C. trachomatis, impairing its energy metabolism and development."
      }
    ],
    "mechanism": "Inhibition of the bacterial respiratory enzyme NQR, disrupting energy production and virulence factor expression.",
    "relevance_score": 5,
    "paper_idx": 421,
    "pmid": "41319186",
    "title": "Asiatic acid, a novel ciprofloxacin adjuvant inhibits Shigella flexneri infection.",
    "year": "2025",
    "doi": "10.1080/19490976.2025.2586329",
    "journal": "Gut microbes",
    "authors": [
      "Maitra P",
      "Bhukta S",
      "Gope A"
    ]
  },
  {
    "relevance_score": 0,
    "error": "parse_failed",
    "paper_idx": 422,
    "pmid": "41345109",
    "title": "GSDMD deficiency attenuates BPD by suppressing macrophage pyroptosis and promoting M2 polarization.",
    "year": "2025",
    "doi": "10.1038/s41420-025-02872-4",
    "journal": "Cell death discovery",
    "authors": [
      "Yang X",
      "Wang X",
      "Yang Y"
    ]
  },
  {
    "drugs": [
      {
        "name": "Asiatic acid",
        "drug_class": "triterpenoid",
        "approved_for": "none (experimental natural compound)"
      },
      {
        "name": "Ciprofloxacin",
        "drug_class": "fluoroquinolone antibiotic",
        "approved_for": "bacterial infections including shigellosis"
      },
      {
        "name": "Nalidixic acid",
        "drug_class": "quinolone antibiotic",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "Chloramphenicol",
        "drug_class": "amphenicol antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Ampicillin",
        "drug_class": "penicillin antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Tetracycline",
        "drug_class": "tetracycline antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Streptomycin",
        "drug_class": "aminoglycoside antibiotic",
        "approved_for": "bacterial infections"
      },
      {
        "name": "Azithromycin",
        "drug_class": "macrolide antibiotic",
        "approved_for": "bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Shigella flexneri",
        "resistance_profile": "MDR (multidrug-resistant)"
      }
    ],
    "findings": [
      {
        "drug": "Asiatic acid",
        "pathogen": "Shigella flexneri",
        "activity_type": "synergy",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": 0.25,
        "key_result": "Asiatic acid synergistically enhances ciprofloxacin activity against S. flexneri, inhibiting biofilm formation and efflux activity."
      },
      {
        "drug": "Ciprofloxacin",
        "pathogen": "Shigella flexneri",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Ciprofloxacin shows activity against S. flexneri, with resistance issues addressed by combination with asiatic acid."
      }
    ],
    "mechanism": "Asiatic acid disrupts bacterial membranes, inhibits efflux pump activity, and prevents biofilm formation, thereby potentiating ciprofloxacin efficacy.",
    "relevance_score": 5,
    "paper_idx": 423,
    "pmid": "41367421",
    "title": "NQR as a target for new antibiotics.",
    "year": "2025",
    "doi": "10.3389/fmicb.2025.1690572",
    "journal": "Frontiers in microbiology",
    "authors": [
      "Gonz\u00e1lez-Montalvo M",
      "Sorescu J",
      "Yuan M"
    ]
  },
  {
    "drugs": [
      {
        "name": "nitrofurantoin",
        "drug_class": "nitrofuran",
        "approved_for": "urinary tract infections"
      },
      {
        "name": "amikacin",
        "drug_class": "aminoglycoside",
        "approved_for": "bacterial infections including UTIs"
      },
      {
        "name": "imipenem",
        "drug_class": "carbapenem",
        "approved_for": "various bacterial infections"
      },
      {
        "name": "meropenem",
        "drug_class": "carbapenem",
        "approved_for": "various bacterial infections"
      }
    ],
    "pathogens": [
      {
        "name": "Escherichia coli",
        "resistance_profile": "ESBL-producing, multidrug-resistant"
      },
      {
        "name": "Klebsiella pneumoniae",
        "resistance_profile": "ESBL-producing, multidrug-resistant"
      }
    ],
    "findings": [
      {
        "drug": "nitrofurantoin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 91.1,
        "fici": null,
        "key_result": "Nitrofurantoin was highly effective against ESBL-producing E. coli isolates with 91.1% susceptibility."
      },
      {
        "drug": "amikacin",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": 71.7,
        "fici": null,
        "key_result": "Amikacin showed 71.7% activity against ESBL-producing E. coli isolates."
      },
      {
        "drug": "imipenem",
        "pathogen": "Escherichia coli",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No resistance was observed to imipenem among ESBL-producing isolates."
      },
      {
        "drug": "meropenem",
        "pathogen": "Klebsiella pneumoniae",
        "activity_type": "direct_antibacterial",
        "evidence_type": "in_vitro",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "No resistance was observed to meropenem among ESBL-producing K. pneumoniae isolates."
      }
    ],
    "mechanism": "Inhibition of bacterial cell wall synthesis by carbapenems and disruption of protein synthesis by aminoglycosides, effective against ESBL-producing strains.",
    "relevance_score": 4,
    "paper_idx": 424,
    "pmid": "41398575",
    "title": "Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.",
    "year": "2025",
    "doi": "10.1186/s12879-025-12349-5",
    "journal": "BMC infectious diseases",
    "authors": [
      "Ndihokubwayo A",
      "Nzoyikorera N",
      "Nyandwi J"
    ]
  },
  {
    "drugs": [
      {
        "name": "Vorinostat",
        "drug_class": "histone deacetylase inhibitor",
        "approved_for": "cutaneous T-cell lymphoma"
      },
      {
        "name": "Tamoxifen",
        "drug_class": "selective estrogen receptor modulator",
        "approved_for": "breast cancer"
      },
      {
        "name": "Simvastatin",
        "drug_class": "HMG-CoA reductase inhibitor (statin)",
        "approved_for": "hyperlipidemia"
      }
    ],
    "pathogens": [
      {
        "name": "HPV 18",
        "resistance_profile": null
      },
      {
        "name": "HPV 16",
        "resistance_profile": null
      }
    ],
    "findings": [
      {
        "drug": "Vorinostat",
        "pathogen": "HPV 18",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Vorinostat showed significant transcriptomic reversal potential in HPV-driven cervical cancer models, suggesting potential for repositioning."
      },
      {
        "drug": "Tamoxifen",
        "pathogen": "HPV 16",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Tamoxifen demonstrated inverse gene expression profiles with HPV-associated cervical tumors, indicating possible therapeutic utility."
      },
      {
        "drug": "Simvastatin",
        "pathogen": "HPV 16",
        "activity_type": "adjuvant",
        "evidence_type": "computational",
        "mic_ug_ml": null,
        "fici": null,
        "key_result": "Simvastatin was identified as a candidate with transcriptomic reversal effects in HPV-positive cervical cancer."
      }
    ],
    "mechanism": "The proposed mechanism involves modulation of epigenetic regulation, hormone receptor pathways, and cholesterol biosynthesis pathways to counteract HPV-driven oncogenic programs.",
    "relevance_score": 4,
    "paper_idx": 425,
    "pmid": "41463692",
    "title": "Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium.",
    "year": "2025",
    "doi": "10.3390/antibiotics14121189",
    "journal": "Antibiotics (Basel, Switzerland)",
    "authors": [
      "Cross J",
      "Gargate N",
      "Rahman K"
    ]
  }
]